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	ABSTRACT 
Background 
Allergy-related disease (ARD) is a major cause of morbidity in high-income countries 
(HICs). Although populations in tropical low-income countries (LICs), and in rural 
(compared to urban) settings, seem to be remarkably protected, the trends are fast 
changing as these communities undergo an epidemiological transition exemplified by 
changing helminth exposure patterns. Helminth exposure is of particular interest in 
understanding the epidemiology of ARD because of the homology between several 
helminth antigens and allergens, and the many similarities between helminth- and 
allergen-specific immune responses. Antibodies, especially IgE, are key constituents of 
the analogous immune responses to helminths and allergens, and are among the chief 
mediators of the effector cell activation underlying ARDs. While mindful of effects of other 
environmental exposures on epidemiological trends of ARDs in LICs, this PhD project 
postulated a crucial role for helminth-induced antibody profiles.  
Methods 
This research project obtained data on current helminth infections and allergy-related 
outcomes, and measured helminth- and allergen-specific antibody profiles, with 
immunoassays that included allergen and carbohydrate microarrays. Samples used 
were collected from Ugandan participants of three cross-sectional surveys: the baseline 
and outcome surveys of a cluster-randomised trial of intensive versus standard 
anthelminthic treatment in rural Schistosoma mansoni (Sm)-endemic islands, and a 
parallel survey in proximate urban communities with lower helminth exposure. A case-
control study on asthma among schoolchildren enabled assessment of a role for 
antibodies in allergic disease.  
Results 
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	Cross-sectional analyses showed that setting (rural vs. urban) was an effect modifier for 
risk factors (such as location of birth, current helminth [Sm] infection and other helminth-
related factors) for atopy and clinical allergy outcomes, and for atopy–clinical allergy 
associations. Although Sm infection was an important risk factor for skin prick test (SPT) 
reactivity and allergen-specific (as) IgE sensitisation (inversely or otherwise), definitive 
statistical proof for a role of helminth exposure in the observed effect modification 
between the two settings was not evident: helminths alone may not fully explain the 
differences observed. 
To obtain further insight into helminth-allergy associations, this project assessed total, 
Sm- and asIgE and asIgG4 and found strong positive associations with current Sm 
infection and atopic sensitisation (but not with ARD), but inverse associations between 
total IgE/ asIgE ratios, asIgG4/ asIgE ratios and SPT reactivity and asthma. This 
supported a role for helminth-induced antibodies in individual positive helminth-atopy 
associations, and for the IgG4–IgE balance and the total IgE–allergen-specific IgE 
balance in the low overall prevalence of clinical allergies in such settings.  
Helminths have a range of antigens that are strikingly homologous to common allergens, 
including cross-reactive carbohydrate determinant (CCD) N-glycans carrying core b-1,2-
xylose and a-1,3-fucose epitopes. Analyses showed distinctive relationships between 
IgE/IgG reactivity to these motifs and Sm infection intensity and the rural (versus urban) 
environment, and implied that they are abundant on common allergen extracts (such as 
house dust mite, German cockroach and peanut extracts used in standard ImmunoCAP 
assays), which likely results in false diagnosis of allergic sensitisation in tropical 
helminth-endemic settings. Microarray component-resolved IgE analyses showed that 
rural participants had lower responses to non-glycosylated, established major allergenic 
protein components, but higher reactivity to CCDs, than urban participants. Elevated 
anti-CCD IgE did not translate into clinical allergy. Indeed, an inverse association 
between asthma and reactivity to core a-1,3-fucose substituted N-glycans suggested 
5
	that reactivity to specific (but not all) CCD epitopes might contribute to protection against 
clinical allergy. 
Conclusions 
The current PhD research provides important insight into mechanisms underlying the 
complex epidemiological helminth-allergy trends in LICs. Notably, this work highlights 
the importance of balance in IgG4–IgE and total IgE–asIgE in inhibition of clinical allergy. 
This work also demonstrates strong associations between Sm exposure and anti-CCD 
IgE, which complicates atopy assessment, with implications for understanding the 
contribution of atopy to ARD in tropical LICs. The finding that schistosomiasis-associated 
core a-1,3-fucose-specific IgE is inversely associated with asthma is suggestive of a 
potential role of specific carbohydrate epitopes in protection against clinical allergy, 
which merits further investigation.
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	PREFACE 
This thesis is written in the ‘Research Paper style’, in accordance with guidelines 
provided by the London School of Hygiene and Tropical Medicine. The results chapters 
consist of four papers that have either been published or submitted for publication in 
peer-reviewed journals, and which describe work emanating from my PhD studies. In 
this thesis, each paper is preceded by a cover sheet that provides publication details and 
states my contribution (as first author) to the work therein. Between the research papers 
is ‘linking material’ that comprises supplementary material (published or to be published 
online with the papers), related unpublished material (if any) and a preamble describing 
how each chapter (paper) logically leads to the next. Three more papers are presented 
as appendices to this thesis. All published papers included in this thesis are open access 
articles of which the authors retain the copyright. The remainder of the thesis comprises 
background literature to the research conducted, details of the clinical, laboratory and 
statistical methods, and a general discussion and summary of the research findings. All 
material was written by Gyaviira Nkurunungi.
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 CHAPTER 1. BACKGROUND 
1.1 The global burden of allergy  
Worldwide, allergy-related diseases (ARDs) are important public health problems.1 
Conditions such as asthma, rhinitis and drug and food allergies can be fatal.2-4 
Additionally, these and other conditions such as eczema, conjunctivitis, urticaria, 
angioedema and insect allergies represent some of the most important causes of chronic 
morbidity. The prevalence of ARDs increased rapidly in the last century, to the extent 
that, currently, allergic rhinitis,1,5 asthma1 and food allergies6 affect approximately 400, 
300 and 200 million people globally, respectively, and 5-30% of children have eczema.7-
9
 Disability-adjusted life years (DALYs) lost due to ARD are substantial. For example, 
DALYs lost due to asthma were approximately 26 million in 2015, contributing 
approximately 1.1% of the global burden of disease,10 and ranking asthma 23rd out of 
310 diseases in a 2015 report of causes of disease burden globally.11 Between 2005 and 
2013, dermatitis (atopic, contact, and seborrheic) and urticaria contributed 9.3 million 
and 4.7 million DALYs lost, respectively, a contribution of 0.4% and 0.2%, respectively, 
to the global disease burden.12 The highest prevalence of ARDs has been reported in 
high-income countries (HICs); however, current time trends point to a sharp increase in 
low- and middle-income countries (LMICs) as well,13 including those in tropical sub-
Saharan Africa.1,14 Due to ill-equipped health sectors, low-income countries (LICs) bear 
the greatest burden of mortality associated with ARD. For example, the mortality rate 
among asthmatics is higher in LICs than in HICs.15 Despite these trends, populations in 
LICs, and in rural (compared to urban) settings, seem to have remained relatively 
protected against allergies.16-20 
1.2 The “old friends hypothesis” 
Approximately 30 years ago, David Strachan analysed data from a survey of over 17000 
British children and observed that younger siblings from larger households seemed 
protected against hay fever.21 He postulated that this was possibly because these 
children had greater exposure to childhood infections, resulting from unhygienic contact  
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	with older siblings. Following these observations, the term ‘hygiene hypothesis’22,23 was 
coined. According to this hypothesis, the rise in ARDs may have resulted (at least in part) 
from a decrease in exposure to infections. Assessment of epidemiological trends in HICs 
provided substantial support for the ‘hygiene hypothesis’: a review by Jean-François 
Bach showed that between 1950 and 2000, a dramatic reduction in the incidence of 
infectious diseases was paralleled by an equal rise in the incidence of autoimmune and 
allergy-related diseases.24 Further support came from studies assessing associations 
between allergy-related conditions and the traditional farming setting (and related 
microbial exposures) in HICs. For example, in a rural European birth cohort, exposure 
to animal sheds was dose-dependently inversely associated with wheezing.25 The United 
States Amish population, who have maintained traditional farming methods, have a 
significantly lower prevalence of asthma and allergic sensitisation compared to the 
Hutterite population, who are of similar genetic descent but have adopted industrialised 
farming.26 A remarkable increase in atopic sensitisation was reported among individuals 
from rural communities in south-west Poland, following an equally significant reduction 
in farm-related exposures in the same population nine years after Poland’s accession to 
the European Union.27 Importantly, the prevalence of atopy did not change significantly 
in small-town populations in the same region. More studies in HICs report comparable 
results.28-31 
Common understanding of the hygiene hypothesis, that infectious diseases play a direct 
role in protection against inflammatory conditions (including allergies),24 is perhaps 
inaccurate.32 In a large study by Benn et al.33 in a Danish birth cohort, infectious diseases 
were not protective against atopic dermatitis; in fact, positive associations were 
observed. By contrast, family size and farm residence were protective, in line with the 
above-mentioned studies.  
More recent evidence from epidemiological and experimental human and animal studies 
backs a different hypothesis, the ‘old friends hypothesis’. It is postulated that many 
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	organisms, ‘old friends’34 that co-evolved with mammalian species, developed 
mechanisms to modulate the expression of inflammatory molecules, as a way of 
ensuring survival and reproductive success within the dominion of a vigilant host immune 
system.  
The close evolutionary relationship between these ‘old friends’ and mammals is 
epitomized by helminth infections: for the most part of history, at least one type or another 
of these complex multicellular organisms has colonised mammalian species.35 In HICs, 
the large reduction in helminths (albeit alongside other infectious agents) during the 
epidemiological transitions of the last century overlapped with the surge in inflammatory 
conditions such as allergies,34 affirming the ‘old friends hypothesis’. Tropical LICs still 
harbour the largest burden of parasitic helminth infections.36 In these countries, several 
studies37-45 have shown that exposure to helminths is associated with protection against 
allergy and may contribute to urban-rural differences in the prevalence of allergy-related 
diseases.46 In Uganda, reports from a birth cohort47 showed that maternal hookworm 
infection modifies risk factors for childhood eczema, suggesting that exposure to 
helminths early in life may also establish protection against allergy.48 
1.3 Global estimates of disease burden due to helminths 
Although better hygiene practices and mass anthelminthic interventions are contributing 
to a decline in helminths in the most affected regions of the world,49 World Health 
Organisation reports estimate that approximately a quarter of the world’s population is 
still infected with at least one helminth.50 Globally, over 200 million people are infected 
with schistosomiasis, while approximately 800 million people are estimated to be infected 
with at least one soil transmitted helminth (STH).50 In 2010, up to 5.2 million DALYs were 
lost globally due to STH infections, while schistosomiasis and lymphatic filariasis 
accounted for approximately 3.3 million and 2.8 million DALYs, respectively.51,52 The 
majority of helminth infections affect resource-restrained regions. Over a billion people 
infected with at least one helminth reside in the Americas, Asia or sub-Saharan Africa.53 
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	Helminth-associated morbidity imposes a huge disease burden in infected individuals. 
For example, chronic Schistosoma infections can cause extensive intestinal and liver 
pathology,54 and have been significantly associated with anaemia, diarrhoea and 
undernutrition.55 Despite the heavy disease burden attributed to helminths, there is 
evidence of wider implications for protection against non-communicable diseases (such 
as clinical allergies, discussed herein and in Research paper 5, Appendix 1, this thesis), 
as well as for susceptibility to communicable diseases (Research paper 5).  
1.4 Cellular and humoral mechanisms of helminth-allergy associations 
Helminths typically induce Th2-type immune responses, characterised by increased 
levels of interleukin (IL)-4, IL-5, IL-13 and immunoglobulin E (IgE).56,57 High levels of 
these responses have also been associated with immunity against several helminth 
parasites.58-61 Akin to helminth infections, allergy-related conditions are associated with 
heightened Th2-type responses.62 These responses are involved in the initiation of 
airway smooth muscle contraction,63 eosinophil recruitment and development,64 mucus 
hyperproduction65 and production of allergen-specific IgE (asIgE) that mediates effector 
cell degranulation.66 Similarities between allergen- and helminth-specific immune 
responses may explain observations, in some instances, of positive helminth-allergy 
associations67 Potential mechanisms are covered extensively in sections 1.4.5 and 
1.4.6.3, below. 
These similarities notwithstanding, helminth infections seem to be protective against 
allergy-related phenotypes.38,42-45,68 This has been attributed to the strong and complex 
network of immunoregulatory mechanisms69,70 aimed at blocking the allergy-like 
responses induced by helminths,71 and which serve to avert helminth destruction and 
elimination from the host. Evidence of the ability of helminths and their products to 
modulate immune responses is derived from animal studies and in vitro immunological 
studies in humans, which further demonstrate spillover effects on bystander antigens,72 
including allergens.73 
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	The proposed cell- and antibody-mediated mechanisms through which helminths may 
down-modulate, or enhance, allergic responses are extensive, spanning almost the 
entire spectrum of the allergy-related immunological pathway. Research paper 5 
(Appendix 1, this thesis) includes a review of how helminths manipulate host systems, 
with a schematic (Figure 1, research paper 5, reproduced below as Figure 1.1) on how 
bystander responses (including allergy) may be influenced by helminth-host interactions.  
 
Figure 1.1. Interactions between helminths and the host immune system, and the impact on 
bystander responses. Red arrows and blue lines denote positive and suppressive effects, respectively. Helminth 
migration in the host results in tissue injury, resulting in release of Damage Associated Molecular Patterns (DAMPs) 
and alarmins. DAMPs and alarmins are involved in the initial activation of eosinophils, type 2 innate lymphoid cells 
(ILC2) and antigen presenting cells (APCs) such as dendritic cells (DCs), which then mediate further inflammation in 
the host. However, some helminth secretory products can suppress alarmin release and DC maturation, and some 
helminth enzymes degrade DAMPs. Helminths also interfere with APC activities, promoting an alternative activation 
phenotype, which results in production of large amounts of IL-10 and TGFβ. These cytokines downmodulate 
eosinophil, ILC2 and DC responses, and promote lymphocyte hyporesponsiveness involving regulatory lymphocytes. 
Helminth interaction with host immunity has spillover effects on responses to bystander antigens. For instance, 
helminth infections may result in impaired immune responses to vaccines and communicable diseases, although 
specific helminth molecules may actually have enhancing effects. Likewise, there is evidence for both inverse and 
positive helminth-allergy associations, although any notable effects on metabolic conditions have been beneficial. 
DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; HMGB1: High Mobility Group Box 1. Figure reproduced from 
Research Paper 5, Appendix 1, this thesis 
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	associations, with a bias towards antibody-mediated mechanisms. 
1.4.1 Interaction of helminths with innate immune cells 
Loss of mucosal and epithelial integrity resulting from helminth migration or encounter 
with allergens and other toxins triggers release of damage-associated molecular patterns 
(DAMPs) and alarmin cytokines such as IL-1α and IL-33.23 DAMPs and alarmins are 
involved in the initial activation of antigen presenting cells (APCs) such as dendritic cells, 
which then mediate further inflammation in the host. Helminth secretory products have 
been shown to suppress alarmin release74 and to secrete enzymes that degrade 
DAMPs.75,76 Further downstream, they interfere with APC activities, promoting an 
alternative activation phenotype, which results in innate cells that produce large amounts 
of IL-10 and TGF-β but insignificant levels of pro-inflammatory cytokines.77,78 The 
modulation of APC function by helminths mainly occurs through the interaction of 
helminth-derived molecules with pattern recognition receptors (PRRs),79-82 and has been 
associated with reduced risk of allergic reactivity in both humans83 and mice.84  
Approximately nine years ago, type 2 innate lymphoid cells (ILC2) were recognised.85 
Important as an innate source of Th2 cytokines during helminth infection,85 ILC2 cells 
have additionally been implicated in initiation of allergy.86,87 There is also evidence of 
potential inhibition of ILC2 activity by Heligmosomoides polygyrus,74 demonstrating the 
broad nature of helminth-mediated innate immunomodulation, which also includes 
inhibition of neutrophil activation88,89 and eosinophil recruitment.90  
1.4.2 Regulatory T and B cells 
Helminths are associated with profound T cell hyporesponsiveness involving regulatory 
T cells (Tregs), with related increases in interleukin (IL)-10 and transforming growth 
factor (TGF)-β.91 Helminth-induced reduced T cell activity may impact on allergy-related 
outcomes: Navarro et al. observed that hookworm anti-inflammatory protein-2 
suppressed airway inflammation in a mouse model of asthma, in a Treg-dependent 
manner,92 and IL-10 induced during chronic schistosomiasis infection among Gabonese 
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	children was shown to be associated with lower prevalence of atopy.45 Besides, in both 
mice93 and humans,94,95 IL-10 and Tregs have been implicated in the mitigation of allergy 
through allergen-specific immunotherapy.  
Helminths also induce B cells with various regulatory properties.96-98 First characterised 
among helminth infected multiple sclerosis patients in 2008 by Correale and 
colleagues,98 these ‘regulatory B cells’ (Bregs) also produce IL-10, are potent producers 
of IgG4,99 and have been associated with inhibition of allergic inflammation.96,98,100 It is 
not very clear where in the allergy cascade B and T cell-derived IL-10 applies its 
modulatory action. IL-10 may impede activities of antigen presenting cells,101,102 and in 
an autocrine manner, inhibit T lymphocyte proliferation and activation by suppressing IL-
2 production.103 In addition to influencing lymphocyte and APC activity, reports indicate 
that IL-10 could inhibit IgE-effector cell degranulation104 and hence limit the associated 
allergic inflammation.45,105  
1.4.3 IgG4-mediated regulation of IgE responses 
By inducing high levels of IL-10, helminths may promote immunoglobulin class switching 
to IgG4. Moreover, chronic helminth infection is associated with elevated serum IgG4 
levels.106 Several studies highlight the importance of helminth-induced IgG4 in allergy: 
serum inhibition of specific IgE was associated with competing IgG4 in a Schistosoma 
mansoni endemic setting,107 while in allergen immunotherapy, high IgG4:IgE ratios have 
been shown to be important.108 Several possible mechanisms may explain IgG4-
mediated protection against IgE-mediated effects. First, IgG4 may block allergen 
recognition by IgE, because both antibodies have similar antigenic specificity.107,109,110 
Secondly, simultaneous binding of the IgE receptor (FcεRI) and the inhibitory IgG 
receptor (FcγRIIB) by IgE and IgG4, respectively, may result in a FcγRIIB-dependent 
inhibition of IgE-mediated effector cell activation.110-112 Alternatively, IgG4 might not have 
a direct mechanistic role in protection against allergy-related outcomes. Instead, the 
inverse association between IgG4 levels and IgE effector function may represent an 
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	‘epiphenomenon’, merely reflective of the abundance of IL-10 (and/or TGF-β)-producing 
Tregs and Bregs.113  
1.4.4 Polyclonal IgE 
There is sufficient evidence to link parasitic helminths to stimulation of polyclonal IgE 
synthesis in humans, including from studies conducted decades ago.114 For example in 
1979, Turner and colleagues showed that Ascaris-specific IgE contributed a small 
proportion of total serum IgE induced by Ascaris lumbricoides, suggesting that this 
parasite mediates production of high levels of IgE that is not specific to the parasite, or 
to inhalant allergens.115 Non-specific polyclonally-stimulated IgE has been proposed to 
inhibit allergic responses by competing with allergen-specific IgE (asIgE) to saturate IgE 
receptors,116 reducing the chances that an allergen will result in cross-linking of FcεRI-
bound IgE and hence effector cell degranulation.117,118 Nonetheless, there is contrasting 
evidence linking high IgE titres to increased expression of IgE receptors on human 
basophils,119 implying that high levels of helminth-induced polyclonally-stimulated IgE 
may potentiate increased effector cell degranulation. Furthermore, Mitre and colleagues 
showed that ratios of polyclonal to asIgE have to exceed 500:1 to suppress basophil 
histamine release,120 yet there is no formal proof of these ratios frequently reaching such 
high levels during helminth infection. Therefore, the question of whether polyclonally 
stimulated IgE mitigates allergic responses remains unresolved. 
1.4.5 Cross-reactivity between helminth and allergen proteins: implications for allergic 
sensitisation and allergic effector responses 
Although many studies report reduced prevalence of allergy-related conditions in 
helminth-infected individuals compared to uninfected controls, contradictory evidence 
(including that shown in Research Paper 6, Appendix 2, this thesis) suggests that in 
some circumstances helminth infections may actually promote allergic responses.121-124	
Helminth-specific immune responses can manifest as allergy-like phenomena, such as 
Loeffler’s syndrome in response to A. lumbricoides,125 cutaneous larva migrans in 
hookworm infection,126 ‘larva currens’ caused by S. stercoralis127 and urticarial rash 
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	induced by several helminths.128 Urticarial reactions have also been observed during 
vaccination against hookworm129 and in response to helminth antigens following 
treatment.130 
In addition, protein allergen structures can predict IgE binding to helminth allergen-like 
proteins,131 and helminths secrete many proteins that are homologous to known 
allergens, meaning that cross-reactive helminth protein-specific IgE may induce allergic 
effector responses. For example, tropomyosin from Ascaris lumbricoides132 and 
Onchocerca volvulus133 is homologous to tropomyosin from Dermatophagoides 
pteronyssinus (Der p 10)132 and cockroach (Blattella germanica, Bla g 7),134 and induces 
basophil histamine release.133 Immunoglobulin E sensitisation to the Ascaris 
lumbricoides tropomyosin Asc l 3 has been shown to be a risk factor for asthma in 
Colombian individuals.135  Other molecules such as paramyosin,136 glutathione-S-
transferase137 and ABA1-like-protein132 have also been identified as homologous to 
allergen proteins known to induce IgE-mediated hypersensitivity. As a result of such 
cross-reactivity, helminth protein-induced IgE may have implications for serologic-based 
assays used in diagnosis of allergic sensitisation.138  
1.4.6 Carbohydrate-specific IgE and allergy 
While the role of protein cross-reactivity in helminth-allergy associations has been 
extensively studied, the importance of cross-reactive carbohydrate groups is less 
understood. A substantial body of evidence shows that carbohydrates are strong 
inducers of Th2-type responses.139-141 Asparagine (N)- and threonine/serine (O)-linked 
glycans are some of the most common environmental immune determinants,142-146 
comprising a vast number of epitopes for antibodies,147-150 including IgE.141,151 Glycans 
were first linked to allergy in 1981, when Aalberse and colleagues,152 in a study among 
venom- and pollen-allergic patients, showed that treatment of food and insect extracts 
with periodate (which destroys carbohydrate structures) annulled the initially observed 
cross-reactivity between patient serum IgE and these extracts. Twelve years later, the 
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	a-1,3-fucose moiety on the N-glycan core (trimannosyl-chitobiose, Man3GlcNAc2)153 was 
shown to be majorly responsible for the IgE cross-reactivity between plant and insect 
glycans.154 It is now known that some of the commonest sources of cross-reactivity 
between allergens and helminths are core modifications on N-glycans expressed by 
insect, plant and helminth proteins (termed cross-reactive carbohydrate determinants, 
CCDs). 
1.4.6.1 Expression of classical CCD epitopes in plants and human parasites  
While the N-glycan trimannosyl-chitobiose core (Man3GlcNAc2) is conserved in all 
eukaryotes, mass spectrometry (MS)-based analyses of classical CCD N-glycans show 
two standout, non-mammalian substitutions145,153 on the Man3GlcNAc2 core: an α-(1,3) 
linkage of fucose to the asparagine-linked N-acetylglucosamine (GlcNAc) and a β-1,2-
xylose linkage to the first mannose of the trimannosyl component (Figure 1, Research 
Paper 3 [this thesis], reproduced below as Figure 1.2). 
Though absent in mammals, core a-1,3-fucose and β-1,2-xylose motifs are expressed 
by invertebrate155,156 and plant glycoproteins,157-159 as well as on surface and secreted 
antigens of schistosomes160 and the nematodes Haemonchus contortus and 
Caenorhabditis elegans.161-164 These core modifications have so far not been detected 
on glycoproteins from other helminths that are prevalent in tropical regions.165 Amongst 
human helminth parasites, the Schistosoma glycome is the most characterised.165-167 
Comprehensive mass spectrometry-based studies have detected neither core β-1,2-
xylose nor core α-1,3-fucose substituted N-glycans in the adult worm stage of 
schistosomes; however, both core substitutions are expressed at the miracidia and egg 
stage. Core β-1,2-xylosylated N-glycans are expressed by cercariae, while α-1,3-fucose 
substitutions have not been found at this life stage.165 
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Figure 1.2. Non-mammalian carbohydrate substitutions on the N-glycan core. Non-
mammalian monosaccharide substitutions are denoted by blue brackets. ± implies that motifs in brackets 
are present or absent in different species. Figure drawn using GlycoWorkbench software, version 2.1 
(European Carbohydrates Database Project). Figure reproduced from Research Paper 3, this thesis. 
 
There are other common antennary modifications to the schistosome Man3GlcNAc2 core, 
which are not established constituents of classical CCD N-glycans. These include 
antennae composed of GalNAcβ1-4GlcNAc (LDN), GalNAcβ1-4(Fucα1-3)GlcNAc (LDN-
F) and Galβ1-4(Fucα1-3)GlcNAc (Lewis X) units. Although these are expressed at all 
schistosome developmental stages (albeit with varying surface expression patterns),168 
they are uncommon in mammalian species,169 and are expressed variably by other 
helminths.165 Figure 1.3 (below) summarises the S. mansoni life cycle, and expression 
(or lack thereof) of 1) core β-1,2-xylose and core α-1,3-fucose and 2) common antennary 
glycan elements, during cercariae, adult worm and egg stages. Research Paper 3 
(Chapter 6) discusses the role of core substituted glycans and other carbohydrates in 
diagnostics, cross-reactivity and associations with protective immunity against 
schistosomes.  
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	1.4.6.2 Clinical relevance of CCDs 
Core a-1,3-fucose and β-1,2-xylose may be the most common N-glycan epitopes 
targeted by human IgE antibodies.170 Although a few studies have reported that anti-
glycan IgE from allergic individuals may trigger histamine release,171,172 and that the 
mammalian glycan epitope galactose-a-1,3-galactose (alpha-gal) triggers anaphylactic 
reactions,173,174 there is overwhelming evidence showing that carbohydrate-specific IgE 
generally has insignificant biological activity. For example, individuals with specific IgE 
to cross-reactive carbohydrate determinants (CCDs) lack SPT and oral reactivity to the 
same molecules.118,141,145,175  
Several explanations have been put forward to justify why, predominantly, carbohydrates 
are benign as allergenic determinants. Early studies proposed that the low affinity of anti-
CCD IgE was responsible for its low biological activity;176,177 however, using surface 
plasmon resonance technology, it was later shown that human IgE and IgG antibodies 
against CCDs had high affinity, even comparable to that of protein-specific antibodies.178 
Another factor contributing to the low biological activity of anti-CCD IgE may be the 
monovalent nature (presence of a single IgE-binding glycan) of most known CCDs (such 
as bromelain) and other glycosylated allergens. For mast cells or basophils to release 
histamine or other mediators, two occupied IgE receptors have to be cross-linked by 
allergens with at least two epitopes. Studies by Mari et al.179,180 showed that bromelain 
did not induce skin reactivity in individuals with anti-CCD IgE, while poly-glycosylated 
horseradish peroxidase (HRP) induced skin reactivity in 21% of individuals with CCD-
specific IgE. However, in the latter case, reactions were weak, and were mostly observed 
in individuals with high anti-CCD IgE levels. The extent to which anti-CCD IgE is benign 
as an allergenic determinant remains poorly understood. 
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Figure 1.3. Schistosoma mansoni life cycle and summary of expression patterns of glycan 
motifs during the cercariae, adult worm and egg stages. Information on glycan expression 
patterns obtained from Hokke and van Diepen, 2016.165 The Schistosoma life cycle has been 
adapted from Elliott et al., 2018,181 with permission from Prof. Elliott, MRC/UVRI and LSHTM 
Uganda Research Unit. Images of S. mansoni life stages and the human body have been adapted 
from Servier Medical Art (https://smart.servier.com). 
 
1.4.6.3 Anti-CCD IgE and helminth-allergy associations 
Cross-reactive carbohydrate determinants on common helminths and allergens may 
account for elevated (but clinically irrelevant) allergen extract-specific IgE levels in 
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	helminth-endemic areas.182 Findings by Amoah et al.183 among Ghanaian schoolchildren 
lend strong support to this hypothesis: S. haematobium infection was associated with 
peanut extract specific-IgE sensitisation, which was in turn strongly associated with anti-
CCD IgE but not with SPT reactivity. Additionally, in antibody inhibition assays, IgE 
reactivity to peanut was inhibited by CCDs and Schistosoma egg antigen (SEA). 
Amoah’s results implied that elevated crude peanut extract-specific IgE levels could be 
attributed to CCDs (expressed by both the crude extract and schistosome antigens), not 
to true protein allergens in the crude extract. Therefore, in addition to contributing to 
positive helminth-allergy associations in helminth-endemic areas, elevated anti-CCD IgE 
levels plausibly obscure the identity of the molecular drivers, and hence interpretation, 
of atopic sensitisation, especially given that it is routinely diagnosed using allergen 
extract-based in vivo SPTs and/or in vitro allergen-specific IgE blood immunoassays. 
1.4.6.4 Could carbohydrate-specific antibodies be protective against allergic disease? 
Analogous to the idea that “blocking” IgG / IgG4 antibodies compete with IgE to bind to 
epitopes on allergens,107,109,110 or that they induce FcγRIIB-dependent inhibition of IgE-
mediated effector cell signalling110-112 (discussed in section 1.4.3), it has been further 
proposed that high affinity CCD-specific IgG antibodies (resulting from routine contact 
with foods and pollen) may block IgE-mediated effector responses184-186 by competing 
with IgE for allergen epitopes.187 This represents another potential mechanism of 
helminth-mediated protection against allergic disease.  
Although largely unexplored, a protective role for helminth-induced anti-CCD IgE is also 
possible. The separation of anti-CCD IgE from clinical symptoms of allergy, coupled with 
its abundance during chronic helminth infection, raises the question of whether elevated 
IgE responses to specific immunogenic glycans during chronic helminth infection might 
dominate over allergen protein-specific IgE, resulting in reduced allergic effector 
responses. A possible mechanism is that CCD-specific IgE competes with allergen 
protein-specific IgE to saturate IgE receptors, reducing the chances that allergen 
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	exposure will result in cross-linking of FceRI-bound IgE to cause effector cell 
degranulation. It is also plausible that, in an effort by the host immune system to 
downregulate elevated anti-CCD antibodies, there are spill-over effects resulting in 
regulation of other responses, including anti-protein IgE. Furthermore, many native 
allergens occur as glycoproteins; therefore, prior elevated exposure to CCDs (perhaps 
from helminth infection) may prime initial and recall IgE responses to preferentially target 
CCD rather than the protein epitopes of allergens. This means that in helminth-endemic 
settings, IgE is less effectively induced against common protein allergens than against 
CCDs.  
Besides, CCDs may be involved in helminth-mediated immunoregulation: most N-
glycans on the Schistosoma egg antigen (SEA)-derived glycoprotein omega-1 (which 
drives both immunoregulatory188 and Th2 responses,189 the latter in a glycan-dependent 
manner82) carry core α-1,3-fucose motifs in combination with terminal Lewis X units.190 
Kappa-5, another major SEA component,191 expresses core b-1,2-xylose and core α-
1,3-fucose substituted glycans.192   
Population studies assessing associations between anti-CCD antibodies and allergic 
disease, as well as mechanistic studies in animal models and in humans, are required 
to test the hypothesis that anti-CCD antibodies may be protective against allergic effector 
responses. It has recently been shown that helminth glycoproteins (including those 
carrying core substitutions) can be reconstructed in plant systems.193 Ready availability 
of tailor-made glycans will be important for mechanistic studies, such as those involving 
animal models, and could aid development of therapeutics. 
1.5 Effect of anthelminthic treatment on allergic sensitisation and disease 
Cross-sectional studies are prone to temporality,194 hence it is important to ascertain 
causality when assessing helminth-allergy associations. For example, although inverse 
helminth-allergy associations could result from helminth-mediated protection against 
allergy-related outcomes, it is also likely that individuals who are genetically predisposed 
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	to allergies could be resistant to helminths. The latter hypothesis draws support from 
studies which report that specific genotypes are associated with both risk of allergy and 
resistance to helminth infections.195,196 Assessing the impact of anthelminthic 
interventions on allergy-related outcomes is thus an important approach for ascertaining 
causality when investigating helminth-allergy associations.  
Several anthelminthic intervention studies have been conducted to assess effects on 
allergy-related outcomes. In a study conducted 26 years ago among Venezuelan 
children, treatment for intestinal helminths was associated with increased SPT reactivity 
and serum levels of allergen-specific IgE.197 Notably, among children in the same setting 
who declined treatment, increased helminth infection prevalence and total IgE levels 
were observed, paralleled by a decrease in SPT reactivity and allergen-specific IgE 
levels. In later studies among Gabonese198 and Vietnamese children199 repeated 
anthelminthic treatment was also associated with increased SPT reactivity. However, 
these studies did not show any effect of anthelminthic treatment on wheeze, eczema or 
other clinical allergies. Other studies report effects of treatment on some clinical allergy 
outcomes, but not others, and some studies have observed a lack of effect of treatment 
on both allergic sensitisation and clinical allergy. For example, Cooper and others found 
that ivermectin treatment for Trichuris trichiura infection among Ecuadorian children was 
associated with increased prevalence of eczema symptoms (but not asthma 
symptoms),200 but did not observe any effect of two-monthly albendazole (for one year) 
on atopy or clinical allergy in a large, cluster-randomised trial among schools in rural 
Ecuador.201  
Barring investigations on the effect of anthelminthic treatment on allergen extract-specific 
IgE (as a measure of atopy), very few studies have included detailed work on the effect 
of anthelminthic treatment on immunological parameters related to allergy, such as IgE-
mediated histamine release, anti-CCD antibody responses, allergen extract-specific IgG, 
or allergen component-resolved antibody reactivity. However, one such study was 
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	conducted in Ugandan school children: while hookworm infection abrogated the 
predicted association between allergen-specific IgE and basophil histamine release, 
albendazole treatment re-established it.202 More animal and population-based studies 
are warranted. 
1.6 Helminths, the rural-urban environment and allergy-related outcomes  
The on-going urbanisation in many tropical LICs is gradually being paralleled by a shift 
in disease patterns.203 Non-communicable diseases, including allergy, seem to be on the 
increase, especially in urban areas of LICs. Links between urbanisation and allergic 
disease are not new. As far back as 1965, urban-rural differences in asthma prevalence 
were being reported among German populations.204 Later, studies in Africa,205 Asia206,207 
and South America208 reported similar results. Factors that are inversely associated with 
allergy-related conditions have been shown to be more common in the rural 
environment, as indicated by studies on the protective effect of traditional farming on 
allergy outcomes (discussed above).25,26,28-31 Rural settings, especially in tropical LICs, 
are characterised by exposure to immunomodulating disease agents such as helminths, 
which have been hypothesised to protect against allergy-related disease.34 Changes in 
environmental exposures due to urbanisation may drive increases in allergy-related 
disease.34 These changes include reduced exposure to helminths. Previous work implies 
that there are other potentially relevant differences in the urban-rural exposure that may 
influence allergy trends, such as animals and related microbial exposure209 and nutrition 
(for example milk pasteurisation27). However, helminths are of special interest because 
of their unique molecular relationship with allergens (discussed above). Whether 
repeated, intensive anthelminthic treatment in endemic rural settings in the tropics may 
shift allergy prevalence or immunological profiles associated with allergy towards an 
urban pattern has not been explored fully. While conceivable, such a shift might be 
hindered by high re-infection rates in most endemic settings210 and the long-lasting 
immunological and epigenetic effects of helminth exposure.211  
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	1.7 Scope of this thesis 
The prevalence of helminth infections is still high in most tropical LICs, especially in rural 
settings. This, coupled with the ongoing epidemiological transition in these countries, 
provides unprecedented opportunities to understand helminth-allergy associations, by 
exploring the underlying immunological mechanisms. In Uganda, the urban-rural divide 
is characterised by differences in helminth exposure intensity between the two settings, 
offering opportunities for investigation of the role of helminths (through specific 
immunological pathways) in mediating population differences in allergy-related 
conditions.  
Antibodies, specifically IgE, are key constituents of the analogous immune responses to 
helminths and allergens, and are among the chief mediators of the effector cell activation 
underlying allergy-related disease. Three studies (described in Chapter 3) have been 
conducted in proximate, yet diverse Ugandan settings, primarily to obtain a comparative 
assessment of phenotypes, prevalence and risk factors for allergy-related diseases in 
rural and urban settings, and among asthmatic schoolchildren (age 5-17 years) and non-
asthmatic controls. These studies provided a unique resource for assessment of the 
impact of the rural-urban environment and helminth exposure on helminth protein and 
carbohydrate-specific antibody profiles and the relevance of these profiles to the 
epidemiological trends of allergy in tropical LICs, specifically Uganda. These 
assessments are important for therapeutic strategies against allergy-related disease and 
for strategies aimed at minimising the impact of improved hygiene on allergy prevalence 
in tropical LICs. 
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Helminth-induced antibody profiles influence the profile of allergic sensitisation and 
disease, and consequently the epidemiological trends pertaining to allergy in tropical 
settings. 
   
The conceptual framework of this thesis is shown in Figure 2.1, below. 
     
Figure 2.1. Conceptual framework. Red arrows indicate positive effects and blue arrows indicate negative effects. 
Standard arrow endings denote promotion, while perpendicular line endings denote inhibition. Helminth antigens may 
cross-react with allergen protein or carbohydrate determinants (1), and/or interact with B cells (2) to elicit strong allergen-
specific IgE (asIgE) responses. Conversely, they might non-specifically induce production of polyclonal IgE (which might 
inhibit allergic responses by competing with asIgE to saturate IgE receptors (3)) or induce IgG4 that will block allergen 
recognition by IgE (4). Helminths such as Schistosoma mansoni contain IgE-binding carbohydrate moieties (also found 
on some allergen glycoproteins; do not translate into allergic effector responses): during chronic helminth infection, 
carbohydrate-specific IgE might dominate over protein-specific IgE, resulting in reduced allergic effector responses (5).  
**Alarmins such as IL-33 promote Th2-mediated inflammation, including IgE production and eosinophil activation, which 
may contribute to pathogenesis of some clinical allergies such as asthma.1 DAMP-induced activation of the 
inflammasome has been implicated in airway hyperreactivity in asthma.2 
APCs: antigen presenting cells; DAMPs: damage-associated molecular patterns. 
CHAPTER 2. THESIS OBJECTIVES AND STRUCTURE
2.1 General hypothesis
2.2 Conceptual framework
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1) To investigate the extent to which helminth exposure influences rural-urban 
differences in prevalence of allergy-related outcomes, and in epidemiological and 
immunological risk factors for these outcomes  
2) To map the association of total, helminth- and allergen extract-specific IgE and 
IgG4 profiles with helminth infection and allergy-related outcomes 
3) To assess associations between helminth (S. mansoni) infection (and intensity) 
and IgE and IgG responses to classical cross-reactive carbohydrate determinant (CCD) 
epitopes 
4) To determine the role of CCD-specific IgE in the epidemiology of allergic 
sensitisation and disease (asthma)  
   
This thesis is written in the ‘Research paper’ format, and comprises eight chapters. Each 
of the seven research papers included in this thesis was written as a stand-alone 
manuscript, albeit using data collected from the same study settings. Therefore, there is 
inevitable duplication of some of the information among the papers, and between the 
papers and the remainder of the thesis. Duplicated material includes information on 
study settings, experimental methods and clinical procedures. The research papers are 
not presented in the chronological order of publication, but rather in the order in which 
research objectives are listed above. 
Chapter 1 is the thesis background. It presents literature on the burden of allergy-related 
outcomes in the tropics, the helminth-allergen interaction and similarities in the immune 
responses associated helminth infections and allergy, current understanding of 
hypothesised mechanisms of inverse and positive helminth-allergy associations and the 
potential role of helminth and allergen protein- and carbohydrate-specific antibodies in 
epidemiological trends of allergy. This section also touches upon current understanding 
of the interaction between the rural-urban environment and helminth infection exposure 
2.3 Thesis objectives
2.4 Thesis structure
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 and how this may influence the epidemiology of allergy in the tropics. Finally, the scope 
of this PhD thesis is given. 
Chapter 2 describes the general hypothesis, thesis objectives and the thesis structure. 
Chapter 3 provides a detailed account of the study design, study setting, relevant clinical 
procedures and experimental methods. 
Chapter 4 (Research Paper 1)3 is the first results chapter, and presents findings from 
cross-sectional analyses of epidemiological and immunological risk factors for atopy and 
clinical allergy outcomes in urban and rural Uganda. This chapter further assesses to 
what extent helminth infections contribute to rural-urban differences in these risk factors, 
in Uganda. 
Chapter 5 (Research Paper 2) describes total, allergen- and S. mansoni-specific IgE 
and IgG4 profiles, and their relationship with S. mansoni infection status, atopic 
sensitisation and clinical allergy in a rural setting with high prevalence of S. mansoni 
infection.4 Although the focus of this thesis is antibodies, this paper also describes 
associations between S. mansoni-specific cytokine profiles and allergy-related 
outcomes, giving a more complete picture of the association between S. mansoni-
specific immune responses and allergy in Uganda. 
Chapter 6 (Research Paper 3) describes population-level antibody responses to key 
components of the schistosome glycome: core -1,2-xylose and -1,3-fucose 
substituted N-glycans.5 This chapter highlights rural-urban differences in these 
responses, describes their relationship with S. mansoni infection and intensity and 
discusses their relevance to diagnostics, cross-reactivity and associations with 
protective immunity against S. mansoni. 
Chapter 7 (Research Paper 4) assesses associations between IgE reactivity to cross-
reactive carbohydrate determinant (CCD) N-glycan epitopes (core -1,2-xylose and/or 
-1,3-fucose, introduced in Chapter 6) and allergic sensitisation and disease.  
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 Chapter 8 discusses the main findings from this PhD project, and provides an account 
of study strengths, limitations and implications. The conclusion and recommendations 
for further research are also included in this chapter. 
Appendices are included after Chapter 8. Appendix 1 is a published narrative literature 
review (Research Paper 5)6 of the benefits and potential detrimental effects of mass 
anthelminthic treatment with regard to responses to vaccines and unrelated diseases 
(such as allergies). Appendix 2 is an original article (Research paper 6)7 describing 
epidemiological associations between helminth infections and allergy-related outcomes 
in the Lake Victoria fishing communities, Uganda, prior to community-wide intensive 
versus standard anthelminthic treatment. Appendix 3 is also an original article 
(Research Paper 7)8 describing an assessment of the impact of community-wide 
intensive versus standard anthelminthic treatment on allergy-related outcomes, helminth 
infection intensity, and helminth-related morbidity in Lake Victoria fishing communities, 
Uganda. Appendix 4 includes copies of ethical approvals. 
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	CHAPTER 3. MATERIALS AND METHODS 
3.1 Preamble 
This chapter provides an overview of context and methods for the work conducted during 
this PhD research. Methods are further summarised in the individual Research Papers.  
3.2 Study design and population 
Most of the data presented in this PhD thesis were obtained using samples from 
participants of three cross-sectional surveys in two proximate settings in Uganda, one 
characterised as rural and the other as urban. The first two surveys were 1) the baseline 
and 2) the allergy outcomes survey of a cluster-randomised trial of community-wide 
intensive versus standard anthelminthic treatment in helminth-endemic Ugandan fishing 
villages. The third survey was a parallel survey of allergy outcomes in proximate urban 
communities with lower helminth exposure. Chapter 5 (Table E5) and Chapter 7 further 
include data from samples obtained from a case-control study among asthmatic children 
and non-asthmatic controls from urban and peri-urban schools in Uganda. These studies 
were part of a portfolio of work on the prevalence, phenotypes and risk factors for allergy-
related outcomes in Uganda, and are described below. 
3.2.1 The LaVIISWA trial   
Residents of 26 fishing villages in the islands of Koome sub-county (Lake Victoria, 
Mukono district, Uganda, Figure 3.1, below) were invited to participate in the Lake 
Victoria Island Intervention Study on Worms and Allergy-related diseases (LaVIISWA; 
ISRCTN47196031, described below and in Appendices 2 and 3 in more detail).1 Koome 
sub-county had a population of 18,778 in 2014, according to the Uganda National 
Population and Housing Census report2. The living conditions in Koome islands are 
characterised by poor housing and sanitation (Figure 3.2, below), and lack of access to 
treated water. Helminth prevalence is very high: up to 85% of individuals living in the 
fishing villages in 2016 were infected with Schistosoma mansoni (based on the urine test 
for circulating cathodic antigen, CCA) and 9% with hookworm (based on PCR detection 
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	of helminth DNA from eggs in stool).3   
 
Figure 3.1. Entebbe peninsula and Koome islands. White dotted demarcation on the Entebbe 
peninsula denotes the boundary of the municipality. Circular features on Koome islands denote fishing 
villages. White circles represent villages that received community-based standard anthelminthic 
treatment, red circles represent villages that received intensive treatment and the yellow circle represents 
the village where the LaVIISWA pilot study was conducted. 
 
The LaVIISWA trial1 was conducted between September 2012 – August 2016. It was an 
open, cluster-randomised trial of mass intensive versus standard anthelminthic 
treatment. Twenty-six villages were randomised 1:1 to receive either intensive or 
standard intervention. Intensive intervention was quarterly single-dose praziquantel 
(40mg/kg, estimated using an extended height pole to include younger children) and 
quarterly triple-dose albendazole (400mg daily, three days) to all individuals that were 
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	one year or older. Standard intervention was annual single-dose praziquantel (40mg/kg, 
estimated using a standard height pole), and six-monthly single-dose albendazole 
400mg to all individuals that were one year or older. There was no follow-up of individual 
participants, as the study did not include a cohort of individuals. This trial was the first of 
its kind, and hence provided the first opportunity for population-level evaluation of 
changes (in antibody profiles) induced by such intervention. A detailed description of the 
LaVIISWA trial, including study design and setting, randomisation procedures, 
interventions, surveys and outcomes has been published, and is included in this PhD 
thesis as Research Paper 7 (Appendix 3).  
LaVIISWA data used in this PhD Research were obtained during two cross-sectional 
surveys. A baseline household survey (October 2012 – July 2013) was conducted before 
the first round of the trial intervention: epidemiological associations between helminth 
infections and allergy-related outcomes are reported in Research paper 6 (Appendix 2, 
this thesis). Chapter 5 (Research Paper 2) presents results (on total, allergen- and S. 
mansoni-specific IgE and IgG4 profiles) obtained from samples collected during the 
baseline survey.  
After three years of the trial intervention, an allergy outcomes survey (September 2015 
– August 2016) was conducted. Before this survey, a census of households in each 
village was done. Seventy households per village were then randomly selected for the 
survey, using a Stata program (College Station, Texas). Household members aged ≥ 
one year were invited to participate. Permission for household participation was granted 
by the household head, or another adult, if the former was absent. Results from the 
outcome survey indicated that intensive versus standard anthelminthic treatment 
reduced hookworm prevalence and S. mansoni infection intensity, but had no effect on 
the overall prevalence of other nematodes and S. mansoni, or allergy-related outcomes 
(Research Paper 7, Appendix 3). Furthermore, there was no evidence of an effect of 
treatment arm on most laboratory outcomes (Table E1, Chapter 5). Therefore, 
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	Chapters 4, 6 and 7 (this thesis) which present results from the ‘rural survey’ have used 
data combined from both trial arms of the LaVIISWA outcome survey. 
3.2.2 The urban survey  
Urban participants were residents of Entebbe Municipality, a lower helminth exposure 
area situated on the northern shores of Lake Victoria (Figure 3.1, above), 40 km 
southwest of the Ugandan capital, Kampala, and 35km (two to three hours by powered 
canoe) from Koome islands. The municipality has different living conditions from Koome 
islands. It is characterised by better housing and sanitation (Figure 3.2, below), and 
access to treated water. The municipality had approximately 69,430 inhabitants in 2014,2 
distributed across two municipality divisions, A and B. Each division comprises two 
wards that are further subdivided into sub-wards. The municipality has a total of 24 sub-
wards, which are its smallest administrative units. 
The urban survey of allergy-related outcomes (September 2016 – September 2017) was 
designed to compare findings with those from the aforementioned high-helminth-
transmission rural surveys. The urban survey was designed in such a way that 
procedures used (including laboratory methods) were identical to those used in the rural 
LaVIISWA outcome survey; the main difference in study design was the lack of 
randomisation to intensive versus standard mass anthelminthic treatment in the urban 
survey. The sampling strategy (described below) was also different, as it was not feasible 
to map and enumerate all households in Entebbe.  
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Figure 3.2. Pictorial representation of living conditions in Koome sub-county and Entebbe Municipality.  
A) Photographs of Koome fishing villages. From left to right: Mwooma and Kitosi villages and an aerial view of Myende fishing village.  
B) Photographs taken in Entebbe municipality. From left to right: Street view of Entebbe town (Post Office sub-ward), residences in Bugonga sub-ward and an aerial view of Katabi 
ward 
Sources: Photographs of Mwooma and Kitosi villages were kindly provided by Prof. Alison Elliott, MRC/UVRI and LSHTM Uganda Research Unit. The aerial view of Myende 
village was taken by Prof. Russell Stothard, from the Liverpool School of Tropical Medicine, and is reused with permission. The satellite image of Katabi ward was obtained from 
Google maps. 
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 Before the start of the survey, each sub-ward was mapped onto satellite images of 
Entebbe municipality with the help of locally available maps. A random point generation 
function of ArcGIS software (version 10.4.1, Environmental Systems Research Institute, 
Redlands, CA) was then used to generate random starting points within each sub-ward. 
The number of starting points selected was proportional to the population size of the sub-
ward. Coordinates of the random starting points generated were loaded onto geographic 
information system (GIS) devices (eTrex®, Garmin™ Ltd, Olathe, KS). These devices 
were then used in the field to identify the selected random points, from which the nearest 
four houses were surveyed. 
 The asthma case-control study  
The asthma study (May 2015 – July 2017) enrolled 5-17-year-old asthmatics and non-
asthmatic controls from primary and secondary schools in Entebbe municipality and the 
surrounding peri-urban and urban areas in Wakiso District in central Uganda. Asthma 
was defined as a history of wheeze in the last 12 months, according to the International 
Study on Allergy and Asthma in Children (ISAAC) paper and video questionnaires. All 
children without a history of wheezing (ever) were eligible as controls for the study, 
provided that they were on the same class register as cases. For each class, a Stata 
programme and the class register were used to randomly select participants such that 
the number of controls was twice the number of cases. Procedures in the asthma study 
were also designed to be identical to those used in the rural and urban surveys. 
   
 Kato-Katz 
The Kato-Katz technique4 was used for qualitative and semi-quantitative diagnosis of 
Schistosoma mansoni infection and intestinal helminth infections caused by hookworm, 
Ascaris lumbricoides and Trichuris trichiura. The technique was conducted on one stool 
sample per participant, prepared as a 41.7 mg thick smear on two slides. Each slide was 
3.2.3
3.3 Parasitological examinations
3.3.1
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	examined under a microscope by different laboratory technologists who were blinded to 
each other’s readings. Results were presented as eggs per gram of stool (epg). 
Schistosoma mansoni infection (Kato-Katz) intensities were categorised according to 
World Health Organisation (WHO) guidelines as follows: light infection 1–99 epg, 
moderate infection 100–399 epg and heavy infection ≥400 epg.  
3.3.2 Detection of helminth DNA in stool 
3.3.2.1 DNA extraction 
The remaining stool sample was stored (suspended in ethanol and frozen at -80oC) and 
later had total DNA (and hence helminth DNA, if present) extracted using the QIAamp 
DNA Mini Kit (catalogue number 51306, QIAGEN) for determination (using multiplex 
real-time PCR) of S. mansoni, Strongyloides stercoralis and hookworm (Necator 
americanus) infections. 
The DNA extraction procedure was conducted with minor changes to the manufacturer’s 
instructions as follows: samples were left to thaw at room temperature (RT) and then 
vortexed for five seconds to homogenise the ethanol-stool mixture. The homogenized 
mixture (0.5 ml) was transferred into a safe-lock microcentrifuge (Eppendorf®) tube and 
centrifuged at 13000 rpm for 3 minutes to get rid of the ethanol. The pellet was re-
suspended in 200 μl of 1X phosphate buffered saline (PBS) containing 2% 
polyvinylpolypyrrolidone (PVPP) (77627, Fluka analytical, Sigma-Aldrich) and frozen 
overnight at -20°C. The stool suspension was heated at 100°C for 10 minutes, 200 µl of 
the QIAGEN tissue lysis buffer (ATL) and proteinase K mixture (9 to 1 ratio) added, and 
samples vortexed and incubated for two hours or overnight at 55°C in a heat block. The 
QIAGEN AL Buffer (400 μl) was then added, mixed thoroughly with the sample by 
vortexing and the mixture incubated at 70°C for 10 minutes. This was followed by 
centrifugation for one minute at 13000 rpm and transfer of the supernatant to 400 μl of 
ethanol (96-100%). The DNA was then purified in QIAamp spin columns using 
consecutive washes with QIAGEN AW1 (500 μl) and AW2 (500 μl) buffers. The QIAGEN 
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	AE buffer (200 μl) was used to elute the DNA. The DNA was quantified on a NanoDrop™ 
2000c spectrophotometer (Thermo Fisher Scientific) and then diluted to 50ng/µl. 
3.3.2.2 Multiplex real-time PCR 
The multiplex real-time PCR was adapted from existing procedures,5,6 and is detailed in 
this section. Below are the specific forward (F) and reverse (R) primers and TaqMan® 
probes that were used to simultaneously detect DNA from three helminth species:  
Necator americanus 
Na58F:  5’-CTGTTTGTCGAACGGTACTTGC-3’ 
Na158R:   5’-ATAACAGCGTGCACATGTTGC-3’ 
Na81MGB:   FAM-5’-CTGTACTACGCATTGTATAC-3’-BHQ1 
Schistosoma mansoni 
Ssp48F:  5’-GGTCTAGATGACTTGATYGAGATGCT-3’ 
Ssp124R:  5’-TCCCGAGCGYGTATAATGTCATTA-3’ 
Ssp78T-RT:  Texas Red-5’-TGGGTTGTGCTCGAGTCGTGGC-3’-BHQ2 
Strongyloides stercoralis  
Stro18S-1530F: 5’-GAATTCCAAGTAAACGTAAGTCATTAGC-3’ 
Stro18S-1630R: 5’-TGCCTCTGGATATTGCTCAGTTC-3’  
Stro18S-1586T: NED-5’-ACACACCGGCCGTCGCTGC-3’-BHQ1 
Phocine herpes virus (PhHV) DNA, extracted from the Phocine herpes virus (kindly 
provided by Dr. Martin Schutten, Erasmus Medical Center, Rotterdam, the Netherlands), 
was included in the PCR master mix, thus distributed to all reaction wells as an internal 
control to check for PCR inhibition. The PhHV forward primer PhHV-267s (5’-
GGGCGAATCACAGATTGAATC-3’), reverse primer PhHV-337as (5’-
GCGGTTCCAAACGTACCAA-3’) and probe PhHV-305tq (Cy5-5’-
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	TTTTTATGTGTCCGCCACCATCTGGATC-3’-BHQ2) were used for Phocin herpes virus 
DNA detection. A positive pool was included on the plate for every run as a test control. 
The positive pool was made up of a mixture of DNA from samples (from among the study 
samples) that were highly positive for S. mansoni and N. americanus on Kato-Katz, and 
DNA positive for S. stercoralis (kindly provided by Dr. Jaco J. Verweij, St. Elisabeth 
Hospital, Tilburg, the Netherlands). The amplification conditions were 10 minutes at 
95oC, 50 cycles of 15 seconds at 95oC, 30s at 60oC and 30s at 72oC. DNA amplification, 
detection and data analysis were attained with the ABI 7500 Fast Real time machine and 
7500 Fast systems software version 1.4.0. Quality control was conducted by Dr. Jaco J. 
Verweij, using a small subset of DNA samples. 
3.3.3 Assessment of circulating cathodic antigen of S. mansoni in urine 
The circulating cathodic antigen (CCA) of S. mansoni was assessed in mid-stream urine 
using a point-of-care test from Rapid Medical Diagnostics, South Africa 
(http://www.rapid-diagnostics.com). The CCA assays were performed according to the 
assay kit manufacturer's instructions. A result was considered invalid if the control band 
did not form. Valid results were presented as negative (no test band) or positive 
(irrespective of whether the test band was weak or strong).  
Schistosoma haematobium is not present in the areas where the studies were 
conducted.7  
3.4 Assessment of allergy-related outcomes 
The main allergy-related outcomes were recent (previous 12 months) self-reported 
wheeze (as a proxy for asthma), skin prick test (SPT) reactivity to common allergens in 
the study settings,8 and allergen-specific IgE (asIgE) sensitisation. Data were also 
obtained on visible flexural dermatitis, recent rhinitis and recent urticarial rash.  
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	3.4.1 Wheeze 
Standardised paper and video questionnaires about wheeze have been shown to have 
good validity for the diagnosis of asthma in epidemiological studies,9,10 and hence were 
used to obtain data on recent (previous 12 months) self-reported wheeze. These 
questionnaires were interviewer-administered, and used guidelines from ISAAC.11 
Wheeze was analysed separately for individuals below and above age five years. The 
principal age group of interest was ≥5 years because wheeze among children aged 
below five years does not necessarily represent asthma:12 it can be caused by conditions 
such as viral bronchiolitis.13  
3.4.2 Visible flexural dermatitis 
Visible flexural dermatitis, the classical physical sign of eczema, was assessed by 
interview using questions from the UK diagnostic criteria on atopic eczema, and by direct 
physical examination as described in Williams’ on-line manual.14 In brief, an individual 
was recorded as having dermatitis in case of an erythematous rash with surface change 
(vesicles, scaling, crusting, oozing, or lichenification) in and around skin creases (fronts 
of neck or ankles, folds of elbow, behind the knees), or among infants, on the cheeks, 
the trunk and the outer surface of the limbs.15,16  
3.4.3 Rhinitis and urticarial rash 
Data on rhinitis (runny/blocked nose or sneezing accompanied by watery and itchy eyes, 
in absence of a cold or ‘flu’) and urticarial rash (pruritic rash with elevated erythematous 
patches [wheals], known as ‘ebilogologo’ in the local Luganda language) were obtained 
using interviewer-administered questionnaires. 
3.4.4 Skin prick test reactivity 
Skin prick test reactivity to common environmental allergens in the study settings8 was 
assessed using standard procedures.17 The allergens assessed were 
Dermatophagoides mix, Blomia tropicalis and German cockroach (Blattella germanica) 
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	(ALK-Abelló; supplied by Laboratory Specialities [Pty] Ltd., South Africa). Individuals 
were considered reactive if they had a wheal ≥3mm in diameter, in presence of histamine 
(positive) and normal saline (negative) controls. Reactivity was analysed primarily as a 
positive SPT response to any of the three allergens versus no response to all three 
allergens. SPT reactivity was also assessed as a positive versus negative response to 
individual allergens.  
3.4.5 Measurement of total and allergen-specific IgE using the ImmunoCAP test 
The ImmunoCAPÒ test (Thermo Fisher Scientific, Uppsala, Sweden)18 was used to 
measure total and crude house dust mite (Dermatophagoides pteronyssinus), peanut 
(Arachis hypogaea), and German cockroach (Blatella germanica) extract-specific 
plasma IgE (asIgE) levels. The ImmunoCAP assay uses an automated system that loads 
serum / plasma on 1) a hydrophilic polymer sponge (the ‘ImmunoCAP’) covalently 
coupled to an allergen (for specific IgE measurement) or 2) an ImmunoCAP reaction 
vessel covalently coupled to an anti-IgE antibody (which reacts with total IgE in sample). 
Unbound IgE is washed off and a conjugate (anti-IgE antibody grafted with β-
galactosidase) is added. The supernatant is then aspirated, and a substrate (methyl-
umbelliferyl-β-D galactoside) deposited on the ImmunoCAP sponge. A stop solution is 
added and the sponge then compressed. The fluorescence generated by the resultant 
eluate, a product of enzyme degradation (methyl umbelliferone, proportional to 
concentration of IgE in serum/plasma), is measured. Results are reported quantitatively 
using a kU/L scale. The calibrator is IgE bound to anti-IgE caps using a six-point 
quantitative curve. Calibration concentration ranges from 0 to 100 kU/L for specific IgE 
and 2 to 5000 kU/L for total IgE.  
A cut-off of 0.35 kU/L was used to define allergen-specific IgE sensitisation to any of 
house dust mite, peanut or cockroach, as recommended by the test manufacturer.19 
Responses were also assessed as continuous outcomes and as positive (≥0.35 kU/L) 
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	versus negative for individual allergens. Total IgE was assessed as a continuous 
outcome.  
3.4.6 Measurement of allergen-specific IgE levels by ELISA 
Crude D. pteronyssinus- and B. germanica extract-specific IgE was measured using an 
in-house ELISA, as follows: all but the first 2 columns of MICROLON® high binding 96-
well plates (Greiner bio-one, UK) were coated with 50μl of D. pteronyssinus or B. 
germanica allergens (Greer Labs, Lenoir, NC, USA) at a concentration of 5μg/ml in in 
bicarbonate (Na2CO3 + NaHCO3) buffer (0.1M, pH 9.6). Two-fold dilutions of human IgE 
(Calbiochem, Beeston, UK) standard, diluted in bicarbonate buffer, were added to the 
first 2 columns of each plate to form standard curves. The plates were then incubated 
overnight at 4ºC. Plates were washed with phosphate-buffered saline (PBS)-Tween 20 
solution, blocked with 150μl of skimmed milk diluted in PBS-Tween 20 at room 
temperature (RT), and incubated overnight at 4ºC with 50μl of plasma samples diluted 
1/20 with 10% fetal bovine serum in PBS-Tween 20 (assay buffer). Plates were washed 
and antibody binding detected by incubating the plates overnight at 4ºC with 0.5μg/ml of 
biotinylated monoclonal mouse anti-human IgE (BD Pharmingen™), followed by a one-
hour incubation with a streptavidin-Horseradish Peroxidase (strep-HRP) conjugate (Mast 
Group Ltd, Bootle, UK), diluted 1/3000 with assay buffer, at RT. Plates were developed 
by addition of 100μl of o-phenylenediamine (Sigma-Aldrich) and reactions stopped with 
30μl of 2M Sulphuric acid. Optical density values were measured at 490nm (reference 
wavelength 630nm) on a 96-well plate ELISA reader. IgE concentrations (ng/ml) were 
interpolated from standard curves using a five-parameter curve fit using Gen5 data 
collection and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). 
This assay had a lower detection limit of 15.6 ng/ml (hence 312 ng/ml in undiluted 
samples). This cut-off was used to assess detectable (versus undetectable) responses 
to either D. pteronyssinus or B. germanica. Responses were also assessed as 
continuous outcomes. 
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	3.4.7 Component-resolved assessment of allergen-specific IgE sensitisation using 
the ISAC microarray 
The ImmunoCAPÒ ISAC (Immuno Solid-phase Allergen Chip) microarray was used to 
measure IgE to 112 natural and recombinant allergen components from 51 allergen 
sources. The ISAC array (Thermo Fisher Scientific, Uppsala, Sweden) is an in vitro semi-
quantitative multi-allergen screening assay used in component-resolved diagnosis of 
allergic sensitisation.20 The test manufacturer's instructions were followed. Briefly, 
ImmunoCAP ISAC sIgE 112 microarray chips were washed, air dried and then incubated 
with 30μl of undiluted participant plasma for two hours in a humidified chamber to enable 
reactions between IgE and allergen components. The chips were washed again, and 
incubated at room temperature for 30 minutes with 30μl of fluorescence-labelled anti-
human IgE detection antibody. After another washing step, the fluorescence intensity of 
each microarray was measured by a scanner (LuxScan 10K/A, CapitalBio, Beijing, 
China). Analysis of the digitalized images was done using Phadia Microarray Image 
Analysis software (Thermo Fisher Scientific). Results were reported in arbitrary semi-
quantitative ISAC Standardised Units (ISU).  
Participants were considered sensitised to an allergen component in case of an ISU 
measurement of 0.3 or higher, based on the test manufacturer’s recommendations.21  
Measurements were also reported as a detectable versus undetectable (lower detection 
limit was 0.06 ISU). 
3.5 Microarray detection of N-glycan-specific IgE and IgG  
Plasma IgE and IgG responses to 135 chemo-enzymatically synthesised N-glycans with 
and without core a-1,3-fucosylation and, or, b-1,2-xylosylation were assessed using a 
non-commercial microarray (Figure S1, Research Papers 3 and 4). The microarray 
slides were constructed by Dr Niels-Christian Reichardt’s glycotechnology laboratory at 
Centro de Investigación Cooperativa en Biomateriales (CIC biomaGUNE), in San 
Sebastián, Spain. The microarray construction procedures have been published.22,23 
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	Each microarray reaction site included fluorescently-labelled bovine serum albumin 
(BSA) as a printing control. The antibody binding assay was adapted from existing 
procedures,24-27 as follows: Nexterion H N-hydroxysuccinimide-coated microarray slides 
(Schott AG, Mainz, Germany) (pre-blocked for 1 hour with 50mM ethanolamine in 50mM 
sodium borate buffer pH 9.0, and stored at -20°C) were thawed at room temperature 
(RT) and covered with silicone gaskets to create seven wells with printed microarrays 
per slide. Each microarray was incubated with 300 μl of a 1:30 plasma dilution in 1% 
BSA - 0.01% Tween20 for one hour at RT while shaking. After sequential washes with 
PBS-0.05% Tween20 and PBS, the slides were incubated for 30 minutes at RT in the 
dark with PromoFluor 647-labelled anti-human IgE (diluted 1/150 in PBS-0.01% 
Tween20) and Cy3-labelled anti-human IgG (diluted 1/1000 in PBS-0.01% Tween20), 
while shaking. After a final wash with PBS-0.05% Tween20, PBS and deionised water, 
sequentially, the slides were dried and kept in the dark until scanning. The slides were 
scanned for fluorescence at a 10μm resolution with a G2565BA scanner (Agilent 
Technologies, CA, USA) using 633nm and 532nm lasers for detection of reactivity to 
glycan-specific IgE and IgG, respectively.  
3.5.1 Glycan microarray image processing and analysis of data 
Using GenePix Pro 7.0 software (Molecular Devices, CA, USA), a spot-finding algorithm 
was used to align and re-size fluorescence spots in the microarray images, without 
setting a composite pixel intensity threshold. Data on median fluorescence intensity 
(MFI) for each spot and the local background were then exported to Microsoft Excel 
software. In all analyses, MFIs that were highlighted as artefacts by the GenePix Pro 7.0 
software were excluded. Further processing of IgG MFIs in Excel was done based on 
procedures described by Oyelaran et al.28 as follows: for each spot, the MFI of the spot 
was subtracted from the local background MFI. For each glycan structure, the average 
over four spots (or fewer, in case of unreliable data that were excluded) was obtained. 
Any MFI values below 150 were set to 150 to reduce noise at the low end of the MFI 
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	range. Median values of negative controls included on each array were subtracted, and 
any negative values set to zero. Datasets were then log2-transformed to normalize the 
data. Further processing of IgE MFIs in Excel was done as described by Amoah et al.,24 
as follows: for each IgE spot, the ratio of the MFI of the spot to the local background MFI 
was obtained and then multiplied by the average of background MFI for all the spots on 
the array. For each of the structures, the average over four spots (or less, in case of 
unreliable data that were excluded) was then log2-transformed.  
3.6 Other experimental methods 
3.6.1 Allergen-specific IgG4 ELISA 
All but the first 2 columns of MICROLON® high binding 96-well plates (Greiner bio-one, 
UK) were coated with 50μl of D. pteronyssinus or B. germanica allergens (Greer Labs, 
Lenoir, NC, USA) at a concentration of 5μg/ml in bicarbonate (Na2CO3 + NaHCO3) buffer 
(0.1M, pH 9.6). Two-fold dilutions of human IgG4 (Sigma-Aldrich) standard, diluted in 
bicarbonate buffer, were added to the first 2 columns of each plate to form standard 
curves. The plates were then incubated overnight at 4ºC. Plates were washed with 
phosphate-buffered saline (PBS)-tween 20 solution, blocked with 150μl of skimmed milk 
diluted in PBS-Tween 20 at room temperature (RT), and incubated overnight at 4ºC with 
50μl of plasma samples diluted 1/40 with 10% fetal bovine serum in PBS-Tween 20 
(assay buffer). Plates were washed and antibody binding detected by incubating the 
plates overnight at 4ºC with 0.5μg/ml of biotinylated monoclonal mouse anti-human IgG4 
(BD Pharmingen™), followed by a one-hour incubation with a streptavidin-Horseradish 
Peroxidase (strep-HRP) conjugate (Mast Group Ltd, Bootle, UK), diluted 1/3000 with 
assay buffer, at RT. Plates were developed by addition of 100μl of o-phenylenediamine 
(Sigma-Aldrich) and reactions stopped with 30μl of 2M Sulphuric acid. Optical density 
values were measured at 490nm (reference wavelength 630nm) on a 96-well plate 
ELISA reader. IgG4 concentrations (ng/ml) were interpolated from standard curves using 
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	a five-parameter curve fit using Gen5 data collection and analysis software (BioTek 
Instruments Inc, Vermont, Winooski, USA). 
3.6.2 Total IgE ELISA 
96-well Maxisorp plates (VWR, U.S.A) were coated with 100μl of polyclonal rabbit anti 
human IgE (Agilent technologies, Dako, Denmark) diluted 1/1000 in bicarbonate buffer 
(0.1M, pH 9.6) and incubated overnight at 4ºC. Plates were then washed with phosphate-
buffered saline (PBS)-tween 20 solution and blocked with 120μl of PBS-bovine serum 
albumin (BSA) solution for 1 hour at room temperature (RT). Plasma samples (100μl) 
diluted 1/50 in assay buffer (0.1M Tris pH 7.5 + 0.05% Tween-20), the blank (assay 
buffer) and National Institute for Biological Standards and Control (NIBSC) international 
IgE standards were added to the plates and incubated for 1 hour at RT. Plates were then 
washed and incubated with 100μl of biotinylated goat anti-human IgE (Vector 
laboratories, U.S.A, 0.5mg/ml), diluted 1/1000 with assay buffer, for 1 hour at RT. After 
another washing step, the plates were incubated with 100μl of streptavidin alkaline 
phosphatase (Roche Life Science), diluted 1/3000 with assay buffer, for 30 minutes at 
RT. 4-nitrophenyl phosphate disodium salt hexahydrate (p-NPP), diluted in 
diethanolamine buffer (DEA, 0.1M), was added, followed by 20 minutes incubation at RT 
in the dark for development. Sodium hydroxide (3M, 100μl) was then added to stop the 
reaction. Plates were read at 405 nm using an ELISA reader. Results were interpolated 
from standard curves using a five-parameter curve fit using Gen5 data collection and 
analysis software (BioTek Instruments Inc, Vermont, Winooski, USA).  
3.6.3 Total IgG4 ELISA 
96-well Maxisorp plates (VWR, U.S.A) were coated with purified mouse anti-human IgG4 
(BD Pharmingen™) in bicarbonate buffer (0.1 M, pH 9.6) overnight at 4ºC, and blocked 
for one hour with 3% skimmed milk in 1X PBS at room temperature (RT). Plates were 
then incubated with plasma samples (diluted 1/800 in 0.1M Tris pH 7.5 + 0.05% Tween 
20) and IgG4 standards (Sigma Aldrich) for one hour. Antibody binding was detected by 
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	incubating the plates with mouse anti-human IgG4 conjugated to horseradish peroxidase 
(Invitrogen) for one hour, followed by a colour reaction with o-phenylenediamine (Sigma 
Aldrich). Reactions were stopped with 2M Sulphuric acid. Absorbance was measured at 
490nm (reference wavelength 630nm) on a 96-well plate ELISA reader. IgG4 
concentrations (ng/ml) were interpolated from standard curves using a five-parameter 
curve fit using Gen5 data collection and analysis software (BioTek Instruments Inc, 
Vermont, Winooski, USA). 
3.6.4 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgE and IgG4 ELISA 
All but the first 2 columns of 4HBX Immulon (Thermo Scientific, NY, USA) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Michael J Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer 
(0.1M, pH 9.6). Two-fold dilutions of human IgE (Calbiochem, Beeston, UK) or IgG4 
(Sigma-Aldrich) standard, diluted in bicarbonate buffer, were added to the first 2 columns 
of each plate to form standard curves. The plates were then incubated overnight at 40C. 
Plates were washed with phosphate-buffered saline (PBS 1X)-tween 20 solution, 
blocked with 150μl of 1% skimmed milk diluted in PBS-Tween 20 at room temperature 
(RT), and incubated overnight at 4ºC with 50μl of plasma samples diluted 1/20 (IgE 
assay) or 1/200 (IgG4 assay) with 0.1% skimmed milk in PBS-Tween 20 (assay buffer). 
Plates were washed and antibody binding detected by incubating the plates overnight at 
4ºC with 0.5μg/ml of biotinylated monoclonal mouse anti-human IgE or IgG4 (BD 
Pharmingen™). This was followed by a one-hour incubation with a streptavidin-
Horseradish Peroxidase (strep-HRP) conjugate (Mast Group Ltd, Bootle, UK), diluted 
1/4000 with assay buffer, at RT. Plates were developed by addition of 100μl of o-
phenylenediamine (Sigma-Aldrich) and reactions stopped after 30 minutes with 25μl of 
2M Sulphuric acid. Optical density values were measured at 490nm (reference 
wavelength 630nm) on a 96-well plate ELISA reader. IgE or IgG4 concentrations (ng/ml) 
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	were interpolated from standard curves using a five-parameter curve fit using Gen5 data 
collection and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). 
3.6.5 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgG ELISA 
All but the first 2 columns of 4HX Immulon (VWR, UK, Cat No 735-0465) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Michael J Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer 
(0.1M, pH 9.6). Two-fold dilutions of human IgG (Sigma-Aldrich), diluted in bicarbonate 
buffer, were added to the first 2 columns of each plate to form standard curves. The 
plates were then incubated overnight at 4ºC. Plates were washed with phosphate-
buffered saline (PBS)-Tween 20 solution, blocked with 150μl of 1% skimmed milk diluted 
in PBS-Tween 20 at room temperature (RT), and incubated overnight at 4ºC with 50μl 
of plasma samples diluted 1/3000 with 0.1% skimmed milk in PBS-Tween 20 (assay 
buffer). Plates were washed and antibody binding detected by incubating the plates for 
1 hour at RT with 0.5μg/ml of polyclonal rabbit anti- human IgG/HRP (Dako, Denmark). 
Plates were developed by addition of 100μl of o-phenylenediamine (Sigma-Aldrich) and 
reactions stopped after 30 minutes with 25μl of 2M Sulphuric acid. Optical density values 
were measured at 490nm (reference wavelength 630nm) on a 96-well plate ELISA 
reader. IgG concentrations (ng/ml) were interpolated from standard curves using a five-
parameter curve fit using Gen5 data collection and analysis software (BioTek 
Instruments Inc, Vermont, Winooski, USA). 
3.7 Selection of samples for antibody studies 
The flow chart for selection of samples for antibody studies is shown in Figure 3.3, 
below. 
In the rural (LaVIISWA outcome) survey, 2961 participants from the 26 study villages 
had a plasma sample stored and hence qualified to be selected for the ImmunoCAP IgE 
test. This test could not be conducted in all participants for cost reasons. Therefore, 780 
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	participants (30 per village) were randomly selected using Stata 13.1 software 
(StataCorp, College Station, Texas, U.S.A). The main LaVIISWA trial analysis aimed to 
compare outcomes between the two trial arms.1,3 A sample size of 780 was expected to 
give 80% power to detect a 35% relative difference in the prevalence of ImmunoCAP 
allergen-specific IgE sensitisation between the two trial arms, based on	an assumed 
overall allergen-specific IgE sensitisation prevalence of 50% (from results at baseline), 
and an estimated coefficient of variation (in IgE levels between clusters) of 0.2. Enzyme-
linked Immunosorbent Assays (ELISAs) for measurement of total, SWA-, SEA- and 
allergen-specific IgE and IgG4, and SWA- and SEA-specific IgG were conducted using 
the same 780 samples.  
Samples for the glycan and ISAC microarray experiments were randomly selected from 
among those with ImmunoCAP data. The aim was to assay 50 samples per trial arm 
(100 in total). A total of 209 (glycan array) and 126 samples (ISAC array experiments, 
respectively), equally distributed across trial arms, were eventually tested, owing to 
availability of further funding from the Royal Society of Tropical Medicine and Hygiene 
(RSTMH) and the European Academy of Allergy and Clinical Immunology (EAACI). 
Although the sample size was arbitrary, and largely determined by available resources, 
similar numbers have been shown to be useful in published studies that have assessed 
differences in microarray-assessed antibody levels between helminth infected and 
uninfected, and allergic and non-allergic individuals,24,29 and between children and 
adults.25  
In the urban survey, 1356 participants had a plasma sample stored. Of these samples, 
1345 had sufficient volume for antibody assays. All of these plasma samples were 
assessed by ELISA for total, SWA-, SEA- and allergen-specific IgE and IgG4, and SWA- 
and SEA-specific IgG. For reasons of cost, the ImmunoCAP IgE test could not be 
conducted in all these samples.  ImmunoCAP data on cockroach- and dust mite-specific 
IgE were available for 780 rural survey participants, hence calculations could be 
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	conducted to estimate how many urban survey plasma samples were required to attain 
significant differences in the prevalence of ImmunoCAP positivity between the urban and 
rural survey. Assuming a 35% prevalence of ImmunoCAP positivity to either cockroach 
or dust mite in the rural survey, 80% power, 5% significance level, and a design effect of 
1.3, 353 urban survey participants were estimated to be enough to detect an absolute 
difference in proportion positive of 0.10 between the rural and urban survey. The design 
effect was considered in the sample size calculations because data from both the rural 
and the urban survey were clustered (rural survey by village and household, urban 
survey by sampling area and household). By definition, the design effect is the ratio of 
the variance of estimates calculated from a cluster survey to the variance of estimates 
calculated under simple random sampling. Therefore, 353 plasma samples were 
randomly selected (using a Stata program) for the ImmunoCAP test; however, only 345 
of these samples were remaining with sufficient volume at the time of the assay and 
could be assessed. 
Urban survey samples for the glycan and ISAC microarray experiments were randomly 
selected from among those with ImmunoCAP data. The main aim was to conduct rural-
urban comparisons of antibody profiles. A sample size of 50 was deemed sufficient, 
based on previous studies doing similar comparisons.24 Eventually, the actual numbers 
of plasma samples that were assayed were 62 and 60 for the glycan and ISAC 
microarrays, respectively, to avoid wastage of unused microarray chips.   
In the asthma case-control study, 557 cases and 1128 controls had a plasma sample 
stored. For cost reasons, 400 participants (200 asthmatics and 200 controls) were 
randomly selected using Stata software. This number had 90% power to detect a 
significant positive association (at an odds ratio of 2) between asthma and ImmunoCAP 
positivity to any of dust mite, cockroach or peanut (IgE ≥0.35 kU/L), based on 5% 
significance level and an assumed prevalence of ImmunoCAP positivity of 55% among 
non-asthmatics (based on results from the urban survey). ELISA-based antibody studies 
84
	were conducted using the same samples. For glycan and ISAC microarray experiments, 
a sample size of 50 cases and 50 controls was deemed sufficient, based on numbers 
used in the rural and the urban survey. 
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	Figure 3.3. Flow chart for selection of samples for antibody studies 
 
 
RURAL (OUTCOME) SURVEY 
26 fishing villages in Koome sub-county 
7741 eligible households 
1820 households randomly selected (70 per village)  
1419 participating households 
 
3566 participating individuals 
2961 participants: blood plasma sample stored 
 
Random sample: glycan 
microarray (n=209) 
 
780 participants (randomly selected, 
approximately 30 per village): 
 
ImmunoCAP®: total and allergen-specific IgE 
test 
ELISA: total, SWA-, SEA- and allergen-specific 
IgE and IgG4 
ELISA: SWA- and SEA-specific IgG 
  
Random sample: ISAC 
microarray (n=126) 
 
URBAN SURVEY 
24 sub-wards in Entebbe municipality 
13421 eligible households 
420 households randomly selected for survey 
416 participating households 
1747 participating individuals 
1356 participants: blood plasma sample stored 
 
Random sample: glycan 
microarray (n=62) 
 
1345 participants: 
 
ELISA: total, SWA-, SEA- and allergen-specific 
IgE and IgG4 
ELISA: SWA- and SEA-specific IgG 
 
ISAC microarray (n=60) 
Insufficient sample 
volume (n=2) 
  
ASTHMA CASE-CONTROL STUDY 
1779 schoolchildren screened for eligibility as asthma 
cases or non-asthmatic controls 
562 cases & 1140 controls enrolled into the study  
557 cases, 1128 controls: plasma sample stored 
Random sample: glycan microarray 
(cases=50, controls=50) 
 
200 randomly selected cases & 200 
randomly selected controls: 
 
ImmunoCAP®: total and allergen-specific 
IgE test 
ELISA: total, SWA-, SEA- and allergen-
specific IgE and IgG4 
ELISA: SWA- and SEA-specific IgG 
 
ISAC microarray (cases=50, 
controls=50) 
345 participants (randomly selected): 
 
ImmunoCAP®: total and allergen-specific IgE 
test 
Insufficient sample 
volume (n=11) 
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 3.8 Data analysis 
Quantitative and qualitative data used in this PhD project were generated from 
questionnaires, standard clinical record forms (including clinical measurements and field 
laboratory measurements, such as parasite counts) and immunological assays. These data 
were entered using Microsoft Access and Excel. Information from questionnaires was also 
captured on ultra-mobile personal computers (UMPCs) and exported to database servers in 
Microsoft Access format. The data were then exported to Stata version 13.1 (StataCorp, 
College Station, Texas, USA), GraphPad Prism versions 6.0e and 7.0a (Fay Avenue, La 
Jolla, CA, USA) and R software (R foundation for Statistical Computing, Vienna, Austria) via 
the RStudio interface (version 1.1.383, RStudio, Inc. Boston, USA), for statistical analysis. 
Analysis of data generated during this PhD project is detailed in the Research Paper 
chapters in this thesis (Chapters 4 – 7) and in Appendix 3 (Research Paper 7). This section 
describes 1) approaches that were used for analysis of data while accounting for the cluster 
survey design of the rural and urban surveys, 2) how normal and skewed immunological 
data were handled, 3) correction for multiple testing and 4) techniques for reduction and 
subsequent analysis of antibody microarray data. 
3.8.1 Adjusting for survey design in the rural surveys and the urban survey 
The rural surveys were characterised by village-level cluster randomisation.1 For the 
outcome survey, initial analyses compared antibody profiles between standard and intensive 
trial intervention, using statistical methods that allowed for within-cluster correlations. 
Primary analyses were done at the cluster level; cluster-specific proportions (for binary 
outcomes) and means (for quantitative outcomes) were calculated and then compared 
between trial arms using t-tests. Adjusted analyses were performed to account for 
confounders that might not have been balanced by the randomisation procedures.  
As already mentioned, intensive versus standard treatment reduced hookworm prevalence 
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 and S. mansoni infection intensity, but it had no effect on the overall prevalence of other 
nematodes, S. mansoni, allergy-related outcomes (Appendix 3) or on most laboratory 
outcomes (this thesis). Therefore, several chapters in this thesis presenting results from the 
‘rural survey’ have used data combined from both trial arms of the LaVIISWA outcome 
survey. These analyses were primarily based on individual-level data and were conducted 
using “svy” survey commands in Stata to allow for the clustering of respondents within 
households and households within clusters. Sampling weights were calculated from the 
number of households in each cluster, to reflect the fact that households in smaller villages 
had a higher probability of selection than households in larger villages (since an equal 
number of households was selected from each village). These sampling weights were also 
employed in the analysis using the svy commands.  
In the urban survey, analysis methods accounted for clustering of respondents within 
households and households within sub-wards. The number of geographical segments 
selected for sampling was proportional to the population size of each sub-ward, hence the 
study design was considered self-weighting. Therefore, svy commands were used to allow 
for clustering within sub-wards but not for weighting.  
3.8.2 Distribution of antibody data 
Similar to most data generated from immunological assays,30 antibody data were 
predominantly right-skewed. Log transformations were applied to normalize the data. In 
some instances, the data maintained a skewed distribution after log transformation. The 
bootstrap resampling method31 is useful in analysis of skewed data without making any 
parametric assumptions; however, it is incompatible with svy commands in Stata and hence 
was not used in analysis of data in this project. Instead, where possible, non-parametric 
statistical tests (such as the Mann Whitney U test and the Kruskal-Wallis test) were 
employed. However, these tests cannot be used for multivariable analyses, hence 
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 regression analyses that assume parametric distributions were used. Of note, use of 
parametric tests to analyse skewed data may still provide approximately valid test statistics, 
provided sample sizes are large enough and the data are not severely skewed.30 
3.8.3 Correction for multiple testing 
Many of the microarray-determined anti-carbohydrate and anti-allergen antibody responses 
(Chapter 6 and Chapter 7) were strongly correlated. The commonly used Bonferroni 
correction for multiple testing would be a conservative approach to use with these data, 
because it assumes independence between tests and is prone to type II errors when the 
sample size is modest.32,33 Therefore, using Stata software, a Monte Carlo simulation 
approach34 based on 1000 permutations was adopted, to generate empirical p-values. An 
example of a Stata ‘do file’ used to perform permutation testing is shown in Appendix 5.  
Chapters 4 and 5 report a large number of statistical tests for associations between 
epidemiological / immunological outcomes and helminth infections and allergy-related 
outcomes. Here, multiplicity was not formally adjusted for; instead, the focus was on patterns 
of association and consistency of results, and on biological plausibility with reference to 
other published findings. 
3.8.4 Anti-glycan antibody responses: data reduction procedures 
Principal component analysis (PCA) was run in Stata as a data reduction technique to 
transform groups of correlated anti-glycan responses into fewer, uncorrelated artificial 
variables (principal components, PCs). Crude and adjusted associations between PC 
scores and various comparison groups were assessed using survey design-based linear 
regression. Another data reduction technique was hierarchical clustering analysis (HCA, 
complete linkage using Euclidean distance), conducted in R to identify homogeneous sets 
of N-glycan-specific responses. The resultant response clusters were assessed for 
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 associations with comparison groups of interest using the global test35,36 executed in R using 
the Globaltest package (version 5.33.0). 
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 CHAPTER 4. URBAN-RURAL DIFFERENCES IN RISK FACTORS FOR ALLERGY-
RELATED OUTCOMES IN UGANDA: A ROLE FOR HELMINTHS? 
4.1 Preamble 
This chapter uses questionnaire, clinical and laboratory data from the LaVIISWA outcome 
survey (hereinafter “rural survey”) and the urban survey (both described in Chapter 3) to 
investigate the extent to which helminth exposure influences rural-urban differences in 
prevalence of allergy-related outcomes, and in epidemiological and immunological risk 
factors for these outcomes (thesis objective 1). Results are presented in Research paper 
1, which is titled “Do helminth infections underpin urban-rural differences in risk factors for 
allergy-related outcomes?”, and which has been published as an original article in Clinical 
and Experimental Allergy.  
Urban-rural differences in 1) prevalence of allergy-related outcomes, helminth infections and 
helminth-specific antibody concentrations, and 2) epidemiological and immunological 
(schistosome-specific antibodies) risk factors for allergy-related outcomes, are shown. 
Importantly, this chapter assesses whether helminth (S. mansoni) infections are effect 
modifiers of associations between the above-mentioned risk factors and allergy-related 
outcomes, and whether they were likely to mediate the differences seen between the urban 
and the rural settings. These analyses lay the foundation for the overarching aim of this 
thesis, which is to understand how helminth- and allergen-specific antibody profiles relate to 
epidemiological trends of allergy in rural and urban Uganda (assessed in more detail in the 
next chapters). 
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 4.2 Research paper 1: Do helminth infections underpin urban-rural differences in 
risk factors for allergy-related outcomes? 
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Summary
Background: It is proposed that helminth exposure protects against allergy‐related
disease, by mechanisms that include disconnecting risk factors (such as atopy) from
effector responses.
Objective: We aimed to assess how helminth exposure influences rural‐urban differ-
ences in risk factors for allergy‐related outcomes in tropical low‐ and middle‐income
countries.
Methods: In cross‐sectional surveys in Ugandan rural Schistosoma mansoni (Sm)‐
endemic islands, and in nearby mainland urban communities with lower helminth
exposure, we assessed risk factors for atopy (allergen‐specific skin prick test [SPT]
reactivity and IgE [asIgE] sensitization) and clinical allergy‐related outcomes (wheeze,
urticaria, rhinitis and visible flexural dermatitis), and effect modification by Sm
exposure.
Results: Dermatitis and SPT reactivity were more prevalent among urban partici-
pants, urticaria and asIgE sensitization among rural participants. Pairwise associations
between clinical outcomes, and between atopy and clinical outcomes, were stronger
in the urban survey. In the rural survey, SPT positivity was inversely associated with
bathing in lakewater, Schistosoma-specific IgG4 and Sm infection. In the urban sur-
vey, SPT positivity was positively associated with age, non‐Ugandan maternal tribe,
being born in a city/town, BCG scar and light Sm infection. Setting (rural vs urban)
was an effect modifier for risk factors including Sm- and Schistosoma-specific IgG4.
In both surveys, the dominant risk factors for asIgE sensitization were Schistosoma‐
specific antibody levels and helminth infections. Handwashing and recent malaria
treatment reduced odds of asIgE sensitization among rural but not urban partici-
pants. Risk factors for clinical outcomes also differed by setting. Despite suggestive
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trends, we did not find sufficient evidence to conclude that helminth (Sm) exposure
explained rural‐urban differences in risk factors.
Conclusions and clinical relevance: Risk factors for allergy‐related outcomes differ
between rural and urban communities in Uganda but helminth exposure is unlikely
to be the sole mechanism of the observed effect modification between the two set-
tings. Other environmental exposures may contribute significantly.
K E YWORD S
allergy, effect modification, helminths, risk factors, Uganda, urban-rural
1 | INTRODUCTION
Advances in health and hygiene practices have transformed high‐
income countries into “cleaner” environments, with reduced infection
exposure. Consequently, homeostatic immunomodulatory effects of
exposure to microbes and parasites that co‐evolved with mammalian
species (the “old friends hypothesis”) have been lost.1 The surge in
allergy‐related diseases alongside other chronic inflammatory dis-
eases in high‐income countries over recent decades has been partly
attributed to this phenomenon.2 Although other environmental expo-
sures3 may contribute, substantial support for the “old friends
hypothesis” comes from studies in high‐income countries,4-9 which
show that traditional farming and related microbial exposures10 are
associated with protection against allergy‐related diseases. Additional
evidence suggests a parallel relationship between ongoing urbaniza-
tion and increasing allergy‐related disease prevalence in tropical low‐
and middle‐income countries (LMICs).11,12
Akin to farming environments in high‐income countries, rural
LMIC settings are relatively protected against allergy‐related dis-
eases.13-17 Animal models and in vitro experiments in human sam-
ples have identified helminths as potent inhibitors of allergic
reactions,18-20 leading to the hypothesis that they are partly respon-
sible for the low overall prevalence of allergy‐related diseases in
tropical LMICs and the observed rural‐urban disparities in allergy‐
related disease prevalence in the same settings.16,21 Helminths may
dissociate risk factors, such as atopy, from allergy‐related disease:
work in Ugandan children showing that hookworm infection dissoci-
ates allergen‐specific IgE from the effector phase of the allergic
response22 is strongly suggestive. However, little comparative analy-
sis of risk factors for allergy in rural vs urban LMIC settings has been
ological transition is ongoing, provides an unprecedented opportunity
to better understand interactions between the environment and the
allergic pathway and allergy‐related disease outcomes.
Using data generated from two surveys in Uganda, one in rural
helminth‐endemic Lake Victoria island fishing villages and another in
nearby mainland urban communities with lower helminth exposure,
we investigated socio‐demographic, behavioural, clinical and
immunological characteristics as risk factors for allergy‐related out-
comes and assessed whether helminth infections contribute to rural‐
urban differences in these risk factors.
2 | METHODS
2.1 | Study settings and procedures
Rural participants were residents of 26 helminth‐endemic fishing vil-
lages of Koome islands, Mukono district, Uganda (population 18 778
in 201423). Urban participants were residents of Entebbe Municipal-
ity, a lower helminth exposure area situated on the northern shores
of Lake Victoria, 40 km southwest of the Ugandan capital, Kampala,
and 35 km from Koome. The municipality had approximately 69 430
inhabitants in 2014,23 distributed across 24 sub‐wards, the smallest
administrative units.
The “rural survey” was part of the Lake Victoria Island Interven-
tion Study on Worms and Allergy‐related diseases (LaVIISWA;
ISRCTN47196031), a cluster‐randomized trial of standard vs inten-
sive anthelminthic intervention, described elsewhere.24,25 A baseline
household survey preceded the trial intervention; helminth‐allergy
associations at baseline have been reported.24 A household‐based
2 | NKURUNUNGI ET AL.
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allergy outcomes survey (the “rural survey”) was conducted between
September 2015 and August 2016, following 3 years of anthel-
minthic intervention: there was no difference in the prevalence of
allergy outcomes between the two trial arms.26 Sampling for the sur-
vey involved random selection of 70 households from each village
using a Stata program. All household members (1 year and older) of
selected households were then invited to participate. Permission for
household participation was granted by the household head.
The urban survey of allergy‐related outcomes (September 2016–
September 2017) was designed intentionally to collect data from
Entebbe municipality for comparison with the helminth‐endemic
rural survey. Before the start of the survey, each sub‐ward was
mapped onto satellite imagery of the municipality. A random point
generation function of ArcGIS software (version 10.4.1, Environmen-
tal Systems Research Institute, Redlands, CA) was then used to gen-
erate random starting points within each sub‐ward. The number of
starting points selected was proportional to the population size of
the sub‐ward. Coordinates of the random starting points generated
were loaded onto geographic information system (GIS) devices
(eTrex®, Garmin™ Ltd, Olathe, KS). These devices were then used in
the field to identify the selected random points, from which the
nearest four houses were surveyed.
There was no randomization to intensive or standard anthel-
minthic treatment in the urban survey; however, all other procedures
were designed to be identical in both the urban and the rural survey.
Following written informed consent and assent, questionnaires
were completed for each participant, capturing socio‐demographic,
clinical and behavioural characteristics as well as asthma, eczema
and allergy symptoms. The latter employed questions based on the
International Study on Allergy and Asthma in Children (ISAAC)
questionnaire. Blood, stool and mid‐stream urine were collected.
Blood samples were used for haemo‐parasitology, HIV serology and
storage of plasma and cells for immunoassays. One stool sample
per participant was examined for intestinal helminth infections
using the Kato‐Katz method27 (two slides, read by different tech-
nologists). The remaining sample was stored and later investigated
for Schistosoma mansoni (Sm), Strongyloides stercoralis and hook-
worm (Necator americanus) infections using multiplex real‐time
PCR.28,29 Urine was assessed for Sm circulating cathodic antigen
(CCA, Rapid Medical Diagnostics, Pretoria, South Africa). Schisto-
soma egg [SEA]‐ and adult worm [SWA] antigen‐specific
immunoglobulin (Ig)E, IgG4 and IgG levels were assessed in plasma
using in‐house ELISAs (Data S1).
Ethics committees of Uganda Virus Research Institute (refs: GC/
127/12/05/03 and GC/127/16/02/547) and London School of
Hygiene and Tropical Medicine, (refs: 6187 and 10709) and the
Uganda National Council for Science and Technology (ref: HS1183
and HS2036) approved both surveys.
2.2 | Allergy‐related outcomes
Outcomes were skin prick test (SPT) reactivity to allergens common
in our setting,30 allergen‐specific IgE (asIgE) sensitization, self‐
reported recent (previous 12 months) wheeze, recent rhinitis, recent
urticarial rash and visible flexural dermatitis.
Skin prick test reactivity (wheal ≥3 mm diameter after 15 min-
utes in the presence of saline [negative] and histamine [positive]
controls) to dust mites (Dermatophagoides mix, Blomia tropicalis) and
German cockroach (Blattella germanica) (ALK‐Abelló; supplied by
Laboratory Specialities [Pty] Ltd., Randburg, South Africa) was
F IGURE 1 Study flowchart
NKURUNUNGI ET AL. | 3
100
assessed using standard procedures.31 SPT reactivity was defined
primarily as a positive response to any of the three allergens. SPT
reactivity was also analysed as a positive vs negative response to
individual allergens.
Whole allergen (Dermatophagoides pteronyssinus, peanut [A hy-
pogaea] and B germanica) extract‐specific plasma IgE (asIgE) was
measured by ImmunoCAP® (ThermoFisher Scientific, Uppsala, Swe-
den) in a sample of 780 and 345 rural and urban survey participants,
respectively, randomly selected from those with sufficient volume of
stored plasma. Allergen‐specific IgE sensitization was defined as a
positive ImmunoCAP response (IgE concentration ≥0.35kU/L) to any
of the three allergens and as a positive vs negative ImmunoCAP
response for individual allergens. ImmunoCAP IgE outcomes were
also analysed as continuous variables.
Wheeze is considered a good proxy for asthma in epidemiological
studies32 and was assessed separately in two age groups (≥5 years
and <5 years) using an interviewer‐administered ISAAC questionnaire.
The principal age group of interest was ≥5 years because wheeze can-
not be assumed to represent asthma in children below 5 years.33
Data on recent rhinitis (runny/blocked nose or sneezing accom-
panied by watery and itchy eyes, in the absence of cold or “flu”) and
urticarial rash (pruritic rash with weals, known as “ebilogologo” in
the local language [Luganda]) were obtained by questionnaire. Visible
flexural dermatitis was assessed (by staff trained on Williams’ online
manual34) as an erythematous rash with surface change in and
around skin creases.35,36
2.3 | Statistical methods
Data analysis was conducted using Stata 13.1 (College Station, TX).
The following were assessed as potential risk factors for allergy‐
related outcomes: socio‐demographic characteristics (age, sex, pres-
ence of older/younger siblings, maternal tribe, paternal tribe, location
of birth and occupation), behavioural characteristics (frequency of
lake contact, type of bathing water, handwashing behaviour, foot-
wear outside the house, smoking and alcohol use), clinical character-
istics (helminth infections, exposure to anthelminthic treatment in
utero, anthelminthic treatment in last 12 months, parental history of
allergies, BCG scar, immunisation history, malaria treatment in last
12 months, malaria infection and HIV infection) and immunological
characteristics (plasma SEA‐ and SWA‐specific IgE, IgG4 and IgG
levels). Additionally, allergy‐related outcomes were independently
assessed as risk factors for each other.
Stata “svy” commands were used to allow for clustering of par-
ticipants within villages and for the non‐self‐weighting design of the
rural survey24 and for clustering by sub‐ward in the urban survey.
Logistic regression was used to compare the prevalence of out-
comes and other characteristics between the rural and urban survey
and to assess associations between each pair of allergy‐related out-
comes in both surveys. Population attributable fractions (PAFs) for
pairs of allergy‐related outcomes were calculated. Interaction tests
were done to assess whether these associations differed by setting.
Unadjusted and adjusted odds ratios (OR) for associations between
exposures and allergy‐related outcomes were estimated using uni-
variable and multivariable logistic regression. Additionally, linear
regression was used in secondary analyses of ImmunoCAP IgE out-
comes as continuous variables. Age, sex (a priori) and factors show-
ing evidence of crude association with an outcome (P < 0.05) were
considered in multivariable analyses for that outcome. We hypothe-
sized that helminth infections might be key mediating factors on the
causal pathway between urban/rural residence and allergy‐related
outcomes; hence, helminths (and Sm-specific antibody responses and
other “helminth‐related” factors such as frequency of lake contact
and occupation) were not included in multivariable analyses for other
risk factors. The potential mediating role of helminths was then
investigated separately by assessing whether associations between
non‐helminth‐related risk factors and allergy‐related outcomes chan-
ged substantially when adjusted for Sm infections and Schistosoma‐
specific antibody levels. These analyses were initially conducted
separately for each survey. Subsequently, we merged data from the
two surveys and tested for interaction between the rural and urban
survey, to assess whether risk factors for allergy outcomes differed
by setting. Here, we also assessed the potential role of helminths in
urban‐rural interactions by comparing interaction P values before
and after adjusting for Sm infection. A 5% significance level was
used for all analyses.
3 | RESULTS
3.1 | Participants’ characteristics
Flowcharts of the surveys are shown in Figure 1. Of 1820 house-
holds randomly selected for the rural survey (70 from each of the 26
villages), 1419 (78%) took part. There were 3566 individuals inhabit-
ing the 1419 participating households; 3323 (93.2%) were inter-
viewed and 3346 (93.8%) had data on at least one allergy‐related
outcome. Of 420 households randomly selected for the urban sur-
vey, 416 (99%) took part. There were 1747 individuals inhabiting the
416 households; 1339 (77%) were interviewed and 1523 (87%) had
data on at least one allergy‐related outcome.
Participant characteristics differed between the two study set-
tings (Table 1). Significantly, rural, compared to urban participants,
were more likely to be infected with helminths (including Sm),
malaria and HIV, had higher median levels of Schistosoma‐specific
antibodies and were more likely to report anthelminthic or malaria
treatment in the previous 12 months. Dermatitis and SPT reactivity
were more prevalent among urban participants, while asIgE sensitiza-
tion and urticaria were more common among rural participants
(Table 1 and Figure 2A). The prevalence of wheeze and rhinitis was
similar between the two communities.
3.2 | Associations between allergy‐related
outcomes
Crude associations between allergy‐related outcomes are shown in
Table 2. Individuals who were ImmunoCAP asIgE sensitized were
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more likely to have a positive SPT response in both surveys; the
PAF for SPT reactivity associated with asIgE sensitization was 86.1%
and 80.9% for the urban and rural survey, respectively. Atopy mea-
sures (asIgE, SPT) were generally more strongly associated with
other allergy‐related conditions in the urban compared to rural
survey; asIgE‐rhinitis (interaction P = 0.081), asIgE‐urticaria (interac-
tion P = 0.056), SPT‐rhinitis (interaction P = 0.019) and SPT‐urticaria
(interaction P = 0.005) associations approached statistical signifi-
cance. Another major difference was that urticaria was associated
with wheeze, rhinitis and SPT reactivity in the urban survey, but not
with any allergy‐related outcome in the rural survey.
We hypothesized that helminth infection, particularly Sm infec-
tion, might mediate this effect modification between the urban and
rural setting (Figure 2B). However, the comparison of crude associa-
tions (reported above) with associations adjusted for current Sm
infection (generally, or categorized by infection intensity) and Schis-
tosoma‐specific antibody concentrations did not show clear differ-
ences in the test statistics (Table S1); hence, any mediating role of
current Sm infection, including effects on interactions between the
rural and urban survey, was not evident.
3.3 | Factors associated with skin prick test
reactivity
Table 3 and Table S2 show factors associated with SPT reactivity to
any of Dermatophagoides mix, B tropicalis or B germanica. In the urban
survey, increasing age, non‐Ugandan maternal tribe, being born in a
city (compared to town or village) and having a BCG scar were posi-
tively associated with SPT reactivity. Additionally, light Sm infection
(KK) and Sm infection (PCR) were positively associated with SPT reac-
tivity in the urban survey, in sharp contrast to observations in the rural
survey, where current Sm infection (KK, PCR and CCA) was associated
with reduced odds of SPT reactivity. This rural‐urban difference was
statistically significant (interaction P values = 0.002 and 0.015 for Sm‐
PCR and Sm‐KK intensity, respectively). Other factors inversely associ-
ated with SPT reactivity in the rural survey were related to helminth
infections and included bathing in lakewater and SWA‐specific IgG4.
In addition to the Sm‐SPT association, tests for interaction
showed that associations between several other risk factors and SPT
reactivity differed by survey setting. Being male (P = 0.015), mater-
nal history of allergies (P = 0.013), SWA‐specific IgG4 (P = 0.011)
and hand washing (P = 0.001) were positively associated with SPT in
the urban survey but inversely associated with the same outcome in
the rural survey. The inverse association between SPT and being
born in a village (compared to town or city) was stronger in the
urban compared to rural survey (P = 0.041).
Associations with SPT reactivity to individual allergens are sum-
marized in Table S3, and paint a similar picture.
Comparison of models with and without additional adjustment
for current Sm infection (generally, or categorized by infection inten-
sity) and Schistosoma‐specific antibodies did not suggest any mediat-
ing role of Sm infection in associations between non‐helminth‐
related risk factors and SPT reactivity, or in interactions between the
rural and urban survey (Table S4A).
3.4 | Factors associated with allergen‐specific IgE
sensitization
Table 4 and Table S5 show factors associated with ImmunoCAP IgE
sensitization to any of D pteronyssinus, A hypogaea or B germanica
extracts. In the urban survey, the presence of younger siblings and
SWA‐specific IgG were associated with asIgE sensitization. Rural par-
ticipants who washed hands after toilet use, slept under a mosquito
net and/or had recently been treated for malaria were less likely to
be asIgE sensitized. Engaging in agricultural/fishing/lake‐related activi-
ties or being unemployed, Sm infection (KK) and intensity, and ele-
vated SWA‐specific IgE increased the odds of asIgE sensitization.
The presence of younger siblings (interaction P = 0.008) and hand
washing (interaction P = 0.003) were associated with reduced odds of
asIgE sensitization in the rural but not the urban survey (Table 4). Adjust-
ing for Sm infection in multivariable analysis models did not suggest a
mediating role for Sm in these rural‐urban differences (Table S4B).
Table S6 summarizes factors associated with ImmunoCAP asIgE
sensitization to individual allergens: Schistosoma‐specific antibody
levels and helminth infections were the predominant risk factors in
both surveys. Hygiene practices (washing and bathing) reduced the
odds of sensitization in the rural but not urban survey.
3.5 | Factors associated with clinical allergy‐related
outcomes
Factors associated with self‐reported recent wheeze, urticarial rash
and rhinitis are shown in Table S7. Risk factors for visible flexural der-
matitis could not be assessed because it was rare in both settings. In
the urban survey, the presence of older siblings, handwashing before
eating, SWA‐specific IgG and SEA‐specific IgG were inversely associ-
ated with wheezing. In the rural survey, female sex and presence of
any nematode infection were inversely associated with wheezing,
while increasing age, SWA‐specific IgG, SEA‐specific IgG and paternal
history of allergies increased the odds of wheezing. Non‐Ugandan
paternal tribe (interaction P < 0.001) increased the odds of wheezing
in the urban but not rural survey, while SWA‐specific IgG (P < 0.001)
and SEA‐specific IgG (P = 0.001) were positively associated with
wheezing in the rural but not the urban survey.
Urban individuals who received any anthelminthic treatment in
the previous 12 months were more likely to report urticarial rash. In
the rural survey, increasing age, maternal history of allergies, SEA‐
specific IgE and recent malaria treatment were associated with urti-
caria. The association between SEA‐specific IgE and urticaria was
positive in the rural but not urban survey (interaction P = 0.022). No
other significant interactions were observed.
Maternal and paternal history of allergies, and HIV infection were
associated with rhinitis in the urban survey. The following were risk
factors for rhinitis in the rural survey: increasing age, presence of
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TABLE 1 Characteristics of study participants
Characteristics
Urban survey
n/N (%)a
Rural survey
n/N (%)a P value*
Socio‐demographic
Age in (y), median (IQR) 20 (8, 31) 24 (8, 34) 0.329**
Male sex 688/1610 (42.7) 1738/3350 (49.5) 0.002
Place of birth
City 53/513 (10.3) 61/2406 (2.9)
Town 138/513 (26.9) 254/2406 (10.4)
Village 322/513 (62.7) 2091/2406 (86.7) <0.001
Maternal tribe, larger region grouping
Central Uganda 605/1331 (45.5) 1197/3304 (36.5)
Other, Ugandan 607/1331 (45.6) 1588/3304 (48.1)
Non‐Ugandan, African 119/1331 (8.9) 519/3304 (15.4) 0.020
Paternal tribe, larger region grouping
Central Uganda 593/1334 (44.5) 1343/3317 (39.8)
Other, Ugandan 624/1334 (46.8) 1556/3317 (47.5)
Non‐Ugandan, African 117/1334 (8.7) 418/3317 (12.7) 0.208
Maternal history of allergies (general) 93/1187 (7.8) 366/2930 (12.7) <0.001
Paternal history of allergies (general) 30/1117 (2.6) 171/2796 (5.7) 0.005
Maternal history of asthma 27/1266 (2.1) 93/2931 (3.4) 0.167
Paternal history of asthma 27/1218 (2.2) 62/2796 (2.3) 0.950
Maternal history of eczema 35/1229 (2.8) 131/2931 (4.5) 0.206
Paternal history of eczema 15/1159 (1.3) 96/2795 (2.9) 0.028
Occupation, grouped by type
Student or child (not at school) 662/1338 (49.5) 1166/3323 (36.7)
Unemployed or housewife 292/1338 (21.8) 301/3323 (8.7)
Agricultural, fishing or lake related 60/1338 (4.5) 1389/3323 (38.8)
Professional or service providers
(Shops, saloons, bars, restaurants, entertainment)
324/1338 (24.2) 467/3323 (15.6) <0.001
Helminth infections
S mansoni (KK) 86/1197 (7.2) 846/2751 (31.8) <0.001
S mansoni intensity (KK)
Uninfected 1111/1197 (92.8) 1905/2751 (68.2)
Low 41/1197 (3.4) 425/2751 (15.7)
Moderate 31/1197 (2.6) 231/2751 (9.1)
Heavy 14/1197 (1.1) 190/2751 (7.1) <0.001
S mansoni (urine CCA) 581/1318 (44.1) 2445/2879 (85.6) <0.001
S mansoni (PCR) 204/1191 (17.1) 1338/2747 (50.0) <0.001
A lumbricoides (KK) 0/1197 (0.0) 14/2751 (0.4)
Trichuris trichiura (KK) 21/1196 (1.8) 245/2751 (7.8) <0.001
N americanus (PCR) 56/1191 (4.7) 259/2747 (8.4) 0.016
S stercoralis (PCR) 29/1191 (2.4) 190/2747 (6.2) <0.001
Schistosoma-specific antibody levels
SEA‐specific IgE (μg/mL), median (IQR) 2.7 (2.6, 2.8) 4.6 (4.3, 4.8) <0.001**
SWA‐specific IgE (μg/mL), median (IQR) 2.2 (2.1, 2.4) 4.9 (4.6, 5.1) <0.001**
SEA‐specific IgG4 (μg/mL), median (IQR) 30.8 (27.8, 37.3) 278.6 (228.7, 322.4) <0.001**
SWA‐specific IgG4 (μg/mL), median (IQR) 42.7 (40.5, 44.1) 108.6 (98.3, 124.7) <0.001**
(Continues)
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TABLE 1 (Continued)
Characteristics
Urban survey
n/N (%)a
Rural survey
n/N (%)a P value*
SEA‐specific IgG (μg/mL), median (IQR) 777.9 (744.6, 806.1) 1975.4 (1848.0, 2096.4) <0.001**
SWA‐specific IgG (μg/mL), median (IQR) 795.4 (771.2, 828.6) 1497.2 (1429.4, 1561.5) <0.001**
Allergy‐related outcomes
Skin prick test reactivity
Any 302/1317 (22.9) 576/3037 (19.1) 0.054
Dermatophagoides mix 228/1317 (17.3) 326/3037 (10.5) <0.001
B tropicalis 184/1317 (13.9) 229/3036 (7.9) <0.001
B germanica 186/1320 (14.1) 350/3035 (11.8) 0.137
Allergen‐specific IgE (≥0.35 kU/L, ImmunoCAP)
Any 148/345 (42.9) 437/780 (55.1) 0.007
D pteronyssinus 104/345 (30.1) 264/780 (33.2) 0.421
B germanica 118/345 (34.2) 393/780 (49.8) <0.001
A hypogaea 41/345 (11.8) 114/780 (14.9) 0.266
Total IgE (kU/L), median (IQR) 159 (56, 522) 672 (249, 1942) <0.001
Wheeze in last 12 mo, age<5 y 3/229 (1.3) 9/547 (1.4) 0.972
Wheeze in last 12 mo, age ≥ 5 y 24/1107 (2.2) 87/2776 (3.2) 0.190
Visible flexural dermatitis 22/1435 (1.5) 5/3111 (0.1) <0.001
Rhinitis in last 12 mo 45/1336 (3.4) 104/3323 (3.2) 0.806
Urticarial rash in last 12 mo 53/1336 (3.9) 334/3322 (9.9) <0.001
Other
Any worm treatment in the last 12 mo 795/1296 (61.3) 2938/3307 (87.7) <0.001
Malaria treatment in the last 12 mos 506/1336 (37.8) 1993/3323 (60.8) <0.001
P falciparum positivity by blood smear 3/1347 (0.2) 102/2923 (3.7) <0.001
HIV infection 66/1339 (4.9) 402/2399 (17.3) <0.001
CCA: circulating cathodic antigen; IQR: interquartile range; KK: Kato‐Katz; PCR: polymerase chain reaction; SEA: Schistosoma egg antigen; SWA: Schis-
tosoma adult worm antigen.
aPercentages adjusted for survey design. Percentages that are significantly higher in one setting compared to the other (P ≤ 0.05) are highlighted in
bold. Adjusting for age and sex differences had no significant impact on these differences.
*P values obtained from survey design‐based logistic regression.
**P values obtained from survey design‐based linear regression.
F IGURE 2 Urban‐rural differences in risk factors for allergy‐related outcomes in Uganda: a role for helminths? A, summary of principal
findings regarding prevalence of allergy‐related outcomes in urban Uganda and in rural Ugandan fishing communities. B, Risk factors for
allergy‐related outcomes differed between urban and rural settings. Our data suggest that helminth exposure is unlikely to be the only factor
involved in this effect modification. Additional hypothesized effect modifiers are indicated
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older siblings, being born in a city (compared to town or village) and
bathing in lakewater. The positive association between HIV and
rhinitis was stronger in the urban compared to the rural survey (in-
teraction P = 0.028). No other significant interactions were
observed.
We did not find any evidence to suggest that current Sm infec-
tion influenced associations between non‐helminth‐related risk fac-
tors and clinical allergy‐related outcomes, and interactions between
the rural and urban survey (Table S4, C-E).
4 | DISCUSSION
We show risk factors for allergy‐related outcomes in proximate
Ugandan rural and urban settings. The rural setting was
characterized by a significantly higher prevalence of Sm and nema-
tode infections compared to the urban setting. The prevalence of
SPT reactivity and visible flexural dermatitis was lower, and that of
asIgE sensitization and urticaria higher, in the rural compared to
urban setting. Risk factors for these outcomes differed by setting.
We investigated the hypothesis that rural‐urban differences in risk
factors for allergy were attributable to differences in current Sm
exposure. Despite observations that the rural environment (and
higher intensity Sm infection within it) was associated with reduced
odds of SPT reactivity, statistical analyses did not confirm a mediat-
ing role for current Sm infection in the rural‐urban differences, imply-
ing that other exposures may play important roles. Similarly, rural‐
urban differences in associations with clinical allergy outcomes could
not categorically be attributed to differences in current Sm infection
between the two settings.
TABLE 2 Crude associations between allergy‐related outcomes
SPT Wheeze Rhinitis Urticaria
asIgE
Urban OR (95% CI) 21.4 (10.2, 44.6) 5.5 (0.4, 68.6) 3.7 (1.2, 11.9) 3.7 (0.8, 16.2)
P value <0.001 0.171 0.028 0.075
PAF (95% CI) 86.1% (81.4, 88.3) 65.5% (−120, 78.8) 53.1% (12.1, 66.6) 53.1% (−18.2, 68.2)
Rural OR (95% CI) 10.3 (5.3, 19.8) 3.9 (1.3, 11.5) 1.1 (0.5, 2.6) 0.9 (0.6, 1.3)
P value <0.001 0.015 0.793 0.651
PAF (95% CI) 80.9% (72.7, 85.1) 62.2% (19.3, 76.5) 5.7% (−57.9, 35.6) −4.7% (−35.8, 12.4)
Interaction P value 0.127 0.792 0.081 0.056
SPT
Urban OR (95% CI) 2.2 (0.6, 8.1) 6.5 (3.4, 12.5) 2.2 (1.6, 2.8)
P value 0.211 <0.001 <0.001
PAF (95% CI) 23.4% (−28.6, 37.6) 54.2% (45.2, 58.9) 20.8% (14.4, 24.6)
Rural OR (95% CI) 3.0 (1.8, 5.1) 2.6 (1.7, 3.9) 1.2 (0.9, 1.6)
P value <0.001 <0.001 0.243
PAF (95% CI) 29.2% (17.6, 31.9) 23.4% (15.5, 27.9) 3.6% (−2.4, 20.9)
Interaction P value 0.647 0.019 0.005
Wheeze
Urban OR (95% CI) 7.4 (1.7, 33.2) 4.9 (1.1, 21.7)
P value 0.011 0.035
Rural OR (95% CI) 11.9 (5.7, 24.9) 1.4 (0.6, 3.3)
P value <0.001 0.403
Interaction P value 0.557 0.127
Rhinitis
Urban OR (95% CI) 9.6 (5.6, 16.4)
P value <0.001
Rural OR (95% CI) 0.7 (0.3, 1.6)
P value 0.429
Interaction P value <0.001
asIgE: ImmunoCAP IgE sensitization to any of D pteronyssinus, A hypogaea, or B germanica on ImmunoCAP; SPT: skin prick test reactivity to any of Der-
matophagoides mix, B tropicalis or B germanica.
Odds ratios (ORs), P values and population attributable fractions (PAFs) were obtained from survey design‐adjusted analyses. Visible flexural dermatitis
was not assessed because it was rare. Significant associations are highlighted in bold. Interaction P values are shown to denote whether tests for inter-
action showed statistical evidence for urban‐rural differences in associations between allergy‐related outcomes, or not.
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TABLE 3 Factors associated with SPT reactivity to any of Dermatophagoides mix, B tropicalis or B germanica
Factor
Urban Rural
Interaction PN (%)a aOR (95% CI)bc P N (%)a aOR (95% CI)bd P
Age 1.02 (1.00, 1.03) 0.035 1.02 (1.00, 1.03) 0.015 0.384
Sex
Male 132 (26) 1 285 (18) 1
Female 170 (21) 0.71 (0.49, 1.02) 0.061 291 (20) 1.09 (0.79, 1.52) 0.558 0.015
Older siblings (Yes/No)
No 73 (22) 1 113 (24) 1
Yes 194 (23) 1.58 (0.90, 2.76) 0.103 341 (22) 0.76 (0.56, 1.03) 0.076 0.133
Occupation
Student or child (not at school) 111 (20) 1 136 (13) 1
Unemployed or housewife 63 (24) 1.21 (0.70, 2.08) 61 (22) 0.79 (0.34, 1.85)
Agricultural, fishing or lake related 11 (20) 0.74 (0.29, 1.87) 273 (22) 0.83 (0.39, 1.72)
Professional or service providers 82 (28) 1.26 (0.77, 2.06) 0.709 103 (25) 0.93 (0.54, 1.62) 0.932 0.473
Maternal tribe
Central Uganda 127 (25) 1 212 (20) 1
Other, Ugandan 113 (21) 0.82 (0.52, 1.30) 272 (19) 0.86 (0.59, 1.27)
Non‐Ugandan, African 26 (25) 1.77 (1.17, 2.70) 0.015 86 (18) 0.76 (0.44, 1.32) 0.613 0.127
Maternal history of allergies
No 192 (21) 1 433 (20) 1
Yes 34 (31) 1.68 (0.89, 3.18) 0.107 71 (15) 0.90 (0.58, 1.41) 0.644 0.013
Location of birth
City 16 (37) 1 12 (21) 1
Town 34 (28) 0.56 (0.30, 1.02) 57 (24) 0.75 (0.37, 1.52)
Village 60 (21) 0.34 (0.18, 0.61) 0.004 397 (21) 0.61 (0.29, 1.28) 0.419 0.041
BCG scar
No 67 (19) 1 228 (19) 1
Yes 234 (24) 2.22 (1.24, 3.97) 0.010 345 (19) 1.31 (0.96, 1.79) 0.083 0.601
Lake contact
Never 72 (18) 1
Rarely 140 (27) 0.92 (0.50, 1.67) 22 (33) 1
Once a month 29 (24) 0.78 (0.39, 1.61)
Once a week 26 (23) 1.04 (0.42, 2.57) 0.896 47 (24) 1.04 (0.64, 1.68)
Daily/almost daily 385 (22) 0.89 (0.54, 1.48) 0.499
Bathe in water from lake?
No 249 (23) 1 25 (36) 1
Yes 18 (18) 0.75 (0.27, 2.06) 0.558 429 (22) 0.41 (0.24, 0.71) 0.002 0.172
Hand washing after toilet
No 19 (12) 1 151 (23) 1
Yes 248 (25) 4.67 (0.88, 24.8) 0.068 303 (22) 0.78 (0.59, 1.02) 0.068 0.001
SWA‐specific IgG4e 1.04 (0.86, 1.24) 0.691 0.77 (0.63, 0.94) 0.013 0.011
SEA‐specific IgEe 1.32 (0.90, 1.91) 0.135 0.58 (0.29, 1.16) 0.119 0.109
Sm infection (KK)
Uninfected 221 (22) 1 376 (21) 1
Infected 20 (26) 1.47 (0.76, 2.83) 0.239 127 (16) 0.68 (0.47, 0.97) 0.038 0.332
Sm infection intensity (KK)
Uninfected 221 (22) 1 376 (21) 1
(Continues)
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Our rural and urban settings were atypical. Observations in the
rural survey are against a backdrop of three years of well‐organized
community‐level anthelminthic intervention25 that led to a decline in
helminth intensity in both standard and intensive treatment arms,
but had no effect on overall Sm prevalence.26 Before analysis of risk
factors, we confirmed a lack of effect of the intensive (compared
with standard) anthelminthic treatment on allergy‐related outcomes.
The urban survey was done in the unusual context of a setting with
considerable exposure to light Sm infection (inferred from 44% urine
CCA positivity). However, this enabled us to adjust for Sm infection
in both settings and hence explore the role of Sm in interactions
between the settings. Recruitment of participants in the urban sur-
vey was done after conclusion of the rural survey; however, this is
unlikely to account for observed urban‐rural differences in allergy
risk factors, as both surveys were conducted by the same research
team, and covered approximately 1 year (so any seasonal effects
were approximately matched). Another potential limitation was the
large number of statistical tests, increasing likelihood of chance find-
ings. However, we were cautious to look for patterns of association
rather than interpreting individual results equally.
In keeping with the “old friends” hypothesis1 and observations
from several studies,37-39 SPT reactivity was less prevalent in the
helminth‐endemic rural setting and was inversely associated with
helminth infections in the same setting. The only exception was Tri-
churis trichiura infection, which was weakly positively associated with
Dermatophagoides SPT (Table S3). This lone observation was also
manifest in the same communities in a baseline household survey
3 years earlier,24 although no other helminth species were associated
with SPT then. The current observations beg further investigation
into the impact of anthelminthic treatment on SPT‐helminth associa-
tions in a helminth‐endemic setting. In mice, allergic airway inflam-
mation is increased during acute Sm infection but reduces drastically
with progression to chronic infection.40 In our urban setting, light Sm
infection was positively associated with SPT reactivity while moder-
ate and heavy infections were inversely associated with the same
outcome (Table 3). “Helminth‐related” behavioural characteristics
were also inversely associated with SPT reactivity in the rural survey.
It is plausible that in these fishing communities, frequent lake con-
tact, bathing in lakewater and handwashing, for example, increase
the risk for Sm infection through contact with infected snails. Indeed,
these characteristics were strongly associated with Sm infection
(P < 0.001). However, the same characteristics were also inversely
associated with asIgE sensitization in the rural survey but not in the
urban survey.
As discussed earlier, Pinot de Moira and colleagues’ study in a
Ugandan village found that hookworm infection abrogated the
TABLE 3 (Continued)
Factor
Urban Rural
Interaction PN (%)a aOR (95% CI)bc P N (%)a aOR (95% CI)bd P
Light 15 (38) 2.39 (1.24, 4.64) 65 (16) 0.66 (0.43, 1.01)
Moderate 3 (12) 0.76 (0.22, 2.61) 40 (18) 0.83 (0.52, 1.34)
Heavy 2 (14) 0.55 (0.05, 6.81) 0.055 22 (12) 0.49 (0.22, 1.14) 0.053 0.015
Sm infection (PCR)
Uninfected 188 (21) 1 289 (22) 1
Infected 48 (25) 1.57 (1.01, 2.43) 0.044 214 (17) 0.66 (0.49, 0.89) 0.010 0.002
Sm infection (CCA)
Negative 163 (24) 1 114 (27) 1
Positive 115 (22) 1.19 (0.69, 2.06) 0.517 414 (18) 0.56 (0.37, 0.83) 0.006 0.184
Malaria treatment, last 12 mo
No 163 (24) 1 234 (21) 1
Yes 100 (22) 0.86 (0.52, 1.42) 0.536 323 (18) 1.08 (0.85, 1.38) 0.502 0.730
HIV
Negative 272 (22) 1 380 (19) 1
Positive 19 (32) 1.82 (0.56, 5.93) 0.302 98 (25) 1.17 (0.74, 1.85) 0.495 0.440
Associations shown in this table are from adjusted analyses. Full table with crude associations is shown in supplementary Table S1. This table shows
only factors that were associated with SPT reactivity (before and/or after adjustment) in either the urban or the rural survey. All other factors that were
assessed are listed in the statistical methods section. Significant associations are highlighted in bold. Interaction P values are shown to establish whether
associations between potential risk factors and SPT reactivity differed, or not, given the setting.
aOR: adjusted odds ratios; CCA: circulating cathodic antigen; KK: Kato‐Katz; PCR: Polymerase Chain Reaction; SEA: Schistosoma egg antigen; SWA:
Schistosoma adult worm antigen.
aNumber (percentage in parenthesis) of SPT reactive individuals in each category.
bOdds ratios (ORs) and 95% confidence intervals (CI) were adjusted for survey design.
cORs were adjusted for location of birth, BCG scar, hand washing after toilet use, alcohol use, age and sex.
dORs were adjusted for HIV infection status, maternal history of allergies, recent malaria treatment, presence/absence of older siblings, age and sex.
eLog10 (concentration+1) transformation applied before analysis.
10 | NKURUNUNGI ET AL.
107
predicted association between Dermatophagoides‐specific IgE and
basophil histamine release.22 We postulated that the rural setting
might interfere with the link between atopic sensitization (asIgE,
SPT) and clinical outcomes (reported wheeze and rhinitis) through
high helminth exposure. Indeed, we found that associations
between asIgE or SPT sensitization and clinical outcomes were
weak among participants from the rural compared to the urban
setting. However, statistical analyses did not suggest that this
TABLE 4 Factors associated with IgE sensitization (ImmunoCAP IgE > 0.35 kU/L) to any of D pteronyssinus, A hypogaea or B germanica
Factor
Urban Rural
Interaction PN (%)a aOR (95% CI)bd P N (%)a aOR (95% CI)bc P
Age 0.99 (0.98, 1.01) 0.547 1.01 (0.98, 1.03) 0.589 0.728
Sex
Male 47 (48) 1 241 (64) 1
Female 101 (41) 0.77 (0.51, 1.15) 0.200 196 (49) 0.69 (0.42, 1.14) 0.140 0.407
Younger siblings (Yes/No)
No 27 (33) 1 61 (62) 1
Yes 106 (46) 2.07 (1.07, 4.01) 0.030 313 (56) 0.76 (0.53, 1.09) 0.129 0.008
Occupation
Student or child (not at school) 68 (48) 1 64 (51) 1
Unemployed or housewife 34 (40) 0.70 (0.31, 1.60) 58 (54) 2.05 (1.38, 3.03)
Agricultural, fishing or lake related 4 (36) 0.56 (0.13, 2.46) 251 (61) 1.87 (1.04, 3.37)
Professional or service providers 27 (38) 0.61 (0.26, 1.43) 0.725 61 (47) 1.38 (0.72, 2.66) 0.014 0.148
Lake contact
Never 39 (45) 1
Rarely 69 (42) 0.98 (0.52, 1.85) 8 (42) 1
Once a month 11 (35) 0.74 (0.38, 1.41)
Once a week 14 (50) 1.32 (0.49, 3.55) 0.835 25 (44) 0.82 (0.23, 2.89)
Daily/almost daily 343 (59) 1.64 (0.45, 5.90) 0.174
Bathe in water from lake?
No 121 (42) 1 15 (63) 1
Yes 12 (57) 1.86 (0.50, 6.87) 0.331 361 (57) 0.42 (0.15, 1.11) 0.078 0.065
Hand washing after toilet
No 15 (39) 1 148 (71) 1
Yes 117 (43) 1.36 (0.69, 2.66) 0.344 228 (50) 0.43 (0.30, 0.61) <0.001 0.003
SWA‐specific IgEe 2.95 (0.51, 17.2) 0.214 6.17 (2.79, 13.6) <0.001 0.459
SWA‐specific IgG4e 1.01 (0.85, 1.19) 0.932 1.07 (0.89, 1.27) 0.470 0.433
SEA‐specific IgG4e 1.11 (0.97, 1.25) 0.102 1.07 (0.95, 1.21) 0.227 0.704
SWA‐specific IgGe 3.33 (1.12, 9.86) 0.031 1.53 (0.82, 2.86) 0.177 0.340
SEA‐specific IgGe 1.77 (0.63, 4.96) 0.260 1.43 (0.88, 2.30) 0.138 0.796
S mansoni infection (KK)
Uninfected 119 (44) 1 271 (55) 1
Infected 6 (43) 1.06 (0.34, 3.35) 0.910 118 (63) 1.52 (1.19, 1.94) 0.002 0.180
S mansoni infection intensity (KK)
Uninfected 119 (44) 1 271 (55) 1
Light 2 (29) 0.66 (0.11, 4.04) 54 (57) 1.74 (1.18, 2.54)
Moderate 2 (50) 1.20 (0.16, 8.79) 35 (66) 0.94 (0.46, 1.90)
Heavy 2 (67) 2.32 (0.13, 40.9) 0.662 29 (73) 2.37 (0.71, 7.83) 0.028 0.536
Any nematode infectionf
No 109 (42) 1 281 (54) 1
Yes 16 (62) 2.34 (0.76, 7.19) 0.130 108 (66) 1.53 (0.94, 2.49) 0.084 0.287
(Continues)
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difference was mediated by current Sm infection. Furthermore, the
PAF for SPT associated with asIgE in both the helminth‐endemic
rural survey and in the urban survey was high, and adjusting for
Sm or Schistosoma‐specific antibodies had no effect on this
association.
Allergen‐specific IgE sensitization, particularly to cockroach, was
more prevalent in the rural compared to the urban setting, possibly
due to the higher helminth prevalence in the former. Additionally,
helminth infections and Schistosoma‐specific antibody levels were
positively associated with asIgE in both surveys. Our immunoassays
measured IgE sensitization to crude allergen extracts; these may con-
tain cross‐reactive components that are conserved in several hel-
minth antigens,41-46 explaining the above associations. These cross‐
reactive components may be less effective at mediating the effector
phase of the allergic response, explaining the lower prevalence of
SPT reactivity in the helminth‐endemic rural survey.
Associations with wheeze and rhinitis should be interpreted with
caution, because these outcomes were relatively rare. Furthermore,
reported wheeze can easily be misclassified in these populations,
because there is no direct translation of the word “wheeze” in the
local languages.24,47 Nonetheless, rural‐urban differences in the risk
factors for these outcomes were visible. For example, while Schisto-
soma‐specific antibody levels were inversely associated with wheez-
ing in the urban survey, the reverse was true in the rural setting.
Urticarial rash was a more common outcome, particularly in the hel-
minth‐endemic rural survey, where it may be indicative of parasite‐
induced skin allergy48 and reaction to parasite antigens following
anthelminthic treatment.49 Support for these deductions comes from
our observations that recent anthelminthic treatment (urban survey)
and SEA‐specific IgE (rural survey) were associated with urticaria.
In conclusion, we show that risk factors for allergy‐related out-
comes differ between rural and urban communities in this tropical
setting. However, our analyses did not confirm a role for current
helminth (Sm) infection as the primary mechanism of the observed
effect modification between the two settings, despite indicative
trends. Differences in other environmental exposures may contribute
significantly.
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Lawrence Lubyayi, Helen Akurut, Fatuma Nalukenge, Justin Okello,
Sebastian Owilla, Wilber Ssembajjwe, Jacob Ochola, Jonathan Levin,
Stephen Nash; clinical officers: Carol Nanyunja, Milly Namutebi,
Christopher Zziwa; nurses: Esther Nakazibwe, Josephine Tumusiime,
Caroline Ninsiima, Susan Amongi, Grace Kamukama, Susan Iwala,
Florence Akello, Asherwin Ritah, Rehema Nampijja, Gloria Zalwango;
internal monitor: Mirriam Akello; field workers: Robert Kizindo, Moses
Sewankambo, Denis Nsubuga, Samuel Kiwanuka, Saadh Nsubuga
Mwagalanyi, Samuelson Nambaale; social sciences: Edward Tumwe-
sige; boatman: David Abiriga; driver: Richard Walusimbi; HIV coun-
selling and testing: Cynthia Kabonesa; Vector Control Programme staff:
James Kaweesa, Edridah Tukahebwa; administrative management:
Moses Kizza; principal investigator: Alison Elliott.
TABLE 4 (Continued)
Factor
Urban Rural
Interaction PN (%)a aOR (95% CI)bd P N (%)a aOR (95% CI)bc P
Slept under mosquito net last night?
No 35 (45) 1 203 (62) 1
Yes 97 (42) 0.93 (0.52, 1.66) 0.958 172 (52) 0.63 (0.41, 0.97) 0.037 0.316
Malaria treatment, last 12 mo
No 83 (45) 1 202 (63) 1
Yes 48 (39) 0.78 (0.46, 1.35) 0.365 221 (51) 0.52 (0.34, 0.81) 0.005 0.185
Associations shown in this table are from adjusted analyses. Full table with crude associations is shown in supplementary Table S1. This table shows
only factors that were associated with IgE sensitization (before and/or after adjustment) in either the urban or the rural survey. All other factors that
were assessed are listed in the statistical methods section. Significant associations are highlighted in bold. Interaction P values are shown to denote
whether tests for interaction showed statistical evidence for urban‐rural differences in associations with IgE sensitization, or not.
aOR: adjusted odds ratios; KK: Kato‐Katz; SWA: Schistosoma adult worm antigen; SEA: Schistosoma egg antigen.
aNumber (percentage in parenthesis) of IgE sensitized individuals in each category.
bOdds ratios (ORs) and 95% confidence intervals (CI) adjusted for survey design.
cAll ORs were adjusted for hand washing after toilet use, mosquito net use, malaria treatment, age and sex.
dAll ORs were adjusted for age and sex.
eLog10 (concentration+1) transformation applied before analysis.
fInfection with any of Ascaris lumbricoides, Trichuris trichiura (assessed by KK), Necator americanus, Strongyloides stercoralis (assessed by PCR).
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 4.3 Supplementary information for Research paper 1 (also available in the article’s 
online repository at https://onlinelibrary.wiley.com/journal/13652222) 
4.3.1 Supplementary methods 
4.3.1.1 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgE and IgG4 ELISA 
All but the first 2 columns of 4HBX Immulon (Thermo Scientific, NY, USA) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Michael J Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer 
(0.1M, pH 9.6). Two-fold dilutions of human IgE (Calbiochem, Beeston, UK) or IgG4 (Sigma-
Aldrich) standard, diluted in bicarbonate buffer, were added to the first 2 columns of each 
plate to form standard curves. The plates were then incubated overnight at 40C. Plates were 
washed with phosphate-buffered saline (PBS 1X)-tween 20 solution, blocked with 150μl of 
1% skimmed milk diluted in PBS-Tween 20 at room temperature (RT), and incubated 
overnight at 40C with 50μl of plasma samples diluted 1/20 (IgE assay) or 1/200 (IgG4 assay) 
with 0.1% skimmed milk in PBS-Tween 20 (assay buffer). Plates were washed and antibody 
binding detected by incubating the plates overnight at 40C with 0.5μg/ml of biotinylated 
monoclonal mouse anti-human IgE or IgG4 (BD Pharmingen™). This was followed by a 1-
hour incubation with a streptavidin-Horseradish Peroxidase (strep-HRP) conjugate (Mast 
Group Ltd, Bootle, UK), diluted 1/4000 with assay buffer, at RT. Plates were developed by 
addition of 100μl of o-phenylenediamine (Sigma-Aldrich) and reactions stopped after 30 
minutes with 25μl of 2M Sulphuric acid. Optical density values were measured at 490nm 
(reference wavelength 630nm) on a 96-well plate ELISA reader. IgE or IgG4 concentrations 
(ng/ml) were interpolated from standard curves using a five-parameter curve fit using Gen5 
data collection and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). 
4.3.1.2 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgG ELISA 
All but the first 2 columns of 4HX Immulon (VWR, UK, Cat No 735-0465) 96-well plates were 
coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor Michael J 
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 Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer (0.1M, pH 
9.6). Two-fold dilutions of human IgG (Sigma-Aldrich), diluted in bicarbonate buffer, were 
added to the first 2 columns of each plate to form standard curves. The plates were then 
incubated overnight at 40C. Plates were washed with phosphate-buffered saline (PBS)-
tween 20 solution, blocked with 150μl of 1% skimmed milk diluted in PBS-Tween 20 at room 
temperature (RT), and incubated overnight at 40C with 50μl of plasma samples diluted 
1/3000 with 0.1% skimmed milk in PBS-Tween 20 (assay buffer). Plates were washed and 
antibody binding detected by incubating the plates for 1 hour at RT with 0.5μg/ml of 
polyclonal rabbit anti- human IgG/HRP (Dako, Denmark). Plates were developed by addition 
of 100μl of o-phenylenediamine (Sigma-Aldrich) and reactions stopped after 30 minutes with 
25μl of 2M Sulphuric acid. Optical density values were measured at 490nm (reference 
wavelength 630nm) on a 96-well plate ELISA reader. IgG concentrations (ng/ml) were 
interpolated from standard curves using a five-parameter curve fit using Gen5 data collection 
and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). 
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 4.3.2 Supplementary tables 
Table S1. Crude versus Sm-adjusted associations between allergy-related outcomes 
  SPT WHEEZE  RHINITIS URTICARIA 
  Unadjusted Adjusted for 
Sm (CCA)* Unadjusted 
Adjusted for 
Sm (CCA)* Unadjusted 
Adjusted for 
Sm (CCA)* Unadjusted 
Adjusted for 
Sm (CCA)* 
asIgE 
URBAN OR (95% CI) 21.4 (10.2, 44.6) 23.6 (10.2, 54.4) 5.5 (0.4, 68.6) 4.4 (0.4, 47.3) 3.7 (1.2, 11.9) 3.7 (1.1, 12.1) 3.7 (0.8, 16.2) 3.4 (0.8, 14.5) 
p value <0.001 <0.001 0.171 0.210 0.028 0.035 0.075 0.092 
RURAL OR (95% CI) 10.3 (5.3, 19.8) 10.1 (4.9, 20.9) 3.9 (1.3, 11.5) 3.0 (0.9, 9.5) 1.1 (0.5, 2.6) 0.99 (0.3, 2.8) 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 
p value <0.001 <0.001 0.015 0.061 0.793 0.979 0.651 0.659 
 Interaction p  0.127 0.074 0.792 0.817 0.081 0.073 0.056 0.089 
SPT 
URBAN OR (95% CI)   2.2 (0.6, 8.1) 1.7 (0.5, 6.1) 6.5 (3.4, 12.5) 5.9 (3.1, 11.4) 2.2 (1.6, 2.8) 2.3 (1.7, 3.0) p value   0.211 0.366 <0.001 <0.001 <0.001 <0.001 
RURAL OR (95% CI)   3.0 (1.8, 5.1) 3.6 (1.9, 6.8) 2.6 (1.7, 3.9) 2.7 (1.7, 4.1) 1.2 (0.9, 1.6) 1.03 (0.7, 1.4) 
p value   <0.001 <0.001 <0.001 <0.001 0.243 0.845 
 Interaction p    0.647 0.281 0.019 0.037 0.005 0.001 
WHEEZE 
URBAN OR (95% CI)     7.4 (1.7, 33.2) 7.1 (1.5, 32.8) 4.9 (1.1, 21.7) 6.1 (1.4, 27.3) 
p value     0.011 0.015 0.035 0.020 
RURAL 
 
OR (95% CI)     11.9 (5.7, 24.9) 14.9 (6.8, 32.5) 1.4 (0.6, 3.3) 1.2 (0.6, 2.7) 
p value     <0.001 <0.001 0.403 0.588 
 Interaction p      0.557 0.375 0.127 0.056 
RHINITIS 
URBAN OR (95% CI)       9.6 (5.6, 16.4) 10.4 (5.4, 19.7) p value       <0.001 <0.001 
 
RURAL 
OR (95% CI)       0.7 (0.3, 1.6) 0.6 (0.2, 1.7) 
p value       0.429 0.321 
 Interaction p        <0.001 <0.001 
Odds ratios (ORs) and p values were obtained from survey design-adjusted analyses. Visible flexural dermatitis was not assessed because it was rare. Significant associations are 
highlighted in bold. 
*Adjusting for other Sm infection variables (KK / PCR), Sm infection intensity (KK) and SWA- and SEA-specific antibodies paints a similar picture. 
asIgE: ImmunoCAP IgE sensitisation to any of D. pteronyssinus, A. hypogaea, or B. germanica on ImmunoCAP; SPT: skin prick test reactivity to any of Dermatophagoides mix, B. tropicalis 
or B. germanica; CCA: Circulating Cathodic Antigen  
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 Table S2. Crude and adjusted associations with SPT reactivity to any of Dermatophagoides mix, B. tropicalis or B. germanica 
  UNADJUSTED ANALYSIS  ADJUSTED ANALYSIS 
     
  URBAN RURAL  URBAN  RURAL   
Factor  N (%)≠ OR (95% CI)¶ p  N (%)≠ OR (95% CI)¶ p   OR (95% CI) ¶# p  OR (95% CI)¶§ p  Interaction p  
              
Age    1.01 (1.00, 1.02) 0.005  1.02 (1.01, 1.03) <0.001  1.02 (1.00, 1.03) 0.035 1.02 (1.00, 1.03) 0.015 0.384 
              
Sex              
Male  132 (26) 1  285 (18) 1   1  1   
Female  170 (21) 0.77 (0.59, 1.02) 0.068 291 (20) 1.00 (0.74, 1.37) 0.979  0.71 (0.49, 1.02) 0.061 1.09 (0.79, 1.52) 0.558 0.015 
Older siblings (Yes/No)              
No  73 (22) 1  113 (24) 1   1  1   
Yes  194 (23) 1.05 (0.78, 1.42) 0.691 341 (22) 0.75 (0.58, 0.98) 0.036  1.58 (0.90, 2.76) 0.103 0.76 (0.56, 1.03) 0.076 0.133 
Occupation              
Student or child (not at school)  111 (20) 1  136 (13) 1   1  1   
Unemployed or housewife  63 (24) 1.22 (0.92, 1.63)  61 (22) 1.68 (1.09, 2.58)   1.21 (0.70, 2.08)  0.79 (0.34, 1.85)   
Agricultural, fishing or lake 
related 
 11 (20) 0.98 (0.44, 2.21)  273 (22) 1.78 (1.41, 2.25)   0.74 (0.29, 1.87)  0.83 (0.39, 1.72)   
Professional or service providers   82 (28) 1.57 (1.16, 2.14) 0.059 103 (25) 1.96 (1.25, 3.06) <0.001  1.26 (0.77, 2.06) 0.709 0.93 (0.54, 1.62) 0.932 0.473 
Maternal tribe              
Central Uganda  127 (25) 1  212 (20) 1   1  1   
Other, Ugandan  113 (21) 0.78 (0.59, 1.03)  272 (19) 1.03 (0.76, 1.35)   0.82 (0.52, 1.30)  0.86 (0.59, 1.27)   
Non-Ugandan, African  26 (25) 1.01 (0.59, 1.71) 0.179 86 (18) 1.03 (0.79, 1.32) 0.977  1.77 (1.17, 2.70) 0.015 0.76 (0.44, 1.32) 0.613 0.127 
Maternal history of allergies              
No  192 (21) 1  433 (20) 1   1  1   
Yes  34 (31) 1.65 (0.95, 2.86) 0.073 71 (15) 0.75 (0.58, 0.95) 0.018  1.68 (0.89, 3.18) 0.107 0.90 (0.58, 1.41) 0.644 0.013 
Location of birth              
City  16 (37) 1  12 (21) 1   1  1   
Town  34 (28) 0.64 (0.38, 1.09)  57 (24) 0.90 (0.42, 1.95)   0.56 (0.30, 1.02)  0.75 (0.37, 1.52)   
Village  60 (21) 0.44 (0.28, 0.68) 0.005 397 (21) 0.89 (0.49, 1.61) 0.932  0.34 (0.18, 0.61) 0.004 0.61 (0.29, 1.28) 0.419 0.041 
115
 BCG scar              
No  67 (19) 1  228 (19) 1   1  1   
Yes  234 (24) 1.39 (1.05, 1.83) 0.021 345 (19) 1.07 (0.89, 1.28) 0.444  2.22 (1.24, 3.97) 0.010 1.31 (0.96, 1.79) 0.083 0.601 
Lake contact              
Never  72 (18) 1      1     
Rarely  140 (27) 1.64 (1.36, 1.99)  22 (33) 1   0.92 (0.50, 1.67)  1   
Once a month  29 (24) 1.42 (0.99, 2.02)      0.78 (0.39, 1.61)     
Once a week  26 (23) 1.37 (0.88, 2.13) 0.021 47 (24) 0.73 (0.44, 1.22)   1.04 (0.42, 2.57) 0.896 1.04 (0.64, 1.68)   
Daily/ almost daily     385 (22) 0.65 (0.44, 0.96) 0.033    0.89 (0.54, 1.48) 0.499   
Bathe in water from lake?              
No  249 (23) 1  25 (36) 1   1  1   
Yes  18 (18) 0.74 (0.32, 1.67) 0.447 429 (22) 0.38 (0.18, 0.80) 0.013  0.75 (0.27, 2.06) 0.558 0.41 (0.24, 0.71) 0.002 0.172 
Hand washing after toilet              
No  19 (12) 1  151 (23) 1   1  1   
Yes  248 (25) 2.49 (1.77, 3.49) <0.001 303 (22) 0.88 (0.68, 1.13) 0.309  4.67 (0.88, 24.8) 0.068 0.78 (0.59, 1.02) 0.068 0.001 
              
SWA-specific IgG4*   1.03 (0.94, 1.13) 0.449  0.87 (0.75, 1.02) 0.093  1.04 (0.86, 1.24) 0.691 0.77 (0.63, 0.94) 0.013 0.011 
SEA-specific IgE*   1.47 (1.02, 2.11) 0.038  1.03 (0.58, 1.81) 0.923  1.32 (0.90, 1.91) 0.135 0.58 (0.29, 1.16) 0.119 0.109 
              
Sm infection (KK)              
Uninfected   221 (22) 1  376 (21) 1   1  1   
Infected  20 (26) 1.22 (0.62, 2.41) 0.552 127 (16) 0.69 (0.53, 0.91) 0.010  1.47 (0.76, 2.83) 0.239 0.68 (0.47, 0.97) 0.038 0.332 
Sm infection intensity (KK)              
Uninfected   221 (22) 1  376 (21) 1   1  1   
Light  15 (38) 2.2 (1.09, 4.46)  65 (16) 0.71 (0.53, 0.95)   2.39 (1.24, 4.64)  0.66 (0.43, 1.01)   
Moderate  3 (12) 0.48 (0.07, 3.03)  40 (18) 0.76 (0.49, 1.18)   0.76 (0.22, 2.61)  0.83 (0.52, 1.34)   
Heavy  2 (14) 0.58 (0.13, 2.75) 0.772 22 (12) 0.55 (0.34, 0.91) 0.017  0.55 (0.05, 6.81) 0.055 0.49 (0.22, 1.14) 0.053 0.015 
Sm infection (PCR)              
Uninfected   188 (21) 1  289 (22) 1   1  1   
Infected  48 (25) 1.26 (0.94, 1.70) 0.117 214 (17) 0.73 (0.55, 0.96) 0.031  1.57 (1.01, 2.43) 0.044 0.66 (0.49, 0.89) 0.010 0.002 
Sm infection (CCA)              
Negative   163 (24) 1  114 (27) 1   1  1   
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 Positive  115 (22) 0.89 (0.64, 1.26) 0.508 414 (18) 0.59 (0.44, 0.80) 0.001  1.19 (0.69, 2.06) 0.517 0.56 (0.37, 0.83) 0.006 0.184 
Malaria treatment, last 
12months 
             
No   163 (24) 1  234 (21) 1   1  1   
Yes  100 (22) 0.91 (0.72, 1.16) 0.461 323 (18) 0.82 (0.68, 0.97) 0.027  0.86 (0.52, 1.42) 0.536 1.08 (0.85, 1.38) 0.502 0.730 
HIV              
Negative  272 (22) 1  380 (19) 1   1  1   
Positive  19 (32) 1.61 (0.97, 2.64) 0.060 98 (25) 1.47 (1.04, 2.08) 0.031  1.82 (0.56, 5.93) 0.302 1.17 (0.74, 1.85) 0.495 0.440 
 
Table shows only factors that were associated with SPT reactivity (before and/or after adjustment) in either the urban or the rural survey. All other factors that were assessed are listed in the statistical 
methods section. Significant associations are highlighted in bold. Interaction p values are shown to denote whether tests for interaction, using the adjusted model, showed statistical evidence for urban-
rural differences in associations with SPT reactivity, or not. 
 
≠Number (percentage in parenthesis) of SPT reactive individuals in each category 
¶Odds ratios (ORs) and 95% confidence intervals (CI) were adjusted for survey design 
#ORs were adjusted for location of birth, BCG scar, hand washing after toilet use, alcohol use, age and sex.  
§ORs were adjusted for HIV infection status, maternal history of allergies, recent malaria treatment, presence/absence of older siblings, age and sex.  
*Log10 (concentration+1) transformation applied before analysis. 
KK: Kato-Katz; PCR: Polymerase Chain Reaction; CCA: Circulating Cathodic Antigen; SWA: Schistosoma adult worm antigen; SEA: Schistosoma egg antigen. 
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 Table S3. Summary of risk factors for SPT reactivity to individual allergen extracts 
  URBAN SURVEY  RURAL SURVEY 
       
Outcome  Factors positively associated with outcome  
Factors inversely 
associated with outcome   
Factors positively 
associated with outcome  
Factors inversely associated with 
outcome  
       
SPT reactivity, 
Dermatophagoides 
mix  
 
• S. mansoni infection [PCR] 
(p=0.062) and intensity (p for 
trend=0.007) 
• Presence of older siblings 
(p=0.005) 
• Female gender (p=0.013) 
• Recent malaria treatment 
(p<0.001) 
 
• T. trichiura infection 
(p=0.046) 
• Age (p=0.015) 
• Type of footwear (sandals 
or shoes, versus bare feet) 
[p=0.034] 
• S. mansoni infection [PCR] (p<0.001) 
• S. mansoni infection [KK] (p=0.001) 
• S. mansoni infection intensity [KK] 
(p<0.001) 
• SWA-specific IgG4 (p=0.001) 
• Bathing in lake water (p=0.016) 
• SEA-specific IgG (p=0.046) 
       
SPT reactivity, B. 
tropicalis 
 
• Age (p=0.032) 
• Maternal history of allergies 
(p=0.004) 
• Hand washing after toilet use 
(p=0.013) 
• SEA-specific IgE (p=0.012) 
• Paternal tribe (p=0.001) 
 
- 
• S. mansoni infection [KK] (p=0.016) 
• S. mansoni infection intensity [KK] 
(p=0.006) 
• SEA-specific IgG (p=0.012) 
• SWA-specific IgG (p=0.041) 
• SEA-specific IgG4 (p=0.009) 
• Bathing in lake water (p<0.001) 
• Presence of older siblings (p=0.034) 
• Daily contact with lake (versus weekly or 
rarely) [p for trend =0.026] 
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SPT reactivity, B. 
germanica 
 • BCG scar (p=0.017) 
• Maternal history of allergies 
(p=0.019) 
• Presence of older siblings 
(p=0.033) 
• SWA-specific IgG4 (p=0.046) 
Location of birth (p for 
trend=0.049) 
 
• Age (p<0.001) 
 
• Presence of older siblings (p=0.043) 
 
P values are from adjusted analyses, conducted as described in the main text. The following were assessed as potential risk factors: age, sex, presence of older/younger siblings, maternal 
tribe, paternal tribe, location of birth, occupation, frequency of lake contact, type of bathing water, hand-washing behaviour [before eating, after toilet use], footwear outside the house, 
smoking, alcohol use, helminth infections, exposure to anthelminthic treatment in utero, anthelminthic treatment in last 12 months, maternal and paternal history of allergy/eczema/asthma, 
BCG scar, immunization history, treatment for malaria in last 12 months, malaria infection, HIV infection and plasma concentration of SEA- and SWA-specific IgE, IgG4 and IgG antibodies. 
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 Table S4. Effect of adjusting for Sm infection on associations between non-helminth-related factors and allergy-related outcomes  
A. SPT reactivity to Dermatophagoides mix, B. tropicalis or B. germanica 
 
 URBAN  RURAL   
Factor OR (95% CI) OR (95% CI) – Additionally adjusted for Sm (CCA)*  OR (95% CI) 
OR (95% CI) – Additionally 
adjusted for Sm (CCA)* 
 Interaction p Interaction p** 
         
Age  1.02 (1.00, 1.03) 1.02 (1.00, 1.03)  1.02 (1.00, 1.03) 1.01 (0.99, 1.03)  0.384 0.544 
         
Sex         
Male 1 1  1 1    
Female 0.71 (0.49, 1.02) 0.74 (0.52, 1.05)  1.09 (0.79, 1.52) 0.95 (0.67, 1.35)  0.015 0.057 
Older siblings (Yes/No)         
No 1 1  1 1    
Yes 1.58 (0.90, 2.76) 1.46 (0.83, 2.58)  0.76 (0.56, 1.03) 0.69 (0.51, 0.96)  0.133 0.139 
Maternal tribe         
Central Uganda 1 1  1 1    
Other, Ugandan 0.82 (0.52, 1.30) 0.79 (0.49, 1.30)  0.86 (0.59, 1.27) 0.81 (0.53, 1.22)    
Non-Ugandan 1.77 (1.17, 2.70) 1.83 (1.23, 2.71)  0.76 (0.44, 1.32) 0.75 (0.41, 1.36)  0.127 0.088 
Maternal history of allergies         
No 1 1  1 1    
Yes 1.68 (0.89, 3.18) 2.2 (1.02, 4.96)  0.90 (0.58, 1.41) 0.95 (0.59, 1.51)  0.013 0.013 
Location of birth         
City 1 1  1 1    
Town 0.56 (0.30, 1.02) 0.70 (0.35, 1.38)  0.75 (0.37, 1.52) 0.82 (0.36, 1.85)    
Village 0.34 (0.18, 0.61) 0.39 (0.23, 0.67)  0.61 (0.29, 1.28) 0.62 (0.28, 1.35)  0.041 0.086 
BCG scar         
No 1 1  1 1    
Yes 2.22 (1.24, 3.97) 2.12 (1.17, 3.84)  1.31 (0.96, 1.79) 1.35 (0.95, 1.91)  0.601 0.863 
Handwashing after toilet use         
No 1 1  1 1    
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 Yes 4.67 (0.88, 24.8) 3.83 (0.73, 20.2)  0.78 (0.59, 1.02) 0.76 (0.59, 0.96)  0.001 0.005 
Malaria treatment, last 
12months      
   
No  1 1  1 1    
Yes 0.86 (0.52, 1.42) 0.91 (0.52, 1.60)  1.08 (0.85, 1.38) 1.11 (0.87, 1.41)  0.730 0.885 
HIV         
Negative 1 1  1 1    
Positive 1.82 (0.56, 5.93) 1.86 (0.58, 5.90)  1.17 (0.74, 1.85) 1.12 (0.71, 1.79)  0.440 0.693 
 
B. IgE sensitisation (ImmunoCAP IgE > 0.35 kU/L) to any of D. pteronyssinus, A. hypogaea or B. germanica 
 
Factor OR (95% CI) OR (95% CI) – Additionally adjusted for Sm (CCA)*  OR (95% CI) 
OR (95% CI) – Additionally 
adjusted for Sm (CCA)* 
 Interaction p Interaction p** 
         
Age  0.99 (0.98, 1.01) 0.99 (0.98, 1.01)  1.01 (0.98, 1.03) 1.01 (0.98, 1.03)  0.728 0.999 
Sex         
Male 1 1  1 1    
Female 0.77 (0.51, 1.15) 0.73 (0.52, 1.03)  0.69 (0.42, 1.14) 0.74 (0.43, 1.29)  0.407 0.511 
Younger siblings (Yes/No)         
No 1 1  1 1    
Yes 2.07 (1.07, 4.01) 2.23 (1.17, 4.23)  0.76 (0.53, 1.09) 0.72 (0.46, 1.12)  0.008 0.002 
Handwashing after toilet use         
No 1 1  1 1    
Yes 1.36 (0.69, 2.66) 1.42 (0.67, 2.96)  0.43 (0.30, 0.61) 0.41 (0.28, 0.61)  0.003 0.003 
Slept under mosquito net last 
night? 
        
No 1 1  1 1    
Yes 0.93 (0.52, 1.66) 0.89 (0.48, 1.66)  0.63 (0.41, 0.97) 0.61 (0.39, 0.95)  0.316 0.317 
Malaria treatment, last 
12months 
        
No 1 1  1 1    
Yes 0.78 (0.46, 1.35) 0.79 (0.43, 1.45)  0.52 (0.34, 0.81) 0.55 (0.34, 0.87)  0.185 0.300 
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 C. Self-reported recent wheeze 
 
Factor OR (95% CI) OR (95% CI) – Additionally adjusted for Sm (CCA)*  OR (95% CI) 
OR (95% CI) – Additionally 
adjusted for Sm (CCA)* 
 Interaction p Interaction p** 
         
Age  1.01 (0.99, 1.02) 1.02 (1.00, 1.03)  1.00 (1.00, 1.03) 1.03 (1.01, 1.04)  0.386 0.378 
Sex         
Male 1 1  1 1    
Female 1.30 (0.55, 3.07) 1.55 (0.82, 2.90)  0.47 (0.31, 0.73) 0.55 (0.34, 0.89)  0.087 0.057 
Older siblings (Yes/No)         
No 1 1  1 1    
Yes 0.36 (0.19, 0.73) 0.29 (0.11, 0.77)  0.88 (0.43, 1.79) 0.91 (0.31, 2.67)  0.177 0.108 
Maternal history of allergies         
No 1 1  1 1    
Yes 3.34 (0.82, 13.6) 2.62 (0.77, 8.92)  1.11 (0.45, 2.71) 1.25 (0.47, 3.35)  0.083 0.162 
Paternal history of allergies         
No 1 1  1 1    
Yes 4.96 (0.81, 30.4) 5.30 (0.77, 36.1)  2.32 (0.97, 5.49) 3.29 (1.34, 8.10)  0.259 0.437 
Paternal tribe          
Central Uganda 1 1  1 1    
Other, Ugandan 1.58 (0.35, 7.16) 1.22 (0.27, 5.48)  0.66 (0.38, 1.18) 0.62 (0.27, 1.41)    
Non-Ugandan 4.25 (1.94, 9.34) 5.59 (2.19, 14.2)  0.61 (0.36, 1.15) 0.46 (0.19, 1.06)  <0.001 <0.001 
Handwashing before eating         
No 1 1  1 1    
Yes 0.11 (0.04, 0.30) 0.15 (0.03, 0.71)  1.08 (0.25, 4.68) 0.79 (0.17, 3.68)  0.051 0.236 
 
D. Urticarial rash 
 
Factor OR (95% CI) OR (95% CI) – Additionally adjusted for Sm (CCA)*  OR (95% CI) 
OR (95% CI) – Additionally 
adjusted for Sm (CCA)* 
 Interaction p Interaction p** 
         
Age  1.02 (0.99, 1.04) 1.01 (0.99, 1.04)  1.03 (1.02, 1.03) 1.03 (1.02, 1.04)  0.512 0.501 
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 Sex         
Male 1 1  1 1    
Female 0.98 (0.54, 1.79) 1.07 (0.55, 2.10)  1.12 (0.85, 1.48) 1.23 (0.84, 1.80)  0.398 0.292 
Maternal tribe         
Central Uganda 1 1  1 1    
Other, Ugandan 0.77 (0.40, 1.49) 0.80 (0.39, 1.65)  1.58 (0.98, 2.54) 1.65 (0.97, 2.79)    
Non-Ugandan 1.18 (0.35, 4.03) 1.15 (0.29, 4.55)  1.74 (0.97, 3.11) 2.07 (1.16, 3.69)  0.970 0.997 
Paternal tribe         
Central Uganda 1 1  1 1    
Other, Ugandan 1.08 (0.55, 3.28) 1.03 (0.42, 2.52)  0.43 (0.29, 0.65) 0.43 (0.27, 0.68)    
Non-Ugandan 1.44 (0.63, 3.28) 1.28 (0.34, 4.80)  0.62 (0.35, 1.08) 0.44 (0.23, 0.84)  0.193 0.411 
Maternal history of allergies         
No 1 1  1 1    
Yes 2.29 (0.83, 6.32) 2.43 (0.84, 7.03)  2.19 (1.50, 3.21) 2.23 (1.51, 3.30)  0.685 0.513 
Paternal history of allergies         
No 1 1  1 1    
Yes 2.19 (0.84, 5.70) 1.62 (0.68, 3.87)  0.79 (0.39, 1.59) 0.90 (0.46, 1.76)  0.096 0.122 
Malaria treatment, last 12 
months 
        
No  1 1  1 1    
Yes 1.25 (0.78, 2.01) 1.21 (0.71, 2.07)  1.69 (1.25, 2.30) 1.69 (1.14, 2.51)  0.149 0.165 
HIV         
Negative 1 1  1 1    
Positive 3.19 (0.80, 12.7) 2.67 (0.64, 11.1)  1.05 (0.63, 1.77) 1.02 (0.62, 1.69)  0.595 0.391 
 
E. Rhinitis 
 
Factor OR (95% CI) OR (95% CI) – Additionally adjusted for Sm (CCA)*  OR (95% CI) 
OR (95% CI) – Additionally 
adjusted for Sm (CCA)* 
 Interaction p Interaction p** 
         
Age  0.99 (0.97, 1.01) 0.99 (0.97, 1.01)  1.02 (1.00, 1.03) 1.02 (1.00, 1.04)  0.576 0.597 
Sex         
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 Male 1 1  1 1    
Female 1.31 (0.71, 2.40) 1.38 (0.69, 2.73)  1.42 (0.69, 2.88) 1.48 (0.72, 3.05)  0.786 0.212 
Older siblings (Yes/No)         
No 1 1  1 1    
Yes 1.72 (0.73, 4.08) 1.67 (0.71, 3.96)  0.63 (0.46, 0.86) 0.61 (0.42, 0.88)  0.098 0.040 
Younger siblings (Yes/No)         
No 1 1  1 1    
Yes 1.59 (0.80, 3.15) 1.58 (0.83, 2.99)  2.07 (0.67, 6.41) 1.81 (0.59, 5.53)  0.859 0.740 
Location of birth         
City 1 1  1 1    
Town 0.09 (0.02, 5.55) 0.08 (0.00, 2.48)  0.50 (0.29, 0.85) 0.66 (0.29, 1.49)    
Village 0.29 (0.03, 3.05) 0.22 (0.03, 1.68)  0.28 (0.12, 0.64) 0.42 (0.15, 1.19)  0.135 0.241 
Maternal history of allergies         
No 1 1  1 1    
Yes 3.56 (1.28, 9.93) 3.95 (1.41, 11.1)  1.58 (0.85, 2.96) 1.69 (0.96, 2.97)  0.676 0.878 
Paternal history of allergies         
No 1 1  1 1    
Yes 3.29 (1.24, 8.76) 3.56 (1.28, 9.93)  1.30 (0.61, 2.76) 1.15 (0.48, 2.79)  0.435 0.264 
Hand washing after toilet         
No 1 1  1 1    
Yes 2.26 (0.68, 7.47) 2.54 (0.81, 7.95)  1.91 (0.92, 3.94) 1.91 (0.85, 4.32)  0.212 0.221 
HIV         
Negative 1 1  1 1    
Positive 3.15 (1.18, 8.39) 2.48 (0.59, 10.4)  1.17 (0.57, 2.40) 1.34 (0.66, 2.72)  0.029 0.228 
 
Table shows only non-helminth-related factors that were associated with SPT reactivity, asIgE sensitisation, wheeze, urticaria and rhinitis in either the urban or the rural survey. All 
other non-helminth-related factors that were assessed are listed in the statistical methods section. Significant associations are highlighted in bold. 
* Adjusting for other Sm infection variables (KK / PCR), Sm infection intensity (KK) and SWA- and SEA-specific antibodies paints a similar picture. 
** Additionally adjusted for Sm infection (CCA) 
CCA: Circulating Cathodic Antigen. 
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 Table S5. Crude and adjusted associations with IgE sensitisation (ImmunoCAP IgE > 0.35 kU/L) to any of D. pteronyssinus, A. 
hypogaea or B. germanica 
  UNADJUSTED ANALYSIS  ADJUSTED ANALYSIS 
       
   URBAN   RURAL   URBAN  RURAL   
  Factor  N (%)≠ OR (95% CI)¶ p  N (%)≠ OR (95% CI)¶ p  OR (95% CI) ¶# p OR (95% CI)¶§ p Interaction p 
              
Age    0.99 (0.98, 1.01) 0.400  1.00 (0.99, 1.02) 0.076  0.99 (0.98, 1.01) 0.547 1.01 (0.98, 1.03) 0.589 0.728 
Sex              
Male  47 (48) 1  241 (64) 1   1  1   
Female  101 (41) 0.75 (0.50, 1.10) 0.136 196 (49) 0.56 (0.36, 0.86) 0.011  0.77 (0.51, 1.15) 0.200 0.69 (0.42, 1.14) 0.140 0.407 
Younger siblings (Yes/No)              
No  27 (33) 1  61 (62) 1   1  1   
Yes  106 (46) 1.76 (0.96, 3.25) 0.065 313 (56) 0.81 (0.57, 1.14) 0.213  2.07 (1.07, 4.01) 0.030 0.76 (0.53, 1.09) 0.129 0.008 
Occupation              
Student or child (not at school)  68 (48) 1  64 (51) 1   1  1   
Unemployed or housewife  34 (40) 0.70 (0.42, 1.16)  58 (54) 1.23 (0.75, 2.01)   0.70 (0.31, 1.60)  2.05 (1.38, 3.03)   
Agricultural, fishing or lake related  4 (36) 0.61 (0.17, 2.12)  251 (61) 1.58 (1.12, 2.24)   0.56 (0.13, 2.46)  1.87 (1.04, 3.37)   
Professional or service providers   27 (38) 0.64 (0.37, 1.11) 0.391 61 (47) 0.78 (0.49, 1.25) 0.020  0.61 (0.26, 1.43) 0.725 1.38 (0.72, 2.66) 0.014 0.148 
Lake contact              
Never  39 (45) 1      1     
Rarely  69 (42) 0.89 (0.49, 1.62)  8 (42) 1   0.98 (0.52, 1.85)  1   
Once a month  11 (35) 0.67 (0.36, 1.26)      0.74 (0.38, 1.41)     
Once a week  14 (50) 1.23 (0.47, 3.19) 1.000 25 (44) 0.93 (0.29, 3.00)   1.32 (0.49, 3.55) 0.835 0.82 (0.23, 2.89)   
Daily/ almost daily     343 (59) 2.22 (0.63, 7.86) 0.034    1.64 (0.45, 5.90) 0.174  
Bathe in water from lake?              
No  121 (42) 1  15 (63) 1   1  1   
Yes  12 (57) 1.85 (0.51, 6.66) 0.327 361 (57) 0.49 (0.19, 1.27) 0.139  1.86 (0.50, 6.87) 0.331 0.42 (0.15, 1.11) 0.078 0.065 
Hand washing after toilet              
No  15 (39) 1  148 (71) 1   1  1   
Yes  117 (43) 1.16 (0.61, 2.23) 0.627 228 (50) 0.37 (0.25, 0.55) <0.001  1.36 (0.69, 2.66) 0.344 0.43 (0.30, 0.61) <0.001 0.003 
              
SWA-specific IgE*   2.54 (0.56, 11.4) 0.209  4.15 (2.05, 8.44) <0.001  2.95 (0.51, 17.2) 0.214 6.17 (2.79, 13.6) <0.001 0.459 
125
 SWA-specific IgG4*   1.01 (0.86, 1.18) 0.898  1.22 (1.02, 1.45) 0.032       1.01 (0.85, 1.19) 0.932 1.07 (0.89, 1.27) 0.470      0.433 
SEA-specific IgG4*   1.10 (0.98, 1.24) 0.090  1.14 (1.02, 1.26) 0.023       1.11 (0.97, 1.25) 0.102 1.07 (0.95, 1.21) 0.227    0.704 
SWA-specific IgG*   2.74 (0.99, 7.59) 0.052  3.04 (1.82, 5.08) <0.001  3.33 (1.12, 9.86) 0.031 1.53 (0.82, 2.86) 0.177      0.340 
SEA-specific IgG*   1.58 (0.63, 4.01) 0.310  2.41 (1.57, 3.66) <0.001  1.77 (0.63, 4.96) 0.260 1.43 (0.88, 2.30) 0.138      0.796 
              
S. mansoni infection (KK)              
Uninfected   119 (44) 1  271 (55) 1   1  1   
Infected  6 (43) 0.95 (0.29, 3.09) 0.931 118 (63) 1.39 (1.02, 1.90) 0.036  1.06 (0.34, 3.35) 0.910 1.52 (1.19, 1.94) 0.002 0.180 
S. mansoni infection intensity (KK)              
Uninfected   119 (44) 1  271 (55) 1   1  1   
Light  2 (29) 0.51 (0.08, 3.09)  54 (57) 1.23 (0.85, 1.78)   0.66 (0.11, 4.04)  1.74 (1.18, 2.54)   
Moderate  2 (50) 1.26 (0.15, 10.8)  35 (66) 1.23 (0.65, 2.32)   1.20 (0.16, 8.79)  0.94 (0.46, 1.90)   
Heavy  2 (67) 2.54 (0.13, 49.7) 0.711 29 (73) 2.44 (0.93, 6.38) 0.019  2.32 (0.13, 40.9) 0.662 2.37 (0.71, 7.83) 0.028 0.536 
Any nematode infection**              
No  109 (42) 1  281 (54) 1   1  1   
Yes  16 (62) 2.22 (0.83, 5.94) 0.108 108 (66) 1.90 (1.29, 2.81) 0.002  2.34 (0.76, 7.19) 0.130 1.53 (0.94, 2.49) 0.084 0.287 
Slept under mosquito net last 
night? 
             
No   35 (45) 1  203 (62) 1   1  1   
Yes  97 (42) 0.88 (0.49, 1.59) 0.678 172 (52) 0.62 (0.41, 0.94) 0.025  0.93 (0.52, 1.66) 0.958 0.63 (0.41, 0.97) 0.037 0.316 
Malaria treatment, last 12months              
No   83 (45) 1  202 (63) 1   1  1   
Yes  48 (39) 0.78 (0.45, 1.34) 0.352 221 (51) 0.53 (0.36, 0.75) 0.001  0.78 (0.46, 1.35) 0.365 0.52 (0.34, 0.81) 0.005 0.185 
 
Table shows only factors that were associated with IgE sensitisation (before and/or after adjustment) in either the urban or the rural survey. All other factors that were assessed are listed in the 
methods section. Significant associations are highlighted in bold. Interaction p values are shown to denote whether tests for interaction, using the adjusted model, showed statistical evidence for urban-
rural differences in associations with IgE sensitisation, or not. 
≠Number (percentage in parenthesis) of IgE sensitised individuals in each category 
¶Odds ratios (ORs) and 95% confidence intervals (CI) adjusted for survey design 
§All ORs were adjusted for hand washing after toilet use, mosquito net use, malaria treatment, age and sex.  
#All ORs were adjusted for age and sex. 
*Log10 (concentration+1) transformation applied before analysis 
**Infection with any of Ascaris lumbricoides, Trichuris trichiura (assessed by KK), Necator americanus, Strongyloides stercoralis (assessed by PCR). 
KK: Kato-Katz; SWA: Schistosoma adult worm antigen; SEA: Schistosoma egg antigen. 
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 Table S6. Summary of risk factors for IgE sensitisation (ImmunoCAP IgE > 0.35 kU/L) to individual allergen extracts 
  URBAN SURVEY  RURAL SURVEY 
       
Outcome  Factors positively associated with outcome  
Factors inversely 
associated with outcome   
Factors positively 
associated with outcome  
Factors inversely 
associated with outcome  
       
D. pteronyssinus-specific IgE 
sensitisation (ImmunoCAP) 
 
• Presence of younger siblings 
(p=0.020) 
• Paternal history of allergies 
(p=0.041) 
• Maternal history of allergies 
(p=0.034) 
- 
 • T. trichiura infection 
(p<0.001) 
• SWA-specific IgG (p=0.016) 
• SEA-specific IgG (p=0.037) 
• Maternal history of allergies 
(p=0.004) 
• Age (p=0.036) 
• engaging in agricultural / 
fishing / lake related 
activities or being 
unemployed (p=0.043) 
• Hand washing after toilet 
use (p=0.008) 
• Bathing in lake water 
(p<0.001) 
• Presence of younger 
siblings (p=0.008) 
• Female gender (p=0.001) 
• Mosquito net use (p=0.052) 
       
B. germanica-specific IgE 
sensitisation (ImmunoCAP) 
 
• SEA-specific IgE (p=0.034) 
• Presence of younger siblings 
(p=0.045) 
• S. mansoni infection (CCA) 
[p=0.024] 
 
• SWA-specific IgE (p<0.001) 
• Any nematode infection 
(p=0.063) 
• Sm infection (KK) [p=0.060] 
• Hand washing after toilet 
use (p=0.001) 
• Bathing in lake water 
(p=0.01) 
• Malaria infection (p=0.01) 
• Recent malaria treatment 
(p=0.010) 
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A. hypogaea-specific IgE 
sensitisation (ImmunoCAP) 
 • SEA-specific IgE (p=0.051) 
• Hookworm infection 
(p=0.031) 
- 
 • SEA-specific IgE (p<0.001) 
• BCG scar (p=0.013) 
• Worm treatment during 
pregnancy (p=0.002) 
• Recent malaria treatment 
(p=0.004) 
       
D. pteronyssinus-specific IgE 
(ImmunoCAP) – continuous 
variable 
 
- - 
 • SWA-specific IgE 
(p=0.004), IgG (p=0.027) 
• SEA-specific IgG (p=0.035) 
• S. mansoni infection (KK) 
(p=0.029) 
• Paternal history of allergies 
(p=0.028) 
• Female gender (p<0.001) 
• Recent malaria treatment 
(p=0.029) 
• Bathing in lake water 
(p=0.023) 
       
B. germanica-specific IgE 
sensitisation (ImmunoCAP)- 
continuous variable 
 
• SWA-specific IgG (p=0.011) 
• SEA-specific IgE (p=0.001) 
- 
 
• SWA-specific IgE (p<0.001) 
and IgG (p=0.008) 
• SEA-specific IgG (p=0.027) 
• A. lumbricoides infection 
(p<0.001) 
• Hand washing (before 
eating [p=0.040], after toilet 
[p=0.002]) 
• Bathing in lake water 
(p=0.008) 
• Malaria infection (p<0.001) 
• Recent malaria treatment 
(p=0.005) 
• Female gender (p=0.004),  
       
128
 A. hypogaea-specific IgE 
sensitisation (ImmunoCAP)- 
continuous variable 
 • S. mansoni infection [PCR] 
(p=0.008) 
• S. stercoralis infection 
(p<0.001) 
• Hookworm infection 
(p=0.003) 
• Any nematode infection 
(p=0.002) 
• SEA-specific IgE (p=0.002), 
IgG4 (p<0.001) and IgG 
(p=0.025) and IgG4 
(p=0.001) 
• SWA-specific IgG (p=0.003) 
• Presence of younger siblings 
(p=0.034) 
- 
 
• SWA-specific IgE 
(p<0.001), IgG (p<0.001), 
• SEA-specific IgE (p=0.001), 
IgG (p<0.001), 
• Hookworm infection 
(p=0.017) 
• Female gender (p=0.011) 
• Recent malaria treatment 
(p=0.002) 
• Bathing in lake water 
(p=0.005) 
• Malaria infection (p=0.043) 
• Hand washing after toilet 
use (p=0.028) 
       
P values are from adjusted analyses, conducted as described in the main text. The following were assessed as potential risk factors: age, sex, presence of older/younger siblings, 
maternal tribe, paternal tribe, location of birth, occupation, frequency of lake contact, type of bathing water, hand-washing behaviour [before eating, after toilet use], footwear outside the 
house, smoking, alcohol use, helminth infections, exposure to anthelminthic treatment in utero, anthelminthic treatment in last 12 months, maternal and paternal history of 
allergy/eczema/asthma, BCG scar, immunization history, treatment for malaria in last 12 months, malaria infection, HIV infection and plasma concentration of SEA- and SWA-specific IgE, 
IgG4 and IgG antibodies. 
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 Table S7. Crude and adjusted associations with clinical allergy-related outcomes 
    UNADJUSTED ANALYSIS  ADJUSTED ANALYSIS 
       
   URBAN   RURAL   URBAN  RURAL  
WHEEZE (AGE≥ 5 YEARS) 
  N (%)≠ OR (95% CI)a p N (%)≠ OR (95% CI)a p  OR (95% CI)a,b p OR (95% CI)a,c p Interaction p 
              
Age    1.02 (0.99, 1.03) 0.067  1.02 (1.01, 1.04) 0.001  1.01 (0.99, 1.02) 0.240 1.00 (1.00, 1.03) 0.003 0.386 
Sex              
Male  8 (2) 1  56 (4) 1   1  1   
Female  16 (2) 1.19 (0.59, 2.42) 0.602 31 (2) 0.45 (0.29, 0.69) 0.001  1.30 (0.55, 3.07) 0.531 0.47 (0.31, 0.73) 0.002 0.087 
Older siblings (Yes/No)              
No  11 (3) 1  20 (4) 1   1  1   
Yes  13 (2) 0.46 (0.24, 0.89) 0.023 62 (4) 0.84 (0.39, 1.77) 0.642  0.36 (0.19, 0.73) 0.006 0.88 (0.43, 1.79) 0.706 0.177 
Occupation              
Student or child (not at school)  12 (3) 1  6 (1) 1   1  1   
Unemployed or housewife  7 (2) 0.88 (0.51, 1.54)  8 (3) 1.24 (0.36, 4.22)   0.46 (0.15, 1.41)  1.68 (0.45, 6.31)   
Agricultural, fishing or lake related  2 (3) 1.26 (0.32, 4.94)  61 (4) 4.35 (1.38, 13.6)   0.44 (0.03, 6.96)  3.85 (0.96, 15.4)   
Professional or service providers   3 (1) 0.35 (0.07, 1.55) 0.563 12 (3) 3.10 (0.86, 11.1) 0.035  0.08 (0.01, 0.77) 0.194 3.75 (0.79, 17.6) 0.258 0.051 
Maternal history of allergies              
No  15 (2) 1  59 (3) 1   1  1   
Yes  7 (7) 4.18 (1.65, 10.6) 0.004 11 (3) 0.95 (0.38, 2.38) 0.926  3.34 (0.82, 13.6) 0.089 1.11 (0.45, 2.71) 0.818 0.083 
Paternal history of allergies              
No  14 (2) 1  55 (3) 1   1  1   
Yes  5 (9) 5.73 (1.34, 24.5) 0.021 9 (4) 2.11 (0.96, 4.61) 0.061  4.96 (0.81, 30.4) 0.080 2.32 (0.97, 5.49) 0.056       0.259 
Paternal tribe               
Central Uganda  8 (2) 1  38 (3) 1   1  1   
Other, Ugandan  12 (2) 1.41 (0.50, 3.96)  39 (3) 0.68 (0.38, 1.20)   1.58 (0.35, 7.16)  0.66 (0.38, 1.18)   
Non-Ugandan, African  4 (4) 2.66 (1.14, 6.19) 0.061 9 (3) 0.65 (0.36, 1.15) 0.193  4.25 (1.94, 9.34) 0.001 0.61 (0.36, 1.15) 0.173 <0.001 
Hand washing before eating              
No  1 (1) 1  3 (3) 1   1  1   
Yes  23 (2) 0.17 (0.05, 0.54) 0.004 79 (4) 0.82 (0.19, 3.51) 0.785  0.11 (0.04, 0.30) <0.001 1.08 (0.25, 4.68) 0.914 0.051 
              
130
 SWA-specific IgG*   0.21 (0.02, 2.18) 0.183  27.4 (4.6, 162.3) 0.001  0.13 (0.02, 0.81) 0.030 26.8 (4.6, 158.6) 0.001 <0.001 
SEA-specific IgG*   0.24 (0.06, 0.97) 0.046  4.87 (1.09, 21.6) 0.038  0.15 (0.05, 0.54) 0.005 5.91 (1.07, 32.4) 0.041 0.001 
SWA-specific IgG4*   1.28 (1.02, 1.63) 0.037  4.53 (0.84, 24.4) 0.076  1.46 (0.98, 2.19) 0.060 5.38 (0.73, 39.9) 0.096 0.276 
              
Any nematode infection              
No  16 (2) 1  60 (4) 1   1  1   
Yes  1 (1) 0.51 (0.06, 4.22) 0.513 12 (2) 0.45 (0.19, 1.05) 0.064  0.92 (0.10, 8.27) 0.937 0.41 (0.18, 0.97) 0.042 0.744 
              
URTICARIAL RASH 
  N (%)≠ OR (95% CI)a p  N (%)≠ OR (95% CI)a p  OR (95% CI)a,d p OR (95% CI)a,e p Interaction p 
              
Age    1.02 (0.99, 1.04) 0.059  1.03 (1.02, 1.04) <0.001  1.02 (0.99, 1.04) 0.179 1.03 (1.02, 1.03) <0.001 0.512 
Sex              
Male  20 (4) 1  160 (9) 1   1  1   
Female  33 (4) 1.09 (0.64, 1.88) 0.734 174 (11) 1.21 (0.94, 1.54) 0.132  0.98 (0.54, 1.79) 0.956 1.12 (0.85, 1.48) 0.399 0.398 
Occupation              
Student or child (not at school)  19 (3) 1  74 (6) 1   1  1   
Unemployed or housewife  13 (4) 1.57 (0.63, 3.91)  45 (15) 2.92 (1.86, 4.56)   0.74 (0.36, 1.52)  1.49 (0.73, 3.00)   
Agricultural, fishing or lake related  5 (8) 3.13 (0.93, 10.5)  162 (12) 2.45 (1.68, 3.56)   0.43 (0.04, 4.56)  1.25 (0.68, 2.28)   
Professional or service providers   16 (5) 1.76 (0.85, 3.63) 0.154 53 (11) 2.14 (1.49, 3.06) <0.001  1.25 (0.33, 4.76) 0.723 0.91 (0.48, 1.70) 0.674 0.595 
Maternal tribe              
Central Uganda  22 (4) 1  100 (8) 1   1  1   
Other, Ugandan  23 (4) 1.04 (0.59, 1.84)  158 (10) 1.22 (0.84, 1.78)   0.77 (0.40, 1.49)  1.58 (0.98, 2.54)   
Non-Ugandan, African  8 (8) 1.92 (0.85, 4.32) 0.254 72 (14) 1.61 (1.17, 2.22) 0.017  1.18 (0.35, 4.03) 0.737 1.74 (0.97, 3.11) 0.091 0.970 
Paternal tribe              
Central Uganda  22 (4) 1  158 (12) 1   1  1   
Other, Ugandan  25 (4) 1.08 (0.54, 2.18)  127 (8) 0.69 (0.55, 0.88)   1.08 (0.55, 3.28)  0.43 (0.29, 0.65)   
Non-Ugandan, African  6 (5) 1.41 (0.65, 3.04) 0.644 49 (12) 0.98 (0.71, 1.37) 0.013  1.44 (0.63, 3.28) 0.625 0.62 (0.35, 1.08) 0.001 0.193 
Maternal history of allergies              
No  36 (3) 1  206 (9) 1   1  1   
Yes  11 (9) 2.68 (1.26, 5.72) 0.013 70 (13) 1.82 (1.31, 2.52) 0.001  2.29 (0.83, 6.32) 0.103 2.19 (1.50, 3.21) <0.001 0.566 
Paternal history of allergies              
No  36 (3) 1  235 (9) 1   1  1   
Yes  6 (9) 2.72 (1.05, 6.98) 0.039 31 (10) 0.97 (0.52, 1.83) 0.946  2.19 (0.84, 5.70) 0.102 0.79 (0.39, 1.59) 0.899 0.096 
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 SEA-specific IgE*   0.89 (0.55, 1.44) 0.630  2.13 (0.81, 5.61) 0.122  0.72 (0.36, 1.46) 0.348 2.83 (1.44, 5.55) 0.004 0.022 
              
Bathe in water from lake?              
No  47 (4) 1  6 (8) 1   1  1   
Yes  6 (5) 1.40 (0.67, 2.89) 0.343 264 (12) 3.03 (1.26, 7.24) 0.015  0.87 (0.32, 2.37) 0.776 3.44 (0.09, 118) 0.479 0.147 
Worm treatment, last 12 months              
No   13 (3) 1  18 (5) 1   1  1   
Yes  40 (5) 1.98 (1.17, 3.35) 0.013 316 (11) 2.04 (1.40, 2.96) 0.001  2.11 (1.11, 4.01) 0.024 1.40 (0.71, 2.77) 0.171 0.248 
Worm treatment in pregnancy              
No  8 (4) 1  11 (11) 1   1  1   
Yes  16 (3) 0.71 (0.22, 2.24) 0.542 6 (5) 0.25 (0.07, 0.86) 0.030  1.02 (0.32, 3.26) 0.975 0.29 (0.07, 1.14) 0.074 0.508 
Malaria treatment, last 12 months              
No   29 (4) 1  90 (7) 1   1  1   
Yes  23 (5) 1.28 (0.81, 2.05) 0.278 240 (12) 1.68 (1.22, 2.32) 0.002  1.25 (0.78, 2.01) 0.329 1.69 (1.25, 2.30) 0.001 0.149 
HIV              
Negative  43 (4) 1  210 (11) 1   1  1   
Positive  5 (9) 2.49 (0.92, 6.79) 0.071 65 (16) 1.55 (1.07, 2.22) 0.020  3.19 (0.80, 12.7) 0.095 1.05 (0.63, 1.77) 0.829 0.595 
              
RHINITIS              
 
 N (%)≠ OR (95% CI)a p  N (%)≠ OR (95% CI)a p  OR (95% CI)a,f p OR (95% CI)a,g p p 
(interaction) 
              
Age   1.01 (0.99, 1.02) 0.102  1.04 (1.03, 1.05) <0.001  0.99 (0.97, 1.01) 0.527 1.02 (1.00, 1.03) 0.019 0.576 
Sex              
Male  14 (3) 1  44 (3) 1   1  1   
Female  31 (4) 1.48 (0.78, 2.80) 0.214 60 (4) 1.14 (0.61, 2.15) 0.668  1.31 (0.71, 2.40) 0.367 1.42 (0.69, 2.88) 0.320 0.786 
Older siblings (Yes/No)              
No  9 (2) 1  30 (6) 1   1  1   
Yes  36 (4) 1.63 (0.88, 2.96) 0.109 69 (4) 0.69 (0.52, 0.93) 0.016  1.72 (0.73, 4.08) 0.204 0.63 (0.46, 0.86) 0.005 0.098 
Younger siblings (Yes/No)              
No  7 (2) 1  8 (2) 1   1  1   
Yes  38 (4) 2.34 (1.20, 4.55) 0.015 91 (5) 1.91 (0.69, 5.23) 0.190  1.59 (0.80, 3.15) 0.171 2.07 (0.67, 6.41) 0.195 0.859 
Occupation              
Student or child (not at school)  13 (2) 1  6 (1) 1   1  1   
Unemployed or housewife  19 (7) 3.46 (1.48, 8.12)  14 (5) 6.21 (2.01, 19.1)   4.75 (1.26, 17.9)  1.68 (0.23, 12.5)   
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 Agricultural, fishing or lake related  2 (3) 1.75 (0.35, 8.84)  58 (4) 8.22 (2.76, 24.5)   2.15 (0.14, 32.1)  2.60 (0.31, 22.1)   
Professional or service providers   11 (3) 1.76 (0.64, 4.83) 0.059 26 (6) 8.34 (2.70, 25.7) 0.007  3.17 (0.56, 17.8) 0.107 2.33 (0.25, 21.4) 0.407 0.259 
Location of birth              
City  3 (6) 1  6 (10) 1   1  1   
Town  2 (1) 0.25 (0.03, 2.28)  14 (6) 0.48 (0.28, 0.81)   0.09 (0.02, 5.55)  0.50 (0.29, 0.85)   
Village  12 (4) 0.65 (0.22, 1.93) 0.456 75 (4) 0.30 (0.14, 0.65) 0.009  0.29 (0.03, 3.05) 0.496 0.28 (0.12, 0.64) 0.011 0.135 
Maternal history of allergies              
No  28 (3) 1  68 (3) 1   1  1   
Yes  11 (9) 3.48 (1.35, 8.99) 0.012 18 (3) 1.07 (0.56, 2.04) 0.822  3.56 (1.28, 9.93) 0.017 1.58 (0.85, 2.96) 0.126 0.676 
Paternal history of allergies              
No  32 (3) 1  70 (3) 1   1  1   
Yes  6 (9) 3.07 (1.27, 7.39) 0.015 10 (3) 0.79 (0.39, 1.58) 0.499  3.29 (1.24, 8.76) 0.019 1.30 (0.61, 2.76) 0.479 0.435 
Lake contact              
Never  9 (2) 1      1     
Rarely  23 (4) 2.15 (1.05, 4.44)  6 (7) 1   1.35 (0.51, 3.61)  1   
Once a month  4 (3) 1.58 (0.43, 5.83)      0.55 (0.09, 3.18)     
Once a week  9 (7) 3.95 (1.85, 8.42) 0.004 11 (5) 1.01 (0.28, 3.62)   2.24 (0.82, 6.07) 0.364 1.29 (0.35, 4.68)   
Daily/ almost daily     82 (4) 0.84 (0.23, 3.03) 0.651    1.30 (0.33, 5.17) 0.807  
Bathe in water from lake?              
No  40 (3) 1  6 (8) 1   1  1   
Yes  5 (4) 1.36 (0.61, 3.05) 0.425 93 (4) 0.42 (0.22, 0.79) 0.010  0.89 (0.39, 2.07) 0.794 0.45 (0.27, 0.78) 0.006 0.223 
Hand washing after toilet              
No  2 (1) 1  22 (3) 1   1  1   
Yes  43 (4) 4.13 (1.06, 15.9) 0.041 77 (5) 1.63 (0.85, 3.14) 0.135  2.26 (0.68, 7.47) 0.169 1.91 (0.92, 3.94) 0.078 0.212 
HIV              
Negative  37 (3) 1  67 (3) 1   1  1   
Positive  5 (9) 2.92 (1.22, 6.99) 0.019 17 (4) 1.61 (0.80, 3.22) 0.172  3.15 (1.18, 8.39) 0.023 1.17 (0.57, 2.40) 0.659 0.029 
 
Table shows only factors that were associated with clinical allergy-related outcomes in either the urban or the rural survey, before and/or after adjustment for confounding. All other factors that were 
assessed are listed in the statistical methods section. Significant associations are highlighted in bold. Interaction p values are shown to denote whether tests for interaction, using the adjusted model, 
showed statistical evidence for urban-rural differences in associations with wheeze / urticarial rash / rhinitis, or not. 
≠Number (percentage in parenthesis) of individuals with respective allergic disease in each category 
aOdds ratios (ORs) and 95% confidence intervals (CI) adjusted for survey design. 
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 bORs adjusted for hand washing before eating, maternal history of allergies, paternal history of allergies, presence of older siblings, age and sex.  
cORs adjusted for age and sex.  
dORs adjusted for maternal history of allergies, paternal history of allergies, alcohol use, age and sex. 
eORs adjusted for HIV infection status, maternal history of allergies, recent malaria treatment, paternal tribe, maternal tribe, age and sex. 
fORs adjusted for presence of younger siblings, maternal history of allergies, paternal history of allergies, hand washing after toilet use, HIV infection, age and sex. 
gORs adjusted for presence of older siblings, location of birth, age and sex. 
*Log10 (concentration+1) transformation applied before analysis 
SWA: Schistosoma adult worm antigen; SEA: Schistosoma egg antigen. 
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 CHAPTER 5. ASSOCIATIONS BETWEEN ALLERGY-RELATED OUTCOMES AND 
HELMINTH- AND ALLERGEN EXTRACT-SPECIFIC ANTIBODY PROFILES 
5.1 Preamble 
This chapter uses questionnaire, clinical and laboratory data from the baseline survey of 
the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases 
(LaVIISWA) to map the association of total, helminth- and allergen extract-specific IgE 
and IgG4 profiles with helminth infection and allergy-related outcomes (thesis objective 
2). Results are presented in Research paper 2 (below), titled “Schistosoma mansoni-
specific immune responses and allergy in Uganda”, published in Parasite Immunology. 
The focus was on infection with Schistosoma mansoni, rather than with other helminths, 
because of its high prevalence in the study setting.  
This chapter also presents extra, unpublished results, showing associations between 
allergy-related outcomes and total, schistosome- and allergen extract-specific IgE and 
IgG4 profiles in 1) the outcome survey of the LaVIISWA trial (after three years of 
community-based intensive versus standard anthelminthic treatment), 2) the urban 
survey and 3) the asthma case-control study. Comparisons of antibody profiles are made 
between intensive and standard trial arms of the rural survey, between the urban and 
rural survey, and between asthmatic and non-asthmatic school children.  
The chapter assesses the relationship between Schistosoma-specific antibody 
responses and allergy-related outcomes, seeking to elucidate antibody mechanisms 
underlying positive helminth-atopy associations and the low overall prevalence of clinical 
allergy in the present study settings. Specifically, the role of IgG4 and total IgE (as a 
proxy for polyclonally-stimulated IgE), relative to allergen-specific IgE, is explored.  
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 5.2 Research paper 2: Schistosoma mansoni-specific immune responses and 
allergy in Uganda 
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Summary
Low	allergy-	related	disease	(ARD)	prevalence	in	low-	income	countries	may	be	partly	
attributed to helminth infections. In the Schistosoma mansoni (Sm)-	endemic	 Lake	
Victoria	islands	(Uganda),	we	recently	observed	positive	helminth-	allergy	associations,	
despite	low	ARD	prevalence.	To	understand	how	Sm- induced cytokine and antibody 
profiles might influence allergic response profiles in this population, we assessed 
Schistosoma	worm	(SWA)-	and	egg	antigen	(SEA)-specific	Th1	(IFN-	γ),	Th2	(IL-	5,	IL-	13)	
and	regulatory	(IL-	10)	cytokine	profiles	(n	=	407),	and	total	(n	=	471),	SWA-	,	SEA-	and	
allergen	 (house	 dust	mite	 [HDM]	 and	 cockroach)-	specific	 (as)IgE	 and	 IgG4	 profiles	
(n	=	2117)	 by	 ELISA.	 Wheeze	 was	 inversely	 associated	 with	 SWA-	specific	 IFN-	γ 
(P	<	.001)	and	IL-	10	(P	=	.058),	and	SEA-	specific	IL-	5	(P	=	.004).	Conversely,	having	a	
detectable	asIgE	response	was	positively	associated	with	SWA-	specific	IL-	5	(P	=	.006)	
and IL- 10 (P	<	.001).	Total,	SWA-	,	SEA-	and	allergen-	specific	IgE	and	IgG4	responses	
were higher among Sm	Kato-	Katz	positive	(SmKK+)	and	skin	prick	test	(SPT)+	individu-
als compared to SmKK- and SPT- individuals. However, total and asIgG4/IgE ratios 
were	lower	among	SPT+	and	wheezing	individuals.	We	conclude	that,	in	this	popula-
tion, helminth- induced antibody and cytokine responses may underlie individual posi-
tive helminth- atopy associations, while the overall IgG4- IgE balance may contribute to 
the low overall prevalence of clinical allergies in such settings.
K E Y W O R D S
allergy,	cytokine,	ELISA,	immunoglobulin,	Schistosoma spp
1  | INTRODUCTION
Helminths have a small range of antigens that are strikingly homolo-
gous to common allergens.1 These antigens induce immunoglobulin 
(Ig)	 E-	mediated	 effector	 responses	 important	 for	 protection	 against	
helminth infection.2,3 To survive in the host, helminths modulate 
this atopic pathway, and this may have a bystander protective ef-
fect	against	allergy-	related	disease	(ARD).4 While several animal and 
human studies provide compelling evidence of this protection,5,6 oth-
ers suggest that in some circumstances helminths may actually pro-
mote enhanced responses to allergens.7,8
Mechanisms underlying helminth- allergy associations in low- 
income	 countries	 (LICs)	 are	 not	 fully	 understood.	 Hypothesized	
pathways that underpin these associations are shown in Figure 1. 
Helminth- induced cytokine and antibody profiles may influence al-
lergic responses and consequently epidemiological trends pertaining 
to	ARDs.5,9 Both helminth- and allergen- specific immune responses 
are	characterized	by	elevated	Th2-	type	responses	(interleukin	[IL]-	4,	LaVIISWA	trial	team	members	are	in	Appendix	1.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
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IL-	5	and	IL-	13).10,11 Helminths, unlike allergens, further induce strong 
immunoregulation	epitomized	by	IL-	10	production.12 Typically, these 
cytokines influence the profile of antibodies involved in helminth in-
fection and allergy. Helminth- induced IL- 10 may drive immunoglobulin 
class switching to IgG413,14 which, akin to the Th2 cytokine- induced15 
polyclonally stimulated IgE, may inhibit development of allergen- 
specific effector responses,5,16 leading to inverse helminth- allergy 
associations. Conversely, helminth- induced protein- specific IgE may 
promote strong, cross- reactive helminth- and allergen- specific re-
sponses, resulting in positive helminth- allergy associations.17,18
Emerging epidemiological data on helminth- allergy associations 
in	 Uganda	 reflect	 the	 complex	 interaction	 between	 helminths	 and	
allergens: while observational analyses in a birth cohort suggested a 
protective effect of childhood and maternal helminths against child-
hood	 eczema19 that was reversed by maternal anthelminthic treat-
ment,20 we recently reported positive helminth- allergy associations 
in a survey conducted in the Schistosoma mansoni (Sm)-	endemic	Lake	
Victoria	islands,	albeit	against	a	backdrop	of	low	ARD	prevalence.21 To 
establish how Sm-induced cytokine and antibody profiles underpinned 
helminth- allergy associations in the above survey, we here describe an 
assessment of Sm-specific cytokine profiles, as well as total, allergen- 
and Sm-specific IgE and IgG4 profiles, and their relationship with Sm 
infection	status,	wheeze	and	atopy.
2  | METHODS
2.1 | Study population
Samples were collected during the baseline household survey preced-
ing	a	cluster-	randomized	trial	of	standard	vs	intensive	anthelminthic	
intervention (the Lake Victoria Island Intervention Study on Worms 
and	 Allergy-	related	 diseases,	 LaVIISWA;	 ISRCTN47196031)	 de-
scribed elsewhere.21,22	Briefly,	each	consenting	LaVIISWA	participant	
completed a questionnaire, provided blood, urine and stool and under-
went	skin	prick	testing	(SPT).	Primary	allergy-	related	outcomes	were	
reported	wheeze	 in	 the	 previous	 12	months	 and	 atopy.	Wheeze	 is	
widely used as a surrogate for asthma in epidemiological studies23 and 
was	assessed	for	all	ages	using	the	International	Study	of	Asthma	and	
Allergies	 in	 Childhood	 (ISAAC)	 questionnaire.	 Such	 symptom	 ques-
tionnaires have been identified as the best way to estimate asthma 
prevalence in epidemiological studies.23	The	ISAAC	questionnaire	was	
used	to	ask	participants	(or	their	caregivers)	if	they	had	ever	wheezed	
and	if	so,	if	they	had	wheezed	in	the	last	12	months.	Details	on	aeti-
ology	were	not	collected.	Atopy	was	defined	as	 (i)	SPT	reactivity	to	
any of Dermatophagoides	mix,	Blomia tropicalis or German cockroach 
(Blattella germanica)	[ALK-	Abelló;	supplied	by	Laboratory	Specialities	
Ltd.,	South	Africa],	 and	 (ii)	detectable	 IgE	 response	 (>312	ng/mL	by	
ELISA21)	to	Dermatophagoides pteronyssinus [hereinafter “house dust 
mite	 (HDM)”]	 and/or	 German	 cockroach	 whole	 allergen	 extracts	
(Greer	Labs,	USA).
Ethics committees of Uganda Virus Research Institute, London 
School	of	Hygiene	and	Tropical	Medicine	and	Uganda	National	Council	
for Science and Technology approved the study.
2.2 | Laboratory methods
Two slides from one stool sample per individual were independently 
examined	by	different	 technicians	 for	Sm	 eggs	 using	 the	Kato-	Katz	
method.24
We	 assessed	 IFN-	γ	 (Th1-	type),	 IL-	5,	 IL-	13	 (Th2-	type)	 and	 IL-	10	
(regulatory)	 levels	 by	 ELISA	 using	 supernatants	 from	 six-	day	whole	
blood cultures stimulated with Schistosoma	 worm	 (SWA)	 and	 egg	
antigens	 (SEA),	 as	 previously	 described.25	 Briefly,	 heparinized	 blood	
was	diluted	with	RPMI	1640	medium	(Life	technologies,	UK)	supple-
mented with penicillin, streptomycin, glutamine and Hepes buffer (all 
from	Life	technologies,	UK),	plated	in	96-	well	culture	plates	and	stim-
ulated (at 37°C, 5% CO2)	with	 10	μg/mL	 SWA	or	 SEA	 (provided	 by	
Professor	Mike	Doenhoff,	University	of	Nottingham)	or	mitogen	(phy-
tohaemagglutinin,	PHA,	Sigma,	UK),	or	left	unstimulated.	Supernatants	
were	harvested	on	day	six	and	stored	at	−80°C	until	analysis.	Cytokine	
F IGURE  1 We	hypothesize	that	the	
Th2 cytokine- induced Sm- specific IgE 
promotes potent, Sm- specific, atopic 
effector responses and Sm elimination from 
the host, and also cross- reactive responses 
to some allergens, resulting in positive 
Sm- allergy associations. By contrast, Sm-
specific IL- 10, IgG4 and/or nonspecific 
polyclonally stimulated IgE inhibit these 
allergy- related outcomes. White and 
shaded arrows denote promotion and 
inhibition, respectively
140
     |  3 of 9NKURUNUNGI et al.
levels	 in	 supernatants	were	measured	 by	 ELISA	 (Becton	 Dickinson,	
USA).	The	net	response	to	each	stimulus	was	calculated	by	subtracting	
the concentration in the unstimulated control well. Response values 
that were below the dynamic range of the assay and those that were 
negative after subtraction of the response in the unstimulated well 
were	assigned	a	value	of	zero.
HDM	and	cockroach	extract-	specific	IgE	and	IgG4	were	measured	
in	 plasma	 using	 an	 in-	house	 ELISA	 described	 previously.20 Briefly, 
MICROLON®	96-	well	plates	(Greiner	bio-	one,	UK)	were	coated	over-
night at 4°C with 5 μg/mL HDM or cockroach allergens and twofold 
dilutions	 of	 human	 IgE	 (Calbiochem,	 Beeston,	 UK)	 or	 IgG4	 (Sigma-	
Aldrich)	standards.	Plates	were	blocked	at	room	temperature	(RT)	with	
1% skimmed milk and incubated overnight at 4°C with plasma samples 
diluted	1/20	(IgE	assay)	or	1/40	(IgG4	assay)	with	10%	foetal	bovine	
serum in PBS- Tween 20. Specific IgE or IgG4 was detected using bioti-
nylated monoclonal mouse anti- human IgE or IgG4 (BD Pharmingen™)	
and	a	streptavidin-	horseradish	peroxidase	conjugate	(Mast	Group	Ltd,	
Bootle,	UK).	O-	phenylenediamine	(Sigma-	Aldrich)	was	used	as	a	sub-
strate, and the reaction stopped with 2M sulphuric acid. Optical den-
sity	values	were	measured	at	490nm	(reference	wavelength	630nm)	on	
a	96-	well	plate	ELISA	reader.	IgE	or	IgG4	concentrations	(ng/mL)	were	
interpolated from standard curves using a five- parameter curve fit 
using Gen5 data collection and analysis software (BioTek Instruments 
Inc,	Vermont,	Winooski,	USA).	Total,	SWA-	and	SEA-	specific	 IgE	and	
IgG4	ELISAs	were	performed	using	similar	 in-	house	procedures	 (de-
tailed	in	this	article’s	supporting	information).
TABLE  1 Characteristics of participants
Characteristic
Survey population 
(N = 2316),  
n/N (%)
Immunological measure, n/N (%)
Cytokine  
responsesa
(N = 407)
Allergen- , SWA- and  
SEA- specific  IgE  
and IgG4b (N = 2117)
Total IgE  
and IgG4c
(N=471)
Age	in	years,	median	(IQR) 24	(8,	32) 9	(6,	16) 25	(10,	33) 19.5	(3,	31.25)
Male	sex 1268/2316	(54.7) 168/407	(41.3) 1152/2117	(54.4) 225/471	(47.7)
PZQ	in	last	12	mo 382/2255	(16.9) 48/393	(12.2) 368/2062	(17.8) 15/459	(15.5)
Helminth infections
S. mansoni	(KK) 1041/1996	(51.4) 204/373	(54.7) 1008/1882	(53.6) 184/428	(42.9)
S. mansoni	(urine	CCA) 661/917	(72.0) 94/128	(73.4) 634/875	(72.5) 101/152	(66.5)
S. mansoni	intensity	(KK)
Uninfected 995/1996	(48.6) 169/373	(45.3) 874/1882	(46.4) 244/428	(57.0)
Low 429/1996	(21.0) 77/373	(20.6) 411/1882	(21.8) 70/428	(16.4)
Moderate 288/1996	(13.7) 56/373	(15.0) 279/1882	(14.8) 51/428	(11.9)
Heavy 324/1996	(16.6) 71/373	(19.0) 318/1882	(16.9) 63/428	(14.7)
Any	nematode	infectiond 788/2004	(39.3) 129/373	(34.6) 738/1889	(39.1) 87/428	(20.3)
Allergy-	related	outcomes
Wheeze	in	last	12	mo 107/2301	(4.7) 14/404	(3.5) 106/2103	(5.04) 58/468	(12.4)
Atopy	(SPT)
Any 404/1976	(19.1) 78/372	(20.9) 403/1961	(20.6) 135/448	(30.1)
Dermatophagoides 190/1978	(9.0) 33/372	(8.9) 189/1963	(9.6) 61/448	(13.6)
Blomia 205/1976	(9.6) 31/372	(8.3) 204/1961	(10.4) 67/447	(14.9)
Cockroach 272/1977	(13.2) 61/372	(16.4) 272/1962	(13.9) 90/448	(20.1)
Atopy	(detectable	asIgE)
Any 1685/2117	(79.6) 320/403	(79.4) 1685/2117	(79.6) 358/471	(76.0)
Dermatophagoides 1534/2115	(72.5) 278/403	(68.9) 1534/2115	(72.5) 326/471	(69.2)
Cockroach 886/2117 (41.9 183/403	(45.4) 886/2117	(41.9) 186/471	(39.5)
PZQ,	Praziquantel	treatment;	KK,	Kato-	Katz;	CCA,	circulating	cathodic	antigen;	SPT,	skin	prick	test;	SWA,	Schistosoma	worm	antigen;	SEA,	Schistosoma egg 
antigen; asIgE: allergen- specific IgE.
aAssessed	using	samples	from	1-	to	17-	year-	olds,	to	allow	comparison	with	related	cellular	immunology	studies	in	an	urban	birth	cohort	(data	not	shown	
here).
bAssessed	in	all	survey	participants	that	had	sufficient	plasma	sample	stored.
cSamples randomly selected from individuals with antigen- specific antibody data.
dInfection with any of Ascaris lumbricoides, Trichuris trichiura (assessed by KK), Necator americanus, Strongyloides stercoralis (assessed by PCR) and Mansonella 
perstans (assessed by modified Knott’s method).
141
4 of 9  |     NKURUNUNGI et al.
2.3 | Statistical methods
Our	 hypothesized	 mode	 of	 action	 of	 S. mansoni- induced cytokines 
and antibodies on allergy- related outcomes is illustrated in Figure 1. 
Using	STATA	13.1	(College	Station,	Texas,	USA),	we	performed	cross-	
sectional analyses to assess whether Sm	 Kato-	Katz	 positivity	 and	
allergy- related outcomes were associated with antibody and cytokine 
levels,	using	the	“svy”	command	to	allow	for	the	non–self-	weighting	
cluster survey design. Raw cytokine and antibody responses were 
skewed, so log10	 (concentration+1)-	transformed	 antibody	 and	 cy-
tokine data were used in our regression models; we back- transformed 
the results to obtain geometric mean ratios and 95% confidence in-
tervals.	Crude	and	age-	and	sex-	adjusted	analyses	were	performed.	
Associations	 between	 antibody	 responses	 were	 estimated	 using	
Spearman’s correlation coefficient (rs).	 We	 used	 a	 5%	 significance	
level for all analyses. P	values	quoted	 in	the	main	text	are	from	ad-
justed analyses.
3  | RESULTS
Questionnaire	 data	 were	 obtained	 from	 2316	 participants.22 Their 
characteristics and those of participants for whom cytokine and an-
tibody responses were assessed are shown in Table 1. Participants 
for	whom	cytokine	(n	=	407)	and	total	antibody	levels	(n	=	471)	were	
assessed	were	a	subset	of	participants	who	had	allergen-	,	SWA-	and	
SEA-	specific	antibody	results	(n	=	2117).	Cytokine	responses	were	as-
sessed using samples from 1- to 17- year- olds, to allow comparison 
with related cellular immunology studies in an urban birth cohort 
(data	not	shown).	Allergen-	,	SWA-	and	SEA-	specific	responses	were	
assessed in all survey participants that had sufficient plasma sample 
stored.
3.1 | S. mansoni-specific cytokines and allergy- 
related outcomes
Individuals who tested positive for Sm	 by	 Kato-	Katz	 (SmKK+)	 had	
higher	 geometric	mean	 concentrations	 of	 SWA-	specific	 type	 2	 and	
regulatory cytokines compared to SmKK- individuals (Table 2),	 but	
this was statistically significant only for IL- 5 (P	=	.034).	 However,	
there was no dose- response relationship with infection intensity 
(Table	S3A).	SEA-	specific	responses	were	similar	between	SmKK+	and	
SmKK- individuals.
Wheeze	 was	 inversely	 associated	 with	 SWA-	specific	 IFN-	γ 
(P	<	.001)	 and	 IL-	10	 (P	=	.058;	Table 2),	 and	SWA-	specific	 IL-	10/IL-	5	
and	SEA-	specific	 IL-	10/IFN-	γ	ratios	 (Table	S1).	Wheezing	 individuals	
also	had	 lower	mean	SEA-	specific	cytokine	responses,	although	sta-
tistical	evidence	for	an	inverse	association	was	observed	only	for	SEA-	
specific IL- 5 (P	=	.004).
Conversely, there was a crude positive association between SPT 
positivity	and	SWA-	specific	 IL-	10	 (P	=	.048;	Table	2);	and	 individuals	
with	detectable	allergen-	specific	(as)IgE	had	higher	SWA-	specific	IL-	5	
(P	=	.006)	and	IL-	10	responses	(P < .001; Table 2)	and	higher	SWA-	and	
SEA-	specific	IL-	10/IFN-	γ	and	IL-	5/IFN-	γ	ratios	(Table	S1).
3.2 | Antibody responses, S. mansoni Kato- Katz 
positivity and allergy
Kato-	Katz	positivity	was	strongly	positively	associated	with	SWA-	and	
SEA-	specific	IgE	and	IgG4	(P	<	.001),	with	HDM-specific IgE (P	=	.006)	
and HDM- and cockroach- specific IgG4 (P < .001; Table 3 and sup-
plementary	 Figure	 S1).	However,	 correlations	 between	Sm antigen- 
specific antibodies and allergen- specific antibodies were weak (rs < .4, 
Table	S2).
Kato-	Katz	 positivity	was	 also	 strongly	 positively	 associated	with	
total IgE (P	<	.001)	(Table	3	and	Figure	S1),	which	was	in	turn	weakly	
correlated	with	SEA-	specific	IgE	but	moderately	correlated	with	SWA-	
specific IgE (rs	=	.31	and	rs	=	.51,	respectively;	Table	S2).	Similarly,	total	
IgG4 (P	<	.001),	total	IgG4/total	IgE	ratios	(P	=	.005)	and	total	IgE/asIgE	
ratios (P	<	.05)	were	positively	associated	with	Kato-	Katz	positivity.	In	
addition, there was a general dose- response relationship between S. 
mansoni	infection	intensity	and	antibody	responses	(Table	S3B).
Cockroach- specific IgE and total IgE were positively associated 
with	 cockroach	 SPT	 reactivity.	 HDM-	specific	 IgE	 and	 IgG4,	 SWA-	
and	SEA-	specific	IgE	and	total	IgE,	were	all	positively	associated	with	
HDM SPT reactivity (Table 3 and Figure S1). In contrast, cockroach 
SPT reactivity was inversely associated with total IgG4/total IgE ratios 
(P	=	.022),	and	HDM	SPT	reactivity	with	 total	 IgE/HDM-	specific	 IgE	
ratios (P	<	.001).
Associations	 between	 wheeze	 and	 antibody	 responses	 (Table	3	
and	Figure	S1),	when	significant,	were	inverse.	HDM	IgG4/IgE	ratios	
(P	=	.032),	 cockroach-	specific	 IgE	 (P	=	.003)	 and	 cockroach-	specific	
IgG4 (P	=	.001)	were	all	inversely	associated	with	wheeze.
4  | DISCUSSION
In this highly Sm-	endemic	setting,	associations	between	wheeze	and	
Sm- specific cytokines and antibodies, when significant, were inverse. 
However, SPT reactivity and detectable asIgE were positively associ-
ated with the same Sm- specific responses.
In this population, Sm	exposure	is	almost	universal,	and	infection	
much	higher	than	indicated	by	Kato-	Katz:	urine	assessment	for	Sm cir-
culating	cathodic	antigen	 (CCA)	 indicated	a	prevalence	of	over	70%,	
compared	to	51.4%	prevalence	by	Kato-	Katz.22	Therefore,	Kato-	Katz	
negativity in many study participants was indicative of lighter (rather 
than	absent)	infection.	This	explains	why,	although	SWA-	specific	Th2-	
type and regulatory cytokine responses were generally higher among 
SmKK+	individuals,	only	SWA-	specific	IL-	5	reached	significant	levels,	
and	why	 SEA-	specific	 responses	were	 similar	 between	 SmKK+	 and	
SmKK- individuals. Further support for these observations comes 
from	 supplementary	 analysis	 (Table	 S4A),	 which	 shows	 that	 cyto-
kine	responses	were	similar	between	SmKK-	CCA+	and	SmKK+CCA±	
individuals.
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TABLE  2 Associations	between	S. mansoni-	specific	cytokine	levels	and	(i)	S. mansoni	infection	status,	(ii)	reported	wheeze	and	(iii)	atopy	(SPT	
reactivity	and	detectable	allergen-	specific	IgE)
Geometric meana
Unadjusted Adjusted for age and sex
Antigen Cytokine SmKK- n = 169 SmKK+ n = 204 GMR (95% CI)b P value GMR (95% CI)b P value
SWA IFN-	γ 1.16 1.13 1.06	(0.86,	1.30) .542 1.05	(0.87,	1.28) .531
IL- 5 14.92 49.47 1.43 (1.13, 1.81) .005 1.32 (1.02, 1.71) .034
IL- 13 7.01 17.56 1.20	(0.94,	1.54) .132 1.15	(0.88,	1.48) .282
IL- 10 3.99 11.58 1.21	(0.97,	1.51) .084 1.16	(0.91,	1.48) .207
SEA IFN-	γ 0.73 0.56 0.97	(0.81,	1.17) .760 0.98	(0.82,	1.18) .884
IL- 5 5.02 3.11 0.84	(0.59,	1.19) .320 0.84	(0.58,	1.19) .319
IL- 13 2.25 1.95 0.86	(0.71,	1.05) .127 0.88	(0.73,	1.06) .190
IL- 10 3.19 4.42 0.93	(0.78,	1.13) .486 0.93	(0.76,	1.13) .477
No wheeze n = 390 Wheeze n = 14
SWA IFN-	γ 1.27 0.23 0.60 (0.45, 0.80) .001 0.57 (0.44, 0.76) <.001
IL- 5 29.12 27.59 1.29	(0.72,	2.33) .373 1.14	(0.63,	2.08) .657
IL- 13 11.75 9.78 1.26	(0.65,	2.45) .465 1.17	(0.58,	2.36) .635
IL- 10 7.91 2.03 0.69 (0.47, 1.01) .059 0.66 (0.43, 1.02) .058
SEA IFN-	γ 0.66 0.33 0.83	(0.66,	1.04) .101 0.83	(0.65,	1.05) .121
IL- 5 4.37 1.20 0.52 (0.33, 0.83) .007 0.51 (0.33, 0.79) .004
IL- 13 2.25 0.96 0.75	(0.44,	1.25) .256 0.76	(0.44,	1.33) .327
IL- 10 4.34 0.59 0.70	(0.35,	1.38) .295 0.71	(0.37,	1.36) .291
SPT− n = 294
SPT+c
n = 78
SWA IFN-	γ 1.03 1.73 1.15	(0.96,	1.36) .115 1.13	(0.94,	1.34) .178
IL- 5 29.23 39.73 1.15	(0.86,	1.52) .330 1.02	(0.75,	1.38) .897
IL- 13 13.54 10.32 0.99	(0.72,	1.36) .961 0.92	(0.67,	1.26) .596
IL- 10 6.79 12.00 1.25 (1.00, 1.55) .048 1.21	(0.95,	1.54) .126
SEA IFN-	γ 0.55 0.99 1.11	(0.82,	1.51) .493 1.13	(0.83,	1.52) .423
IL- 5 4.54 3.68 1.00	(0.70,	1.45) .965 0.98	(0.67,	1.43) .935
IL- 13 2.81 1.09 0.84	(0.56,	1.25) .376 0.85	(0.58,	1.25) .413
IL- 10 4.12 3.09 0.94	(0.76,	1.16) .560 0.96	(0.75,	1.22) .730
Undetectable asIgE 
n = 83
Detectable asIgEd
n = 320
SWA IFN-	γ 1.73 1.11 0.87	(0.62,	1.24) .444 0.86	(0.60,	1.23) .396
IL- 5 16.44 34.25 1.43 (1.16, 1.75) .001 1.32 (1.09, 1.61) .006
IL- 13 9.75 12.66 1.09	(0.77,	1.55) .599 1.04	(0.74,	1.47) .806
IL- 10 3.76 9.26 1.34 (1.18, 1.51) <.001 1.30 (1.16, 1.46) <.001
SEA IFN-	γ 1.12 0.56 0.79	(0.56,	1.13) .190 0.79	(0.57,	1.11) .176
IL- 5 3.78 4.17 1.13	(0.81,	1.58) .459 1.12	(0.82,	1.54) .450
IL- 13 2.21 2.21 0.88	(0.65,	1.22) .449 0.90	(0.67,	1.21) .484
IL- 10 3.49 4.17 1.05	(0.92,	1.21) .424 1.06	(0.93,	1.21) .382
SmKK−,	Kato-	Katz	negative	result	(S. mansoni),	single	stool	sample;	SmKK+,	Kato-	Katz	positivity	for	S. mansoni, single stool sample; SPT, skin prick test; 
SWA,	Schistosoma	worm	antigen;	SEA,	Schistosoma egg antigen; asIgE, allergen- specific IgE; GMR, geometric mean ratio; 95% CI, 95% confidence interval. 
P	values	≤.05	are	highlighted	in	bold.
aAll	cytokine	concentrations	in	pg/mL.
bGeometric mean ratios and 95% confidence intervals adjusted for the survey design.
cSPT reactivity to any one of Dermatophagoides	mix,	Blomia tropicalis or Blattella germanica.
dDetectable IgE to either Dermatophagoides pteronyssinus or Blattella germanica.
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All	 statistically	 significant	 associations	 between	 atopy	 and	 Sm- 
specific	 cytokine	 responses	 were	 positive.	 Associations	 with	 whole	
blood cytokine responses are best interpreted taking into account total 
cell counts, but these data were unavailable. However, atopy- antibody 
associations were also positive. Besides, these results mirror our previ-
ous epidemiological observations in this population, where Sm infection 
was positively associated with Dermatophagoides- specific IgE, and atopy- 
wheeze	associations	were	stronger	in	the	presence	of	Sm infection.21
TABLE  3 Associations	between	antibody	(IgE	and	IgG4)	levels	and	Kato-	Katz	positivity	(S. mansoni),	SPT	reactivity	and	reported	wheeze
Geometric meana
Antigen Antibody/antibody ratio SmKK− SmKK+ aGMR (95% CI)bc P value
SWA IgE 1080 2433 1.54 (1.28, 1.84) <.001
IgG4 4031 27 355 3.71 (3.14, 4.37) <.001
SEA IgE 1412 1833 1.32 (1.15, 1.52) <.001
IgG4 18 962 241 763 5.51 (4.55, 6.67) <.001
House dust mite IgE 0.782 10.678 1.25 (1.07, 1.45) .006
IgG4 0.001 0.192 1.79 (1.51, 2.13) <.001
IgG4/IgE ratio 0.002 0.033 1.18	(0.58,	2.41) .629
Cockroach IgE 18.8 19.2 1.00	(0.82,	1.22) .989
IgG4 0.002 0.292 1.50 (1.34, 1.68) <.001
IgG4/IgE ratio 0.001 0.027 1.32	(0.94,	1.85) .110
Total IgE 969 3073 1.37 (1.22, 1.54) <.001
Total IgG4 51 453 233 745 1.94 (1.49, 2.52) <.001
Total IgG4/total IgE ratio 52.16 75.24 1.36 (1.11, 1.67) .005
Total IgE/cockroach IgE ratio 3.79 12.60 1.32 (1.06, 1.66) .014
Total IgE/dust mite IgE ratio 0.562 1.301 1.13 (1.02, 1.25) .016
Cockroach SPT− Cockroach SPT+
SWA IgE 1704 1894 1.12	(0.94,	1.32) .173
IgG4 12 860 14 155 1.04	(0.85,	1.28) .675
SEA IgE 1611 1876 1.12	(0.97,	1.29) .092
IgG4 84 831 101 778 1.08	(0.92,	1.27) .319
Dust mite IgE 2.6 42.2 1.59 (1.35, 1.89) <.001
IgG4 0.022 0.061 1.06	(0.87,	1.29) .498
IgG4/IgE ratio 0.009 0.001 0.56 (0.36, 0.85) .010
Cockroach IgE 18.9 39.1 1.25 (1.08, 1.46) .004
IgG4 0.054 0.686 1.15	(0.95,	1.39) .129
IgG4/IgE ratio 0.003 0.017 0.69	(0.47,	1.02) .064
Total IgE 1462 2787 1.22 (1.05, 1.42) .011
Total IgG4 90 643 126 688 0.84	(0.65,	1.07) .163
Total IgG4/total IgE ratio 60.41 45.80 0.75 (0.58, 0.95) .022
Total IgE/cockroach IgE ratio 6.07 9.22 1.01	(0.82,	1.25) .894
Total IgE/dust mite IgE ratio 0.849 0.868 0.93	(0.84,	1.03) .140
Dust mite SPT− Dust mite SPT+
SWA IgE 1667 2409 1.26 (1.00, 1.57) .043
IgG4 13 088 12 565 1.04	(0.79,	1.36) .744
SEA IgE 1623 1887 1.23 (0.99, 1.53) .055
IgG4 85 471 102 026 1.20	(0.85,	1.68) .271
Dust mite IgE 2.5 242.9 2.10 (1.57, 2.81) <.001
IgG4 0.020 0.245 1.41 (0.99, 1.99) .052
IgG4/IgE ratio 0.009 0.001 0.49	(0.23,	1.04) .064
(Continues)
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Our	 results	 were	 unexpected	 in	 view	 of	 earlier	 findings	 from	
Gabon9 which showed an inverse association between dust mite 
SPT	and	SWA-	specific	 IL-	10	 (albeit	we	used	whole	blood	cultures,	
compared to peripheral blood mononuclear cells in the Gabon 
study).	However,	although	IL-	10	 is	chiefly	 immunomodulatory,26-28 
it may also enhance IgE production in already IgE- switched B cells;13 
these may be abundant in individuals from this helminth- endemic 
setting.	SWA-	and	SEA-	specific	 IgE	were	weakly	positively	associ-
ated with HDM SPT reactivity, perhaps unsurprisingly, as helminth 
antigens may induce cross- reactive helminth- and allergen- specific 
IgE effector responses. Total serum IgE, elevated during helminth 
infection mainly due to increased synthesis of polyclonal IgE, has 
been proposed to inhibit allergic responses.29,30 However, contrast-
ing	evidence	links	high	serum	IgE	levels	to	increased	expression	of	
IgE receptors on human basophils,31 and we show positive associ-
ations between total IgE and SPT reactivity to both cockroach and 
dust mite.
In keeping with the original hypothesis, associations between 
wheeze	and	cytokine	and	antibody	responses,	when	significant,	were	
inverse. Furthermore, total and allergen- specific IgG4/IgE ratios were 
mostly inversely associated with atopy, implying that the regulatory 
role	of	IgG4	against	allergy	might	best	be	assessed	relative	to	IgE.	Also,	
lower	total/asIgE	ratios	among	HDM	SPT+	individuals	are	consistent	
with the perception that high total/asIgE ratios may be protective 
against allergic responses, because nonspecific polyclonal IgE may 
compete with asIgE to saturate IgE receptors.29
One limitation of assessing helminth- allergy associations and un-
derlying	mechanisms	in	this	population	is	the	almost	universal	expo-
sure to helminths, and lack of data on duration of infection. We also 
report a large number of statistical tests, so some apparently “signifi-
cant”	findings	could	have	occurred	by	chance.	As	we	anticipated	that	
some of our measures might be correlated, we did not formally adjust 
for multiplicity, instead we focussed on patterns of association and con-
sistency of results, and on biological plausibility with reference to other 
Dust mite SPT− Dust mite SPT+
Cockroach IgE 19.9 33.7 1.21 (1.03, 1.43) .024
IgG4 0.065 0.405 1.13	(0.85,	1.50) .395
IgG4/IgE ratio 0.004 0.013 0.71	(0.48,	1.04) .075
Total IgE 1533 2802 1.24 (1.03, 1.49) .025
Total IgG4 89 885 156 204 1.09	(0.86,	1.38) .438
Total IgG4/total IgE ratio 57.43 55.45 0.89	(0.72,	1.11) .292
Total IgE/cockroach IgE ratio 6.41 8.11 1.01	(0.82,	1.26) .893
Total IgE/dust mite IgE ratio 0.937 0.517 0.81 (0.74, 0.89) <.001
No wheeze Wheeze
SWA IgE 1672 2627 1.15	(0.81,	1.64) .425
IgG4 12 753 14 802 1.05	(0.71,	1.54) .808
SEA IgE 1636 1547 0.93	(0.66,	1.29) .662
IgG4 81 698 145 978 1.16	(0.77,	1.73) .449
House dust mite IgE 2.8 26.6 1.35	(0.89,	2.04) .148
IgG4 0.007 0.008 0.85	(0.59,	1.25) .407
IgG4/IgE ratio 0.011 0.001 0.45 (0.22, 0.93) .032
Cockroach IgE 21.2 2.9 0.69 (0.55, 0.87) .003
IgG4 0.021 0.006 0.65 (0.53, 0.82) .001
IgG4/IgE ratio 0.004 0.002 1.14	(0.47,	2.74) .760
Total IgE 1630 1522 0.88	(0.72,	1.07) .205
Total IgG4 100 983 74 475 0.85	(0.61,	1.17) .302
Total IgG4/total IgE ratio 61.00 47.36 0.95	(0.77,	1.18) .683
Total IgE/cockroach IgE ratio 6.29 6.86 0.91	(0.78,	1.05) .187
Total IgE/dust mite IgE ratio 0.857 0.752 0.91	(0.77,	1.05) .188
SWA,	Schistosoma	worm	antigen;	SEA,	Schistosoma egg antigen; SmKK−,	Kato-	Katz	negative	result	(S. mansoni),	single	stool	sample;	SmKK+,	Kato-	Katz	
positive result, single stool sample; aGMR, adjusted geometric mean ratio; 95% CI, 95% confidence interval. P	values	≤0.05	are	highlighted	in	bold.
aAll	antibody	concentrations	in	ng/mL.
bAll	geometric	mean	ratios	and	95%	confidence	intervals	adjusted	for	survey	design,	age	and	sex.
cGeometric	mean	ratios	and	95%	confidence	intervals	for	associations	between	antibody	levels	and	SPT	reactivity	and	wheeze	were	additionally	adjusted	
for SmKK result.
TABLE  3  (Continued)
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findings.	Another	potential	limitation	is	that	wheeze	was	relatively	rare	
in the study population, and hence, some of our comparison groups 
(such	as	the	age	group	1-	17	years)	had	a	low	prevalence.	Besides,	re-
ported	wheeze	could	easily	be	misclassified	in	this	population	due	to	
lack	of	a	direct	translation	of	“wheeze”	in	the	native	languages.21
Nonetheless,	 our	 results	 generally	 agree	 with	 our	 epidemiolog-
ical observations in the same population,21 where we found a very 
low prevalence of clinical allergies, despite positive helminth- atopy 
associations.
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 5.3 Supplementary information for Research paper 2 (available in the article’s 
online repository at https://onlinelibrary.wiley.com/doi/10.1111/pim.12506 ) 
5.3.1 Experimental methods 
5.3.1.1 S. mansoni worm (SWA)- and egg (SEA)-specific IgE and IgG4 ELISA 
All but the first 2 columns of 4HX Immulon (Thermo Scientific, NY, USA) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Mike Doenhoff, University of Nottingham) in bicarbonate buffer (0.1M, pH 9.6). Two-fold 
dilutions of human IgE (Calbiochem, Beeston, UK) or IgG4 (Sigma-Aldrich) standard, 
diluted in bicarbonate buffer, were added to the first 2 columns of each plate to form 
standard curves. The plates were then incubated overnight at 40C. Plates were washed 
with phosphate-buffered saline (PBS)-tween 20 solution, blocked with 150μl of skimmed 
milk diluted in PBS-Tween 20 at room temperature (RT), and incubated overnight at 40C 
with 50μl of plasma samples diluted 1/20 with 10% fetal bovine serum in PBS-Tween 20 
(assay buffer). Plates were washed and antibody binding detected by incubating the 
plates overnight at 40C with 0.5μg/ml of biotinylated monoclonal mouse anti-human IgE 
or IgG4 (BD Pharmingen™), followed by a 1 hour incubation with a streptavidin-
Horseradish Peroxidase (strep-HRP) conjugate (Mast Group Ltd, Bootle, UK), diluted 
1/3000 with assay buffer, at RT. Plates were developed by addition of 100μl of o-
phenylenediamine (Sigma-Aldrich) and reactions stopped with 30μl of 2M Sulphuric acid. 
Optical density values were measured at 490nm (reference wavelength 630nm) on a 96-
well plate ELISA reader. IgE or IgG4 concentrations (ng/ml) were interpolated from 
standard curves using a five-parameter curve fit using Gen5 data collection and analysis 
software (BioTek Instruments Inc, Vermont, Winooski, USA). 
5.3.1.2 Total IgE ELISA 
96-well Maxisorp plates (VWR, U.S.A) were coated with 100μl of polyclonal rabbit anti 
human IgE (Agilent technologies, Dako, Denmark) diluted 1/1000 in bicarbonate buffer 
(0.1M, pH 9.6) and incubated overnight at 4oC. Plates were then washed with phosphate-
148
 buffered saline (PBS)-tween 20 solution and blocked with 120μl of PBS-bovine serum 
albumin (BSA) solution for 1 hour at room temperature (RT). Plasma samples (100μl) 
diluted 1/50 in assay buffer (0.1M Tris pH 7.5 + 0.05% Tween-20), the blank (assay 
buffer) and National Institute for Biological Standards and Control (NIBSC) international 
IgE standards were added to the plates and incubated for 1 hour at RT. Plates were then 
washed and incubated with 100μl of biotinylated goat anti-human IgE (Vector 
laboratories, U.S.A, 0.5mg/ml), diluted 1/1000 with assay buffer, for 1 hour at RT. After 
another washing step, the plates were incubated with 100μl of streptavidin alkaline 
phosphatase (Roche Life Science), diluted 1/3000 with assay buffer, for 30 minutes at 
RT. 4-nitrophenyl phosphate disodium salt hexahydrate (p-NPP), diluted in 
diethanolamine buffer (DEA, 0.1M), was added, followed by 20 minutes incubation at RT 
in the dark for development. Sodium hydroxide (3M, 100μl) was then added to stop the 
reaction. Plates were read at 405 nm using an ELISA reader. Results were interpolated 
from standard curves using a five-parameter curve fit using Gen5 data collection and 
analysis software (BioTek Instruments Inc, Vermont, Winooski, USA).  
5.3.1.3 Total IgG4 ELISA 
96-well Maxisorp plates (VWR, U.S.A) were coated with purified mouse anti-human IgG4 
(BD Pharmingen™) in bicarbonate buffer (0.1 M, pH 9.6) overnight at 4oC, and blocked 
for 1 hour with 3% skimmed milk in 1X PBS at room temperature (RT). Plates were then 
incubated with plasma samples (diluted 1/800 in 0.1M Tris pH 7.5 + 0.05% Tween-20) 
and IgG4 standards (Sigma Aldrich) for one hour. Antibody binding was detected by 
incubating the plates with mouse anti-human IgG4 conjugated to horseradish peroxidase 
(Invitrogen) for one hour, followed by a colour reaction with o-phenylenediamine (Sigma 
Aldrich). Reactions were stopped with 2M Sulphuric acid. Absorbance was measured at 
490nm (reference wavelength 630nm) on a 96-well plate ELISA reader. IgG4 
concentrations (ng/ml) were interpolated from standard curves using a five-parameter 
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 curve fit using Gen5 data collection and analysis software (BioTek Instruments Inc, 
U.S.A).
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 5.3.2 Supplementary tables and figures 
Table S1. Associations between S. mansoni-specific cytokine ratios and i) S. mansoni 
infection status, ii) reported wheeze and iii) atopy (SPT reactivity and detectable 
allergen-specific IgE) 
    Unadjusted  Adjusted for age and sex 
Antigen Ratio Geometric mean†  GMR (95% CI)‡ p value  GMR (95% CI) ‡ p value 
 
 
SmKK- 
n=169 
SmKK+ 
n=204 
      
SWA  IL-10/ IFN-γ 3.29 10.46  1.23 (0.89, 1.71) 0.192  1.18 (0.85, 1.65) 0.297 
 IL-10/ IL-5 0.26 0.23  0.91 (0.74, 1.11) 0.337  0.92 (0.74, 1.15) 0.456 
 
IL-10/ IL-13 0.56 0.65  0.95 (0.71, 1.29) 0.767  0.95 (0.67, 1.33) 0.745 
 IL-5/ IFN-γ 12.79 43.52  1.36 (1.03, 1.80) 0.028  1.25 (0.94, 1.65) 0.120 
 
IL-13/ IFN-γ 6.01 15.45  1.11 (0.81, 1.53) 0.498  1.03 (0.75, 1.43) 0.824 
SEA  IL-10/ IFN-γ 4.54 8.14  1.00 (0.75, 1.34) 0.985  0.97 (0.73, 1.29) 0.849 
 
IL-10/ IL-5 0.65 1.39  0.97 (0.72, 1.31) 0.853  0.96 (0.71, 1.32) 0.826 
 
IL-10/ IL-13 1.42 2.16  0.96 (0.72, 1.29) 0.807  0.95 (0.69, 1.32) 0.768 
 IL-5/ IFN-γ 6.88 5.55  0.94 (0.69, 1.29) 0.723  0.91 (0.66, 1.25) 0.550 
 
IL-13/ IFN-γ 3.09 3.49  0.85 (0.67, 1.07) 0.175  0.85 (0.68, 1.05) 0.123 
 
 
No wheeze 
n=390 
Wheeze 
n=14 
      
SWA IL-10/ IFN-γ 6.22 8.82  0.99 (0.68, 1.42) 0.961  0.97 (0.61, 1.55) 0.902 
 IL-10/ IL-5 0.26 0.07  0.79 (0.69, 0.91) 0.001  0.83 (0.70, 0.97) 0.023 
 IL-10/ IL-13 0.66 0.21  0.78 (0.53, 1.15) 0.206  0.79 (0.52, 1.21) 0.267 
 IL-5/ IFN-γ 22.87 119.94  2.51 (1.14, 5.51) 0.024  2.25 (1.03, 4.96) 0.044 
 IL-13/ IFN-γ 9.23 42.54  2.21 (0.91, 5.43) 0.079  2.08 (0.85, 5.06) 0.100 
SEA IL-10/ IFN-γ 6.78 1.78  0.52 (0.34, 0.80) 0.004  0.53 (0.37, 0.74) 0.001 
 IL-10/ IL-5 0.99 0.49  1.44 (0.48, 4.24) 0.493  1.49 (0.53, 4.21) 0.432 
 IL-10/ IL-13 1.88 0.61  0.78 (0.53, 1.16) 0.212  0.79 (0.55, 1.15) 0.220 
 IL-5/ IFN-γ 6.59 3.62  0.57 (0.32, 1.05) 0.069  0.55 (0.29, 1.02) 0.058 
 IL-13/ IFN-γ 3.40 2.90  0.69 (0.46, 1.03) 0.072  0.69 (0.45, 1.06) 0.088 
 
 
SPT- 
n=294 
SPT+§ 
n=78 
      
SWA IL-10/ IFN-γ 6.68 6.85  0.97 (0.76, 1.25) 0.840  0.94 (0.73, 1.22) 0.639 
 
IL-10/ IL-5 0.22 0.32  1.06 (0.86, 1.30) 0.532  1.11 (0.92, 1.34) 0.276 
 IL-10/ IL-13 0.48 1.22  1.28 (0.94, 1.74) 0.107  1.31 (0.99, 1.74) 0.056 
 
IL-5/ IFN-γ 28.51 22.94  0.99 (0.74, 1.33) 0.954  0.87 (0.67, 1.14) 0.324 
 
IL-13/ IFN-γ 13.2 5.96  0.89 (0.62, 1.27) 0.515  0.83 (0.59, 1.15) 0.253 
SEA IL-10/ IFN-γ 7.53 3.37  0.88 (0.63, 1.23) 0.444  0.88 (0.63, 1.22) 0.432 
 IL-10/ IL-5 0.88 0.92  1.01 (0.82, 1.23) 0.955  1.05 (0.85, 1.28) 0.635 
 IL-10/ IL-13 1.37 3.15  1.26 (0.89, 1.77) 0.175  1.31 (0.95, 1.83) 0.095 
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  IL-5/ IFN-γ 8.11 3.71  0.86 (0.59, 1.26) 0.435  0.81 (0.55, 1.16) 0.234 
 IL-13/ IFN-γ 5.01 1.09  0.72 (0.50, 1.02) 0.064  0.71 (0.50, 1.00) 0.051 
 
 
Undetecta-
ble asIgE 
n=83 
Detectable 
asIgE¶ 
n=320 
      
SWA IL-10/ IFN-γ 2.05 8.44  1.47 (1.07, 2.02) 0.019  1.46 (1.09, 1.94) 0.012 
 IL-10/ IL-5 0.22 0.26  0.99 (0.83, 1.20) 0.999  1.02 (0.86, 1.23) 0.749 
 IL-10/ IL-13 0.36 0.72  1.09 (0.87, 1.37) 0.430  1.10 (0.88, 1.36) 0.370 
 IL-5/ IFN-γ 9.47 30.88  1.69 (1.21, 2.37) 0.003  1.58 (1.17, 2.14) 0.004 
 IL-13/ IFN-γ 5.62 11.42  1.31 (0.96, 1.77) 0.080  1.25 (0.96, 1.62) 0.093 
SEA IL-10/ IFN-γ 2.97 7.79  1.41 (0.99, 1.99) 0.055  1.43 (1.03, 1.96) 0.032 
 IL-10/ IL-5 0.88 1.01  0.97 (0.73, 1.30) 0.878  0.99 (0.77, 1.28) 0.972 
 IL-10/ IL-13 1.51 1.85  1.04 (0.76, 1.41) 0.785  1.05 (0.79, 1.39) 0.703 
 IL-5/ IFN-γ 3.37 7.38  1.58 (1.16, 2.15) 0.005  1.55 (1.15, 2.08) 0.005 
 IL-13/ IFN-γ 1.96 3.89  1.13 (0.92, 1.40) 0.233  1.14 (0.93, 1.39) 0.186 
†All antibody concentrations in pg/ml. 
‡Geometric mean ratios and 95% confidence intervals adjusted for the survey design.  
§SPT reactivity to any one of Dermatophagoides mix, Blomia tropicalis or Blattella germanica.  
¶Detectable IgE to either Dermatophagoides pteronyssinus or Blattella germanica.  
SmKK-: Kato-Katz negative result (S. mansoni), single stool sample; SmKK+: Kato-Katz positivity for S. mansoni, single 
stool sample; SWA: Schistosoma worm antigen; SEA: Schistosoma egg antigen; asIgE: allergen-specific IgE; GMR: 
geometric mean ratio; 95% CI: 95% confidence interval. 
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 Figure S1. Summary of associations between antibody levels and i) S. mansoni infection, ii) SPT reactivity and iii) wheeze
 
Red and blue arrows denote positive and inverse associations, respectively. The thickness of the arrows shows the level of statistical significance. P values were obtained 
from linear regression analyses, after adjusting for survey design, age and sex. Furthermore, analyses assessing associations between antibody levels and SPT reactivity 
and wheeze were additionally adjusted for S. mansoni infection (Kato-Katz). SPT: skin prick test; SWA: Schistosoma worm antigen; SEA: Schistosoma egg antigen. 
Positive association, p <0.1
Positive association, p <0.05
Positive association, p <0.01
Positive association, p <0.001
Inverse association, p <0.1 
Inverse association, p <0.05
Inverse association, p <0.01
Inverse association, p <0.001
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Table S2. Correlation between antibody profiles 
 SWA IgE SEA IgE SWA IgG4 SEA IgG4 
Dust mite 
IgE 
Cockroach 
IgE 
Dust mite 
IgG4 
Cockroach 
IgG4 Total IgE Total IgG4 
SWA IgE 1          
SEA IgE 0.5202 1         
SWA IgG4 0.4409 0.2622 1        
SEA IgG4 0.3783 0.3074 0.6997 1       
Dust mite IgE 0.3823 0.2631 0.2462 0.218 1      
Cockroach IgE 0.2302 0.2895 0.0992 0.0707 0.3539 1     
Dust mite IgG4 0.1217 0.1702 0.2756 0.2425 0.1589 0.013 1    
Cockroach IgG4 0.1485 0.2062 0.2423 0.1701 0.1055 0.1014 0.5729 1   
Total IgE 0.5128 0.3095 0.4796 0.3764 0.3767 0.1575 0.1708 0.211 1  
Total IgG4 0.2201 0.2042 0.5052 0.4573 0.0861 0.0147 0.3902 0.3371 0.3977 1 
 
Table shows Spearman’s rank correlation coefficients (rs), calculated to estimate strength of association between antibody responses. Hinkle and colleagues’ criteria1 were used 
to interpret rs values: 0.7 – 1.00: high correlation; 0.5 – 0.7: moderate correlation; 0.3 – 0.5: low correlation; 0.00 – 0.3: little if any correlation. 
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 Table S3. Associations between S. mansoni infection intensity and antibody and cytokine responses  
A 
Antigen Cytokine Geometric mean†  aGMR (95% CI) ‡ 
  SmKK- SmKKlow SmKKmod SmKKheavy  SmKKlow SmKKmod SmKKheavy 
SWA  IFN-γ 1.16 2.67 1.14 0.45  1.49 (0.99, 2.25) 0.96 (0.70, 1.33) 0.77 (0.61, 0.96) 
 IL-5 14.92 28.67 80.23 61.04  1.09 (0.82, 1.45) 1.57 (1.09, 2.25) 1.42 (0.95, 2.09) 
 
IL-13 7.01 15.58 17.63 19.92  1.11 (0.85, 1.45) 1.17 (0.85, 1.60) 1.17 (0.79, 1.72) 
 
IL-10 3.99 9.65 13.68 12.39  1.08 (0.79, 1.49) 1.18 (0.87, 1.61) 1.25 (1.03, 1.51) 
SEA  IFN-γ 0.73 1.25 0.42 0.29  1.26 (0.96, 1.65) 0.92 (0.68, 1.25) 0.78 (0.67, 0.92) 
 
IL-5 5.02 6.18 3.08 1.49  1.10 (0.75, 1.62) 0.75 (0.49, 1.14) 0.67 (0.48, 0.93) 
 
IL-13 2.25 5.64 1.50 0.76  1.22 (0.98, 1.51) 0.78 (0.61, 1.02) 0.66 (0.54, 0.83) 
 
IL-10 3.19 7.32 4.63 2.45  1.12 (0.91, 1.38) 0.88 (0.67, 1.16) 0.78 (0.59, 1.05) 
 
B 
Antigen 
Antibody/ 
antibody ratio 
Geometric mean¶  aGMR (95% CI) ‡ 
  SmKK- SmKKlow SmKKmod SmKKheavy  SmKKlow SmKKmod SmKKheavy 
SWA  IgE 1080 2075 2544 2849  1.38 (1.08, 1.75) 1.48 (1.21, 1.82) 1.84 (1.52, 2.23) 
 IgG4 4031 14132 26403 62356  2.69 (2.28, 3.16) 3.77 (2.82, 5.05) 5.75 (4.41, 7.50) 
SEA  IgE 1412 1870 1953 1688  1.22 (1.06, 1.39) 1.50 (1.26, 1.78) 1.35 (1.06, 1.71) 
 IgG4 18962 170274 229400 391440  4.45 (3.47, 5.71) 5.86 (4.66, 7.37) 7.04 (5.59, 8.87) 
Dust mite  IgE 0.782 3.926 10.552 39.482  1.05 (0.86, 1.27) 1.33 (1.12, 1.56) 1.51 (1.14, 2.01) 
 IgG4 0.001 0.059 0.274 5.939  1.50 (1.18, 1.91) 1.65 (1.31, 2.08) 2.51 (2.04, 3.07) 
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  IgG4/IgE ratio 0.002 0.013 0.024 0.155  1.37 (0.62, 3.03) 1.10 (0.67, 1.81) 1.03 (0.37, 2.82) 
Cockroach IgE 18.87 15.60 16.66 28.37  0.97 (0.78, 1.21) 1.02 (0.74, 1.42) 1.02 (0.86, 1.19) 
 IgG4 0.002 0.091 0.147 3.349  1.43 (1.25, 1.65) 1.43 (1.22, 1.68) 2.01 (1.69, 2.39) 
 IgG4/IgE ratio 0.001 0.009 0.015 0.176  1.35 (0.91, 2.03) 1.08 (0.64, 1.83) 1.49 (0.91, 2.44) 
 
 Total IgE 969 2548 2208 4946  1.21 (1.01, 1.45) 1.19 (1.06, 1.35) 1.80 (1.62, 2.00) 
 Total IgG4 51453 115588 235755 520703  1.57 (1.31, 1.89) 2.07 (1.53, 2.66) 2.42 (1.59, 3.66) 
 
Total IgG4/ 
total IgE ratio 52.16 45 107 100  1.21 (0.96, 1.52) 1.56 (1.17, 2.08) 1.39 (1.08, 1.79) 
 
Total IgE/ 
cockroach IgE 
ratio 
3.79 11.23 8.47 19.30  1.27 (0.92, 1.76) 1.08 (0.87, 1.36) 1.64 (1.31, 2.04) 
 
Total IgE/ dust 
mite IgE ratio 0.562 1.66 0.78 1.52  1.17 (1.02, 1.32) 1.04 (0.86, 1.26) 1.17 (1.03, 1.34) 
†All cytokine concentrations in pg/ml.  
¶All antibody concentrations in ng/ml. 
‡Geometric mean ratios and 95% confidence intervals adjusted for the survey design, age and sex.  
SmKK-: Kato-Katz negative result (S. mansoni), single stool sample; SmKKlow: Kato-Katz positivity, low infection intensity (1-99 eggs/g); SmKKmod: Kato-Katz positivity, 
moderate infection intensity (100-399 eggs/g); SmKKheavy: Kato-Katz positivity, heavy infection intensity (≥400 eggs/g); SWA: Schistosoma worm antigen; SEA: 
Schistosoma egg antigen; aGMR: adjusted geometric mean ratio; 95% CI: 95% confidence interval.  
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Table S4. Comparison of cytokine and antibody responses between SmKK-CAA+ participants and (i) SmKK-CCA- and (ii) SmKK+CAA+/- 
individuals† 
A 
Antigen Cytokine Geometric mean  aGMR (95% CI) ‡§ 
  SmKK-CCA+ SmKK-CCA- SmKK+CCA+/-  SmKK-CCA- SmKK+CCA+/- 
SWA IFN-γ 1.83 0.57 1.33  0.71 (0.52, 0.97) 0.90 (0.66, 1.23) 
 IL-5 17.81 10.80 40.28  0.80 (0.47, 1.35) 1.38 (0.95, 2.01) 
 
IL-13 9.54 5.91 14.62  0.71 (0.43, 1.19) 1.06 (0.68, 1.65) 
 
IL-10 5.72 2.15 15.27  0.68 (0.55, 0.86) 1.25 (0.93, 1.69) 
SEA IFN-γ 0.57 1.09 0.46  0.98 (0.56, 1.74) 0.96 (0.63, 1.46) 
 
IL-5 15.15 2.35 3.26  0.49 (0.33, 0.74) 0.69 (0.46, 1.04) 
 
IL-13 2.79 1.15 1.85  0.66 (0.44, 1.00) 0.96 (0.56, 1.65) 
 
IL-10 5.40 1.63 5.45  0.66 (0.45, 0.98) 0.97 (0.66, 1.41) 
B 
Antigen 
Antibody /  
antibody ratio 
Geometric mean  aGMR (95% CI) ‡ 
  SmKK-CCA+ SmKK-CCA- SmKK+CCA+/-  SmKK-CCA- SmKK+CCA+/- 
SWA IgE 1244 843 3058  0.92 (0.50, 1.67) 1.67 (1.13, 2.48) 
 IgG4 4830 2291 27587  0.60 (0.45, 0.79) 2.85 (2.01, 4.03) 
SEA IgE 1473 1453 1927  0.76 (0.43, 1.37) 1.42 (1.14, 1.76) 
 IgG4 33789 6311 218820  0.30 (0.14, 0.65) 3.63 (2.28, 5.77) 
Dust mite IgE 0.61 0.45 22.59  1.06 (0.82, 1.38) 1.46 (1.16, 1.84) 
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  IgG4 0.001 0.001 0.221  1.03 (0.75, 1.39) 1.46 (1.12, 1.92) 
 IgG4/IgE ratio 0.004 0.004 0.015  0.79 (0.32, 1.95) 0.57 (0.27, 1.21) 
Cockroach IgE 20.17 9.61 17.85  0.92 (0.74, 1.14) 0.98 (0.75, 1.27) 
 IgG4 0.079 0.005 0.609  0.82 (0.63, 1.06) 1.26 (1.09, 1.47) 
 IgG4/IgE ratio 0.004 0.000 0.035  0.86 (0.49, 1.51) 1.24 (0.78, 1.96) 
        
 Total IgE 696 1222 3302  1.16 (0.82, 1.65) 1.69 (1.15, 2.48) 
 Total IgG4 44075 5543 282711  0.91 (0.67, 1.21) 1.79 (1.10, 2.92) 
 
Total IgG4/ 
total IgE ratio 63.31 43.75 80.71  0.83 (0.65, 1.05) 1.04 (0.65, 1.65) 
 
Total IgE/ 
cockroach IgE 
ratio 
2.26 5.65 19.62  1.04 (0.76, 1.41) 1.40 (0.90, 2.18) 
 
Total IgE/ dust 
mite IgE ratio 0.29 0.82 1.33  1.03 (0.90, 1.18) 1.14 (0.95, 1.35) 
†279 (cytokine responses), 1242 (allergen and S. mansoni-specific antibody responses) and 319 (total antibody responses) individuals missing CCA result; not included in 
analysis 
‡Geometric mean ratios and 95% confidence intervals adjusted for the survey design, age and sex.  
§SmKK-CCA+ used as the base category 
SmKK-: Kato-Katz negative result (S. mansoni), single stool sample; SmKK+: Kato-Katz positive result (S. mansoni), single stool sample; CCA-: Negative result for S. 
mansoni circulating cathodic antigen; CCA+: Positive result for S. mansoni circulating cathodic antigen; SmKK+CCA+/-: SmKK+ result, irrespective of CCA result; SWA: 
Schistosoma worm antigen; SEA: Schistosoma egg antigen; aGMR: adjusted geometric mean ratio; 95% CI: 95% confidence interval.  
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 5.4 Chapter 5: extra, unpublished results  
5.4.1 LaVIISWA year three outcome survey: impact of intensive versus standard 
anthelminthic treatment on IgE and IgG4 profiles 
The results reported in this chapter, so far, are from the LAVIISWA baseline survey, 
which preceded three years of community-based intensive versus standard 
anthelminthic treatment. Allergy-related trial outcomes were assessed after the three 
years of intervention, in a household-based survey: for all primary outcomes, there was 
no evidence of a difference in prevalence between intensive and standard trial arms 
(Research Paper 7, Appendix 3, this thesis). The present analysis also shows no 
evidence of an impact of intensive versus standard anthelminthic treatment on IgE and 
IgG4 profiles (Table E1, below).  
 
Table E1. Impact of community-based intensive versus standard anthelminthic treatment 
on IgE and IgG4 profiles in the LaVIISWA outcome survey 
Outcome Geometric mean  Unadjusted  Adjusted for age & sex 
 Standard Intensive 
 GMR (95% CI) p  GMR (95% CI) p 
Schistosoma-specific 
antibody concentration 
(ELISA, ng/ml) 
        
SWA-specific IgE  4457  4451  0.99 (0.88, 1.14) 0.98  0.99 (0.87, 1.14) 0.95 
SWA- specific IgG4  91628  73379  0.79 (0.50, 1.23) 0.28  0.78 (0.52, 1.17) 0.22 
SEA- specific IgE  4196  4494  1.07 (0.90, 1.26) 0.45  1.06 (0.90, 1.25) 0.44 
SEA- specific IgG4  112276  73352  0.64 (0.29, 1.41) 0.25  0.65 (0.29, 1.45) 0.28 
asIgE concentration 
(ImmunoCAP, kU/L) 
        
House dust mite  0.158  0.129  0.78 (0.51, 1.17) 0.22  0.76 (0.51, 1.13) 0.17 
Cockroach  0.342  0.289  0.82 (0.55, 1.22) 0.31  0.81 (0.55, 1.20) 0.28 
Peanut  0.074  0.066  0.89 (0.64, 1.23) 0.47  0.89 (0.65, 1.23) 0.49 
asIgE and IgG4 
concentration (ELISA, 
ng/ml) 
        
House dust mite-specific 
IgE 26.5 23.0  0.82 (0.48, 1.39) 0.45  0.81 (0.49, 1.35) 0.40 
House dust mite-specific 
IgG4 13.7 12.2  0.86 (0.63, 1.17) 0.32  0.89 (0.68, 1.2) 0.37 
Cockroach-specific IgE 32.9 39.7  1.20 (0.76, 1.89) 0.41  1.28 (0.81, 2.01) 0.28 
Cockroach-specific IgG4 14.6 13.4  0.91 (0.57, 1.47) 0.69  0.93 (0.59, 1.46) 0.75 
         
Total IgE (ImmunoCAP, 
kU/L) 754 618  0.80 (0.61, 1.04) 0.09  0.79 (0.62, 1.00) 0.05 
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5.4.2 LaVIISWA year three outcome survey: relationships between antibody 
responses, KK positivity and allergy 
Table E2 (below) shows associations between antibody responses and S. mansoni KK 
positivity and allergy in the outcome survey (both trial arms, combined).  Kato-Katz 
positivity was strongly positively associated with SWA- and SEA-specific IgE and IgG4 
and with total IgE, total IgG4, total IgG4 / total IgE ratios and total IgE / asIgE ratios. Total 
and allergen-specific IgE were positively associated with cockroach and HDM SPT 
reactivity. In contrast, cockroach SPT was inversely associated with total IgE / allergen-
specific IgE ratios, and HDM SPT reactivity was inversely associated with SWA-specific 
IgE, total IgE / allergen-specific IgE ratios, and HDM IgG4 / IgE ratios. 
These results are similar to those observed at baseline (Research paper 2, above). The 
main difference was in the association between antibodies and wheeze: positive 
associations with SWA-specific IgG4 and HDM-specific IgE were observed in the 
outcome survey (Table E2) unlike in the baseline survey, where any associations, when 
significant, were inverse. Associations with wheeze should be interpreted with caution, 
as prevalence of wheeze was very low (Research Paper 1). 
 
Table E2. LaVIISWA year three outcome survey: associations between antibody (IgE 
and IgG4) levels and Kato-Katz positivity (S. mansoni), SPT reactivity and reported 
wheeze 
Antigen Antibody / antibody ratio Geometric mean  aGMR (95% CI)
 ‡# p value 
Total IgG4 (ELISA, ng/ml) 22170 17515  0.78 (0.55, 1.10) 0.15  0.78 (0.55, 1.08) 0.13 
Total IgG4/ total IgE ratio 
(ELISA/ImmunoCAP) 36.5 38.7  1.07 (0.88, 1.30) 0.50  1.05 (0.87, 1.26) 0.60 
Total IgE/ cockroach IgE 
ratio (ImmunoCAP) 2081 1971  0.94 (0.71, 1.25) 0.66  0.94 (0.71, 1.25) 0.65 
Total IgE/ dust mite IgE 
ratio (ImmunoCAP) 3967 3929  0.99 (0.71, 1.39) 0.97  0.98 (0.69, 1.38) 0.92 
Total IgE/ peanut IgE 
ratio (ImmunoCAP) 10581 9717  0.90 (0.69, 1.18) 0.43  0.90 (0.68, 1.19) 0.44 
 
asIgE: allergen-specific IgE; GMR: geometric mean ratio; CI: confidence interval 
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  SmKK- SmKK+    
       
SWA  IgE§ 4009 5901  1.43 (1.26, 1.62) <0.001 
 IgG4§ 54728 201397  3.33 (2.00, 5.54) <0.001 
SEA  IgE§ 4026 5328  1.36 (1.13, 1.64) 0.002 
 
IgG4§ 49572 371634  5.33 (2.77, 10.23) <0.001 
Dust mite (ImmunoCAP) IgE¶ 0.133 0.209  1.50 (0.93, 2.42) 0.090 
Dust mite (ELISA) IgE§ 23.46 33.42  1.33 (0.84, 2.12) 0.214 
 IgG4§ 12.28 14.18  1.11 (0.82, 1.50) 0.480 
 IgG4/IgE ratio§ 12.03 9.89  0.93 (0.61, 1.41) 0.711 
Cockroach (ImmunoCAP) IgE¶ 0.293 0.407  1.28 (0.88, 1.89) 0.188 
Cockroach (ELISA) IgE§ 31.53 41.93  1.13 (0.56, 2.28) 0.731 
 IgG4§ 11.89 20.01  1.52 (0.87, 2.67) 0.135 
 IgG4/IgE ratio§ 5.06 6.92  1.52 (1.07, 2.15) 0.021 
Peanut (ImmunoCAP) IgE¶ 0.062 0.095  1.28 (0.96, 1.69) 0.089 
       
 Total IgE¶ 536.7 1305.7  2.26 (1.78, 2.87) <0.001 
 
Total IgG4§ 17026 30653  1.98 (1.22, 3.23) 0.008 
 
Total IgG4/ 
total IgE ratio 41.36 28.62  0.77 (0.64, 0.94) 0.012 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
1662.6 3138.3  1.96 (1.38, 2.77) 0.001 
 Total IgE/ dust 
mite IgE ratio¶ 
3143.31 5818.10  1.86 (1.13, 3.08) 0.017 
 
Total IgE/ 
peanut IgE 
ratio¶ 
8968.01 14121.30  1.74 (1.32, 2.30) <0.001 
 
  
Cockroac
h SPT- 
Cockroac
h SPT+    
       
SWA  IgE§ 4481 4316  1.04 (0.85, 1.29) 0.685 
 IgG4§ 86035 58160  0.87 (0.36, 2.13) 0.754 
SEA  IgE§ 4348 4327  1.00 (0.86, 1.15) 0.958 
 
IgG4§ 90368 93691  1.23 (0.52, 2.92) 0.622 
Dust mite (ImmunoCAP) IgE¶ 0.116 0.607  5.67 (3.43, 9.38) <0.001 
Dust mite (ELISA) IgE§ 25.03 23.23  0.89 (0.34, 2.36) 0.812 
 IgG4§ 13.05 11.86  1.14 (0.73, 1.78) 0.541 
 IgG4/IgE ratio§ 11.61 12.98  1.58 (0.82, 3.04) 0.162 
Cockroach (ImmunoCAP) IgE¶ 0.241 1.982  8.25 (5.16, 13.19) <0.001 
Cockroach (ELISA) IgE§ 32.87 73.13  1.32 (0.46, 3.83) 0.592 
 IgG4§ 13.31 19.16  1.25 (0.64, 2.44) 0.507 
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  IgG4/IgE ratio§ 5.41 4.79  1.28 (0.66, 2.47) 0.448 
Peanut (ImmunoCAP) IgE¶ 0.06 0.12  2.32 (1.57, 3.44) <0.001 
       
 Total IgE¶ 652.99 934.25  1.71 (1.21, 2.44) 0.004 
 
Total IgG4§ 18805 27184  1.29 (0.77, 2.16) 0.317 
 
Total IgG4/ 
total IgE ratio 38.17 32.95  0.71 (0.50, 1.02) 0.060 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
2516 474  0.23 (0.16, 0.34) <0.001 
 Total IgE/ dust 
mite IgE ratio¶ 
4606 1421  0.36 (0.28, 0.46) <0.001 
 
Total IgE/ 
peanut IgE 
ratio¶ 
10551 7679  0.73 (0.57, 0.92) 0.009 
       
  
Dust mite 
SPT- 
Dust mite 
SPT+    
       
SWA  IgE§ 4520 3969  0.95 (0.83, 1.08) 0.385 
 IgG4§ 90655 36677  0.49 (0.27, 0.87) 0.017 
SEA  IgE§ 4389 4005  0.96 (0.83, 1.10) 0.524 
 
IgG4§ 89975 96456  1.39 (0.73, 2.62) 0.303 
Dust mite (ImmunoCAP) IgE¶ 0.10 2.27  31.0 (17.66, 54.36) <0.001 
Dust mite (ELISA) IgE§ 20.14 123.69  8.45 (3.54, 20.18) <0.001 
 IgG4§ 12.99 12.39  1.26 (0.65, 2.43) 0.481 
 IgG4/IgE ratio§ 13.40 4.44  0.31 (0.18, 0.54) <0.001 
Cockroach (ImmunoCAP) IgE¶ 0.28 0.91  3.50 (2.09, 5.87) <0.001 
Cockroach (ELISA) IgE§ 35.46 41.90  1.25 (0.53, 2.94) 0.604 
 IgG4§ 14.53 10.42  0.85 (0.32, 2.20) 0.720 
 IgG4/IgE ratio§ 5.45 4.87  0.95 (0.39, 2.25) 0.898 
Peanut (ImmunoCAP) IgE¶ 0.07 0.09  1.77 (1.16, 2.72) 0.011 
       
 Total IgE¶ 675.19 744.28  1.25 (0.93, 1.69) 0.137 
 
Total IgG4§ 20462 14579  0.55 (0.27, 1.12) 0.095 
 
Total IgG4/ 
total IgE ratio 38.14 33.31  0.71 (0.44, 1.16) 0.162 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
2289 778  0.38 (0.28, 0.51) <0.001 
 Total IgE/ dust 
mite IgE ratio¶ 
5534 335  0.05 (0.04, 0.08) <0.001 
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Total IgE/ 
peanut IgE 
ratio¶ 
10394 8315  0.69 (0.48, 1.01) 0.054 
      
  
No 
wheeze Wheeze    
       
SWA  IgE§ 4424 5038  1.09 (0.86, 1.38) 0.448 
 IgG4§ 79765 157428  2.06 (1.14, 3.72) 0.019 
SEA  IgE§ 4346 3899  0.97 (0.79, 1.19) 0.769 
 
IgG4§ 90025 134327  1.14 (0.37, 3.48) 0.815 
Dust mite (ImmunoCAP) IgE¶ 0.139 0.343  3.83 (1.08, 13.61) 0.039 
Dust mite (ELISA) IgE§ 24.15 68.35  6.64 (1.06, 41.64) 0.044 
 IgG4§ 12.7 27.07  1.43 (0.37, 5.44) 0.590 
 IgG4/IgE ratio§ 11.94 11.43  0.59 (0.13, 2.62) 0.476 
Cockroach (ImmunoCAP) IgE¶ 0.312 0.47  2.12 (0.67, 6.69) 0.192 
Cockroach (ELISA) IgE§ 34.59 87.54  5.57 (0.94, 32.96) 0.058 
 IgG4§ 13.53 41.40  2.33 (0.92, 5.88) 0.073 
 IgG4/IgE ratio§ 5.33 7.72  0.89 (0.20, 3.86) 0.867 
Peanut (ImmunoCAP) IgE¶ 0.069 0.088  1.26 (0.81, 1.96) 0.296 
       
 Total IgE¶ 667.95 1199.8  1.62 (0.95, 2.78) 0.076 
 
Total IgG4§ 19456 27638  1.33 (0.76, 2.33) 0.311 
 
Total IgG4/ 
total IgE ratio 38.12 29.50  0.81 (0.45, 1.47) 0.471 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
1990.86 2570.97  0.84 (0.36, 1.97) 0.675 
 Total IgE/ dust 
mite IgE ratio¶ 
3968.74 3160.90  0.49 (0.17, 1.44) 0182 
 
Total IgE/ 
peanut IgE 
ratio¶ 
9987.71 14279.90  1.29 (0.79, 2.11) 0.300 
       
§Antibody levels detected by ELISA. Concentrations are in ng/ml.  
¶Antibody levels detected by ImmunoCAP. Concentrations are in kU/L. 
‡All geometric mean ratios and 95% confidence intervals adjusted for survey design, age and sex.  
#Geometric mean ratios and 95% confidence intervals for associations between antibody levels and SPT 
reactivity and wheeze were additionally adjusted for SmKK result. 
SWA: Schistosoma worm antigen; SEA: Schistosoma egg antigen; SmKK-: Kato-Katz negative result (S. 
mansoni), single stool sample; SmKK+: Kato-Katz positive result, single stool sample; aGMR: adjusted 
geometric mean ratio; 95% CI: 95% confidence interval. 
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 5.4.3 Urban survey of allergy-related outcomes: relationships between antibody 
responses, S. mansoni Kato-Katz/PCR positivity and allergy 
In the urban survey, total, SWA-, SEA- and allergen-specific IgE and IgG4 
concentrations were all positively associated with S. mansoni infection (Table E3, 
below), mirroring observations in the rural baseline and outcome surveys (presented 
above). Total and allergen-specific IgE and IgG4 concentrations were positively 
associated with cockroach and HDM SPT reactivity, while allergen-specific IgG4/ IgE 
ratios, total IgG4/ total IgE ratios and total IgE/ allergen-specific IgE ratios were inversely 
associated with the same outcomes. 
HDM- and SWA-specific IgG4 were positively associated with wheeze, while SWA-
specific IgE was inversely associated with the same outcome. Similar to the rural 
baseline survey, prevalence of wheeze was very low (shown in Research Paper 1), 
hence associations with wheeze should be interpreted with caution. 
 
Table E3. Urban survey: associations between antibody (IgE and IgG4) levels and Kato-
Katz / PCR positivity (S. mansoni), SPT reactivity and reported wheeze  
Antigen Antibody / antibody ratio Geometric mean  aGMR (95% CI)
 ‡# p value 
       
  Sm- Sm+    
       
SWA  IgE§ 2188 3949  1.75 (1.58, 1.94) <0.001 
 IgG4§ 12134 80715  5.93 (3.76, 9.38) <0.001 
SEA  IgE§ 2434 4660  1.88 (1.63, 2.16) <0.001 
 
IgG4§ 981 83098  65.9 (41.4, 104.8) <0.001 
Dust mite (ImmunoCAP) IgE¶ 0.18 0.25  1.39 (0.65, 3.00) 0.379 
Dust mite (ELISA) IgE§ 16.57 38.20  2.08 (1.05, 4.12) 0.037 
 IgG4§ 19.56 29.02  1.62 (0.99, 2.66) 0.056 
 IgG4/IgE ratio§ 20.90 17.53  0.95 (0.56, 1.61) 0.839 
Cockroach (ImmunoCAP) IgE¶ 0.18 0.22  1.09 (0.63, 1.88) 0.745 
Cockroach (ELISA) IgE§ 18.04 38.12  1.91 (1.03, 3.53) 0.040 
 IgG4§ 8.78 24.28  2.54 (1.37, 4.71) 0.005 
 IgG4/IgE ratio§ 5.61 5.53  0.99 (0.62, 1.62) 0.994 
Peanut (ImmunoCAP) IgE¶ 0.03 0.06  2.06 (1.23, 3.46) <0.008 
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 Total IgE¶ 143 360  2.62 (1.81, 3.79) <0.001 
 
Total IgG4§ 12197 25104  1.96 (1.45, 2.64) <0.001 
 
Total IgG4/ 
total IgE ratio 99.57 84.34  0.73 (0.38, 1.41) 0.327 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
807 1674  2.39 (1.56, 3.66) <0.001 
 Total IgE/ dust 
mite IgE ratio¶ 
837 1489  1.86 (0.95, 3.64) 0.068 
 
Total IgE/ 
peanut IgE 
ratio¶ 
4788 6482  1.38 (0.96, 1.98) 0.076 
 
  
Cockroac
h SPT- 
Cockroac
h SPT+    
       
SWA  IgE§ 2367 2551  1.08 (0.99, 1.16) 0.057 
 IgG4§ 15174 21505  1.41 (0.87, 2.30) 0.152 
SEA  IgE§ 2645 3187  1.13 (1.03, 1.23) 0.012 
 
IgG4§ 2131 1171  0.28 (0.12, 0.63) 0.004 
Dust mite (ImmunoCAP) IgE¶ 0.12 4.74  40.19 (19.2, 84.24) <0.001 
Dust mite (ELISA) IgE§ 12 257  
20.92 (11.9, 
36.66) <0.001 
 IgG4§ 20.9 27.4  1.61 (1.25, 2.09) 0.001 
 IgG4/IgE ratio§ 28.01 4.38  0.18 (0.13, 0.23) <0.001 
Cockroach (ImmunoCAP) IgE¶ 0.13 1.70  
13.49 (7.19, 
25.32) <0.001 
Cockroach (ELISA) IgE§ 16.39 79.46  4.64 (2.00, 10.78) 0.001 
 IgG4§ 9.08 23.59  3.45 (1.76, 6.77) 0.001 
 IgG4/IgE ratio§ 5.88 4.21  0.81 (0.42, 1.56) 0.514 
Peanut (ImmunoCAP) IgE¶ 0.03 0.13  7.37 (2.58, 21.09) 0.001 
       
 Total IgE¶ 141 505  4.19 (2.80, 6.28) <0.001 
 
Total IgG4§ 12517 17417  1.32 (0.83, 2.12) 0.223 
 
Total IgG4/ 
total IgE ratio 109.80 50.05  0.41 (0.24, 0.70) 0.002 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
1071 302  0.31 (0.15, 0.64) 0.003 
 Total IgE/ dust 
mite IgE ratio¶ 
1227 110  0.10 (0.04, 0.25) <0.001 
 
Total IgE/ 
peanut IgE 
ratio¶ 
5231 4002  0.62 (0.26, 1.47) 0.261 
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Dust mite 
SPT- 
Dust mite 
SPT+    
       
SWA  IgE§ 2365 2526  0.99 (0.91, 1.09) 0.915 
 IgG4§ 15601 19133  0.88 (0.44, 1.75) 0.707 
SEA  IgE§ 2655 3018  1.02 (0.86, 1.19) 0.835 
 
IgG4§ 1884 2337  0.55 (0.26, 1.17) 0.113 
Dust mite (ImmunoCAP) IgE¶ 0.09 4.86  47.48 (24.1, 93.68) <0.001 
Dust mite (ELISA) IgE§ 10 298  
24.69 (12.9, 
47.39) <0.001 
 IgG4§ 20.05 32.33  2.10 (1.53, 2.87) <0.001 
 IgG4/IgE ratio§ 30.46 4.17  0.17 (0.11, 0.28) <0.001 
Cockroach (ImmunoCAP) IgE¶ 0.14 0.70  3.99 (1.84, 8.67) 0.001 
Cockroach (ELISA) IgE§ 18.04 39.09  2.17 (0.89, 5.26) 0.085 
 IgG4§ 9.25 17.54  1.92 (1.17, 3.15) 0.012 
 IgG4/IgE ratio§ 5.40 6.37  1.22 (0.65, 2.30) 0.526 
Peanut (ImmunoCAP) IgE¶ 0.03 0.08  3.58 (1.60, 7.99) 0.003 
       
 Total IgE¶ 142 347  2.46 (1.65, 3.67) <0.001 
 
Total IgG4§ 12527 16210  1.26 (0.85, 1.87) 0.233 
 
Total IgG4/ 
total IgE ratio 106.99 70.48  0.65 (0.40, 1.05) 0.073 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
1024 506  0.61 (0.35, 1.07) 0.080 
 Total IgE/ dust 
mite IgE ratio¶ 
1530 75  0.05 (0.03, 0.10) <0.001 
 
Total IgE/ 
peanut IgE 
ratio¶ 
5238 4212  0.71 (0.39, 1.29) 0.244 
      
  
No 
wheeze Wheeze    
       
SWA  IgE§ 2386 2344  0.87 (0.76, 0.99) 0.033 
 IgG4§ 15235 43668  2.21 (1.22, 3.99) 0.011 
SEA  IgE§ 2716 2842  0.84 (0.68, 1.03) 0.087 
 
IgG4§ 1798 12209  1.98 (0.29, 13.37) 0.467 
Dust mite (ImmunoCAP) IgE¶ 0.18 0.75  2.18 (0.44, 10.89) 0.325 
Dust mite (ELISA) IgE§ 18.51 25.09  0.72 (0.08, 6.66) 0.760 
 IgG4§ 21.83 50.53  3.21 (1.09, 9.39) 0.035 
 IgG4/IgE ratio§ 21.52 40.46  4.17 (0.63, 27.42) 0.130 
Cockroach (ImmunoCAP) IgE¶ 0.18 0.39  1.30 (0.24, 6.89) 0.746 
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 Cockroach (ELISA) IgE§ 21.24 11.49  0.42 (0.08, 2.24) 0.295 
 IgG4§ 10.45 7.87  0.80 (0.19, 3.22) 0.744 
 IgG4/IgE ratio§ 5.58 5.07  1.35 (0.41, 4.43) 0.608 
Peanut (ImmunoCAP) IgE¶ 0.03 0.09  2.45 (0.37, 16.21) 0.334 
       
 Total IgE¶ 156 354  1.96 (0.73, 5.23) 0.170 
 
Total IgG4§ 13545 16560  0.97 (0.19, 4.84) 0.968 
 
Total IgG4/ 
total IgE ratio 112.00 55.98  0.45 (0.06, 3.32) 0.411 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
863 918  1.49 (0.70, 3.20) 0.284 
 Total IgE/ dust 
mite IgE ratio¶ 
863 497  0.94 (0.19, 4.71) 0.938 
 
Total IgE/ 
peanut IgE 
ratio¶ 
4814 3829  0.85 (0.32, 2.22) 0.721 
       
§Antibody levels detected by ELISA. Concentrations are in ng/ml.  
¶Antibody levels detected by ImmunoCAP. Concentrations are in kU/L. 
‡All geometric mean ratios and 95% confidence intervals adjusted for survey design, age and sex.  
#Geometric mean ratios and 95% confidence intervals for associations between antibody levels and SPT 
reactivity and wheeze were additionally adjusted for Sm result. 
SWA: Schistosoma worm antigen; SEA: Schistosoma egg antigen; Sm-: Kato-Katz/PCR negative result (S. 
mansoni), single stool sample; Sm+: Kato-Katz/PCR positive result, single stool sample; aGMR: adjusted 
geometric mean ratio; 95% CI: 95% confidence interval. 
 
5.4.4 Urban-rural differences in IgE and IgG4 profiles 
Concentrations of total, SWA-, SEA- and allergen-specific IgE and IgG4 differed between 
the urban and rural (LaVIISWA outcome) survey (Table E4, below). Concentrations of 
total, SWA- and SEA-specific antibodies were higher in the rural survey. This may be 
attributed to the higher prevalence of S. mansoni infection in rural compared to the urban 
survey. Crude cockroach and peanut extract-specific IgE levels were also higher in the 
rural survey. Crude allergen extracts may contain cross-reactive components that are 
also expressed by helminths (which are more prevalent in the rural setting). 
Unexpectedly, HDM-specific IgG4, HDM IgG4/ IgE and total IgG4/ total IgE ratios were 
higher in the urban survey, and HDM-specific IgE levels were similar between the two 
settings. 
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Table E4. Urban-rural comparisons of IgE and IgG4 profiles 
 Urban survey Rural survey 
p value 
 Median (IQR) Median (IQR) 
    
Schistosoma-specific 
antibodies   
 
SWA-specific IgE* 2229.4 (1543.4, 3738.2) 4962.1 (3006.6, 6727.7) <0.001 
SWA-specific IgG4* 42718 (24995.3, 71493.8) 108848.3 (51932.6, 273563.7) <0.001 
SEA-specific IgE* 2707.1 (1802.2, 4517.3) 4589.7 (3063.3, 6581.8) <0.001 
SEA-specific IgG4* 30886.5 (0.0, 101818.1) 274995.7 (70015.25, 839375.0) <0.001 
    
Allergen-specific antibodies / 
antibody ratios   
 
House dust mite (HDM)    
IgE** 0.1 (0.0, 0.7) 0.2 (0.0, 0.6) 0.141 
IgE* 0.1 (0.1, 965.2) 0.1 (0.1, 1050.4) 0.211 
IgG4* 15.6 (3.2, 100.2) 8.4 (2.1, 47.0) <0.001 
IgG4/IgE ratio* 8.3 (0.0, 319.3) 1.0 (0.0, 99.4) 0.002 
Cockroach    
IgE** 0.1 (0.0, 0.6) 0.4 (0.1, 1.5) 0.006 
IgE* 0.1 (0.1, 816.9) 75.3 (0.1, 1086.2) 0.006 
IgG4* 0.1 (0.1, 130.8) 0.1 (0.1, 186.8) 0.017 
IgG4/IgE ratio* 1.0 (0.1, 1.0) 1.0 (0.0, 1.0) 0.973 
Peanut-specific IgE** 0.0 (0.0, 0.1) 0.1 (0.0, 0.2) <0.001 
    
Total antibodies / antibody 
ratios   
 
Total IgE** 158.8 (56.7, 522.5) 672.2 (249.5, 1942.5) <0.001 
Total IgG4* 27051.2 (14942.4, 37539.6) 32907.6 (19501.6, 47302) 0.001 
Total IgG4* / total IgE ratio** 107.2 (377.0, 38.9) 36.3 (12.9, 104.3) <0.001 
Total IgE / cockroach IgE ratio** 938.8 (330.6, 2472.8) 2286.3 (683.9, 7124.1) <0.001 
Total IgE / dust mite IgE ratio** 1371.3 (361.4, 3195.4) 4938.6 (1572.5, 12029.1) <0.001 
Total IgE / peanut IgE ratio** 6262.3 (2138.0, 15152.3) 14243.1 (5827.2, 25282.8) <0.001 
 
P values were obtained from survey design-based linear regression. Adjusting for age and sex differences had no 
significant impact on observed differences. 
*Antibody levels detected by ELISA. Concentrations are in ng/ml.  
**Antibody levels detected by ImmunoCAP. Concentrations are in kU/L. 
IQR: Interquartile range; SEA: Schistosoma egg antigen; SWA: Schistosoma adult worm antigen 
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 5.4.5 Associations between antibody responses and asthma status among 
schoolchildren 
The asthma case-control study (described in the methods chapter) provided a unique 
opportunity to assess associations between allergy-related disease (asthma) and total, 
schistosome- and allergen-specific IgE and IgG4 concentrations. Total and allergen-
specific IgE, but not IgG4 levels were strongly positively associated with asthma (Table 
E5, below). The perception that high IgG4 / IgE ratios and total / allergen-specific IgE 
ratios may be protective against clinical allergy is supported by analyses in the urban 
survey and the rural surveys above. Findings from the asthma case-control study provide 
further support: asthmatic schoolchildren had lower allergen-specific IgG4 / IgE ratios 
and total IgE / allergen-specific IgE ratios compared to non-asthmatic controls. 
 
Table E5. Asthma case-control study: associations between antibody (IgE and IgG4) 
levels and asthma status 
Antigen Antibody / antibody ratio Geometric mean  aGMR (95% CI)
 ‡ p value 
       
  
Non-asthmatic 
controls Asthmatics    
       
SWA  IgE§ 1694 1957  1.14 (0.88, 1.47) 0.312 
 IgG4§ 13247 14775  1.12 (0.57, 2.20) 0.743 
SEA  IgE§ 2051 2531  1.19 (0.90, 1.57) 0.233 
 
IgG4§ 2351 1467  0.61 (0.21, 1.80) 0.372 
Dust mite (ImmunoCAP) IgE¶ 0.33 1.56  4.79 (2.72, 8.44) <0.001 
Dust mite (ELISA) IgE§ 20.32 99.39  4.99 (2.33, 10.72) <0.001 
 IgG4§ 72.05 58.37  0.89 (0.55, 1.44) 0.625 
 IgG4/IgE ratio§ 51.52 12.23  0.24 (0.12, 0.48) <0.001 
Cockroach (ImmunoCAP) IgE¶ 0.32 0.64  2.03 (1.39, 2.97) <0.001 
Cockroach (ELISA) IgE§ 19.76 51.35  2.65 (1.31, 5.34) 0.007 
 IgG4§ 20.22 22.13  1.11 (0.61, 2.0) 0.736 
 IgG4/IgE ratio§ 8.81 5.35  0.62 (0.33, 1.16) 0.133 
Peanut (ImmunoCAP) IgE¶ 0.06 0.08  1.37 (0.97, 1.92) 0.071 
       
 Total IgE¶ 252 372  1.53 (1.13, 2.05) 0.005 
 
Total IgG4§ 13549 16837  1.22 (0.69, 2.15) 0.486 
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Total IgG4/ 
total IgE ratio 82.85 62.37  0.72 (0.48, 1.07) 0.106 
 
Total IgE/ 
cockroach IgE 
ratio¶ 
789.08 590.89  0.75 (0.57, 0.99) 0.047 
 Total IgE/ dust 
mite IgE ratio¶ 
779 249  0.33 (0.21, 0.50 <0.001 
 
Total IgE/ 
peanut IgE 
ratio¶ 
4500 4840  1.08 (0.81, 1.42) 0.605 
 
§Antibody levels detected by ELISA. Concentrations are in ng/ml.  
¶Antibody levels detected by ImmunoCAP. Concentrations are in kU/L. 
‡All geometric mean ratios and 95% confidence intervals adjusted for age and sex.  
SWA: Schistosoma worm antigen; SEA: Schistosoma egg antigen; aGMR: adjusted geometric mean ratio; 95% 
CI: 95% confidence interval. 
 
 
5.4.6 Summary of conclusions from unpublished data in Chapter 5  
Research Paper 2 presents results from the LAVIISWA baseline survey. Data presented 
in section 5.4 are unpublished, and were obtained from the LaVIISWA allergy outcomes 
survey, the urban survey and the asthma case-control study. Below is a summary of 
what these extra data add to Chapter 5: 
a. Despite reduction in S. mansoni intensity (shown in Research Paper 7, 
Appendix 3, this thesis), community-wide intensive versus standard 
anthelminthic treatment in the LaVIISWA outcome survey had no effect on total, 
SWA-, SEA- and allergen extract-specific IgE and IgG4 profiles. 
b. The general pattern of associations between antibody responses, S. mansoni 
infection and allergy-related outcomes among LaVIISWA baseline survey 
participants mirrored observations among LaVIISWA outcome survey and the 
urban survey participants 
c. There were urban-rural differences in concentrations of total, allergen-, SEA- and 
SWA-specific antibodies. These were concomitant with urban-rural differences in 
helminth infection exposure and prevalence of allergy-related outcomes. 
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 d. Findings that asthmatic schoolchildren had lower allergen-specific IgG4/ IgE 
ratios and total IgE / allergen-specific IgE ratios (compared to non-asthmatic 
controls) support the hypothesis that high IgG4/ IgE ratios and total IgE/ allergen-
specific IgE ratios may be protective against clinical allergy. 
 
171
 CHAPTER 6. CARBOHYDRATE-SPECIFIC ANTIBODIES AND SCHISTOSOMA 
MANSONI INFECTION 
6.1 Preamble 
This chapter presents findings obtained using data from the rural and urban survey 
(described in Chapter 3) to assess associations between helminth (S. mansoni) infection 
(and intensity) and IgE and IgG responses to classical cross-reactive carbohydrate 
determinant (CCD) epitopes (thesis objective 3). Results are presented in Research 
paper 3 (below), titled “Microarray assessment of N-glycan-specific IgE and IgG profiles 
associated with Schistosoma mansoni infection in rural and urban Uganda”. This 
manuscript has been accepted for publication as an original article in Scientific Reports.  
There are important similarities between helminth antigens and common environmental 
allergens, key among them presence of non-mammalian core β-1,2-xylose and α-1,3-
fucose substitutions on N-glycans expressed by schistosome, invertebrate and plant 
proteins. Immune responses to schistosomes are shaped to a great extent by the 
Schistosoma glycome. Responses to non-mammalian core modified N-glycans may 
impact schistosome and/or allergy diagnostics, or be utilised in interventions against 
schistosome infection or allergy. Furthermore, profiling these responses could be useful 
in understanding mechanisms of schistosome-allergy associations. Detailed research, 
including characterisation of these responses at a population level, is needed to 
determine their role and potential applications.  
The current chapter maps associations of core β-1,2-xylose and core α-1,3-fucose with 
S. mansoni infection (and intensity) and the urban-rural environment in Uganda, using 
glycan microarray plasma IgE and IgG binding studies. This chapter further discusses 
the importance of glycan-specific antibodies in immunity to schistosome infection, 
diagnostics and cross-reactivity, serving as an important prologue to Chapter 7, which 
builds upon this thesis’ overarching hypothesis (that helminth-induced antibodies 
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 influence allergy profiles) to further postulate a key role for IgE to cross-reactive 
carbohydrate determinants in the epidemiology of allergy in the tropics. 
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6.2 Research Paper 3: Microarray assessment of N-glycan-specific IgE and IgG 
profiles associated with Schistosoma mansoni infection in rural and urban 
Uganda 
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SUMMARY 
Core b-1,2-xylose and a-1,3-fucose are antigenic motifs on schistosome N-glycans, as 
well as prominent IgE targets on some plant and insect glycoproteins. To map the 
association of schistosome infection with responses to these motifs, we assessed 
plasma IgE and IgG reactivity using microarray technology among Ugandans from rural 
Schistosoma mansoni (Sm)-endemic islands (n=209), and from proximate urban 
communities with lower Sm exposure (n=62). IgE and IgG responses to core b-1,2-
xylose and a-1,3-fucose modified N-glycans were higher in rural versus urban 
participants. Among rural participants, IgE and IgG to core b-1,2-xylose were positively 
associated with Sm infection and concentration peaks coincided with the infection 
intensity peak in early adolescence. Responses to core a-1,3-fucose were elevated 
regardless of Sm infection status and peaked before the infection peak. Among urban 
participants, Sm infection intensity was predominantly light and positively associated with 
responses to both motifs. Principal component and hierarchical cluster analysis reduced 
the data to a set of variables that captured core b-1,2-xylose- and a-1,3-fucose-specific 
responses, and confirmed associations with Sm and the rural environment. Responses 
to core b-1,2-xylose and a-1,3-fucose have distinctive relationships with Sm infection 
and intensity that should further be explored for associations with protective immunity, 
and cross-reactivity with other exposures.  
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INTRODUCTION 
Schistosomiasis is second only to malaria as a parasitic cause of human morbidity, with 
over 230 million infections globally, the majority of which occur in tropical and subtropical 
sub-Saharan Africa1-3. Despite important strides in coverage of anthelminthic treatment, 
reductions in infection prevalence have only been modest4-6, and the long struggle for a 
vaccine breakthrough continues7. The host immunological response to Schistosoma 
infection is shaped to a significant extent by schistosome surface-exposed and secreted 
glycans and glycoproteins. For example, anti-glycan antibody responses dominate the 
host humoral response to schistosome larvae and eggs8-10 and Schistosoma soluble egg 
antigen (SEA)-mediated Th2-polarisation profoundly relies on glycosylation11,12. In a 
mouse model for periovular granuloma formation, periodate treatment of SEA-coated 
beads inhibited their granulomogenic activity13, further demonstrating the functional 
relevance of glycan-specific responses in Schistosoma-mediated immunity and 
pathology. A better understanding of the human immune response to the Schistosoma 
glycome may be beneficial to the current drive towards identification of better 
Schistosoma diagnostic markers and potent vaccine candidates14-18. 
Current insights into the Schistosoma glycome, the most characterised among parasites, 
have been particularly aided by mass spectrometry-based (MS) studies19-21. Analysis of 
asparagine (N)-linked glycans expressed by schistosomes reveals two standout, non-
mammalian substitutions22,23 on the trimannosyl-chitobiose core (Man3GlcNAc2, 
conserved in all eukaryotes): an α-1,3-fucose (α3Fuc) linked to the asparagine-linked N-
acetylglucosamine (GlcNAc) of the chitobiose component and a β-1,2-xylose (b2Xyl) 
linked to the β-mannose of the trimannosyl component24 (Figure 1). These substitutions 
are also found on nematode glycans from Haemonchus contortus and Caenorhabditis 
elegans25-28, and on invertebrate29,30 and plant glycans31-33, but have so far not been 
detected on glycans from other helminths prevalent in the tropics19. Detailed MS studies 
have neither detected core b2Xyl nor core α3Fuc modified N-glycans in adult 
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schistosome worms but both are present in miracidia and eggs, while cercariae express 
core b2Xyl but no α3Fuc on the core GlcNAc19. Other common alterations to the 
schistosome Man3GlcNAc2 core include addition of antennae composed of GalNAcb1-
4GlcNAc (LacdiNAc, LDN), GalNAcb1-4(Fuca1-3)GlcNAc (fucosylated LacdiNAc, LDN-
F) and Galb1-4(Fuca1-3)GlcNAc (Lewis X, LeX) units. These antennary modifications 
are expressed in schistosomes (at all developmental stages, albeit with varying surface 
expression patterns)34 but are rare  in mammals35, and occur variably in other helminth 
species19. 
                      
Figure 1. Non-mammalian carbohydrate substitutions on the N-glycan 
core. Non-mammalian monosaccharide substitutions are denoted by blue brackets. ± implies 
that motifs in brackets are present or absent in different species. Figure drawn using 
GlycoWorkbench software, version 2.1 (European Carbohydrates Database Project). 
 
 Core b2Xyl and α3Fuc modified schistosome egg N-glycoproteins induce potent Th2-
type cellular responses36. In plants, core b2Xyl and α3Fuc may be the most common N-
glycan epitopes targeted by human IgE37,38. It is plausible that N-glycan core 
substitutions play a major role in the glycan-dependent host response to chronic 
schistosomiasis. For example, most N-glycans on the SEA-derived glycoprotein omega-
1 carry core α3Fuc motifs in combination with terminal LeX units39. Omega-1 drives both 
immunoregulatory40 and Th2 responses41, the latter in a glycan-dependent manner12. 
β-1,2-xylose
⍺-1,3-fucose
±
± Trimannosyl-
chitobiose core 
Asn
N-acetylglucosamine
Mannose
Xylose
Fucose
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Kappa-5, another major component of the Th2-polarising SEA42, expresses glycans 
modified with both core b2Xyl and core α3Fuc43. Whether protective immunity against 
Schistosoma infection and reinfection (long associated with host IgE responses44,45) can 
be credited to these epitopes will require further investigations in animal and human 
studies.  
The advent of glycan microarray technology enabled serum/plasma profiling of 
antibodies raised to a wide repertoire of N-glycan variants during schistosome infections. 
This technology has been employed in a small number of human studies. Recently, in 
Ghana, sera from a few S. haematobium infected schoolchildren showed elevated IgE 
responses to core b2Xyl modified N-glycans on a synthetic glycan microarray46, and in 
sera from a small cohort of Schistosoma mansoni (Sm)-infected children and adults near 
Lake Albert, Uganda, IgG1-4 subclass responses to core b2Xyl and α3Fuc motifs were 
examined using the same array47. Two other human studies employing shotgun 
microarrays constructed of complex native schistosome N-glycans showed strong anti-
glycan IgG and IgM responses against a wider range of N-glycans during schistosome 
infections48,49. A better understanding of population-level immune responses to 
Schistosoma glycans is important for research and clinical applications, and requires 
larger, well-defined immuno-epidemiological studies in endemic settings.  
Fishing villages in the Lake Victoria islands of Koome, Uganda, have a high prevalence 
of Sm50-53, and have been surveyed as part of a portfolio of studies on helminth infections 
and allergy-related outcomes in Uganda. This setting provided a unique opportunity, 
within the context of a well-characterised large study50, to correlate epidemiological 
trends pertaining to Sm infection (and intensity) with microarray-detected plasma IgE 
and IgG responses to N-glycans with and without core a-1,3-fucosylation and/or b-1,2-
xylosylation. Plasma from residents of nearby mainland urban communities with lower 
Sm exposure enabled us to make rural-urban comparisons of anti-glycan antibody 
responses. 
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METHODS 
Study design and population  
Individuals included in the current investigation were randomly selected using a Stata 
program (StataCorp, College Station, USA) from participants of two cross-sectional 
surveys in rural and urban Uganda, who had a sufficient volume of stored plasma. The 
rural survey was the outcome survey (year three, September 2015 – August 2016) of the 
Lake Victoria Island Intervention Study on Worms and Allergy-related diseases 
(LaVIISWA; ISRCTN47196031)50, a cluster-randomised trial of community-based 
standard versus intensive anthelminthic intervention in 26 Sm-endemic fishing villages 
of Koome islands (Lake Victoria, Uganda). The trial description50,53 and survey results 
after three years of intervention52 have been published: briefly, standard intervention 
included annual, community-based, mass drug administration of praziquantel; intensive 
intervention included quarterly praziquantel. The urban survey (September 2016 – 
September 2017) was conducted in the 24 sub-wards of Entebbe municipality, an area 
with lower helminth exposure, located on the northern shores of Lake Victoria 
(approximately 35km from Koome). It was designed to collect data from an urban setting 
for comparison with the Sm-endemic rural survey.  
In both surveys, intestinal helminth infections were assessed using the Kato-Katz (KK) 
method54 on a single stool sample (prepared on two slides, read by different technicians). 
The remaining sample was stored at -80°C and later investigated for Sm, Necator 
americanus and Strongyloides stercoralis infections using multiplex real-time PCR55,56. 
Mid-stream urine was also assessed for Sm circulating cathodic antigen (CCA) using a 
point-of-care test (Rapid Medical Diagnostics, Pretoria, South Africa). Schistosoma 
haematobium is not present in the surveyed areas57. Blood samples were processed to 
obtain plasma for immunological measurements, including N-glycan-specific IgE and IgG 
by microarray (detailed below) and Schistosoma egg [SEA]- and adult worm [SWA] 
antigen-specific IgE, IgG4 and IgG by ELISA (supplementary material).  
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The research ethics committees of the Uganda Virus Research Institute and the London 
School of Hygiene and Tropical Medicine, and the Uganda National Council for Science 
and Technology approved this work. All methods were performed in accordance with 
guidelines and regulations of these committees. Informed consent was obtained from 
all participants and/or their legal guardians and assent from children aged ³ 8 years. 
Microarray detection of N-glycan-specific IgE and IgG  
Immunoglobulin E and G responses to 135 chemically synthesised glycans with and 
without core a-1,3-fucosylation and, or, b-1,2-xylosylation (supplementary Figure S1) 
were assessed using a non-commercial microarray. Fluorescently-labeled bovine serum 
albumin (BSA) was included as an array printing control. Microarray construction 
procedures have been described in detail elsewhere48,58. The glycan antibody binding 
assay was adapted from existing procedures17,46,49,59, as follows: Nexterion H N-
hydroxysuccinimide-coated microarray slides (Schott AG, Mainz, Germany) (pre-
blocked with 50mM ethanolamine in 50mM sodium borate buffer pH 9.0, and stored at -
20°C) were thawed at room temperature (RT) and covered with silicone gaskets to create 
seven wells with printed microarrays per slide. Each microarray was incubated with 300 
μl of a 1:30 plasma dilution in 1% BSA - 0.01% Tween20 for one hour at RT while 
shaking. After sequential washes with PBS-0.05% Tween20 and PBS, the slides were 
incubated for 30 minutes at RT in the dark with PromoFluor 647-labelled anti-human IgE 
(diluted 1/150 in PBS-0.01% Tween20) and Cy3-labelled anti-human IgG (diluted 1/1000 
in PBS-0.01% Tween20), while shaking. After a final wash with PBS-0.05% Tween20, 
PBS and deionised water, sequentially, the slides were dried and kept in the dark until 
scanning. The slides were scanned for fluorescence at a 10μm resolution with a 
G2565BA scanner (Agilent Technologies, CA, USA) using 633nm and 532nm lasers for 
detection of reactivity to glycan-specific IgE and IgG, respectively. 
Data analysis 
Using GenePix Pro 7.0 software (Molecular Devices, CA, USA), a spot-finding algorithm 
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was used to align and re-size fluorescence spots in the microarray images, without 
setting a composite pixel intensity threshold. Data on median fluorescence intensity 
(MFI) for each spot and the local background were then exported to Microsoft Excel 
software, where background MFI subtraction was done for each glycan structure, 
averaged over four spots. Further processing of IgG and IgE MFIs in Excel was done as 
described by Oyelaran et al.60 and Amoah et al.46, respectively, to yield log2-transformed 
values. 
Graphical representations of antibody responses and further data analyses were done 
using Stata 13.1 (College Station, Texas, USA), R (R foundation for Statistical 
Computing, Vienna, Austria) via the RStudio interface (version 1.1.383, RStudio, Inc. 
Boston, USA) and GraphPad Prism (version 6.0e, Fay Avenue, La Jolla, CA, USA). 
Schistosoma mansoni infection and the rural-urban environment were the main 
exposures of interest: we compared anti-glycan antibody responses between Sm 
infected and uninfected participants separately in the rural and urban survey, and 
thereafter between rural and urban participants. Initial analyses considered each anti-
glycan antibody response independently, while further analyses combined antibody 
responses to reduce the dimensionality of the outcome data, as detailed below. 
Rural-urban differences in Sm prevalence and Schistosoma-specific antibodies were 
assessed using survey design-based logistic and linear regression, respectively. Most 
log2-transformed anti-glycan IgE responses maintained a skewed distribution. Therefore, 
Mann-Whitney tests were used to assess differences in individual glycan structure-
specific antibody responses between Sm infected and uninfected participants and 
between rural and urban participants. Most log2-transformed anti-glycan IgG responses 
were normally distributed and were assessed using unpaired t tests. The Kruskal-Wallis 
(IgE responses) and one-way ANOVA test (IgG responses) were also conducted to 
assess differences along the infection intensity gradient. Since many of the anti-glycan 
antibody responses were correlated, the above tests were conducted within a Monte 
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Carlo simulation approach based on 1000 permutations, to generate empirical p-values 
corrected for multiple testing. 
Given the large number of outcomes, two data reduction techniques were used to 
investigate associations between exposures and outcomes. First, principal component 
analysis (PCA) was run in Stata to transform groups of correlated anti-glycan responses 
into fewer, uncorrelated artificial variables (principal components, PCs), which were then 
compared by 1) survey setting, and 2) Sm infection and intensity status using survey 
design-based linear regression. Second, unsupervised hierarchical clustering analysis 
(HCA, complete linkage using Euclidean distance) was conducted in R to further identify 
homogeneous sets of N-glycan-specific responses. The resultant IgE and IgG clusters 
were then assessed for associations with survey setting and Sm infection using the 
global test61-63 executed in R with the Globaltest package (version 5.33.0). 
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RESULTS 
Characteristics of the rural and urban survey participants included in this analysis are 
presented in Table 1. Rural participants were, on average, older [median age (IQR) 22 
(5, 37)] than urban participants [median age (IQR) 11 (5, 18)] (p<0.001). A significantly 
higher percentage of rural, compared to urban participants, were infected with Sm (KK, 
p=0.002; PCR, p<0.001; CCA, p=0.015). Furthermore, median levels of total IgE 
(p<0.001) and SEA- and SWA-specific IgE (p<0.001), IgG4 (p=0.001) and IgG (p=0.002 
and p<0.001, respectively) were higher among rural compared to urban participants. 
Characteristic Rural (n=209) Urban (n=62) p value    
Age in years, median (IQR) 22 (5, 37) 11 (5, 18) <0.001* 
Male sex, n/N (%)§ 97/209 (44.3) 18/62 (29.0) 0.163¶ 
Helminth infections, n/N (%)§    
S. mansoni (single KK) 54/197 (34.5) 4/48 (8.3) 0.002¶ 
S. mansoni intensity (KK) 
Uninfected (0 eggs/g) 
Light (0-99 eggs/g) 
Moderate (100-399 eggs/g) 
Heavy (³400 egg/g) 
 
143/197 (65.5) 
29/197 (17.2) 
14/197 (10.2) 
11/197 (7.0) 
 
44/48 (91.7) 
3/48 (6.3) 
1/48 (2.1) 
0/48 (0.0) 
 
0.002¶ 
S. mansoni (PCR) 77/196 (44.9) 6/48 (12.5) <0.001¶ 
S. mansoni (urine CCA) 118/199 (66.0) 21/58 (36.2) 0.015¶ 
Any nematode infection# 43/196 (18.7) 1/48 (2.1) 0.001¶ 
    
Total IgE (kU/L), median (IQR) 548.4 (404.4, 666.9) 103.3 (63.8, 146.5) <0.001* 
    
Schistosoma egg and worm-
specific antibody levels, 
(μg/ml), median (IQR) 
  
 
SEA-specific IgE 4.2 (2.6, 6.6) 2.2 (1.4, 3.6) <0.001* 
SWA-specific IgE  3.9 (2.4, 5.9) 2.1 (1.3, 3.1) <0.001* 
SEA-specific IgG4  161.0 (45.9, 663.8) 8.8 (0.0, 48.4) 0.001* 
SWA-specific IgG4  71.6 (39.5, 188.1) 32.1 (7.8, 57.9) 0.001* 
SEA-specific IgG  1687.3 (848.1, 2727.7) 730.7 (527.4, 1413.4) 0.002* 
SWA-specific IgG  1432.4 (845.8, 1941.6) 804.5 (572.7, 1311.3) <0.001* 
 
Table 1. Study participants: Schistosoma mansoni infection and Schistosoma-
specific antibodies 
§Percentages adjusted for survey design.  
¶P values obtained from survey design-based logistic regression. 
*P values obtained from survey design-based linear regression.  
#Infection with any of Strongyloides stercoralis, Necator americanus (assessed by PCR), Trichuris trichiura, 
Ascaris lumbricoides (assessed by KK) and Mansonella perstans (assessed by modified Knott’s method). 
Percentages / medians that are significantly higher in one setting compared to the other (p≤0.05) are highlighted 
in bold. 
KK: Kato-Katz; PCR: Polymerase Chain Reaction; CCA: Circulating Cathodic Antigen; IQR: Interquartile range; 
SEA: Schistosoma egg antigen; SWA: Schistosoma adult worm antigen 
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We recently reported that community-based intensive versus standard anthelminthic 
intervention in the rural survey reduced Sm infection intensity but had no effect on the 
overall Sm prevalence (measured using the urine CCA test)52. The current analysis found 
no evidence of an effect of intensive versus standard treatment on total IgE, SEA- or 
SWA-specific antibodies, or on antibody reactivity to any of the N-glycans on the 
microarray.  Therefore, data from the rural survey were not stratified by trial treatment 
arm in the further analyses presented herein.  
Associations between S. mansoni infection and IgE and IgG responses to 
individual core b-1,2-xylosylated and core a-1,3-fucosylated N-glycans 
In the rural survey, IgE and IgG responses to the b2Xyl modified Man3GlcNAc2 core 
(G34) were significantly higher among Sm infected (KK and/or PCR, and CCA positive), 
compared to uninfected individuals, and were positively associated with Sm infection 
intensity (KK) [Figure 2, a-f] and SWA- and SEA-specific IgE and IgG (supplementary 
Table S1). Observations were similar for the N-glycan core carrying both b2Xyl and 
a3Fuc (G37). However, IgE and IgG responses to the N-glycan core carrying a3Fuc only 
(G73) were similar between Sm infected and uninfected rural individuals (Figure 2, a-f), 
but positively associated with SWA- and SEA-specific IgE and IgG (Table S1).  
In the urban survey, IgE and IgG reactivity to core b2Xyl and/or core a3Fuc modified 
glycans was also higher in Sm infected (KK and/or PCR) compared to uninfected 
individuals, although differences were not statistically significant (Figure 2, g-j). 
However, IgE reactivity to core a3Fuc and core a3Fuc + core b2Xyl modified glycans 
was significantly positively associated with SEA- and SWA-specific IgE (Table S1).
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Figure 2. Associations between S. mansoni infection and IgE and IgG reactivity to N-glycans carrying non-mammalian core modifications.  
Plasma from S. mansoni infected and uninfected rural and urban individuals were assessed for IgE and IgG reactivity to N-glycan structural variants with and without a-1,3-fucosylation and b-
1,2-xylosylation, on a microarray platform. Box-and-whisker plots show background-subtracted and log2-transformed median fluorescence intensities (MFI) representing IgE (a, b, c, g, h) and 
IgG (d, e, f, i, j) reactivity to the Man3GlcNAc2 core structure (G42) and to a3Fuc- and/or b2Xyl-carrying Man3GlcNAc2 core structures (G34, G73 and G37). The plots show a horizontal line 
denoting the median, a box indicating the interquartile range (IQR), and whiskers drawn using the Tukey method (1.5 times IQR). Outliers (greater than 1.5 times IQR away from the median) 
are plotted as individual points. Mann-Whitney (IgE responses) and unpaired t test (IgG responses) were conducted within the framework of a Monte Carlo simulation algorithm based on 1000 
permutations (in order to adjust for multiple testing), to assess differences between infected and uninfected individuals. The Kruskal-Wallis (IgE responses) and one-way ANOVA test (IgG 
responses) were also conducted using the permutation approach to assess differences along the infection intensity gradient (b and e) in the rural survey.  
#Infection prevalence and intensity was relatively low in the urban survey so analysis by Sm intensity is not shown for the urban setting. 
*p<0.05; **p<0.01; ***p<0.001.  
Sm: S. mansoni infection determined by detection of eggs in a single stool sample by Kato-Katz and/or PCR (rural infected n=84, uninfected n=113; urban infected n=6, uninfected n=42); 
CCA: S. mansoni infection determined by a positive urine circulating cathodic antigen (CCA) result (rural infected n=118, uninfected n=81; urban infected n=21, uninfected n=37). 
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In the rural survey, Sm infection prevalence (and intensity) and median levels of 
Schistosoma-specific antibodies (except SEA-IgE) and b-1,2-xylosylated glycan (G34)-
specific IgE and IgG were highest among 10-14-year old individuals (Figure 3). 
However, IgE and IgG reactivity to glycans carrying either core a3Fuc (G73) or both core 
b2Xyl and core a3Fuc (G37) peaked earlier (in the 5-9-year age group), akin to SEA-
specific IgE. Age-stratified antibody reactivity patterns were less clear in the urban 
survey. 
Immunoglobulin E and G responses to other N-glycan structural variants with core b2Xyl 
or both core b2Xyl and core a3Fuc48 were also higher in Sm infected versus uninfected 
individuals (Figure S2). IgE and IgG reactivity to non-xylosylated and non-fucosylated 
glycans was not associated with Sm infection (data not shown), except for those glycans 
with antennae constructed of LDN-F (G90) and LeX (G89) units (Figure S3).  
Infection with other helminths, malaria or HIV was not associated with IgE or IgG 
reactivity to any glycans on the microarray (data not shown). 
Principal component analysis of anti-glycan antibody responses 
Antibody responses to individual core modified N-glycans were strongly correlated. 
Principal component analysis (PCA) was conducted to summarise these responses, and 
to evaluate to what extent the resultant principal components (PCs) were associated with 
Sm infection.  
Scatterplots of PC1 and PC2 loadings are shown in Figure 4. In the rural survey, the 
first two IgE and IgG PCs each accounted for 37% of the total variance in the data (IgE: 
PC1 28.2%, PC2 8.8%; IgG: PC1 27.7%, PC2 9.7%). Principal component 1 was 
characterized by responses to core b2Xyl and/or a3Fuc modified glycans while PC2 was 
characterized by responses to non-xylosylated and non-fucosylated glycans (Figure 4, 
panel a and b). Scores for IgE PC1, but not PC2, were higher among Sm infected (KK 
or PCR) compared to uninfected individuals (crude p=0.028, age- and sex-adjusted 
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p=0.167). Similarly, IgG PC1 scores were higher among Sm infected (KK or PCR) 
compared to uninfected individuals (crude p=0.009, adjusted p=0.027). There were no 
differences in PC scores between CCA+ and CCA- individuals.  
In the urban survey, the first two IgE and IgG PCs accounted for 31% and 35% of the 
total variance, respectively (IgE: PC1 19.4%, PC2 11.5%; IgG: PC1 24.2%, PC2 10.6%). 
Interestingly, most IgE responses to glycans carrying core b2Xyl without a3Fuc clustered 
with non-xylosylated and non-fucosylated glycans in PC2 while responses to glycans 
carrying both core b2Xyl and a3Fuc and those carrying core a3Fuc without b2Xyl 
clustered together in PC1 (Figure 4, panel c). Akin to the rural survey, scores for IgE 
and IgG PC1 were higher among Sm infected compared to uninfected urban individuals. 
Scores for PC1 were positively associated with SWA- and SEA-specific IgE and IgG in 
both surveys, while PC2 scores were inversely associated with the same Schistosoma-
specific antibodies (Table S1). 
In addition to PCA, we conducted HCA to further identify groups of anti-glycan IgE and 
IgG responses that might be jointly elicited in Sm infected versus uninfected individuals. 
Figure S4 shows clusters of IgE and IgG responses in the rural and urban survey, and 
the dominant core substitutions on the glycans in these clusters. Generally, antibody 
clusters comprising core b2Xyl modified glycans were positively associated with Sm 
infection and intensity in both surveys (Table S2). 
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Figure 3. Age-stratified prevalence of S. mansoni infection and median IgE and IgG reactivity to SWA, SEA and a-1,3-fucosylated 
and b-1,2-xylosylated N-glycans. (a) and (e): rural and urban prevalence and intensity of S. mansoni infection, by age group. (b) and (f): Median IgG, IgG4 and IgE 
reactivity to SWA and SEA, by age group, among rural and urban participants, respectively. (c) and (g): Median IgE reactivity to the Man3GlcNAc2 core and to a3Fuc- and/or 
b2Xyl modified Man3GlcNAc2 core structures, by age group, among rural and urban participants, respectively. Plotted results are from all participants, irrespective of Sm 
infection status. (d) and (h): Median IgG reactivity to the Man3GlcNAc2 core and to a3Fuc- and/or b2Xyl-modified Man3GlcNAc2 core structures, by age group, among rural 
and urban participants, respectively. Plotted results are from all participants, irrespective of Sm infection status. 
CCA: S. mansoni infection determined by a positive urine circulating cathodic antigen (CCA) result; KK: S. mansoni infection determined by detection of eggs in a single 
stool sample by Kato-Katz (KK); epg: eggs per gram of stool; SWA: Schistosoma adult worm antigen; SEA: Schistosoma egg antigen 
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Figure 4. Principal component analysis of anti-glycan antibody responses. Scatterplots of first (PC1) and second factor (PC2) loadings derived from principal 
component analysis of IgE and IgG responses to 135 synthetic N-glycans. Box-and-whisker plots show comparison of PC1 and PC2 scores between S. mansoni infected and uninfected 
individuals. The plots show a horizontal line denoting the median, a box indicating the interquartile range (IQR), and whiskers drawn using the Tukey method (1.5 times IQR). Outliers 
(greater than 1.5 times IQR away from the median) are plotted as individual points. Panels a and b show IgE and IgG profiles, respectively, among rural participants. Panels c and d 
show IgE and IgG profiles, respectively, among urban participants. Associations between factor loading scores and S. mansoni infection and intensity were assessed by linear regression 
analysis in Stata 13.1. Crude and age- and sex-adjusted p values are shown for significant associations. All analyses were adjusted for survey design using the ‘svy’ command in Stata. 
PC1: Principal Component 1; PC2: Principal Component 2; Sm: S. mansoni infection determined by detection of eggs in a single stool sample by Kato-Katz and/or PCR (rural infected 
n=84, uninfected n=113; urban infected n=6, uninfected n=42); CCA: S. mansoni infection determined by a positive urine circulating cathodic antigen (CCA) result (rural infected n=118, 
uninfected n=81; urban infected n=21, uninfected n=37). 
 
Rural-urban comparisons of anti-glycan antibody responses 
Immunoglobulin E responses to individual core b2Xyl and/or a3Fuc modified glycans were higher among rural compared to urban participants, 
as exemplified in Figure 5a. Principal component analysis of data combined from both surveys yielded distinct groups of anti-glycan responses 
(Figure 5b and 5f): PC1 was characterized by responses to core b2Xyl and/or a3Fuc modified glycans while PC2 was characterized by 
responses to non-xylosylated and non-fucosylated glycans. Scores for IgE PC1 (Figure 5c), but not PC2 (Figure 5d), were higher among rural 
compared to urban individuals (p=0.002). Differences in IgG PC1 scores were not statistically significant. However, IgG PC2 scores were lower 
among rural compared to urban individuals (p=0.013).  
Further assessment by HCA showed that clusters that comprised IgE responses to core b2Xyl and/or a3Fuc modified glycans (IgE-C1, IgE-C2 
and IgE-C4; Figure S5) were positively associated with the rural setting (Table S4), while IgE-C3 (characterised by very low responses, raised 
against non-xylosylated and non-fucosylated glycans) was positively associated with the urban setting. Immunoglobulin G response clusters were 
generally similar between rural and urban settings, except for IgG-C7 which comprised responses to non-xylosylated and non-fucosylated glycans 
and was positively associated with the urban setting. 
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Figure 5. Rural-urban comparisons of anti-glycan antibody responses. (a, e): Box-and-whisker plots showing background-subtracted and log2-transformed median 
fluorescence intensities (MFI) representing IgE and IgG reactivity to individual a3Fuc- and/or b2Xyl-carrying Man3GlcNAc2 core structures in rural versus urban participants. The plots 
show a horizontal line denoting the median, a box indicating the interquartile range (IQR), and whiskers drawn using the Tukey method (1.5 times IQR). Outliers (greater than 1.5 times 
IQR away from the median) are plotted as individual points. Mann-Whitney (IgE responses) and unpaired t test (IgG responses) were conducted within the framework of a Monte Carlo 
simulation algorithm based on 1000 permutations, to assess differences between rural and urban individuals. (b, f): First and second principal component loadings of N-glycan-specific 
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IgE and IgG responses among all participants, irrespective of survey setting. (c, d, g, h): Box-and-whisker plots showing comparison of PC1 and PC2 scores between rural and urban 
individuals. Associations between PC scores and survey setting were assessed by linear regression in Stata 13.1. Crude and age- and sex-adjusted p values are shown for significant 
associations. All analyses were adjusted for survey design using the ‘svy’ command in Stata.  
*p<0.05; **p<0.01; ***p<0.001. 
PC1: Principal Component 1; PC2: Principal Component 2 
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DISCUSSION 
By studying rural Sm-endemic Ugandan fishing communities and a proximate urban 
community, we have dissected antibody responses to core b2Xyl and a3Fuc modified 
N-glycans. Antibody responses to the core modified glycans were higher in the rural 
communities compared to a proximate urban community. In the urban community, IgE 
and IgG to both core b2Xyl and core a3Fuc were positively associated with Sm infection. 
In the rural communities, IgE and IgG to core b2Xyl were strongly positively associated 
with Sm infection while reactivity to core a3Fuc was elevated in both Sm infected and 
uninfected individuals. In the rural communities the concentration of antibodies to core 
a3Fuc modified N-glycans peaked ahead of the peak of Sm infection intensity, while the 
peak of antibodies to N-glycans with only core b2Xyl coincided with it. 
The positive association between current Sm infection and IgE and IgG reactivity to N-
glycans carrying only core a3Fuc in the urban, but not the rural communities, might 
reflect universal exposure to infection, and persistence of light infection despite 
treatment, in the rural setting. Core a3Fuc is abundant on N-glycans from Sm eggs but 
is not expressed by cercarial and adult worm N-glycans19,20,24. It is plausible that 
responses to core a3Fuc persist after active infection in high Sm exposure rural settings: 
in mice, eggs and hepatic granulomas persist long after clearance of worms64. Another 
explanation for elevated responses to a3Fuc in the rural communities, regardless of Sm 
infection status, is cross-reactivity. Core α-1,3-fucosylation and b-1,2-xylosylation are 
also present on certain plant and insect glycoproteins29,30,65, hence similar core a3Fuc 
responses in both Sm infected and uninfected individuals may also be explained by an 
exposure other than schistosomes, more prevalent in the rural than the urban setting, 
that carries core a3Fuc. The observation that antibodies to core b2Xyl were significantly 
higher among Sm infected individuals in both urban and rural settings implies a dominant 
role for core b2Xyl (compared to core a3Fuc) in Sm-specific humoral immunity, shown 
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here for the first time. It also appears that responses only to core b2Xyl are more 
responsive to change in Sm exposure: core b2Xyl is abundant on cercarial N-glycans 
despite being absent in adult worms. 
The prominent contribution of core b2Xyl and a3Fuc to cross-reactivity between 
schistosomes and other environmental exposures such as pollen, hymenoptera venom 
and vegetable foods22,37,38 is a caveat against the use of core modified glycans in 
schistosome diagnostic tests. Cross-reactivity with other helminth infections might also 
occur, but only a few other helminth species25-28, none of which are prevalent in humans 
in our survey settings, have so far been demonstrated to express glycans with core b2Xyl 
and a3Fuc motifs. More extensive glycomic studies of other helminths in our survey 
settings (S. stercoralis, hookworm, T. trichiura, A. lumbricoides, M. perstans) are 
warranted. However, we did not find any significant associations between these 
infections and IgE or IgG reactivity to core modified glycans. 
Our observations that IgE and IgG reactivity to N-glycans modified with antennae 
carrying LDNF and LeX units were associated with Sm infection in both surveys are 
consistent with previous studies in animal models and in humans49,66. No associations 
were observed with responses to glycans carrying unsubstituted LDN units.  
Principal component analysis indicated strong correlations between antibody responses 
to b-1,2-xylosylated glycans and responses to a-1,3-fucosylated glycans in both surveys. 
Core b2Xyl and a3Fuc epitopes can be found on similar Sm antigens, where they may 
be expressed on the same glycoproteins and glycans (such as those expressed by 
SEA)19, inducing analogous immune responses36. Non-xylosylated and non-fucosylated 
glycans with antennae constructed of LDN, LDN-F or LeX units may be expressed on 
the same Sm antigens as glycans with core b2Xyl and a3Fuc motifs. Furthermore, these 
terminal antennary substitutions can occur on the same glycans as core b2Xyl and 
a3Fuc19,39,43. However, PCA showed that responses to non-core-substituted glycans with 
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LDN, LDN-F or LeX units did not cluster with core b2Xyl/a3Fuc substituted glycans. 
Temporal changes in expression of glycans on Sm antigens have been reported20,34; it is 
possible that these two groups of glycans are expressed at varying magnitudes during 
Sm antigen maturation. Positive associations between Sm infection and the first principal 
component (representing responses to core b2Xyl and a3Fuc) reflect the important role 
of these core substitutions in the glycan-dependent host response to Sm. To further 
evaluate their contribution to the host immune response to Sm, it will be important to 
compare their antibody reactivity with that of other highly antigenic terminal motifs absent 
from glycans on the array used in this study, such as multi-fucosylated LDN motifs59. It 
is important to note that while IgG is abundantly detected to many schistosome glycans, 
and is triggered by Sm infection, only to core b2Xyl and a3Fuc modified glycans is IgE 
abundantly detected46,47,67. 
Notably in the urban survey, PCA showed that IgE responses to core b2Xyl modified 
glycans clustered with responses to non-xylosylated and non-fucosylated glycans 
(Figure 4c), and IgG responses to core b2Xyl and a3Fuc separated out less distinctly 
(Figure 4d) than in the rural survey. The observed b2Xyl clustering patterns may be 
attributed to the greater intensity of repeated exposure to schistosome cercariae (core 
b2Xyl) and sustained egg deposition (core b2Xyl and a3Fuc) among rural compared to 
urban participants.  In other words, rural-urban differences in antibody responses to core 
modified glycans may be indicative of differences in the intensity of Sm infection and/or 
degree of exposure between the two settings. However, this study did not have sufficient 
power to assess statistical interactions between the rural and the urban setting. Rural-
urban differences in antibody responses to core modified glycans may also be explained 
by exposures other than schistosomes (mentioned above), perhaps more prevalent in 
the rural than the urban setting; however, this is unlikely as we observed strong 
associations between Sm infection and reactivity to core modified N-glycans, particularly 
to those carrying core b2Xyl. It is also noteworthy that urban survey participants were 
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significantly younger than rural participants; however, this disparity did not seem to 
influence the observed rural-urban differences in anti-glycan responses, as observed 
from test statistics before and after adjusting for age. 
One of the key challenges in schistosomiasis vaccine development is the risk of allergic 
(IgE) sensitisation to candidate vaccine antigens68. Glycans are attractive vaccine 
candidates because they are generally considered to be benign as allergenic 
determinants69,70. There are a few known exceptions, such as the galactose-α-1,3-
galactose (α-1,3-gal) epitope (found in non-primate mammalian proteins, and shown to 
elicit severe allergy)71, so assessment for any associations between IgE to antigenic Sm 
glycans and allergy-related phenomena are important. The case for consideration of core 
modified Sm glycans as Schistosoma vaccine candidates will also need definite proof for 
an association between reactivity to core modified glycans and protection from Sm 
infection/re-infection. Our data suggests that a protective role, if any, is more plausible 
for core b2Xyl than core a3Fuc: in the rural survey, antibody responses to core a3Fuc 
(G73 and G37, Figure 3C and 3D) peaked in childhood, prior to the Sm infection peak in 
early adolescence, while responses to core b2Xyl (G34) coincided with the Sm infection 
peak (preceding the more ‘protected’ period in adulthood). However, concrete evidence 
is required from further population and mechanistic studies exploring the role of Sm N-
glycans in protective immunity. For example, it may be important to assess antibodies to 
these core modifications (and other antigenic terminal motifs) in re-infection study 
cohorts evaluating the immunological characteristics of individuals who are Sm-resistant 
following anthelminthic treatment. 
In conclusion, we provide an immuno-epidemiological description of IgE and IgG 
responses to N-glycans in rural and urban Uganda, highlighting the significance of core 
b2Xyl and core a3Fuc to the glycan-dependent host immune response during chronic 
schistosomiasis.  Moreover, our data imply that IgE and IgG responses to core b2Xyl 
and a3Fuc modified N-glycans have distinctive relationships with Sm infection and 
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intensity, which may reflect their different contributions towards protective immunity 
against Sm that need to be further explored using mechanistic animal and human 
studies. 
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6.3 Supplementary information for Research paper 3 (also available in the 
article’s online repository at https://www.nature.com/srep/) 
6.3.1 Experimental methods 
6.3.1.1 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgE and IgG4 ELISA 
All but the first 2 columns of 4HBX Immulon (Thermo Scientific, NY, USA) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Michael J Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer 
(0.1M, pH 9.6). Two-fold dilutions of human IgE (Calbiochem, Beeston, UK) or IgG4 
(Sigma-Aldrich) standard, diluted in bicarbonate buffer, were added to the first 2 columns 
of each plate to form standard curves. The plates were then incubated overnight at 4ºC. 
Plates were washed with phosphate-buffered saline (PBS 1X)-tween 20 solution, 
blocked with 150μl of 1% skimmed milk diluted in PBS-Tween 20 at room temperature 
(RT), and incubated overnight at 4ºC with 50μl of plasma samples diluted 1/20 (IgE 
assay) or 1/200 (IgG4 assay) with 0.1% skimmed milk in PBS-Tween 20 (assay buffer). 
Plates were washed and antibody binding detected by incubating the plates overnight at 
4ºC with 0.5μg/ml of biotinylated monoclonal mouse anti-human IgE or IgG4 (BD 
Pharmingen™). This was followed by a 1-hour incubation with a streptavidin-
Horseradish Peroxidase (strep-HRP) conjugate (Mast Group Ltd, Bootle, UK), diluted 
1/4000 with assay buffer, at RT. Plates were developed by addition of 100μl of o-
phenylenediamine (Sigma-Aldrich) and reactions stopped after 30 minutes with 25μl of 
2M Sulphuric acid. Optical density values were measured at 490nm (reference 
wavelength 630nm) on a 96-well plate ELISA reader. IgE or IgG4 concentrations (ng/ml) 
were interpolated from standard curves using a five-parameter curve fit using Gen5 data 
collection and analysis software (BioTek Instruments Inc, Vermont, Winooski, USA). 
6.3.1.2 S. mansoni adult worm (SWA)- and egg (SEA)-specific IgG ELISA 
All but the first 2 columns of 4HX Immulon (VWR, UK, Cat No 735-0465) 96-well plates 
were coated with 50μl of SWA [8 μg/ml] or SEA [2.4 μg/ml] (purchased from Professor 
Michael J Doenhoff, University of Nottingham) in bicarbonate (Na2CO3 + NaHCO3) buffer 
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(0.1M, pH 9.6). Two-fold dilutions of human IgG (Sigma-Aldrich), diluted in bicarbonate 
buffer, were added to the first 2 columns of each plate to form standard curves. The 
plates were then incubated overnight at 4ºC. Plates were washed with phosphate-
buffered saline (PBS)-Tween 20 solution, blocked with 150μl of 1% skimmed milk diluted 
in PBS-Tween 20 at room temperature (RT), and incubated overnight at 4ºC with 50μl of 
plasma samples diluted 1/3000 with 0.1% skimmed milk in PBS-Tween 20 (assay 
buffer). Plates were washed and antibody binding detected by incubating the plates for 
1 hour at RT with 0.5μg/ml of polyclonal rabbit anti- human IgG/HRP (Dako, Denmark). 
Plates were developed by addition of 100μl of o-phenylenediamine (Sigma-Aldrich) and 
reactions stopped after 30 minutes with 25μl of 2M Sulphuric acid. Optical density values 
were measured at 490nm (reference wavelength 630nm) on a 96-well plate ELISA 
reader. IgG concentrations (ng/ml) were interpolated from standard curves using a five-
parameter curve fit using Gen5 data collection and analysis software (BioTek 
Instruments Inc, Vermont, Winooski, USA). 
208
		
6.3.2 Supplementary figures and tables 
Figure S1. Synthetic N-glycan structural variants on the microarray 
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Table S1. Associations between anti-glycan and Schistosoma adult worm- and egg-
specific antibody responses 
  Associations between anti-glycan IgE & anti-Sm IgE  
Associations between anti-glycan IgG & anti-
Sm IgG  
 Glycan SEA-specific IgE SWA-specific IgE  SEA-specific IgG SWA-specific IgG 
   β (95% CI) p β (95% CI) p  β (95% CI) p β (95% CI) p 
RURAL 
 
G42 
-0.02 
(-0.07, 0.03) 
0.364 
-0.00 
(-0.04, 0.04) 
0.927  
1.06  
(-0.11, 2.24) 
0.075 
3.06  
(1.95, 4.16) 
<0.001 
URBAN 
0.1 
(0.0, 0.1) 
0.050 
0.1 
(-0.2, 0.3) 
0.660  
0.48 
(-2.05, 3.01) 
0.678 
-0.68 
(-4.36, 3.01) 
0.688 
RURAL 
 
G34 
0.76 
(0.36, 1.16) 
0.001 
0.86 
(0.60, 1.11) 
<0.001  
2.67  
(0.67, 4.68) 
0.011 
5.66  
(3.26, 8.07) 
<0.001 
URBAN 
0.1 
(-0.1, 0.3) 
0.165 
0.78 
(-0.02, 1.58) 
0.056  
1.43 
(-1.06, 3.92) 
0.225 
1.49 
(-2.07, 5.05) 
0.369 
RURAL 
 
G73 
0.81 
(0.36, 1.26) 
0.001 
0.52 
(-0.29, 1.33) 
0.205  
1.61  
(0.05, 3.16) 
0.044 
2.71  
(0.66, 4.75) 
0.012 
URBAN 
0.25 
(0.02, 0.47) 
0.036 
1.01 
(0.31, 1.69) 
0.009  
1.62 
(-1.29, 4.54) 
0.239 
1.21 
(-1.75, 4.18) 
0.379 
RURAL 
 
G37 
1.13 
(0.52, 1.74) 
0.001 
1.07 
(0.39, 1.74) 
0.003  
2.26  
(0.44, 4.08) 
0.017 
4.55  
(3.46, 5.65) 
<0.001 
URBAN 
0.29 
(0.04, 0.56) 
0.029 
1.61 
(0.88, 2.33) 
0.001  
1.79 
(-1.52, 5.11) 
0.251 
1.95 
(-1.53, 5.45) 
0.236 
RURAL 
 
G63 
-0.01 
(-0.11, 0.08) 
0.762 
0.01 
(-0.09, 0.11) 
0.865  
0.32  
(-0.11, 0.75) 
0.137 
0.99  
(0.19, 1.78) 
0.016 
URBAN 
0.05 
(0.01, 0.11) 
0.025 
0.15  
(-0.16, 0.46) 
0.316  
0.36 
(-1.30, 2.03) 
0.632 
0.55 
(-1.83, 2.95) 
0.609 
RURAL 
 
G90 
0.04 
(0.02, 0.05) 
<0.001 
0.05 
(0.03, 0.08) 
<0.001  
1.39  
(0.19, 2.59) 
0.025 
3.41  
(2.09, 4.73) 
<0.001 
URBAN 
-0.00  
(-0.02, 0.01) 
0.437 
-0.00 
(-0.04, 0.04) 
0.890  
2.68 
(0.97, 4.37) 
0.006 
3.24 
(1.00, 5.47) 
0.010 
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RURAL 
 
G89 
0.04 
(-0.03, 0.04) 
0.813 
0.01 
(-0.04, 0.49) 
0.815  
1.24  
(-0.04, 2.51) 
0.057 
3.40  
(1.11, 5.68) 
0.005 
URBAN 
0.00  
(-0.01, 0.01) 
0.980 
-0.04 
(-0.09, 0.01) 
0.118  
2.46 
(0.33, 4.59) 
0.028 
3.51 
(1.24, 5.77) 
0.007 
RURAL 
PC1 
6.51 
(2.69, 10.34) 
0.002 
5.85 
(1.80, 9.91) 
0.006  
4.27  
(0.22, 8.33) 
0.040 
9.96  
(6.75, 13.18) 
<0.001 
URBAN 
1.93 
(-1.39, 5.25) 
0.222 
9.48 
(2.66, 16.31) 
0.012  
5.02 
(-4.49, 14.5) 
0.263 
5.88 
(-3.58, 15.3) 
0.193 
RURAL 
PC2 
-2.74 
(-4.64, -0.83) 
0.007 
-1.15 
(-3.25, 0.92 
0.263  
-1.82  
(-3.41,-0.23) 
0.027 
-2.64  
(-4.46, -0.81) 
0.006 
URBAN 
-1.89 
(-4.33, 0.55) 
0.114 
-5.15 
(-11.2, 0.86) 
0.084  
-0.89 
(-2.94, 1.15) 
0.347 
-0.87 
(-0.28, 1.15) 
0.354 
Table shows regression coefficients (β) and corresponding 95% confidence intervals (95% CI) and p-values for associations 
between anti-glycan antibody responses and Schistosoma adult worm (SWA)- and egg (SEA)-specific antibody responses, among 
rural and urban participants. The Man3GlcNac2 core structure (G42), a3fuc- and/or b2xyl-carrying Man3GlcNac2 core structures 
(G34, G73 and G37) and N-glycan core structures carrying LDN (G63), lLDNF (G90) and Lewis X (G89) antennae were chosen to 
represent the wide range of Schistosoma-associated N-glycans on the array. PC1 and PC2 denote first and second factor 
loadings derived from principal component (PC) analysis of IgE and IgG responses to the 135 synthetic N-glycans. PC1 was 
characterised by responses to core b2xyl and/or core a3fuc modified glycans while PC2 was characterised by responses to non-
xylosylated and non-fucosylated glycans (figure 4 in main paper, panels a and b).  
All associations are adjusted for the survey design using the ‘svy’ command in Stata 13.1, and for age and sex.  
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Figure S2. Associations between S. mansoni infection (KK and/or PCR) and IgE and IgG reactivity to N-glycan structural variants carrying a1-3 fucose 
and/or b1-2 xylose 
RURAL SURVEY 
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URBAN SURVEY 
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Figure shows background-subtracted and log2-transformed median fluorescence intensities (MFIs) representing IgE (a, c, e, g, i, k) and IgG (b, d, f, h, j, l) reactivity to a-1,3-
fucosylated and b-1,2-xylosylated N-glycans, among S. mansoni infected (KK and/or PCR) [open circles] and uninfected (closed circles) rural and urban individuals. Mann-
Whitney (IgE responses) and unpaired t test (IgG responses) were conducted within the framework of a Monte Carlo simulation algorithm based on 1000 permutations, to 
assess differences between infected and uninfected individuals. 
*p<0.05; **p<0.01; ***p<0.001  
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Figure S3. Associations between S. mansoni infection and IgE and IgG reactivity to N-glycans carrying GalNAcb1-4GlcNAc (LDN), GalNAcb1-
4(Fuca1-3)GlcNAc (LDNF) and Galb1-4(Fuca1-3)GlcNAc (LeX) antennae 
RURAL 
                   
URBAN 
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Plasma from S. mansoni infected and uninfected rural and urban individuals were assessed for IgE and IgG reactivity to N-glycan structural variants. Box-and-whisker plots show background-
subtracted and log2-transformed median fluorescence intensities (MFI) representing IgE (a, b, c, g, h) and IgG (d, e, f, i, j) reactivity to the conserved, non-modified N-glycan core structure 
(Man3GlcNAc2, G42) and to N-glycan core structures carrying LDN (G63), LDNF (G90) and Lewis X (G89) antennae.  
Mann-Whitney (IgE responses) and unpaired t test (IgG responses) were conducted within the framework of a Monte Carlo simulation algorithm based on 1000 permutations, to assess differences 
between infected and uninfected individuals. The Kruskal-Wallis (IgE responses) and one-way ANOVA test (IgG responses) were also conducted using the permutation approach to assess 
differences along the infection intensity gradient (b and e) in the rural survey. 
*p<0.05; **p<0.01; ***p<0.001. 
Sm: S. mansoni infection determined by detection of eggs in a single stool sample by Kato-Katz and/or PCR (rural infected n=84, uninfected n=113; urban infected n=6, uninfected n=42). 
CCA: S. mansoni infection determined by a positive urine circulating cathodic antigen (CCA) result (rural infected n=118, uninfected n=81; urban infected n=21, uninfected n=37). 
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Figure S4. Hierarchical cluster analysis of anti-glycan IgE and IgG responses 
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Hierarchical cluster analysis (complete linkage using Euclidean distance) was conducted using the ‘pheatmap’ package in R. Background-subtracted and log2-transformed IgE and IgG median 
fluorescence intensities are shown on the y-axes, within clusters. The dominant core modifications on the glycans in these clusters are also shown. X-axes represent individual participants. a) Five 
major clusters of IgE responses were identified in the rural survey: cluster 1 (IgE-C1) comprised glycans carrying either only the core a3Fuc or both the core a3Fuc and b2Xyl, IgE-C2 and IgE-C3 
comprised b-1,2-xylosylated glycans only, IgE-C4 and IgE-C5 comprised non-xylosylated and non-fucosylated glycans. b) Three major IgE clusters identified in the urban survey: IgE-C1 comprised 
glycans with core a3Fuc or both core a3Fuc and b2Xyl, IgE-C2 comprised non-xylosylated and non-fucosylated glycans, IgE-C3 comprised a mixture of b-1,2-xylosylated, non-xylosylated and non-
fucosylated glycans. c) Six major IgG clusters identified in the rural survey: IgG-C1, IgG-C2, IgG-C3 and IgG-C6 were dominated by non-xylosylated and non-fucosylated glycans, IgG-C4 comprised 
glycans with either core a3Fuc or b2Xyl or both, IgG-C5 comprised b-1,2-xylosylated glycans only. d) Six major IgG clusters in the urban survey: IgG-C1 comprised glycans with either only core 
b2Xyl or both the core a3Fuc and b2Xyl, IgG-C2 a mixture of b-1,2-xylosylated, non-xylosylated and non-fucosylated glycans, IgG-C3 comprised glycans carrying either only core a3Fuc or both core 
a3Fuc and b2Xyl. IgE-C5 and IgE-C6 comprised non-xylosylated and non-fucosylated glycans. 
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Table S2. Global test p-values for associations between anti-glycan antibody response 
clusters and S. mansoni infection  
 
RURAL IgE-C1 (  /  + ) 
IgE-C2 
( ) 
IgE-C3 
( ) 
IgE-C4 
 
IgE-C5 
  
       
Sm (KK) 0.284 <0.001 0.019 0.036 0.533  
Sm (PCR) 0.795 0.039 0.353 0.431 0.556  
CCA 0.872 0.681 0.617 0.928 0.992  
Infection intensity (KK) 0.385 <0.001 0.003 0.032 0.850  
       
URBAN IgE-C1 (  /  + ) 
IgE-C2 
 
IgE-C3 
( )    
       
Sm (KK) 0.371 0.826 0.002    
Sm (PCR) 0.314 0.604 0.134    
CCA 0.733 0.652 0.421    
Infection intensity (KK) 0.904 0.925 <0.001    
       
       
RURAL IgG-C1  
IgG-C2 
 
IgG-C3 
 
IgG-C4 
(  /  / ) 
IgG-C5 
( ) 
IgG-C6 
 
       
Sm (KK) 0.319 0.028 0.150 0.064 0.056 0.451 
Sm (PCR) 0.701 0.373 0.241 0.180 0.090 0.539 
CCA 0.175 0.934 0.939 0.695 0.678 0.394 
Infection intensity (KK) 0.117 0.054 0.196 0.019 0.024 0.285 
       
URBAN IgG-C1 (  /  + ) 
IgG-C2 
( ) 
IgG-C3 
(  /  + ) 
IgG-C4 
( ) 
IgG-C5 
 
IgG-C6 
 
       
Sm (KK) 0.834 0.077 0.371 0.066 0.031 0.237 
Sm (PCR) 0.498 0.252 0.180 0.103 0.569 0.408 
CCA 0.775 0.875 0.945 0.253 0.596 0.679 
Infection intensity (KK) 0.807 0.167 0.828 0.106 0.022 0.368 
 
Table shows age and sex-adjusted global test p-values obtained from a linear regression analysis in R using the 
‘Globaltest’ package. The global test, described by Goeman et al., 20061, was used here to assess associations 
between anti-glycan IgE and IgG clusters (from hierarchical cluster analysis) and S. mansoni infection. All statistically 
significant associations shown in this table are positive, except for the association between IgG-C5 (Urban survey) and 
Sm (KK) and infection intensity. 
KK: Kato-Katz; PCR: Polymerase Chain Reaction; CCA: Circulating Cathodic Antigen; Sm: Schistosoma mansoni 
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Table S3. Global test p-values for associations between anti-glycan antibody response 
clusters and Schistosoma-specific antibodies 
 
RURAL IgE-C1 (  /  + ) 
IgE-C2 
( ) 
IgE-C3 
( ) 
IgE-C4 
 
IgE-C5 
  
       
SWA-specific IgE <0.001 0.003 0.001 0.008 0.073  
SEA-specific IgE <0.001 0.008 <0.001 0.523 0.031  
       
URBAN IgE-C1 (  /  + ) 
IgE-C2 
 
IgE-C3 
( )    
       
SWA-specific IgE <0.001 0.255 <0.001    
SEA-specific IgE 0.021 0.372 0.022    
       
RURAL IgG-C1  
IgG-C2 
 
IgG-C3 
 
IgG-C4 
(  /  / ) 
IgG-C5 
( ) 
IgG-C6 
 
       
SWA-specific IgG 0.079 <0.001 0.005 <0.001 <0.001 0.077 
SEA-specific IgG 0.453 <0.001 0.012 <0.001 0.003 0.221 
       
URBAN IgG-C1 (  /  + ) 
IgG-C2 
( ) 
IgG-C3 
(  /  + ) 
IgG-C4 
( ) 
IgG-C5 
 
IgG-C6 
 
       
SWA-specific IgG 0.219 0.518 0.034 0.045 0.872 0.357 
SEA-specific IgG 0.063 0.303 0.016 0.075 0.918 0.434 
 
Table shows age and sex-adjusted global test p-values obtained from a linear regression analysis in R using the 
‘Globaltest’ package. The global test (Goeman et al., 20061) was used to assess associations between anti-glycan IgE 
and IgG clusters (defined by hierarchical clustering analysis) and Schistosoma adult worm (SWA) and egg (SEA)-
specific IgE and IgG. All statistically significant associations shown in this table are positive. 
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Figure S5. Hierarchical cluster analysis of anti-glycan antibody responses in 
individuals from both rural and urban settings 
 
 
 
 
Hierarchical cluster analysis (complete linkage using Euclidean distance) of N-glycan-specific IgE and IgG responses (y-axis). 
X-axes represent individual participants.  
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Table S4. Global test p-values for associations between anti-glycan antibody response 
clusters and survey setting 
 
IgE-C1 
( /  + ) 
IgE-C2 
( ) 
IgE-C3 
 
IgE-C4 
(  / ) 
IgE-C5 
   
       
0.095* 0.024* 0.006# 0.094* 0.146*   
       
IgG-C1 
 
IgG-C2 
( ) 
IgG-C3 
 
IgG-C4 
 
IgG-C5 
( /  + ) 
IgG-C6 
( ) 
IgG-C7 
 
       
0.245# 0.508* 0.179* 0.222* 0.123* 0.223* 0.009# 
 
Table shows age and sex-adjusted global test p-values obtained from a linear regression analysis in R 
using the ‘Globaltest’ package. The global test (Goeman et al., 20061) was used to assess associations 
between anti-glycan IgE and IgG clusters (defined by hierarchical clustering analysis) and survey 
setting.  
*Positive association between antibody response cluster and rural setting 
#Positive association between antibody response cluster and urban setting 
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CHAPTER 7. HELMINTH CARBOHYDRATE-SPECIFIC IgE AND ITS ROLE IN THE 
EPIDEMIOLOGY OF ALLERGY IN UGANDA 
7.1 Preamble 
Findings presented in this chapter are from analyses of data obtained from the rural and 
the urban survey, and from the asthma case-control study. These studies are described 
in detail in Chapter 3. The present chapter assesses the role of cross-reactive 
carbohydrate determinant (CCD)-specific IgE in the epidemiology of allergic sensitisation 
and disease (asthma) in Uganda (thesis objective 4). Results are presented in 
Research paper 4 (below), titled “Schistosomiasis-associated carbohydrate-specific IgE 
and the epidemiology of allergy: studies from Uganda”. This manuscript has been 
submitted for publication as an original article in the Journal of Allergy and Clinical 
Immunology.  
As shown in Chapter 6, the rural environment and S. mansoni infection and intensity 
were strongly associated with antibody reactivity to core β-1,2-xylose and ⍺-1,3-fucose 
substituted N-glycans. These N-glycan core substitutions are integral constituents of 
classical CCDs, which are some of the commonest sources of cross-reactivity between 
S. mansoni and allergens. This chapter explores impact of CCD-specific IgE on allergic 
sensitisation and disease (asthma), hypothesising that CCD-specific IgE obscures true 
allergic sensitisation, and may be involved in protection against clinical allergy.
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7.2 Research Paper 4: Schistosomiasis-associated carbohydrate-specific IgE and 
the epidemiology of allergy: studies from Uganda  
 
 
224
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SUMMARY 
Background 
Cross-reactive carbohydrate determinants (CCDs) on schistosome and allergen 
glycoproteins may influence allergy epidemiology in the tropics. 
Objective 
We explored the impact of Schistosoma mansoni (Sm) exposure and rural-urban 
environment on anti-CCD IgE, and its relevance to allergic sensitisation and asthma. 
Methods 
Among Ugandan residents of rural Sm-endemic islands (n=780), proximate urban 
communities with lower helminth exposure (n=345), and asthmatic (n=200) and non-
asthmatic schoolchildren (n=200), we measured IgE against house dust mite (HDM), 
cockroach and peanut extracts by ImmunoCAP®. In subsets, we measured IgE to 
allergen components by ISAC® microarray, and to core b-1,2-xylose and/or a-1,3-fucose 
substituted N-glycans (“classical” CCD targets for IgE) by glycan microarray. 
Results 
IgE sensitisation to crude allergen extracts was highly prevalent (55% in rural, 43% in 
urban participants; 73% in asthmatics, 54% in controls). By contrast, IgE sensitisation to 
established major allergenic components from HDM, cockroach and peanut was low 
amongst rural, urban and non-asthmatic participants (0%-12%, versus 18%-36% in 
asthmatics). Instead, up to 40% of all participants recognised insect venom and CCD-
bearing components. Reactivity to classical CCD epitopes was positively associated with 
Sm infection, rural environment and allergen extract-specific IgE, but not with 
sensitisation to major allergenic components. CCD-specific IgE was not associated with 
skin reactivity; however, reactivity specifically to core a-1,3-fucosylated N-glycans was 
lower among asthmatics. 
Conclusion 
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Reactivity to Sm CCDs obscures IgE sensitisation to established major allergenic 
components. The inverse association between reactivity to a-1,3-fucosylated CCD 
epitopes and asthma merits further investigation for a possible protective role in 
development of allergic disease. 
 
KEY WORDS 
Cross-reactive carbohydrate determinant (CCD), helminth, Schistosoma mansoni, 
allergy, asthma, IgE sensitisation, ISAC, ImmunoCAP, microarray, b-1,2-xylose, a-1,3-
fucose 
KEY MESSAGES 
1. In Uganda, sensitisation to allergen extracts does not reflect sensitisation to their 
established major allergenic components, but rather to other, cross-reactive 
environmental antigens, particularly CCDs expressed by some helminths. 
2. Reactivity to a-1,3-fucose, a “classical” CCD target for IgE, is inversely 
associated with asthma. 
CAPSULE SUMMARY 
In Uganda, IgE responses to classical CCD glycans are not merely a smokescreen that 
obscures readouts for atopy assessment: IgE to core a-1,3-fucosylated CCD epitopes 
associates inversely with clinical allergy, through yet-to-be-defined mechanisms. 
ABBREVIATIONS USED 
LICs: low-income countries; CCD: cross-reactive carbohydrate determinant; Sm: 
Schistosoma mansoni; LaVIISWA: the Lake Victoria Island Intervention Study on Worms 
and Allergy-related diseases; ISAAC: International Study on Allergy and Asthma in 
Children; SPT: skin prick test; SWA: Schistosoma adult worm antigen; SEA: 
Schistosoma egg antigen; PCR: polymerase chain reaction; CCA: circulating cathodic 
230
		
antigen; ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardized units; HDM: 
house dust mite; PCA: principal component analysis
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INTRODUCTION 
There are important similarities in host immune responses to helminths and allergens, 
and in their molecular targets.1 Helminths elicit strong, complex immunoregulatory 
networks to block allergy-like responses induced during infection, primarily to avert their 
own destruction and elimination.2 Spill-over effects of this immunoregulation include 
inhibition of allergic effector responses,3 perhaps contributing to lower prevalence of 
clinical allergies in low-income countries [LICs] (compared to high-income countries) and 
rural (compared to urban) settings.4 However, studies in human populations imply 
diverse and complex relationships between helminth infections and allergy-related 
outcomes. For example, in rural Schistosoma mansoni (Sm)-endemic Ugandan fishing 
communities, we found that low prevalence of clinical allergies was paralleled by high 
levels of specific IgE against extracts from common allergen sources and positive 
helminth-atopy associations.5 
Mechanistic studies assessing the impact of protein cross-reactivity between helminths 
and allergens have provided important insights into helminth-allergy associations.6 For 
example, the Onchocerca volvulus tropomyosin (structurally homologous to dust mite 
tropomyosins) induces basophil histamine release7 and some Sm venom allergen-like 
(SmVAL) proteins (with orthologues in wasps) and tegumental allergen-like (SmTAL) 
proteins show allergenic activity.8,9 
The importance of carbohydrate cross reactivity in helminth-allergy associations is less 
understood. Some of the commonest sources of cross-reactivity between allergens and 
some helminths are specific types of asparagine (N) linked glycan modifications found 
on plant, insect and some helminth proteins (termed cross-reactive carbohydrate 
determinants, CCDs). The N-glycan trimannosyl-chitobiose core (Man3GlcNAc2) is 
conserved in eukaryotes. “Classical” CCD N-glycans expressed by invertebrate and 
plant proteins,10,11 and on antigenic surfaces and in secretomes of schistosome eggs 12 
and some nematodes,13-16 carry additional, non-mammalian, IgE-binding motifs: 1) β-
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(1,2) xylose linked to the first mannose of the trimannosyl component and/or 2) α-(1,3) 
fucose linked to the asparagine-linked N-acetylglucosamine (GlcNAc) of the glycan 
core.17,18 Glycoproteins carrying such N-glycans are potent immune determinants,10,19-22 
inducing strong Th2-type responses,23 and comprising epitopes for antibodies,24-27 
including IgE.28-30 However, the relevance of these glycan motifs in allergy is unclear. 
Barring observations from a few studies,31-33 anti-CCD IgE has poor biological function: 
individuals with specific IgE to CCDs lack skin and oral reactivity to the same 
molecules.10,29,34 Therefore, in helminth-endemic LICs, elevated, yet clinically irrelevant 
allergen extract-specific IgE levels may, to an important extent, be attributed to CCDs.35 
Among Ghanaian schoolchildren, Schistosoma haematobium infection was associated 
with peanut-IgE-sensitisation, which was in turn strongly associated with anti-CCD IgE, 
but not clinical peanut allergy.36 The separation of anti-CCD IgE from clinical allergy 
symptoms, coupled with abundance of immunogenic CCDs on some schistosome 
antigens, led us to hypothesise that enhanced anti-CCD IgE responses during chronic 
Sm infection might dominate over allergen protein-specific IgE, resulting in reduced 
allergic effector responses. 
We conducted three studies in varied Ugandan settings to obtain a comparative 
assessment of allergy-related disease phenotypes, prevalence and risk factors in rural37 
and urban38 settings, and among asthmatic children and controls. These studies provide 
an unprecedented opportunity to assess the impact of rural-urban environment and Sm 
exposure on anti-CCD IgE profiles and the relevance of these profiles to epidemiological 
trends of allergy in tropical LICs. 
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METHODS 
Study design and population 
The three studies comprised rural and urban cross-sectional surveys on allergy 
outcomes and a case-control study on asthma risk factors among schoolchildren in 
Uganda. 
The rural survey (September 2015 – August 2016) was conducted in Sm-endemic fishing 
villages of Koome islands, Lake Victoria, Uganda. It was the three-year outcome survey 
of the Lake Victoria Island Intervention Study on Worms and Allergy-related diseases 
(LaVIISWA; ISRCTN4719603139), a cluster-randomised trial of community-wide 
standard versus intensive anthelminthic treatment.5,39 The urban survey (September 
2016 – September 2017) was conducted in Entebbe municipality, a lower helminth 
exposure, urban setting38 situated on northern shores of Lake Victoria. 
The asthma study (May 2015 – July 2017) enrolled children with asthma and controls 
from schools in Entebbe and surrounding areas. Asthma was defined as history of 
wheeze in the last year, using the International Study on Allergy and Asthma in Children 
(ISAAC) questionnaire.40 Children in the same class as cases, with no history of 
wheezing, were eligible as controls. A Stata program (College Station, Texas, USA) was 
used to randomly select participants from each class register such that the number of 
controls was twice the number of cases. 
Recent wheeze was also assessed in the rural and urban surveys using ISAAC 
questionnaires. Other procedures were identical in all three studies, including 
assessment of skin prick test (SPT) reactivity to Dermatophagoides mix, Blomia 
tropicalis and Blattella germanica (ALK-Abelló; supplied by Laboratory Specialities [Pty] 
Ltd., South Africa), visible flexural dermatitis (evaluated following Williams’ on-line 
manual41), and questionnaire-determined recent rhinitis and urticarial rash. 
Parasitological examinations 
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Infection with intestinal helminths was investigated using the Kato-Katz technique42 
conducted on one stool sample per participant (two slides, read by different technicians). 
In the urban and rural surveys, stool was further examined for Sm, Necator americanus 
and Strongyloides stercoralis infections using PCR43,44, and urine for Sm circulating 
cathodic antigen (CCA, Rapid Medical Diagnostics, South Africa). 
Measurement of allergen- and glycan-specific IgE 
Allergen- and glycan-specific IgE measurements were conducted in a subset of samples 
per study (Figure 1), randomly selected using Stata software. Sample size 
considerations are detailed in the Online Repository.  
Crude house dust mite (D. pteronyssinus, HDM), peanut (Arachis hypogaea), and 
German cockroach (B. germanica) extract-specific plasma IgE levels were measured 
using the ImmunoCAPÒ specific IgE test [Thermo Fisher Scientific] (hereinafter 
‘ImmunoCAP’), with ≥0.35kU/L defining allergic sensitisation.45 
The ImmunoCAPÒ ISAC (Immuno Solid-phase Allergen Chip) microarray (Thermo 
Fisher Scientific)46,47 was used to measure IgE to 112 allergen components from 51 
sources (Table S1, Online Repository). The array comprises 67 recombinant 
components (produced in E. coli, hence non-glycosylated48); and 45 components purified 
from natural extracts. Previous work has shown that the glycan epitope from bromelain 
(nMUXF3) and glycoproteins from pollen (nPhl p 4, nCyn d 1, nPla a 2, nCry j 1, nCup a 
1) and food (nJug r 2), are recognised by anti-CCD IgE, while other natural, possibly 
glycosylated allergens on the ISAC are not.49 Therefore, herein, ‘CCD-bearing 
components’ denotes ISAC components confirmed to carry core β-1,2-xylose and/or ⍺-
1,3-fucose substituted N-glycans. The binding assay is described in Online Repository. 
Participants with an ISAC Standardised Unit (ISU) measurement of ≥0.3 were 
considered sensitised to that allergen component.46,50 Measurements were also reported 
as detectable versus undetectable (lower detection limit: 0.06 ISU). 
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Samples were also assessed for Schistosoma egg [SEA]- and adult worm [SWA] 
antigen-specific IgE, IgG and IgG4, by ELISA (described elsewhere56). 
Statistical analysis 
Statistical analyses were done in Stata 13.1, GraphPad Prism 7.0a (Fay Avenue, CA, 
USA) and R via the RStudio interface (version 1.1.383, Boston, USA). Initial analyses in 
the rural survey investigated the impact of trial intervention on IgE profiles using a cluster-
level approach, as previously described.37 Differences in characteristics between rural 
and urban survey participants and between asthmatic and non-asthmatic children were 
assessed using logistic or linear regression, allowing for the survey designs (clustering 
and weighting). Unadjusted analysis of differences in individual N-glycan- / allergen-
specific IgE levels between rural and urban participants, and between asthmatics and 
controls was done using the Mann-Whitney U test, correcting for multiple testing using a 
Monte Carlo simulation approach57 with 1000 permutations, to generate empirical p-
values. For analyses comparing prevalences of ISAC-determined IgE sensitisation 
between these groups, chi-squared tests (or Fisher’s exact test, for expected cell counts 
<5) were used. 
Since anti-glycan IgE responses were strongly correlated, they were further analysed 
using principal component analysis (PCA). Participants from all studies were pooled and 
principal component (PC) scores generated. Unadjusted and age- and sex-adjusted 
A non-commercial microarray of 135 chemo-enzymatically synthesised glycans with and 
without β-1,2-xylosylation and/or !-1,3-fucosylation (Figure S1) was employed to 
measure plasma anti-glycan IgE. Microarray construction procedures have been 
published.51,52 The IgE binding assay and the microarray image processing procedures 
were adapted from previous studies,27,53-55 and are detailed in Online Repository. Median 
fluorescence intensities (MFIs) reported herein represent anti-glycan IgE concentrations, 
because fluorescence-labelled anti-human IgE was used to detect plasma IgE bound to 
individual glycans on the array.
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associations between PC scores and atopic sensitisation, asthma status, Sm infection 
and survey setting were assessed using linear regression. 
Ethics statement 
This work was approved by ethics committees of Uganda Virus Research Institute and 
London School of Hygiene and Tropical Medicine, and Uganda National Council for 
Science and Technology. Informed consent was obtained from all participants and/or 
their legal guardians. Assent was obtained from children ≥8 years.
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RESULTS 
Participants’ characteristics 
Data on ImmunoCAP-determined IgE sensitisation were available for 780, 345 and 400 
participants of the rural survey, urban survey and asthma study, respectively (Figure 1). 
For the rural survey, we present data combined from both anthelminthic treatment arms, 
because there was no effect of trial arm on ImmunoCAP- or ISAC-determined IgE 
sensitisation, anti-glycan IgE reactivity (Table S2) or prevalence of Sm CCA positivity.37  
Table 1 shows participants’ characteristics. Rural participants were on average older 
than urban participants (p=0.001) and more likely to be male. SPT reactivity to 
Dermatophagoides mix (p=0.003) and B. tropicalis (p=0.025) was higher among urban 
participants, while total IgE (p<0.001) and allergen extract-specific IgE sensitisation 
(ImmunoCAP concentration ≥0.35 kU/L), particularly to cockroach (p<0.001), was higher 
among rural participants. Urticarial rash was more common in rural participants 
(p<0.001), while wheeze, rhinitis and dermatitis were rare in both settings. Rural, 
compared to urban participants, were more frequently infected with Sm (p<0.001), T. 
trichiura (p=0.002), hookworm (p=0.016) and S. stercoralis (p=0.001), and had higher 
median levels of SEA- and SWA-specific IgE, IgG and IgG4 (p<0.001). Adjusting for age 
and sex did not impact these differences. 
Asthmatics, compared to non-asthmatic controls, had higher prevalence of SPT 
reactivity, ImmunoCAP IgE sensitisation, dermatitis and rhinitis, and higher total IgE 
levels. Prevalence of helminth infections in the asthma study was low, but concentrations 
of SEA- and SWA-specific antibodies were moderate and similar between asthmatics 
and non-asthmatics. 
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Figure 1. Selection of samples for the ImmunoCAP® test and the ISAC® and glycan microarray assays 
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Table 1. Characteristics of study participants 
Characteristics  Rural survey Urban survey   Case-control study on asthma in schoolchildren n/N (%)  
  n/N (%)* n/N (%)* p¶  Non-asthmatics Asthmatics p 
Socio-demographic          
Age in years, median (IQR)  28 (21, 36) 22 (10, 32) 0.001  10 (8, 13) 11 (10, 14) 0.017 
Male sex  377/780 (46.4) 97/345 (28.1) <0.001  94/200 (46.7) 92/200 (46.0) 0.841 
Allergy-related outcomes         
Skin prick test reactivity         
Any 
Dermatophagoides mix 
Blomia tropicalis 
Blatella germanica 
 164/780 (21.3) 
87/780 (10.0) 
54/780 (6.8) 
98/780 (13.9) 
72/336 (21.4) 
61/336 (18.2) 
41/336 (12.2) 
45/337 (13.4) 
0.955 
0.003 
0.025 
0.811 
 60/198 (30.3) 
47/198 (23.7) 
45/198 (22.7) 
32/198 (16.2) 
105/198 (53.0) 
91/198 (45.9) 
90/198 (45.4) 
48/198 (24.2) 
<0.001 
<0.001 
<0.001 
0.046 
asIgE sensitisation (≥0.35 
kU/L, ImmunoCAP) 
        
Any 
D. pteronyssinus 
Blatella germanica 
Arachis hypogaea 
 437/780 (55.1) 
264/780 (33.2) 
393/780 (49.8) 
114/780 (14.9) 
148/345 (42.9) 
104/345 (30.1) 
118/345 (34.2) 
41/345 (11.9) 
0.007 
0.421 
<0.001 
0.266 
 108/200 (54.0) 
72/200 (36.0) 
90/200 (45.0) 
24/200 (12.0) 
145/199 (72.9) 
117/200 (58.5) 
112/199 (56.3) 
39/200 (19.5) 
<0.001 
<0.001 
0.025 
0.041 
asIgE concentration (kU/L, 
ImmunoCAP), median (IQR) 
        
D. pteronyssinus 
Blatella germanica 
Arachis hypogaea 
 0.2 (0.0, 0.6) 
0.4 (0.1, 1.5) 
0.1 (0.0, 0.2) 
0.1 (0.0, 0.7) 
0.1 (0.0, 0.6) 
0.0 (0.0, 0.1) 
0.229 
0.949 
0.877 
 0.1 (0.0, 1.9) 
0.3 (0.1, 1.1) 
0.1 (0.0, 0.2) 
1.0 (0.1, 37.5) 
0.6 (0.1, 2.9) 
0.1 (0.0, 0.2) 
<0.001 
<0.001 
0.101 
Total IgE (kU/L, 
ImmunoCAP), median (IQR) 
 672 (250, 1942) 159 (57, 523) <0.001  279 (98, 648) 487 (115, 1248) 0.018 
Wheeze in last 12 months, 
age<5 years 
 1/58 (0.9) 2/37 (5.4) 0.188     
Wheeze in last 12 months, 
age≥5 years 
 24/716 (2.9) 5/272 (1.8) 0.308  0/200 (0.0) 200/200 (100.0)  
Visible flexural dermatitis  4/780 (0.5) 3/345 (0.9) 0.462  3/199 (1.5) 13/198 (6.6) 0.019 
Rhinitis in last 12 months  34/774 (4.2) 11/309 (3.6) 0.700  11/199 (5.5) 43/198 (21.7) <0.001 
Urticaria in last 12 months  98/773 (12.4) 11/309 (3.6) <0.001  5/199 (2.5) 6/198 (3.0) 0.754 
Helminth infections         
S. mansoni (KK)  187/679 (29.5) 14/284 (4.9) <0.001  8/194 (4.1) 12/184 (6.5) 0.302 
S. mansoni intensity (KK) 
Uninfected 
Low 
Moderate 
Heavy 
  
492/679 (70.5) 
94/679 (14.7) 
53/679 (8.9) 
40/679 (5.8) 
 
270/284 (95.1) 
7/284 (2.5) 
4/284 (1.4) 
3/284 (1.1) <0.001 
  
186/194 (95.9) 
4/194 (2.1) 
3/194 (1.5) 
1/194 (0.5) 
 
172/184 (93.5) 
7/184 (3.8) 
3/184 (1.6) 
2/184 (1.1) 0.328 
S. mansoni (urine CCA)§  590/724 (82.4) 108/309 (34.9) <0.001     
S. mansoni (PCR)§  310/679 (47.5) 43/282 (15.3) <0.001     
A. lumbricoides (KK)  2/679 (0.2) 0/284 (0)   0/194 (0) 1/184 (0.5)  
T. trichiura (KK)  44/679 (6.2) 4/284 (1.4) 0.002  4/194 (2.1) 2/184 (1.1) 0.456 
N. americanus (PCR)  72/679 (9.9) 12/282 (4.3) 0.016  3/194 (1.6)# 2/184 (1.1)# 0.697 
S. stercoralis (PCR)§  58/679 (7.5) 4/282 (1.4) 0.001     
Schistosoma-specific 
antibody levels (μg/ml), 
median (IQR) 
 
   
 
   
SEA-specific IgE   4.6 (3.1, 6.6) 2.6 (1.7, 4.4) <0.001  2.4 (1.5, 4.0) 2.4 (1.7, 3.9) 0.566 
SWA-specific IgE   4.9 (3.0, 6.7) 2.3 (1.5, 3.4) <0.001  1.9 (1.3, 3.4) 2.0 (1.5, 3.3) 0.914 
SEA-specific IgG4   282 (70, 839) 27 (0, 90) <0.001  27 (0, 77) 26 (0, 68) 0.255 
SWA-specific IgG4   109 (52, 275) 39 (18, 65) <0.001  38 (22, 64) 39 (22, 60) 0.871 
SEA-specific IgG   1975 (1061, 3098) 
739 (599, 
1476) <0.001 
 736 (602, 1318) 693 (593, 1117) 0.686 
SWA-specific IgG   1499 (999, 2140) 
791 (612, 
1200) <0.001 
 825 (644, 1130) 737 (615, 1061) 0.495 
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Table shows characteristics for individuals with data on ImmunoCAP-determined IgE sensitisation. Probability values are shown for 
differences in characteristics between rural and urban survey participants and between asthmatic schoolchildren and non-asthmatic 
controls. 
*Percentages were adjusted for survey design. Percentages / medians that were significantly higher in one group compared to the 
other (p≤0.05) are highlighted in bold. Adjusting for age and sex had little impact on these differences. 
¶P values obtained from survey design-based logistic or linear regression. 
§Information not collected in the asthma case-control study. 
#Necator americanus infection detected by Kato-Katz in the asthma case-control study. 
asIgE: allergen-specific IgE; KK: Kato-Katz; PCR: Polymerase Chain Reaction; CCA: Circulating Cathodic Antigen; IQR: Interquartile 
range; SEA: Schistosoma egg antigen; SWA: Schistosoma adult worm antigen 
 
Overall responses to structures on the ISAC and N-glycan microarray 
Figure 2 shows prevalence of sensitisation (IgE≥0.3 ISU) to allergen components on the 
ISAC microarray. Among rural participants, sensitisation to components on the array was 
dominated by reactivity to insect venom proteins (rPol d 5, rVes v 5, rApi m 1) and 
components bearing classical CCDs. Among urban participants and non-asthmatics, 
sensitisation patterns were more varied: HDM, venom, food and CCD-bearing 
components contributed most to sensitisation. However, sensitisation among asthmatics 
was dominated by reactivity to major recombinant and natural HDM allergens. 
Figure 3 shows average MFIs for structures on the glycan microarray. Although the 
highest responses were raised predominantly against core β-1,2-xylose and/or α-1,3-
fucose substituted N-glycans in all three studies, responses to a few other carbohydrate 
structural elements such as tri-mannose (G99), fucosylated GlcNAc (G111) and 
galactose-alpha-1,3-galactose (α-1,3-gal) [G112, G113] were also as high. 
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Figure 2. Prevalence of sensitisation (IgE≥0.3 ISU) to allergen components on the ISAC microarray 
 
Figure shows only allergen components to which IgE ≥ 0.3 ISU was raised. Natural and recombinant allergens are denoted by the prefixes (n) and (r), respectively, on 
the allergen name. ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardised units; CCD: Cross-reactive carbohydrate determinant 
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Plasma from rural and the urban survey participants (panel A) and asthmatic and non-asthmatic schoolchildren (panel B) were assessed for IgE reactivity to glycan 
structural variants with and without α-1,3-fucosylation and β-1,2-xylosylation, on a microarray platform.  
Graphs show background-subtracted and log2-transformed median fluorescence intensities (MFI). Only structures with an average MFI above 4.75 are shown. The entire 
collection of structures on the microarray is shown in supplementary Figure E1. 
Figure 3. Responses to structures on the glycan microarray
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Sensitisation to allergen extracts does not reflect sensitisation to their commonly 
accepted major components  
In all study settings, sensitisation (ImmunoCAP IgE ≥0.35 kU/L) to HDM, German 
cockroach and peanut extracts was high (Table 1). Fifty five percent and 43% of rural 
and urban participants and 73% and 54% of asthmatic schoolchildren and their controls, 
respectively, were sensitised to at least one of the three extracts. Skin reactivity to each 
extract was far lower than prevalence of IgE sensitisation to the same extracts. 
However, sensitisation to both natural and recombinant forms of established major 
allergenic components of these extracts was very low among rural and urban survey 
participants, and among non-asthmatic schoolchildren (Figure 4): 0%-3% (rural), 0%-
10% (urban) and 0%-12% (non-asthmatics) of tested participants were sensitised (IgE 
≥0.30 ISU) to HDM, cockroach and peanut components on ISAC. The picture was 
strikingly different among asthmatics: 18%-36% were sensitised to HDM allergens (42% 
to at least one) and 0-10% to cockroach; but none to peanut components.  
Reactivity to CCDs and venom proteins dominates ISAC-determined IgE profiles, 
and is strongly associated with the rural environment  
Despite the low prevalence of ISAC-determined IgE sensitisation to major natural and 
recombinant components of common allergens in our study settings,58 many participants 
mounted responses to components bearing classical CCDs (Figures 5A and 5C) and 
wasp venom proteins (rVes v5, rPol d 5) (Figures 5B and 5D). 
A higher proportion of rural, compared to urban participants, recognised CCDs and 
venom proteins (Table S3 and Figures 5A and 5B). However, this was statistically 
significant only for the CCDs nPhl p4 and nCry j 1 and the venoms rPol d 5 and rVes v 
5. Conversely, a higher proportion of urban, compared to rural participants, recognised 
recombinant major allergens of HDM (Table S3 and Figure 4A), the food components 
rApi g 1 and rMal d 1 and the cat allergen rFel d 4 (Table S3). 
Although reactivity to HDM components was higher among asthmatics compared to 
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controls, reactivity to components bearing classical CCDs, venom proteins and most 
other allergen components on the array was generally similar between the two groups 
(Figure 4 and Table S3). 
Figure 4. IgE reactivity to allergen extracts and their major allergenic components 
 
ImmunoCAP-determined IgE sensitisation to HDM, German cockroach and peanut extracts and ISAC-determined IgE 
sensitisation to the major allergenic components in these extracts. Natural and recombinant allergens on the ISAC array are 
denoted by the prefixes (n) and (r), respectively, on the allergen name. Cut-offs of 0.35 kU/L and 0.30 ISU are shown to 
define which ImmunoCAP and ISAC responses, respectively, are important for clinical diagnosis of allergic sensitisation. 
The Mann-Whitney U test was conducted within the framework of a Monte Carlo simulation algorithm based on 1000 
permutations (in order to adjust for multiple testing), to assess differences between rural and urban individuals (panels A, B 
and C), and between asthmatics and their controls (panels D, E and F): *p<0.05; **p<0.01; ***p<0.001. 
HDM: house dust mite; ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardised units; CCD: cross-reactive 
carbohydrate determinant 
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Figure 5. IgE reactivity to venoms and CCD-bearing components on the ISAC array 
 
Natural and recombinant allergens are denoted by the prefixes (n) and (r), respectively, on the allergen name. Cut-offs of 0.30 ISU are shown to define which ISAC-determined IgE 
responses are important for clinical diagnosis of allergic sensitisation.  
The Mann-Whitney U test was conducted within the framework of a Monte Carlo simulation algorithm based on 1000 permutations (in order to adjust for multiple testing), to assess 
differences between rural and urban individuals, and between asthmatics and their controls: *p<0.05; **p<0.01; ***p<0.001. 
ISU: ISAC standardised units; CCD: cross-reactive carbohydrate determinant 
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Associations between helminth infections and ISAC-determined CCD- and venom-
specific IgE 
Schistosomes share common carbohydrate structures with some allergens.18 A higher 
proportion of Sm infected compared to uninfected rural participants recognised CCDs 
and venom and fungal proteins on the ISAC array; however, this difference was 
statistically significant only for venom and fungal allergens (Table S4). Helminth 
prevalence was low in the urban survey and in the asthma study, hence associations 
with helminths were not examined there. 
Reactivity to core b-1,2-xylose/a-1,3-fucose is positively associated with Sm 
infection and sensitisation to allergen extracts, but not to their established major 
components 
Cross-reactive carbohydrate determinants expressed by several insect and plant 
glycoproteins, and by some nematodes and trematodes (such as schistosomes), are 
typified by presence of α-1,3-linked core fucose and β-1,2-linked core xylose motifs.11,18 
We combined the three studies and further explored associations between CCD-specific 
IgE and Sm infection and atopic sensitisation using microarray binding studies of core b-
1,2-xylose and a-1,3-fucose substituted N-glycans.  
Responses to individual core substituted N-glycans were strongly correlated and were 
combined using PCA. Figure 6A shows scatterplots of PC1 and PC2 loadings (all 
participants). PC1 was characterised by responses to core b-1,2-xylose and/or a-1,3-
fucose substituted N-glycans while PC2 was characterised by responses to non-
xylosylated and non-fucosylated glycans. There were positive associations between PC1 
scores and 1) Sm infection (Figure 6B) [but not other helminths, data not shown], 2) 
HDM, cockroach and peanut extract-sensitisation (on ImmunoCAP), 3) CCD- and insect 
venom-sensitisation [on ISAC] (Figures 6C-G) and 4) the rural environment (Figure 6H). 
However, no associations were observed between PC1 scores and sensitisation to any 
of the major natural and recombinant HDM, cockroach and peanut components on ISAC 
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(Figure 6C-E). 
Reactivity to core a-1,3-fucose substituted N-glycans is inversely associated with 
asthma 
No associations were observed between glycan microarray-assessed IgE response PC 
scores and allergic effector responses (asthma or SPT reactivity (Figure 6I-J). 
Assessment of associations between asthma and responses to individual glycans on the 
array showed that asthmatics, compared to controls, mounted significantly lower 
responses to N-glycans carrying core a-1,3-fucose only or in combination with a-1,6-
fucose, but not to any other structures on the array (Figure 7).
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Figure 6. Associations between anti-glycan IgE responses and atopic sensitisation and asthma 
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Figure shows data combined from all three studies. Figure 6A shows a scatterplot of first (PC1) and second factor (PC2) loadings derived from principal component 
analysis of IgE responses to 135 synthetic N-glycans. Box-and-whisker plots show associations between PC scores and (B) S. mansoni infection [Kato-Katz and/or 
PCR, infected n=88; uninfected n=154], (C) crude D. pteronyssinus extract-specific IgE sensitisation (ImmunoCAP IgE≥0.35 kU/L) and sensitisation (IgE≥0.3 ISU) to 
any of the dust mite components on the ISAC array, (D) crude German cockroach extract-specific IgE sensitisation and sensitisation to any of the German cockroach 
components on the ISAC array, (E) crude peanut (A. hypogaea) extract-specific IgE sensitisation and sensitisation to any of the peanut components on the ISAC array, 
(F) IgE sensitisation (IgE≥0.30 ISU) to any of the CCD-bearing components on the ISAC array, (G) IgE sensitisation to any of the insect venom components on the 
ISAC array, (H) the rural-urban environment, (I) SPT reactivity to any of Dermatophagoides mix, German cockroach or Blomia tropicalis, (J) asthma status. 
Horizontal lines in the plots represent medians and boxes denote interquartile ranges (IQR). Whiskers were drawn using the Tukey method (1.5 times IQR). Individual 
points represent outliers (>1.5 times IQR away from median). 
Associations between PC scores and the various comparison groups were assessed using linear regression analysis in Stata 13.1. Age- and sex-adjusted p values are 
shown. 
PC1: Principal Component 1; PC2: Principal Component 2; Sm: S. mansoni infection determined by Kato-Katz and/or PCR; ISAC: Immuno Solid-phase Allergen Chip; 
CCD: cross-reactive carbohydrate determinant; SPT: skin prick test  
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Figure 7. Associations between asthma and IgE reactivity to glycans  
          
(A) Heatmap of average log2-transformed MFIs representing IgE reactivity to each individual glycan structure on the array, in asthmatic versus non-asthmatic schoolchildren. 
*p<0.05. (B) Box-and-whisker plots showing MFIs representing IgE reactivity to core a-1,3-fucosylated N-glycan structures. (C) Box-and-whisker plots showing MFIs representing 
IgE reactivity to core β-1,2-xylosylated N-glycan structures. Horizontal lines in the plots represent medians and boxes denote interquartile ranges (IQR). Whiskers were drawn using 
the Tukey method (1.5 times IQR). Individual points represent outliers (> 1.5 times IQR away from median). The Mann-Whitney U test was conducted within the framework of a 
Monte Carlo simulation algorithm based on 1000 permutations (in order to adjust for multiple testing), to assess differences between asthmatic and non-asthmatic schoolchildren.  
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DISCUSSION  
We conducted a component-resolved assessment of associations between IgE 
responses and allergy outcomes among Ugandan rural and urban individuals, and 
among asthmatic schoolchildren and their controls. We hypothesised that anti-CCD IgE 
might contribute to protection against clinical allergy, and found that there was a specific 
inverse association between reactivity to core a-1,3-fucose substituted N-glycans and 
asthma. We also found that among rural, urban and non-asthmatic participants, 
sensitisation to extracts from common environmental allergens did not reflect 
sensitisation to their established major allergenic components; rather, many participants 
recognised CCDs and venom proteins, both known to be expressed on Sm antigens. By 
contrast, a high proportion of asthmatics were sensitised to both HDM extract and its 
major components, lending substantial support to increasing evidence that much asthma 
in tropical LICs is atopic, contrary to earlier perception.59,60 Detailed assessment of IgE 
reactivity to core b-1,2-xylose and/or a-1,3-fucose (well-known, non-mammalian, 
“classical” CCDs) using a synthetic glycan microarray revealed strong positive 
associations with Sm infection, the rural environment and ImmunoCAP-determined 
allergen extract-specific IgE sensitisation, but not with ISAC-determined sensitisation to 
major natural and non-glycosylated recombinant components of these allergen extracts.  
Allergen extracts contain a mixture of allergenic and non-allergenic components,61 as 
well as cross-reactive protein and carbohydrate components that are conserved in other 
environmental antigens such as those from schistosomes.62 This obscures the identity 
of the molecular drivers, and hence interpretation, of atopic sensitisation, which is 
regularly diagnosed using allergen extract-based in vivo SPTs and/or in vitro extract-
specific IgE blood immunoassays. Our results show that this has important implications 
for diagnosis of atopy and use of population attributable fractions to assess the 
contribution of atopy to allergy-related disease in tropical LICs.  
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The high prevalence of sensitisation to allergen extracts but low sensitisation to their 
major allergenic components in our high-Sm-transmission rural setting is reminiscent of 
previous findings by Hamid et al. among Indonesian schoolchildren from areas endemic 
for soil-transmitted helminths (STH) but not schistosomes.35 Hamid’s results imply that 
cross-reactive protein motifs and/or CCDs from environmental antigens other than 
schistosomes play an important role in allergy epidemiology. While exposure to STH 
might theoretically contribute, expression of “classical” CCD epitopes in most STH is not 
yet well mapped, with STH glycomes understudied compared to the Schistosoma 
glycome. However, absence of significant associations between anti-CCD IgE and 
infection with any STH in our studies opposes the notion that STH express “classical” 
CCDs.  
Sensitisation to components bearing classical CCDs in our studies was more common 
than sensitisation to major allergenic components, suggesting that in this setting, IgE to 
allergen extracts is raised predominantly against carbohydrate groups shared with 
environmental antigens, such as helminths. There is evidence showing that cross-
sensitisation between Schistosoma antigens and peanut, pollen or insect venom 
allergens is predominantly caused by CCDs.36,63,64 Our results also imply that CCDs 
contribute considerably to sensitisation to HDM and cockroach allergens in helminth-
endemic settings.   
Although insect venom N-glycans carry core a-1,3-fucose motifs65,66 (which, akin to core 
b-1,2-xylose, are expressed on Schistosoma egg N-glycans17), this is unlikely to explain 
why responses to wasp venom components were elevated among rural and Sm infected 
participants, as the ISAC array contains recombinant forms of these components. The 
observed responses possibly reflect sensitisation to Venom-Allergen-Like (VAL) proteins 
expressed by schistosomes67 and other helminths such as hookworm68 and Brugia 
malayi.69 Screening the Sm GeneDB database 
(http://www.genedb.org/Homepage/Smansoni) for protein homology between Sm and 
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wasp venoms yields 46 Sm protein sequences producing high-scoring segment pairs 
with up to 43% identity and 56% similarity to Pol d 5, and 41 Sm proteins with up to 42% 
identity and 78% similarity to Ves v 5. 
Higher levels of IgE to CCDs in rural compared to urban participants, and among Sm 
infected compared to uninfected participants, imply that Sm infection in our setting 
contributes considerably to high anti-CCD IgE levels and consequently to high 
prevalence of ImmunoCAP sensitisation to allergen extracts expressing these CCDs. It 
is likely that previously observed positive associations between Sm and HDM extract-
specific IgE in our rural setting5 are partially attributable to CCD-sensitisation. In the 
same population, prevalence of clinical allergies is low, supporting the hypothesis that 
helminths may protect against allergic effector responses. The role of CCDs in protection 
against allergy, if any, is unclear. Alpha-1,3-gal has been implicated in meat allergy;33 
however, our studies did not find any evidence of this, despite elevated α-1,3-gal-specific 
IgE concentrations. Other than α-1,3-gal-specific IgE, carbohydrate-specific IgE rarely, 
if ever, translates into clinical allergy.10,29,34,36 We postulated that elevated IgE responses 
to specific immunogenic glycans during chronic Sm infection might dominate over 
allergen protein-specific IgE, resulting in reduced allergic effector responses. Many 
native allergens occur as glycoproteins; therefore, prior high exposure to specific CCDs 
(perhaps resulting from Sm infection) may prime initial and recall IgE responses to 
preferentially target specific CCD rather than the protein epitopes of allergens. Thus in 
Sm-endemic settings, IgE may be less effectively induced against common protein 
allergens than against CCDs, as implied by responses to components on the ISAC array 
in the present study.  
In our setting, ISAC-determined anti-CCD IgE was not inversely associated with SPT 
reactivity or asthma, and PCA of microarray-determined anti-glycan IgE responses 
suggested no overall association (inverse or otherwise) between asthma and anti-glycan 
IgE. However, analysis of levels of IgE to individual glycans revealed that reactivity to 
254
		
core a-1,3-fucose substituted N-glycans was lower among asthmatic schoolchildren 
compared to controls. We now hypothesise that responses to specific glycans are not 
merely a smokescreen that obscures readouts for assessment of atopy; they may be 
important in protection against allergic disease through specific, yet-to-be-defined, 
mechanisms. Further mechanistic investigations in animal and human studies are 
required to investigate this hypothesis. Current efforts to reconstruct helminth 
glycoproteins (including those carrying N-glycan core substitutions) in plant systems70 
offer great promise for availability of tailored glycan epitopes for initial testing in animal 
models. 
Overall, our data indicate that in tropical LICs, IgE to allergen extracts (detected in 
standard ImmunoCAP assays) reflects sensitisation to a myriad of environmental 
exposures (absent in high-income countries), such as CCDs expressed by some 
helminths, and may not accurately define allergy-related disease phenotypes. In fact, 
our findings suggest that reactivity to specific (but not all) CCD epitopes might contribute 
to protection against clinical allergy.
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 Sample size considerations 
In the rural survey, 2961 participants from the 26 study villages had a plasma sample 
stored and hence provided the sampling frame for selection for the ImmunoCAP IgE test. 
780 participants (approximately 30 per village) were randomly selected using Stata 13.1 
software (StataCorp, College Station, Texas, U.S.A). The rural survey was the three-
year outcome survey of the Lake Victoria Island Intervention Study on Worms and 
Allergy-related diseases (LaVIISWA; ISRCTN471960311). The main LaVIISWA trial 
analysis aimed to compare outcomes between the two trial arms,1,2 hence a sample size 
of 780 was expected to give 80% power to detect a 35% relative difference in the 
prevalence of ImmunoCAP allergen-specific IgE sensitisation between the two trial arms, 
based on an assumed overall allergen-specific IgE sensitisation prevalence of 50% (from 
results at baseline), and an estimated coefficient of variation (in IgE levels between 
clusters) of 0.2.  
Samples for the glycan and ISAC microarray experiments were randomly selected from 
among those with ImmunoCAP data. We initially aimed for 50 samples per trial arm (100 
in total), and managed to test a total of 209 (glycan array) and 126 samples (ISAC array 
experiments, respectively), owing to availability of further funding. Similar numbers have 
been shown to be useful in published studies that have assessed differences in 
microarray-assessed antibody levels between helminth infected and uninfected, and 
allergic and non-allergic individuals,3,4 and between children and adults.5  
In the urban survey, 1356 participants had a plasma sample stored. ImmunoCAP data 
on cockroach- and dust mite-specific IgE were available for rural survey participants, 
hence calculations could be conducted to estimate how many urban survey plasma 
samples were required to attain significant differences in the prevalence of ImmunoCAP 
positivity between the urban and rural survey. Assuming a 35% prevalence of 
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ImmunoCAP positivity to either cockroach or dust mite in the rural survey and a design 
effect of 1.3, 353 urban survey participants were required for 80% power to detect an 
absolute difference in proportion positive of 0.10 between the rural and urban survey. 
For the glycan and ISAC microarray experiments, a sample size of 50 was deemed 
sufficient to detect differences between the rural and urban setting, based on previous 
studies doing similar comparisons.3  
In the asthma case-control study, 557 cases and 1128 controls had a plasma sample 
stored. Four hundred participants (200 asthmatics and 200 controls) were randomly 
selected for the ImmunoCAP test. This number was expected to yield 90% power to 
detect a significant positive association (at an odds ratio of 2) between asthma and 
ImmunoCAP positivity to any of dust mite, cockroach or peanut (IgE ≥0.35 kU/L). For 
glycan and ISAC microarray experiments, a sample size of 50 cases and 50 controls 
was deemed sufficient, based on numbers used in the rural and the urban survey. 
 ImmunoCAP ISACÒ sIgE 112 test 
This test was conducted according to the manufacturer’s instructions. The ISAC 
(Immuno Solid-phase Allergen Chip) comprises four reaction sites, each printed with 112 
allergen components in a microarray format. Before the immunoassay, each microarray 
chip was washed to remove any allergens that were non-covalently bound to the 
microarray surface. Each reaction site was then incubated with 30 μl of undiluted 
participant plasma for two hours at room temperature in a humidified chamber to enable 
reactions between IgE and allergen components. Following a washing step, each 
microarray was incubated for 30 minutes with 30 μl of fluorescence-labeled anti-human 
IgE detection antibody. Unbound detection antibody was washed off and the 
fluorescence intensity of each microarray measured using a scanner (LuxScan 10K/A, 
CapitalBio, Beijing, China). Analysis of the resultant digitalized images was done using 
Phadia Microarray Image Analysis software (Thermo Fisher Scientific). Results were 
reported in arbitrary semi-quantitative ISAC Standardised Units (ISU). 
7.3.1.2
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 Microarray detection of N-glycan-specific IgE  
Each reaction site on each microarray slide included fluorescently-labeled bovine serum 
albumin (BSA) as a printing control. The NEXTERION®-coated microarray slides [Schott 
AG, Germany] used in the IgE binding assay were blocked (during microarray 
construction) with 50mM ethanolamine in 50mM sodium borate buffer pH 9.0, and stored 
at -20°C. On the day of the binding assay, they were thawed at room temperature (RT) 
and covered with silicone gaskets to create seven wells with printed microarrays per 
slide. Each microarray was incubated with 300 μl of a 1:30 plasma dilution in 1% BSA - 
0.01% Tween20 for one hour at RT while shaking. After sequential washes with PBS-
0.05% Tween20 and PBS, the slides were incubated for 30 minutes at RT in the dark 
with PromoFluor 647 (VWR, USA)-labeled anti-human IgE clone MH25-1 (Sanquin, 
Amsterdam, Netherlands) [diluted 1/150 in PBS-0.01% Tween20], while shaking. After a 
final wash with PBS-0.05% Tween20, PBS and deionised water, sequentially, the slides 
were dried and kept in the dark until scanning. The slides were scanned for fluorescence 
at a 10μm resolution with a G2565BA scanner (Agilent Technologies, CA, USA) using a 
633nm laser. 
 Glycan microarray image processing  
Using GenePix Pro 7.0 software (Molecular Devices, CA, USA), a spot-finding algorithm 
was used to align and re-size fluorescence spots in the microarray images, without 
setting a composite pixel intensity threshold. Data on median fluorescence intensity 
(MFI) for each spot and the local background were then exported to Microsoft Excel 
software. In all analyses, MFIs that were highlighted as artefacts by the GenePix Pro 7.0 
software were excluded. Further processing of IgE MFIs in Excel was done as described 
by Amoah et al.,3 as follows: for each IgE spot, the ratio of the MFI of the spot to the local 
background MFI was obtained and then multiplied by the average of background MFI for 
all the spots on the array. For each of the structures, the average over four spots (or 
less, in case of unreliable data that were excluded) was then log2-transformed. 
7.3.1.3
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 Supplementary tables and figures 
Table S1. List of allergen components on the ImmunoCAP ISAC® microarray (source: 
Thermo Fisher Scientific, Uppsala, Sweden) 
Allergen 
component Allergen source Latin name Protein group 
nAct d 1 Kiwi Actinidia deliciosa   
nAct d 2 Kiwi Actinidia deliciosa Thaumatine-like protein 
nAct d 5 Kiwi Actinidia deliciosa   
rAct d 8 Kiwi Actinidia deliciosa PR-10 protein 
rAln g 1 Alder Alnus glutinosa PR-10 protein 
rAlt a 1 Alternaria Alternaria alternata   
rAlt a 6 Alternaria Alternaria alternata Enolase 
nAmb a 1 Ragweed Ambrosia artemisiifolia   
rAna o 2 Cashew nut Anacardium occidentale Storage protein, 11S globulin 
rAni s 1 Anisakis Anisakis simplex   
rAni s 3 Anisakis Anisakis simplex Tropomyosin 
rApi g 1 Celery Apium graveolens PR-10 protein 
rApi m 1 Honey bee venom Apis mellifera Phospholipase A2 
nApi m 4 Honey bee venom Apis mellifera Melittin 
rAra h 1 Peanut Arachis hypogaea Storage protein ,7S globulin 
rAra h 2 Peanut Arachis hypogaea Storage protein, Conglutin 
rAra h 3 Peanut Arachis hypogaea Storage protein, 11S globulin 
nAra h 6 Peanut Arachis hypogaea Storage protein, Conglutin 
rAra h 8 Peanut Arachis hypogaea PR-10 protein 
rAra h 9 Peanut Arachis hypogaea Lipid transfer protein (nsLTP) 
nArt v 1 Mugwort Artemisia vulgaris   
nArt v 3 Mugwort Artemisia vulgaris Lipid transfer protein (nsLTP) 
rAsp f 1 Aspergillus Aspergillus fumigatus   
rAsp f 3 Aspergillus Aspergillus fumigatus   
rAsp f 6 Aspergillus Aspergillus fumigatus Mn superoxide dismutase 
rBer e 1 Brazil nut Bertholletia excelsa Storage protein, 2S albumin 
rBet v 1 Birch Betula verrucosa PR-10 protein 
rBet v 2 Birch Betula verrucosa Profilin 
rBet v 4 Birch Betula verrucosa Polcalcin 
rBla g 1 Cockroach Blattella germanica   
rBla g 2 Cockroach Blattella germanica   
rBla g 5 Cockroach Blattella germanica   
7.3.2
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nBla g 7 Cockroach Blattella germanica Tropomyosin 
rBlo t 5 House dust mite Blomia tropicalis   
nBos d 4 Cow’s milk Bos domesticus Alpha-lactalbumin 
nBos d 5 Cow’s milk Bos domesticus Beta-lactoglobulin 
nBos d 6 Cow’s milk and meat Bos domesticus Serum albumin 
nBos d 8 Cow’s milk Bos domesticus Casein 
nBos d 
lactoferrin Cow’s milk Bos domesticus Transferrin 
rCan f 1 Dog Canis familiaris Lipocalin 
rCan f 2 Dog Canis familiaris Lipocalin 
nCan f 3 Dog Canis familiaris Serum albumin 
rCan f 5 Dog Canis familiaris Arginine esterase 
rChe a 1 Goosefoot Chenopodium album   
rCla h 8 Cladosporium Cladosporium herbarum   
rCor a 1.0101 Hazel pollen Corylus avellana PR-10 protein 
rCor a 1.0401 Hazelnut Corylus avellana PR-10 protein 
rCor a 8 Hazelnut Corylus avellana Lipid transfer protein (nsLTP) 
nCor a 9 Hazelnut Corylus avellana Storage protein, 11S globulin 
nCry j 1 Japanese ceder Cryptomeria japonica   
nCup a 1 Cypress Cupressus arizonica   
nCyn d 1 Bermuda grass Cynodon dactylon Grass group 1 
nDer f 1 House dust mite Dermatophagoides farinae   
rDer f 2 House dust mite Dermatophagoides farinae   
nDer p 1 House dust mite Dermatophagoides pteronyssinus   
rDer p 10 House dust mite Dermatophagoides pteronyssinus Tropomyosin 
rDer p 2 House dust mite Dermatophagoides pteronyssinus   
rEqu c 1 Horse Equus caballus Lipocalin 
nEqu c 3 Horse Equus caballus Serum albumin 
nFag e 2 Buckwheat Fagopyrum esculentum Storage protein, 2S albumin 
rFel d 1 Cat Felis domesticus Uteroglobin 
nFel d 2 Cat Felis domesticus Serum albumin 
rFel d 4 Cat Felis domesticus Lipocalin 
rGad c 1 Cod Gadus callarias Parvalbumin 
nGal d 1 Egg white Gallus domesticus Ovomucoid 
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nGal d 2 Egg white Gallus domesticus Ovalbumin 
nGal d 3 Egg white Gallus domesticus Conalbumin/Ovotransferrin 
nGal d 5 Egg yolk/chicken meat Gallus domesticus Livetin/Serum albumin 
rGly m 4 Soybean Glycine max PR-10 protein 
nGly m 5 Soybean Glycine max Storage protein, Beta-conglycinin 
nGly m 6 Soybean Glycine max Storage protein, Glycinin 
rHev b 1 Latex Hevea brasiliensis   
rHev b 3 Latex Hevea brasiliensis   
rHev b 5 Latex Hevea brasiliensis   
rHev b 6.01 Latex Hevea brasiliensis   
rHev b 8 Latex Hevea brasiliensis Tropomyosin 
nJug r 1 Walnut Juglans regia Storage protein, 2S albumin 
nJug r 2 Walnut Juglans regia Storage protein, 7S globulin 
nJug r 3 Walnut Juglans regia Lipid transfer protein (nsLTP) 
rLep d 2 Storage mite Lepidoglyphus destructor   
rMal d 1 Apple Malus domestica PR-10 protein 
rMer a 1 Annual mercury Mercurialis annua Profilin 
nMus m 1 Mouse Mus musculus Lipocalin 
nMUXF3 Sugar epitope from Bromelain   Tropomyosin 
nOle e 1 Olive Olea europaea   
nOle e 7 Olive Olea europaea Lipid transfer protein (nsLTP) 
rOle e 9 Olive Olea europaea   
rPar j 2 Wall pellitory Parietaria judaica Lipid transfer protein (nsLTP) 
nPen m 1 Shrimp Penaeus monodon Tropomyosin 
nPen m 2 Shrimp Penaeus monodon Arginine kinase 
nPen m 4 Shrimp Penaeus monodon Sarcoplasmic Ca-binding protein 
rPhl p 1 Timothy grass Phleum pratense Grass group 1 
rPhl p 11 Timothy grass Phleum pratense   
rPhl p 12 Timothy grass Phleum pratense Profilin 
rPhl p 2 Timothy grass Phleum pratense Grass group 2 
nPhl p 4 Timothy grass Phleum pratense   
rPhl p 5 Timothy grass Phleum pratense Grass group 5 
rPhl p 6 Timothy grass Phleum pratense   
rPhl p 7 Timothy grass Phleum pratense Polcalcin 
rPla a 1 Plane tree Platanus acerifolia   
nPla a 2 Plane tree Platanus acerifolia   
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rPla a 3 Plane tree Platanus acerifolia Lipid transfer protein (nsLTP) 
rPla l 1 Plantain (English) Plantago lanceolata   
rPol d 5 Paper wasp venom Polistes dominulus Venom, Antigen 5 
rPru p 1 Peach Prunus persica PR-10 protein 
rPru p 3 Peach Prunus persica Lipid transfer protein (nsLTP) 
nSal k 1 Saltwort Salsola kali   
nSes i 1 Sesame seed Sesamum indicum Storage protein, 2S albumin 
rTri a 14 Wheat Triticum aestivum Lipid transfer protein (nsLTP) 
rTri a 19.0101 Wheat Triticum aestivum Omega-5 gliadin 
nTri a aA_TI Wheat Triticum aestivum   
rVes v 5 Common wasp venom Vespula vulgaris Venom, Antigen 5 
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Figure S1. Collection of synthetic structural variants on the glycan microarray
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Table S2. Impact of community-based intensive versus standard anthelminthic treatment on IgE profiles in the rural survey 
  
n/N (%) / geometric mean  Unadjusted  Adjusted for age and sex 
Outcome 
Standard Intensive  
RR§ / GMR# 
(95% CI) 
p-value  
RR§ / GMR# 
(95% CI) 
p-value 
          
ImmunoCAP-determined IgE         
          
 Dermatophagoides, cockroach or peanut positivity (IgE≥0.35kU/L) 223/390 (57.2%) 214/390 (54.9%)  0.95 (0.81, 1.10) 0.46  0.94 (0.80, 1.10) 0.41 
 Dermatophagoides positivity (IgE>0.35kU/L) 134/390 (34.4%) 130/390 (33.3%)  0.95 (0.76, 1.20) 0.67  0.96 (0.77, 1.19) 0.68 
 German cockroach positivity (IgE>0.35kU/L) 201/390 (51.5%) 192/390 (49.2%)  0.94 (0.80, 1.11) 0.47  0.94 (0.79, 1.11) 0.42 
 Peanut positivity (IgE>0.35kU/L) 59/390 (15.1%) 55/390 (14.1%)  0.92 (0.59, 1.41) 0.68  0.91 (0.58, 1.41) 0.66 
 Concentration of IgE to Dermatophagoides GM: 0.158 GM: 0.129  0.78 (0.51, 1.17) 0.22  0.76 (0.51, 1.13) 0.17 
 Concentration of IgE to cockroach GM: 0.342 GM: 0.289  0.82 (0.55, 1.22) 0.31  0.81 (0.55, 1.20) 0.28 
 Concentration of IgE to peanut GM: 0.074 GM: 0.066  0.89 (0.64, 1.23) 0.47  0.89 (0.65, 1.23) 0.49 
         
ISAC-determined IgE sensitisation (IgE≥0.3 ISU)         
          
 CCD-bearing components 9/72 (12.5%) 12/54 (22.2%)  1.87 (0.79, 4.41) 0.13  2.46 (0.92, 6.57) 0.12 
 Venoms 11/72 (15.3%) 16/54 (29.6%)  1.87 (0.90, 3.90) 0.10  1.23 (0.55, 2.79) 0.59 
 Dust mites 1/72 (1.4%) 3/54 (5.7%)  2.80 (0.23, 33.85) 0.41  3.3 (0.27, 40.80) 0.36 
          
Glycan-specific IgE mean fluorescence intensity         
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G42 
GM: 4.778 GM: 4.760  0.99 (0.99, 1.00) 0.34  0.99 (0.99, 1.00) 0.24 
 
 
G34 
GM: 4.847 GM: 4.834  1.02 (0.98, 1.06) 0.44  1.02 (0.98, 1.06) 0.31 
 
 
G73 
GM: 5.070 GM: 5.106  1.01 (0.96, 1.06) 0.79  1.01 (0.96, 1.07) 0.61 
 
 
G37 
GM: 5.205 GM: 5.322  1.02 (0.96, 1.09) 0.50  1.03 (0.97, 1.10) 0.34 
          
§Risk ratios (mean of the cluster proportions in intensive arm divided by the mean of the cluster proportions in standard arm) were calculated to assess the impact of trial 
intervention on ImmunoCAP-determined IgE sensitisation to crude house dust mite, German cockroach and peanut, and on ISAC-determined sensitisation to at least one 
allergen component within the larger allergen groupings of CCDs, venoms, and dust mites. 
#Geometric mean ratios were calculated to assess the impact of trial intervention on the concentration of ImmunoCAP-determined IgE sensitisation to individual allergens 
and on IgE mean fluorescence intensities to representative glycans on the array. 
RR: risk ratio; GM: geometric mean; GMR: geometric mean ratio; CI: confidence interval; ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardised units 
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Table S3. Differences in ISAC-determined IgE reactivity in the rural versus urban setting and among asthmatics versus non-asthmatics 
  % with detectable IgE, ISAC % with IgE≥0.30 ISU, ISAC  % with detectable IgE, ISAC % with IgE≥0.30 ISU, ISAC 
Component 
 Rural 
(n=126) 
Urban 
(n=60) p 
Rural 
(n=126) 
Urban 
(n=60) p 
 Non-
asthmatics 
(n=50) 
Asthmatics 
(n=50) p 
Non-
asthmatics 
(n=50) 
Asthmatics 
(n=50) p 
CCD-bearing 
components 
              
nJug r 2  23.8 25.0 0.859 9.5 5.0 0.225  36.0 38.0 0.836 10.0 16.0 0.375 
nMUXF3  11.1 5.0 0.139 4.8 1.7 0.279  18.0 18.0 1.000 10.0 6.0 0.463 
nPhl p 4  28.6 10 0.005 14.3 8.3 0.181  34.0 32.0 0.832 16.0 12.0 0.566 
nCry j 1  9.5 1.7 0.040 2.4 1.7 0.612  8.0 14.0 0.340 2.0 10.0 0.094 
nCup a 1  8.7 3.3 0.148 2.4 1.7 0.612  12.0 14.0 0.767 4.0 12.0 0.142 
nCyn d 1  19.8 10.0 0.067 11.1 6.7 0.249  24.0 24.0 1.000 16.0 18.0 0.791 
nPla a 2  13.5 6.7 0.128 6.3 0.0 0.041  26.0 24.0 0.818 8.0 10.0 0.728 
Venoms               
rPol d 5  39.7 20 0.008 19.0 11.7 0.207  38.0 40.0 0.838 26.0 22.0 0.641 
rVes v 5  24.6 10 0.001 9.5 3.0 0.225  32.0 26.0 0.511 20.0 8.0 0.085 
rApi m 1  5.6 5.0 0.207 4.8 1.0 0.279  10.0 0.0 0.023 0.0 0.0  
nApi m 4  4.8 0.0 0.090 1.6 0.0 0.458  2.0 0.0 0.317 0.0 0.0  
Cross-reactive 
protein 
components 
              
Tropomyosins               
nBla g 7  4.0 1.7 0.369 2.4 1.7 0.612  8.0 12.0 0.507 2.0 10.0 0.094 
rDer p 10  3.9 1.7 0.369 3.2 1.7 0.481  6.0 12.0 0.296 2.0 10.0 0.094 
nPen m1  4.8 5.0 0.600 4.0 1.7 0.369  12.0 12.0 1.000 4.0 12.0 0.142 
rAni s 3  5.6 3.3 0.400 3.2 1.7 0.549  4.0 10.0 0.242 2.0 8.0 0.171 
rHev b 8  0.8 1.7 0.542 0.8 1.7 0.542  4.0 0.0 0.155 2.0 0.0 0.317 
Polcalcins               
rBet v 4  0.0 0.0  0.0 0.0   0.0 2.0 0.500 0.0 0.0  
rPhl p 7  0.8 0.0 0.677 0.0 0.0   2.0 2.0 0.753 0.0 2.0 0.500 
Profilins               
rPhl p 12  1.6 0.0 0.458 0.0 0.0   2.0 0.0 0.500 0.0 0.0  
rBet v 2  0.0 1.7 0.323 0.0 0.0   2.0 0.0 0.500 2.0 0.0 0.500 
rMer a 1  0.8 1.7 0.542 0.0 0.0   2.0 2.0 0.753 2.0 0.0 0.500 
273
		
Dust mites               
nDer p 1  2.4 8.3 0.073 2.4 5.0 0.296  16.0 28.0 0.149 12.0 26.0 0.075 
rDer p 2  2.4 13.3 0.006 1.6 10.0 0.015  10.0 36.0 0.002 8.0 36.0 <0.001 
nDer f 1  6.3 5.0 0.502 2.4 1.7 0.612  16.0 28.0 0.149 12.0 22.0 0.185 
rDer f 2  2.4 8.3 0.073 1.6 8.3 0.036  14.0 36.0 0.012 8.0 36.0 <0.001 
rBlo t 5  0.8 6.7 0.038 0.0 5.0 0.032  8.0 20.0 0.085 4.0 18.0 0.026 
rLep d 2  0.0 6.6 0.010 0.0 6.7 0.010  12.0 32.0 0.016 8.0 24.0 0.029 
               
Cockroach               
rBla g 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rBla g 2  0.0 1.7 0.323 0.0 0.0   2.0 10.0 0.102 0.0 2.0 0.500 
rBla g 5  0.8 0.0 0.677 0.0 0.0   0.0 2.0 0.500 0.0 0.0  
Food allergens               
rAna o 2  4.8 6.7 0.411 2.4 3.3 0.519  4.0 4.0 0.691 2.0 0.0 0.500 
rApi g 1  2.4 10.0 0.033 0.0 0.0   0.0 0.0  0.0 0.0  
nPen m2  4.8 5.0 0.600 5.6 6.7 0.498  16.0 16.0 1.000 10.0 12.0 0.500 
nPen m 4  0.8 0.0 0.677 0.0 0.0   6.0 2.0 0.309 4.0 2.0 0.500 
nBos d 4  0.8 0.0 0.677 0.0 0.0   2.0 4.0 0.500 2.0 0.0 0.500 
nBos d 6  0.0 0.0  0.0 0.0   10.0 6.0 0.357 0.0 0.0  
nBos d 8  3.2 0.0 0.207 1.6 0.0 0.458  0.0 0.0  0.0 0.0  
nBos d lactoferrin  2.4 0.0 0.308 0.0 0.0   8.0 12.0 0.370 4.0 4.0 0.691 
nGal d 1  3.9 8.3 0.186 0.0 3.3 0.103  2.0 0.0 0.500 2.0 0.0 0.500 
nGal d 2  3.2 3.3 0.631 0.8 0.0 0.677  0.0 0.0  0.0 0.0  
nGal d 3  0.8 3.3 0.244 0.8 1.7 0.542  2.0 0.0 0.500 0.0 0.0  
nGal d 5  3.9 0.0 0.139 0.8 0.0 0.677  0.0 2.0 0.500 0.0 0.0  
rGly m 4  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nGly m 5  0.0 0.0  0.0 0.0   2.0 0.0 0.500 2.0 0.0 0.500 
nGly m 6  0.0 1.7 0.323 0.0 0.0   6.0 6.0 0.661 2.0 0.0 0.500 
rMal d 1  0.8 13.3 0.001 0.0 0.0   10.0 4.0 0.218 6.0 0.0 0.121 
rPru p 1  3.9 3.3 0.596 1.6 1.7 0.692  6.0 4.0 0.500 0.0 0.0  
rPru p 3  0.0 0.0  0.0 0.0   0.0 2.0 0.500 0.0 0.0  
rTri a 14  2.4 0.0 0.308 0.0 0.0   0.0 0.0  0.0 0.0  
rTri a 19.0101  7.1 5.0 0.420 1.6 1.7 0.692  0.0 0.0  0.0 0.0  
nTri a aA_TI  0.8 0.0 0.677 0.0 0.0   2.0 4.0 0.500 0.0 0.0  
nAct d 1  0.8 0.0 0.677 0.8 0.0 0.677  6.0 0.0 0.121 2.0 0.0 0.500 
nAct d 2  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
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nAct d 5  0.8 0.0 0.677 0.8 0.0 0.677  0.0 0.0  0.0 0.0  
rAct d 8  1.6 1.6 0.692 0.8 0.0 0.677  8.0 4.0 0.339 4.0 0.0 0.247 
rAra h 1  0.8 0.0 0.677 0.0 0.0   0.0 4.0 0.247 0.0 0.0  
rAra h 2  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
rAra h 3  1.6 0.0 0.458 1.6 0.0 0.458  0.0 0.0  0.0 0.0  
nAra h 6  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rAra h 8  0.0 3.3 0.103 0.0 0.0   0.0 6.0 0.121 0.0 0.0  
rAra h 9  0.8 0.0 0.677 0.0 0.0   0.0 2.0 0.500 0.0 0.0  
rBer e 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rCor a 1.0401  0.0 1.7 0.323 0.0 0.0   2.0 0.0 0.500 0.0 0.0  
rCor a 8  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nCor a 9  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nJug r 1  0.0 0.0  0.0 0.0   0.0 2.0 0.500 0.0 0.0  
nJug r 3  0.0 0.0  0.0 0.0   2.0 0.0 0.500 2.0 0.0 0.500 
rPla l 1  0.0 0.0  0.0 0.0   6.0 0.0 0.121 2.0 0.0 0.500 
nSes i 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nFag e 2  0.0 0.0  0.0 0.0   2.0 0.0 0.500 2.0 0.0 0.500 
Pollen               
rAln g 1  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
nArt v 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nArt v 3  0.0 0.0  0.0 0.0   2.0 0.0 0.500 0.0 0.0  
rBet v 1  1.6 0.0 0.458 0.0 0.0   10.0 8.0 0.500 4.0 0.0 0.247 
rChe a 1  0.8 0.0 0.677 0.0 0.0   2.0 4.0 0.500 0.0 0.0  
rMer a 1  0.8 1.7 0.542 0.0 0.0   2.0 2.0 0.753 2.0 0.0 0.500 
nOle e 7  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rOle e 9  2.4 3.3 0.519 0.0 0.0   0.0 4.0 0.247 0.0 2.0 0.500 
rPar j 2  0.0 0.0  0.0 0.0   2.0 4.0 0.500 0.0 2.0 0.500 
rCor a 1.0101  2.4 3.3 0.519 0.8 1.7 0.542  4.0 6.0 0.500 0.0 2.0 0.500 
rPhl p 1  0.0 1.7 0.323 0.0 0.0   6.0 2.0 0.309 4.0 0.0 0.247 
rPhl p 11  0.8 1.7 0.542 0.8 0.0 0.677  0.0 4.0 0.247 0.0 0.0  
rPhl p 12  1.6 0.0 0.458 0.0 0.0   2.0 0.0 0.500 0.0 0.0  
rPhl p 2  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rPhl p 5  0.8 0.0 0.677 0.0 0.0   4.0 0.0 0.247 0.0 0.0  
rPhl p 6  1.6 1.7 0.692 0.0 1.7 0.323  0.0 0.0  0.0 0.0  
rPhl p 7  0.8 0.0 0.677 0.0 0.0   2.0 2.0 0.753 0.0 2.0 0.500 
rPla a 1  6.4 3.3 0.319 3.2 1.7 0.481  10.0 6.0 0.357 4.0 2.0 0.500 
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rPla a 3  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nSal k 1  0.8 0.0 0.677 0.8 0.0 0.677  4.0 10.0 0.218 0.0 4.0 0.247 
Fungi               
rAlt a 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
rAlt a 6  1.6 3.3 0.388 0.8 1.7 0.542  4.0 4.0 0.691 0.0 0.0  
nAmb a 1  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
rAsp f 1  5.6 8.3 0.334 0.8 0.0 0.677  4.0 0.0 0.247 0.0 0.0  
rAsp f 3  6.4 11.7 0.169 1.6 1.7 0.692  2.0 2.0 0.753 0.0 0.0  
rAsp f 6  3.9 1.7 0.369 1.6 0.0 0.458  4.0 0.0 0.247 4.0 0.0 0.247 
rCla h 8  0.8 0.0 0.677 0.0 0.0   0.0 2.0 0.500 0.0 0.0  
Other, animal               
rAni s 1  0.0 0.0  0.0 0.0   2.0 0.0 0.500 2.0 0.0 0.500 
rCan f 2  0.8 1.7 0.542 0.0 0.0   0.0 0.0  0.0 0.0  
nCan f 3  0.0 0.0  0.0 0.0   0.0 4.0 0.247 0.0 0.0  
rCan f 5  2.4 1.7 0.612 0.8 0.0 0.677  4.0 0.0 0.247 2.0 0.0 0.500 
rEqu c 1  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
nEqu c 3  0.0 0.0  0.0 0.0   0.0 2.0 0.500 0.0 0.0  
rFel d 1  0.0 0.0  0.0 0.0   0.0 0.0  0.0 0.0  
nFel d 2  2.4 6.7 0.153 0.0 0.0   6.0 10.0 0.357 2.0 0.0 0.500 
rFel d 4  0.8 6.7 0.038 0.0 0.0   2.0 2.0 0.753 0.0 2.0 0.500 
nMus m 1  0.0 0.0  0.0 0.0   2.0 6.0 0.309 2.0 4.0 0.500 
Latex                
rHev b 1  1.6 1.7 0.692 1.6 1.7 0.692  2.0 0.0 0.500 0.0 0.0  
rHev b 3  0.8 1.7 0.542 0.8 1.7 0.542  0.0 0.0  0.0 0.0  
rHev b 5  0.8 0.0 0.677 0.0 0.0   0.0 0.0  0.0 0.0  
rHev b 6.01  1.6 1.7 0.692 0.8 1.7 0.542  2.0 0.0 0.500 2.0 0.0 0.500 
rHev b 8  0.8 1.7 0.542 0.8 1.7 0.542  4.0 0.0 0.247 2.0 0.0 0.500 
 
Table shows proportions of participants that had an ISAC-detectable IgE response or were sensitised (IgE≥0.3 ISU) to components on the array. The Chi-square / Fisher’s 
exact test was conducted to assess differences in proportions between rural and urban individuals, and between asthmatics and their controls. These tests were conducted 
within the framework of a Monte Carlo simulation algorithm based on 1000 permutations in order to adjust for multiple testing. 
ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardised units 
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Table S4. ISAC-determined IgE reactivity among helminth infected and uninfected rural 
survey participants 
 
Allergen group 
 
% with detectable IgE, ISAC array 
 
% with IgE≥0.30 ISU, ISAC array 
 Any worm 
infection 
(n=62) 
Uninfected 
(n=50) p 
 Any worm 
infection 
(n=62) 
Uninfected 
(n=50) p 
CCD-bearing components  38.7 26.0 0.155  17.7 14.0 0.592 
Venoms  59.7 32.0 0.004  30.7 12.0 0.018 
Dust mites  8.1 6.0 0.484  3.2 4.0 0.606 
Cockroach   4.8 2.0 0.394  3.2 2.0 0.581 
Peanuts  1.6 2.0 0.696  1.6 2.0 0.696 
Food components 
(including peanuts) 
 51.6 38.0 0.150  25.8 18.0 0.324 
Pollen  38.7 30.0 0.336  16.1 16.0 0.985 
Fungal allergens  19.4 2.0 0.003  6.5 0.0 0.090 
Domesticated animals  4.8 4.0 0.601  1.6 0.0 0.554 
         
  Sm+ (n=53)* Sm- (n=58)   Sm+ (n=37) Sm- (n=75)  
CCD-bearing components  35.9 29.3 0.462  15.1 15.5 0.951 
Venoms  60.4 34.5 0.006  30.2 13.8 0.036 
Dust mites  9.4 5.2 0.309  3.8 3.5 0.656 
Cockroach   3.8 3.5 0.656  1.9 3.5 0.534 
Peanuts  0.0 1.7 0.523  0.0 1.7 0.523 
Food components 
(including peanuts) 
 49.1 41.4 0.417  20.8 22.4 0.832 
Pollen  35.9 32.8 0.732  15.1 15.5 0.951 
Fungal allergens  18.9 3.5 0.009  5.7 1.7 0.276 
Domesticated animals  5.7 3.5 0.457  1.9 0.0 0.477 
         
 
 Any 
nematode 
infection¶ 
(n=26) 
Uninfected 
(n=86)  
 Any 
nematode 
infection¶ 
(n=26) 
Uninfected 
(n=86)  
CCD-bearing components  38.5 31.4 0.502  19.2 15.1 0.617 
Venoms  57.7 44.2 0.227  23.1 22.1 0.916 
Dust mites  7.7 6.9 0.595  0.0 4.7 0.342 
Cockroach   3.9 3.5 0.658  3.9 2.3 0.551 
Peanuts  3.9 1.2 0.412  3.9 1.2 0.412 
Food components 
(including peanuts) 
 53.9 43.0 0.332  34.6 18.6 0.086 
Pollen  38.5 33.7 0.657  15.4 16.3 0.592 
Fungal allergens  23.1 8.1 0.037  11.5 1.2 0.038 
Domesticated animals  0.0 5.8 0.260  0.0 1.2 0.768 
Table shows proportions of rural participants (categorised by helminth infection status) that had an ISAC-detectable 
IgE response or were sensitised (IgE≥0.3 ISU) to at least one allergen component within the larger allergen groupings 
of CCDs, venoms, dust mites, cockroach, peanut, food, pollen, fungi and domesticated animals. Chi-square / Fisher’s 
exact tests were conducted to assess differences between helminth infected and uninfected participants. These tests 
were conducted within the framework of a Monte Carlo simulation algorithm based on 1000 permutations in order to 
adjust for multiple testing. 
*Schistosoma mansoni infection determined by Kato-Katz and/or PCR 
¶Infection with any of Ascaris lumbricoides, Trichuris trichiura (assessed by KK), Necator americanus, Strongyloides 
stercoralis (assessed by PCR) and Mansonella perstans (assessed by modified Knott’s method). 
ISAC: Immuno Solid-phase Allergen Chip; ISU: ISAC standardised units 
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CHAPTER 8. SUMMARISING DISCUSSION AND CONCLUSIONS 
8.1 Preamble 
Each Research Paper in this thesis includes a detailed discussion of the results 
presented therein. This chapter summarises the main findings in each of the papers, 
interprets and synthesises these findings, highlights study strengths and limitations, and 
offers recommendations for future research. 
8.2 Summary and interpretation of main findings 
8.2.1 Research Paper 1 (Chapter 4) 
Research Paper 1 shows prevalence and risk factors for SPT reactivity (to common 
environmental allergens in the study setting1), allergen extract-specific IgE sensitisation, 
wheeze, rhinitis, urticaria and visible flexural dermatitis, in Ugandan rural and urban 
settings. Urban-rural differences in prevalence and risk factors for these allergy-related 
outcomes, and in prevalence of helminth infection, are shown. The rural setting had a 
significantly higher prevalence of helminth infections, allergen extract-specific IgE 
sensitisation and urticarial rash, compared to the urban setting. Prevalence of SPT 
reactivity and visible flexural dermatitis was higher in the urban setting. 
Inverse associations between SPT reactivity and 1) the rural setting, 2) helminth 
infections in the rural setting, are in line with previously published findings that support a 
protective role (against allergy) for helminths and the rural environment.2-4 Interestingly 
in the urban setting, light S. mansoni infection was positively associated with SPT 
reactivity, while moderate and heavy infections were inversely associated with the same 
outcome. This is not a new phenomenon: protective effects of helminths on allergic 
effector responses may depend on intensity and chronicity of infection:5,6 heavy, chronic 
helminth infections are associated with immunoregulation (with spill-over inhibitory 
effects on allergic responses), while light and/or acute infections may promote allergy-
like responses.5 This phenomenon may not apply in the rural setting described in this 
thesis because it is a highly endemic area characterised by heavy infections. Positive 
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associations between allergen extract-specific IgE and helminth infections and helminth-
specific antibodies, in both the rural and the urban survey, may be attributed to protein 
cross-reactivity and/or carbohydrate cross-reactivity between helminth antigens and 
allergens (the latter is assessed in Chapters 6 and 7). 
Risk factors for allergy-related outcomes (dominated by helminth [S. mansoni] infection 
and helminth-related immunological and epidemiological factors) also differed by setting. 
Pairwise associations between clinical allergy outcomes, and between atopy and clinical 
allergy outcomes, were stronger among urban compared to rural participants. Setting 
(rural versus urban) was an effect modifier for several allergy risk factors; for example, 
associations between SPT reactivity and S. mansoni infection and Schistosoma-specific 
IgG4 were positive in the urban setting and inverse in the rural setting. 
Research Paper 1 further investigated the hypothesis that helminth (S. mansoni) 
infections are effect modifiers of associations between risk factors and allergy-related 
outcomes, and whether they were likely to mediate the differences in prevalence and 
risk factors for allergy-related outcomes, between the urban and the rural setting. Despite 
indicative trends, statistical analyses implied that the helminths (specifically S. mansoni) 
are unlikely to be the sole mechanism of the observed effect modification between the 
low-helminth exposure urban setting and the high-helminth-transmission rural setting. 
Instead, observations that S. mansoni infections were important risk factors for allergy-
related outcomes (inversely or otherwise) imply that helminths mainly impact allergy-
related outcomes through direct effects, rather than as risk modifiers.  
Notably, work conducted by Pinot de Moira and colleagues among Ugandan children7 
showed that hookworm, but not S. mansoni infection, dissociated house dust mite-
specific IgE from histamine release. This implies that there might be differences in 
mechanisms between S. mansoni and other helminth infections. Analyses conducted in 
Research Paper 1 did not show a role for hookworm or other helminths; however, the 
low prevalence of other helminths gave little power to assess any such effects.  
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8.2.2 Research Paper 2 (Chapter 5) 
Research paper 2 reports findings from the LaVIISWA baseline survey, showing that 
total, SWA-, SEA- and allergen extract-specific IgE and IgG4 responses are positively 
associated with both S. mansoni infection and SPT reactivity. This paper presents results 
from data collected before community-based anthelminthic intervention was provided as 
part of the LaVIISWA trial. Further, unpublished results presented in Chapter 5 show that 
a similar trend was observed after three years of the LaVIISWA trial, as well as in a 
parallel urban survey. Similar to helminth infection prevalence patterns in the rural and 
urban surveys, concentrations of total, SWA-, SEA- and allergen extract-specific IgE and 
IgG4 responses were higher among rural compared to urban survey participants. The 
observation that allergen extract-specific IgE levels were also higher in the rural survey 
may be attributed to cross-reactivity between helminth antigens and common 
environmental allergens in this setting.8-12 
These antibody responses did not differ between intensive and standard trial arms in the 
rural survey. The main outcome survey of the LaVIISWA trial also found no evidence of 
a difference in prevalence of allergy-related disease between intensive and standard trial 
arms (Research Paper 7, Appendix 3, this thesis). Factors potentially contributing to 
the lack of impact on allergy outcomes are discussed in Research paper 7, and include 
failure to eliminate helminth infections from villages in both trial arms, and the 
longstanding immunological effects of helminth exposure in this endemic setting. In the 
current analysis, persistence of antibodies at pre-intervention levels, and the similarity in 
antibody profiles between trial arms, may explain lack of differences in clinical allergy 
outcomes between the trial arms, at least in part. 
Although IgG4 responses and SWA- and SEA-specific antibody concentrations were 
similar between asthmatic schoolchildren and non-asthmatic controls in the asthma 
case-control study (unpublished results, section 5.4), total and allergen extract-specific 
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IgE concentrations were higher among asthmatics, providing support to mounting 
evidence that most asthma in the tropics is atopic, contrary to previous perception.13,14 
The potential protective role of IgG4 against allergic effector responses may best be 
assessed relative to IgE. Thesis Chapter 5 shows that total and allergen-specific IgG4/ 
IgE ratios and total IgE/ allergen-specific IgE ratios were inversely associated with SPT 
reactivity, wheezing and asthma. These results strengthen the argument that the IgG4–
IgE balance and/or the total IgE–allergen-specific IgE balance (both significantly 
influenced by helminth infection) are important in protection against clinical allergy. 
Potential mechanisms are discussed in Chapter 1, and include 1) IgG4-mediated 
blockage of allergen recognition by IgE (when IgG4 and IgE have similar antigenic 
specificity15-17), 2) FcγRIIB-dependent IgG4 inhibition of IgE-mediated effector cell 
activation17-19 and 3) saturation of IgE receptors by non-specific, polyclonally-stimulated 
IgE20  hence reducing chances that an allergen will result in cross-linking of FcεRI-bound 
IgE.8,21 
8.2.3 Research Paper 3 (Chapter 6) 
Chapter 6 presents microarray analysis of IgE and IgG responses to core b-1,2-
xylosylated and a-1,3-fucosylated N-glycans, showing that responses to these core 
modified N-glycans were higher in the S. mansoni-endemic rural communities compared 
to lower S. mansoni transmission urban communities. Mass spectrometry-based 
studies,22-24 have shown that core b-1,2-xylose and core a-1,3-fucose motifs are not only 
present on glycoproteins of common environmental allergens from plant and invertebrate 
sources, they are also expressed during specific schistosome life stages (Figure 1.3, 
Chapter 1). This may explain the urban-rural differences (in reactivity to core b-1,2-xylose 
and a-1,3-fucose) observed in the current study settings. 
Research Paper 3 further shows that associations between S. mansoni infection and IgE 
and IgG reactivity to core modified N-glycans vary by setting. In the urban setting, IgE 
and IgG responses to both core b-1,2-xylose and core a-1,3-fucose were positively 
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associated with S. mansoni infection. However, in nearby rural communities, IgE and 
IgG responses to core b-1,2-xylose were strongly positively associated with S. mansoni 
infection while reactivity to core a-1,3-fucose was elevated in both S. mansoni infected 
(Sm KK+/PCR+) and uninfected (Sm KK-/PCR-) individuals. As discussed in Research 
Paper 3, these observations may be attributed to the universal S. mansoni infection 
exposure in the rural setting, where ‘uninfected’ individuals carry light infections not 
detectable by Kato-Katz and/or PCR. Core a-1,3-fucose motifs can be found on N-
glycans from S. mansoni eggs, but not on N-glycans from cercariae and adult 
worms.22,23,25 It is possible that responses to core a-1,3-fucose persist following active 
infection in the high S. mansoni exposure rural communities. Moreover, it has been 
shown that eggs and hepatic granulomas stay long after clearance of worms in mice.26 
Also in the rural communities, the concentration of antibodies to core a-1,3-fucose 
modified N-glycans peaked ahead of the peak of S. mansoni infection intensity, while the 
peak of antibodies to N-glycans with only core b-1,2-xylose coincided with it. These 
results suggest that reactivity to core b-1,2-xylose is more responsive to change in S. 
mansoni exposure: core b-1,2-xylose is present on cercariae, despite being absent in 
adult worms.22,23,27  
The distinctive relationships between S. mansoni infection (and intensity) and reactivity 
to core β-1,2-xylose and α-1,3-fucose modified N-glycans warrant further exploration for 
associations with protective immunity against S. mansoni. In Chapter 7 (discussed 
below), associations between reactivity to core modified N-glycans and sensitisation to 
other environmental exposures (other than S. mansoni) were explored.  
8.2.4 Research Paper 4 (Chapter 7) 
Chapter 7 aimed to assess to what extent cross-reactive carbohydrate determinant 
(CCD)-specific IgE determines helminth-allergy associations in Uganda. The main 
hypothesis was that elevated IgE responses to specific immunogenic CCD N-glycans 
during chronic helminth infection might dominate over allergen protein-specific IgE, 
283
	 
resulting in reduced allergic effector responses.  The ImmunoCAP® test was employed 
to measure IgE against house dust mite, cockroach and peanut extracts. The ISAC® 
microarray provided a component-resolved assessment of IgE reactivity to natural and 
recombinant allergen components, including those known to carry CCDs. The key 
features of classical CCDs are N-glycans with core b-1,2-xylose and core a-1,3-fucose 
substitutions. To further elucidate reactivity to CCDs in Ugandan individuals, a glycan 
microarray was employed to measure IgE to glycans with and without core b-1,2-xylose 
and core a-1,3-fucose substitutions. 
ImmunoCAP-determined allergen extract-specific IgE sensitisation was higher in the 
rural compared to the urban survey, and among asthmatics compared to non-asthmatic 
controls, similar to findings shown in Chapter 4. However, sensitisation to allergen 
extracts did not reflect sensitisation to their major, established natural and recombinant 
allergenic components among non-asthmatics and rural and urban participants. Allergen 
extracts may contain cross-reactive protein and carbohydrate components that are 
conserved in other environmental antigens such as those from S. mansoni.8 Therefore, 
sensitisation to established major allergenic components is rare in the study settings 
(especially among helminth infected, rural individuals), and estimation of true prevalence 
of allergic sensitisation is complicated by protein and/or carbohydrate cross-reactivity 
between helminths and allergens. 
This postulation is supported by the observation that many participants recognised 
natural purified CCD-bearing components on the ISAC allergen microarray, suggesting 
that in this setting, allergen extract-specific IgE may primarily be raised against 
carbohydrate groups shared with other environmental antigens, such as helminths. 
Studies have shown that CCDs contribute significantly to cross-sensitisation between 
Schistosoma antigens and peanut, pollen or insect venom allergens.9,10,28 Here also, 
glycan array-determined responses to classical CCD epitopes (core b-1,2-xylose and 
core a-1,3-fucose) were strongly associated with S. mansoni infection and allergen 
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extract-specific IgE. Sensitisation to recombinant insect venom components was also 
high, especially among S. mansoni infected individuals. This may be attributed to 
sensitisation to Venom-Allergen-Like proteins expressed by schistosomes.29 
As mentioned before, one of the key differences between the rural and the urban setting 
was in helminth infection prevalence and intensity. Chapter 7 shows that IgE reactivity 
to venom protein components, CCD-bearing components (measured by ISAC) and 
classical CCD N-glycan epitopes (assessed by glycan microarray), was higher among 
rural participants. Conversely, responses to the major components (predominantly 
recombinant proteins) from common environmental allergens in this setting,1 especially 
house dust mite, were higher in the urban compared to rural setting, and among 
asthmatics compared to controls. These data imply that in the rural Sm-endemic settings, 
IgE may be less effectively induced against established major allergenic protein 
components	than against CCDs. 
Carbohydrate-specific IgG has been hypothesised to block IgE-mediated 
responses;9,10,30,31 this thesis further hypothesised a protective role for CCD-specific IgE 
against allergic effector responses. However, ISAC-determined CCD-specific IgE was 
similar between asthmatics and non-asthmatic controls, and between SPT positive and 
negative individuals. Instead, glycan microarray IgE reactivity to core a-1,3-fucosylated 
N-glycans was inversely associated with asthma. In line with this finding, Do et al.32 
recently found that an N-glycan from Bla g 2, a major German cockroach allergen, 
inhibited basophil histamine release and IL-4 production. A more detailed analysis of this 
N-glycan revealed that it was core fucosylated. However, Do et al. did not show a 
protective role for N-glycan-specific IgE. Moreover, glycosylated Bla g 2 was a stronger 
inducer of basophil activation than its de-glycosylated counterpart. These findings, and 
those reported in this thesis, imply that reactivity to specific glycans or glycan motifs may 
be important in protection against allergic disease through yet-to-be-defined 
mechanisms. More experimental studies are required to unravel the potential 
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mechanisms. 
In helminth-endemic settings, it is also important to consider that any observed inverse 
associations between CCD-specific antibodies and clinical allergy may denote an 
epiphenomenon, simply reflective of helminth-mediated protection against allergies 
through other mechanisms. Therefore, studies exploring potential protective roles of 
CCDs in absence of helminth infection are important. Wilbers and colleagues33 have 
recently demonstrated that helminth glycoproteins, including those carrying core b-1,2-
xylose and a-1,3-fucose substituted N-glycans, can be reconstructed in plant systems.33 
This provides an important avenue for obtaining tailored carbohydrate epitopes to 
explore the potential protective role of specific glycans, using animal models and in vitro 
human experiments. 
8.3 Thesis strengths 
8.3.1 Sample sizes and similar procedures across studies 
This PhD thesis presents findings from analyses of data collected from three well-
designed large studies on allergy in Uganda. The large sample sizes enabled precise 
assessment of associations between epidemiological and immunological factors related 
to helminths and allergy. Where subsets of samples were chosen for analysis, such as 
for the N-glycan and allergen microarray assays, selections were done in such a way 
that sample sizes were comparable to or larger than those reported in similar studies.34-
38 
The LaVIISWA trial, the urban survey and the asthma study were all designed specifically 
to examine allergy-related outcomes, and the methods (and procedures) were designed 
to be as similar as possible between the studies. This ensured validity of the comparisons 
(of immunological profiles and other factors) made between the studies. 
286
	 
8.3.2 Methods 
Robust methods were used in laboratory and statistical analyses. For example, a 
component-resolved microarray approach was used to profile allergic responses, 
complementing the singleplex immunoassays used for allergy testing. Statistical 
procedures such as PCA and HCA were used in data reduction (and consequently for 
analysis) of complex allergen and glycan microarray data. For these data, methods used 
to compute multiplicity corrected p-values ensured that the findings were statistically 
plausible. Several quality control (QC) measures were also implemented for several 
laboratory analyses. For example, QC for PCR on stool-derived DNA was conducted by 
collaborators in the Netherlands (Dr Jaco Verweij, Laboratory for Medical Microbiology 
and Immunology, St Elisabeth Hospital, Tilburg), glycan microarray analyses were 
conducted in conjunction with colleagues in the glycobiology department at the Leiden 
University Medical Centre, and the ImmunoCAP® and the ImmunoCAP® ISAC 
immunoassays were semi-automated with appropriate internal controls. Appropriate 
data management and cleaning procedures were also in place, as described in the 
Methods section 3.8. 
8.3.3 New findings 
This thesis highlights the potential role of the total IgE – allergen-specific IgE balance 
and the IgG4 – IgE balance in mitigation of allergic effector responses, providing 
evidence from large population-based studies. Results showing the potential importance 
of the IgG4 – IgE balance in protection against clinical allergy build upon previous 
findings that apportion it a significant role in allergen-specific immunotherapy.39 
This thesis shows, for the first time, that antibody responses to the classical CCD 
epitopes (core b-1,2-xylose and a-1,3-fucose) have distinctive relationships with S. 
mansoni infection and intensity, possibly reflecting their different contributions to 
immunity to S. mansoni. This thesis further provides invaluable insights into the potential 
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protective effect of IgE reactivity to specific CCD epitopes (such as core a-1,3-fucose) 
against clinical allergy, which has not been assessed before in human participants.   
8.4 Thesis limitations 
The research papers presented in this thesis report a large number of statistical tests, 
increasing the possibility of chance findings. In Chapters 4 and 5, no formal adjustment 
for multiple testing was done, instead the focus was placed on biological credibility in 
reference to published works, as well as on consistency of findings and trends of 
associations between exposures and outcomes. In Chapters 6 and 7, correction for 
multiple testing was done by conducting permutation tests using a Monte Carlo 
simulation approach. 
A large proportion of the data used in this thesis was obtained from cross-sectional 
surveys; so, assessment of temporality was not possible. Therefore, it was difficult to 
establish causality when assessing helminth-allergy associations. The LaVIISWA trial 
was originally designed to address this; however, intensive versus standard 
anthelminthic treatment had no effect on most primary study outcomes. Nonetheless, 
important deductions can be made from this thesis’ findings, owing to the strong patterns 
of associations observed. 
As discussed in Research Paper 1 (Chapter 4), rural communities had received three 
years of mass anthelminthic treatment at the time of the allergy outcomes survey, while 
the urban community had considerable exposure to light helminth infections. However, 
the two settings were still quite distinct, as helminth prevalence remained high in the rural 
setting (presumably due to high re-infection rates), providing an interesting sample for 
assessing the impact of urban-rural differences in helminth infection exposure on allergy 
related outcomes.    
In the rural population, exposure to helminths was universal, and there were no data on 
duration of infection. This is a potential limitation in assessment of helminth-allergy 
associations and underlying mechanisms. Therefore, comparisons with the low helminth 
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exposure urban setting were important in assessment of plausibility of deductions 
derived from analysis of helminth-allergy associations in the rural setting. 
8.5 Conclusion(s) 
This thesis presents an immuno-epidemiological description of antibody profiles 
associated with helminth infection, allergic sensitisation and clinical allergy in rural and 
urban Uganda, providing important insight into mechanisms underlying the complex 
helminth-allergy associations in tropical low-income countries. 
The major conclusions from this PhD research are 
1. Despite suggestive trends, there was no statistical proof that helminth (S. 
mansoni) infection mediates urban-rural differences in prevalence and risk factors for 
allergy-related outcomes in Uganda, implying that helminths are not the sole mechanism. 
Other environmental exposures are likely to play a role. The observation that S. mansoni 
infection was an important risk factor for allergy-related outcomes (inversely or 
otherwise) implies that helminths mainly impact allergy-related outcomes through direct 
effects, rather than as risk modifiers. 
2. In communities exposed to helminth infections, the IgG4 – IgE balance and the 
total IgE – allergen-specific IgE balance may be important in protection against clinical 
allergy. 
3. In tropical settings, helminth-induced CCD-specific antibody responses 
(specifically IgE) obscure readouts for assessment of atopy. 
4. Inverse associations between asthma and IgE to a-1,3-fucose substituted N-
glycans imply that antibodies against specific CCD epitopes may be important in 
protection against clinical allergy, through yet-to-be-defined mechanisms. 
8.6 Antibody-mediated mechanisms of helminth-allergy associations: future 
perspectives 
Chapter 5 highlights the potential importance of the IgG4 – IgE balance in protection 
against clinical allergy. Immunoglobulin G4 has been implicated in IgG4-related 
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disease.40 Despite this, immunoregulation during chronic helminth infection appears to 
be a more prominent role for IgG4,15 as well as induction of allergen tolerance during 
specific immunotherapy.39 Besides, IgG4 does not activate the complement system or 
lead to formation of immune complexes, and is not associated with mast cell or basophil 
degranulation.41 Its major mode of action against inflammation seems to be blockage of 
IgE-mediated processes. This thesis offers solid support for the regulatory role of IgG4. 
Further experimental animal studies would be ideal for studying the protective role of 
IgG4; however, they are hampered by the absence of IgG4 in mice. Therefore, in vitro 
human experiments should be the focus of future work. For example, by using a high-
throughput microarray screening platform, helminth antigens that induce strong serum 
IgG4 responses and little or no IgE may be identified. Such antigens may be important 
for therapeutic strategies against clinical allergy. For example, IgG4 induced by such 
antigens may trigger FcγRIIB-dependent inhibition of IgE-effector cell degranulation.17-19 
Immune responses to some helminths are shaped to a great extent by the glycome and 
this has been clearly demonstrated for schistosomes (in this thesis and elsewhere).  
Responses to carbohydrate antigens may be part of the worm’s strategy to protect itself 
from IgE-mediated attack; however, they may also contribute to protective immunity 
against helminth infection, or could be useful in diagnostics, but detailed research is 
needed to determine their role and potential applications. Furthermore, profiling of 
helminth CCD-specific responses may improve current understanding of potential 
mechanisms of protection against allergy. Before work conducted as part of this PhD 
research, these responses were not yet well characterised at a population level. Chapter 
6 highlights rural-urban differences in IgE and IgG responses to key components of the 
schistosome glycome (core b-1,2-xylose and a-1,3-fucose substituted N-glycans) and 
shows that responses to these components have distinctive relationships with S. 
mansoni infection and intensity. It has been previously implied that responses to cross-
reactive carbohydrates have the potential to inhibit clinical peanut allergy;28 Although 
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results presented in Chapter 7 of this thesis showed no overall difference in CCD-specific 
IgE between participants with and without SPT positivity or asthma, there were inverse 
associations between reactivity to core a-1,3-fucose substituted N-glycans and asthma, 
signifying potential for specific CCD epitopes in protection against asthma. Definitive 
proof of CCD-mediated protection against clinical allergy is required and mechanistic 
studies in animal models, and using human samples in in vitro experiments, are 
warranted.  
Overall, findings presented in this thesis provide important insight into mechanisms 
underlying the complex epidemiological helminth-allergy trends in Uganda. This is 
important for approaches aimed at reducing the impact of the on-going epidemiological 
transition on allergy prevalence in the tropics and for therapeutic strategies against 
allergy-related diseases. 
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Worms have co-evolved with humans over millions of years. To survive, they manipulate host systems by
modulating immune responses so that they cause (in the majority of hosts) relatively subtle harm.
Anthelminthic treatment has been promoted as a measure for averting worm speciﬁc pathology and to miti-
gate subtle morbidities which may include effects on anaemia, growth, cognitive function and economic
activity. With our changing environment marked by rapid population growth, urbanisation, better hygiene
practices and anthelminthic treatment, there has been a decline in worm infections and other infectious dis-
eases and a rise in non-communicable diseases such as allergy, diabetes and cardiovascular disease. This
review reﬂects upon our age-old interaction with worms, and the broader ramiﬁcations of life without worms
for vaccine responses and susceptibility to other infections, and for allergy-related and metabolic disease. We
touch upon the controversy around the beneﬁts of mass drug administration for the more-subtle morbidities
that have been associated with worm infections and then focus our attention on broader, additional aspects
of life without worms, which may be either beneﬁcial or detrimental.
Keywords: Allergy, Anthelminthic, Helminths, Infectious diseases, Metabolic disease, Vaccines
Introduction
Over a billion people are estimated to be infected with hel-
minths, most living in areas of poverty.1,2 Helminths have co-
existed with mammals for millions of years. Their lifecycles have
evolved to ensure their survival while minimising harm to the
mammalian host. Soil transmitted helminths (STH) such as hook-
worm, Ascaris lumbricoides, Trichuris trichiura and Strongyloides
stercoralis spend part of their lifecycle in soil and gain access to
their human host through skin penetration or ingestion. For the
ﬁlarial nematodes, an insect vector takes up microﬁlariae dur-
ing a blood meal and, after development in the insect, the
parasite is injected into the next host during another blood
meal. For water borne helminths such as Schistosoma, cer-
cariae shed by the snail intermediate host access the deﬁnitive
human host by skin penetration during contact with infested
water. After migratory and development stages, adult worms
lodge in body tissues such as the gut, blood vessels and lym-
phatics. In most cases, helminths do not replicate in the mam-
malian host.3
Helminths induce short and long term morbidity, and path-
ology in some body systems: gastrointestinal tract (malabsorp-
tion, diarrhoea, macro and micronutrient deﬁciencies, bleeding,
intestinal obstruction, rectal prolapse), liver (peri-portal ﬁbrosis,
cholangitis, cholangiocarcinoma, hepatocellular carcinoma),
cardiovascular system (anaemia), lymphatic system (lymphoe-
dema), central nervous system (blindness, epilepsy), genito-
urinary tract (haematuria, hydronephrosis, bladder cancer),
lungs (Loefﬂer’s syndrome).4 These effects depend on the type
and number of helminths in the host. Treatment is deserved to
avert these harmful effects.
Societies in developing countries are experiencing remarkable
population growth, urbanisation and lifestyle changes. With bet-
ter hygiene and ‘deworming’ interventions, helminth infections
are declining. Concurrently, there is a rise in non-communicable
diseases (NCDs) such as diabetes5 and cardiovascular diseases,6
contributing signiﬁcantly to global mortality and attributed
largely to changes in diet and lifestyle. Could the decline in hel-
minth infections be playing a role in this epidemiological trans-
ition? With helminth elimination the ultimate goal of mass drug
administration (MDA) programmes,7 it is of interest to reﬂect on
the prospect of a worm-free life. Do we clearly understand, are
we ready for, the consequences of life divorced from the part-
nership established over millions of years? In this narrative
review we discuss current evidence regarding the beneﬁts of
MDA, ways in which worms manipulate us, and the possible
© The Author 2017. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.
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effects of helminth infection on responses to vaccines and unre-
lated infectious diseases, and on allergy and metabolic disease.
How much do we beneﬁt from MDA?
MDA entails administration of anthelminthic medicines without
reference to an individual’s infection status, or test of cure. The
World Health Assembly endorsed MDA for school children as a
schistosomiasis and STH control strategy for high transmission
settings8 and this has been widely adopted.
MDA policy is premised on anticipated beneﬁts for helminth-
speciﬁc pathology, maternal anaemia, birth weight, childhood
growth, anaemia, cognitive function, school performance and
long term economic returns. We do not question the beneﬁt of
MDA for controlling pathologies such as schistosome-induced
ﬁbrosis, hookworm-induced anaemia, elephantiasis and river
blindness. However, the impact of MDA on more subtle morbid-
ities associated with helminths has been difﬁcult to demonstrate.
Mass treatment for hookworm in the American south at the
turn of 20th century was associated with greater school enrol-
ment, attendance and literacy and long-term gain in income.9
Further, in 2004, Miguel and Kremmer published a highly inﬂu-
ential report showing an association between school-based
MDA and reduced school absenteeism among Kenyan chil-
dren.10 Ten years later, these children who were dewormed at
school had more years of school enrolment, more time in
employment and longer work hours each week.11 However,
recent reanalyses of the original data have highlighted the chal-
lenges of evaluating such interventions.12,13
A large cluster-randomised trial in India with one million pre-
school children showed little effect of regular deworming on
mortality in pre-school children.14 A Cochrane review15 con-
cluded that treating children known to have STH may improve
weight gain but evidence of beneﬁts on haemoglobin, school
attendance and cognitive function is limited; also that commu-
nity based treatment programmes had little or no effect on
these outcomes. Similarly, a systematic review found the evi-
dence insufﬁcient to link helminths to cognitive performance16
and a further meta-analysis concluded that mass deworming of
children had little or no effect on weight, height, cognition,
school attendance or mortality.17
WHO recommends anthelminthic treatment during preg-
nancy, hoping that it will reduce maternal anaemia, increase
birth weight and reduce mortality. The beneﬁts are not yet
clear.18 We, and others, have found limited overall effects19 of
anthelminthic use during pregnancy on maternal anaemia, and
none on birth weight, perinatal mortality or congenital abnor-
malities.20–23 Anthelminthic treatment during pregnancy did not
affect infectious disease incidence or response to immunisa-
tion.24,25 A Cochrane review notes that evidence is insufﬁcient
to recommend use of anthelminthic medication for pregnant
women in the ﬁrst trimester and administration of a single dose
anthelminthic was not associated with any impact on maternal
anaemia.26
There has been debate on the policy of MDA27 and system-
atic review methodology has been questioned in its application
to helminths.28,29 However, it brings to light the need for more
evidence to support MDA and to understand fully its beneﬁts.
How do worms manipulate us?
The age-old colonisation of mammals by helminths has been
successful mainly because of the latter’s shrewd manipulation
of host systems (Figure 1).
Helminths employ enzymes and other excretory/secretory
proteins to disrupt and alter host tissues, thus successfully
migrating, feeding, establishing niches and developing strategies
to exit the host to complete their life-cycles. For example,
Schistosoma cercariae contain proteases that aid in skin pene-
tration30 while the major excretory/secretory protein of Trichuris
trichiura induces pore formation to facilitate helminth entrench-
ment in the gut.31
Loss of mucosal and epithelial integrity as helminths take root
in the host is often accompanied by release of inﬂammatory
mediators, such as alarmins and damage associated molecular
patterns,32 normally detrimental to the helminth and its host.
However, helminth excretory/secretory products also work to off-
set this. For example, secreted products of Heligmosomoides
polygyrus block production of the alarmin IL-33, a key inducer of
Th2-type inﬂammation.33 Besides, to curb host morbidity from
helminth-inﬂicted tissue injury, helminth-induced mediators
spearhead tissue healing and remodelling.34
But perhaps the helminth’s most potent survival weapon is
the wide array of mechanisms developed to evade or regulate a
vigilant host immune system. At the helm are helminth-induced
Th2-type and regulatory immune responses. Helminth-induced
Th2 cytokines interleukin (IL)-4 and IL-13 promote alternative
activation of macrophages, resulting in production of large
amounts of immunomodulatory IL-10 and transforming growth
factor (TGF)-β,35 and T cell hypo-responsiveness involving regula-
tory T cells.36 Helminth-induced, IL-10-producing ‘regulatory B
cells’ have also been demonstrated.37 A notable consequence
of helminth-induced immunomodulation is the attenuation of
responses to ‘bystander’ antigens,38 widely implicated in the
helminth-associated modulation of immune responses to a
number of non-communicable and communicable diseases.
Helminth-allergy interactions are a good example of the
bystander effect. Although antigenic targets for allergen- and
helminth-speciﬁc immune responses are similar,39 helminth
infections seem to be protective against allergy-related condi-
tions in both humans and mice. Current evidence32,40 points to
an extensive array of immunomodulatory mechanisms under-
lying inverse helminth-allergy associations. They range from
induction of IL-10-producing regulatory T cells, regulatory B cells
and alternatively activated antigen presenting cells, promotion
of polyclonal IgE synthesis and immunoglobulin class switching
to IgG4, to suppression of release of alarmins (such as IL-33)
and inhibition of type 2 innate lymphoid cell activity.
Host metabolic responses may also be inﬂuenced by
helminth infections. For example, S. mansoni egg antigen-
treated obese mice have increased levels of white adipose
tissue Th2-type cells, modiﬁed macrophage activation and
reduced adipose tissue mass and improved insulin sensitiv-
ity.41 Non-obese diabetic mice infected with H. polygyrus and
Trichinella spiralis are protected against type-1 diabetes
through the Th2-associated reduction of inﬂammatory auto-
immune responses.42 There is also recent evidence in humans
and mice that helminths may protect against inﬂammatory
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bowel diseases through Th2-type immunity-mediated expansion
of a protective microbiota.43
Helminth-induced bystander response suppression is a
double-edged sword. We may beneﬁt from helminth-driven
regulation of non-communicable diseases, as elaborated above.
However, helminth excretory/secretory products and Th2 cyto-
kines have been shown to suppress anti-microbial functions of
innate immune cells (dendritic cells and macrophages), leading
to increased differentiation of regulatory T cells and Th2 cells
while impeding the development of protective Th1-type
responses and potentially compromising immunity to several
communicable diseases.
Worms and vaccines
Following recognition of the Th1/Th2 hypothesis,44 the contrast-
ing ability of mycobacterial and helminth antigens to elicit Th1
and Th2 responses, respectively, and mutual inhibition between
these opposing effects,45 it was proposed that helminth co-
infection might account for the poor efﬁcacy of vaccines such
as BCG in tropical settings and the high prevalence of TB and
HIV in Africa.46 As helminth prevalence declines, will vaccines
become more effective, and susceptibility to other infectious
diseases decrease?
Studies in animal models largely suggest that this will be the
case. In the mouse, infection with H. polygyrus (a nematode
with a life-cycle conﬁned to the gut) modiﬁed the response to a
malaria protein vaccine, resulting in reduced antibody and Th1
responses, increased Th2 and regulatory responses and
impaired protection against malaria challenge.47 Treatment of
the helminth before, but not after, immunisation abrogated
these effects, emphasising the importance of co-infection at the
time of immunisation. Similar effects of H. polygyrus have been
reported for a DNA malaria vaccine, but not for live, irradiated
sporozoites,48 or for live BCG,49 indicating that the impact of a
particular helminth differs by vaccine type: protein, DNA or live
attenuated organisms. Mice infected with Schistosoma species
(which cause systemic infections) show impaired induction of
protective immunity both to malaria50 and to TB challenge
(following BCG),51 indicating that different helminth infections
have different effects. Schistosoma infections also resulted in
Figure 1. Interactions between helminths and the host immune system, and the impact on bystander responses. Red arrows and blue lines denote
positive and suppressive effects, respectively. Helminth migration in the host results in tissue injury, resulting in release of Damage Associated
Molecular Patterns (DAMPs) and alarmins. DAMPs and alarmins are involved in the initial activation of eosinophils, type 2 innate lymphoid cells (ILC2)
and antigen presenting cells (APCs) such as dendritic cells (DCs), which then mediate further inﬂammation in the host. However, some helminth
secretory products can suppress alarmin release and DC maturation, and some helminth enzymes degrade DAMPs. Helminths also interfere with
APC activities, promoting an alternative activation phenotype, which results in production of large amounts of IL-10 and TGFβ. These cytokines
downmodulate eosinophil, ILC2 and DC responses, and promote lymphocyte hyporesponsiveness involving regulatory lymphocytes. Helminth inter-
action with host immunity has spillover effects on responses to bystander antigens. For instance, helminth infections may result in impaired immune
responses to vaccines and communicable diseases, although speciﬁc helminth molecules may actually have enhancing effects. Likewise, there is
evidence for both inverse and positive helminth-allergy associations, although any notable effects on metabolic conditions have been beneﬁcial.
DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid; HMGB1: High Mobility Group Box 1.
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impaired antibody responses to toxoid and protein vaccines—
but a study on hepatitis B immunisation showed a gradual
recovery of the response when the infection was treated after
immunisation.52 The life-cycle of Trichinella spiralis involves an
intestinal phase, followed by encystment in skeletal muscle;
suppression of the IgA response to cholera toxin53 and to hepa-
titis B immunisation54 has been demonstrated during the intes-
tinal, but not the muscle, stages of the life-cycle. While these
experiments demonstrate suppressive effects, intraperitoneal
injection of Ascaris extract concurrently with BCG has been
shown to enhance macrophage activation and suppress BCG
replication55 and a protein from the ﬁlarial worm Onchocerca
volvulus shows promise as an adjuvant for inﬂuenza vaccine.56
Together, studies in mice show that helminth infections have
important potential to supress vaccine responses, but that hel-
minth species, stage of life-cycle, timing of helminth exposure
and treatment, and characteristics of the vaccine may be
important determinants of the outcome and that speciﬁc hel-
minth molecules may actually have enhancing effects. As well,
differences between murine models are likely to result from
genetics of the host and intensity of helminth infection used.
In humans, studies of the impact of helminth co-infection on
vaccine responses are important in their own right, and also
offer an important surrogate for studies on susceptibility to
infections, which are much more difﬁcult to undertake. The
bystander modulatory effects of chronic helminth infections are
of potential direct signiﬁcance in adolescents and adults when
primary or recall immunisation occurs in this age group. For
example, for human papilloma virus immunisation, tetanus and
other boosters, and during outbreaks, such as the recent Yellow
Fever and Ebola epidemics; also when novel vaccines are under-
going initial evaluations in older populations. Observational
studies among children and adults have shown associations
between helminth infection and suppression of antibody and
Th1 responses, particularly during systemic ﬁlarial infections and
schistosomiasis: vaccines affected include BCG, tetanus, typhoid
and a candidate malaria vaccine.57–65 Hepatitis B immunisation
may also be impaired in the context of schistosomiasis66 but
effects may be limited to those with hepatosplenic disease, call-
ing into question the causal mechanisms involved.67 Clinical
trials may help us to test whether helminth induced immuno-
modulation is causal in suppression of vaccine responses and,
so far, these have been conﬁned to effects of geohelminths.
Treatment of geohelminths with albendazole has been shown
to improve the Th1 response to BCG,68,69 and the antibody and
Th1 response to oral cholera vaccine.70,71 No studies have yet
investigated the effects of treating schistosomiasis or ﬁlariases
but, on balance, the data so far suggest that vaccine responses
will improve with the elimination of worms.
However, the majority of vaccines in current use target
pathogens that cause substantial disease and death in early
life. They are administered to the very youngest age groups in
whom chronic helminth infections have yet to establish them-
selves. In these age groups, it is maternal infection status that
is potentially of greatest importance in terms of impacting on a
newborn’s capacity for induction of vaccine-speciﬁc responses.
Evidence that the human fetus could be sensitised in utero to
helminths and mycobacterial antigen72 suggested that prenatal
exposure might inﬂuence infant vaccine responses. Indeed,
initial studies by Malhotra and colleagues showed an associ-
ation between sensitisation to Schistosoma or ﬁlarial antigens in
utero and a Th2 bias to the infant response to BCG immunisa-
tion.73 Malhotra and colleagues also described adverse associa-
tions between prenatal exposure to hookworm and other
helminths and the response to diphtheria toxoid and
Haemophilus inﬂuenzae type B (HiB) immunisation in infancy,74
but this has not been conﬁrmed by results from Uganda where
the only association observed was a possible enhancement of
IgG responses to pertussis toxin, HiB and hepatitis B among
infants of mothers with Strongyloides.25,75,76 A study in Ecuador
also showed no association between exposure to maternal geo-
helminths and infant responses to diphtheria toxoid, tetanus,
pertussis, measles, Rubella or HiB, but enhanced IgA responses
to polio and rotavirus.77 An important consideration is that the
infant outcome may vary depending on the nature and timing
of the exposure to parasite antigens: Malhotra and colleagues
showed that infant DT responses were enhanced if the infant
was sensitised to malaria antigens, but suppressed if the infant
was ‘tolerised’.74 Only one substantive trial has investigated the
effects of treating helminths during pregnancy on infant vaccine
responses: this did not conﬁrm ﬁndings from an earlier pilot78
and gave only weak evidence of an effect of treating maternal
hookworm on the infant response to tetanus or BCG immunisa-
tion.24,25 Further work is needed to understand whether hel-
minth elimination among pregnant women will alter the infant
response to key vaccines.
Given the complex effects of helminths on vaccine responses
it is not surprising that effects on infectious disease susceptibil-
ity are complex too (reviewed elsewhere).79–81 A possible unify-
ing hypothesis, supported by recent evidence from mouse
models,82 is that chronic helminth co-infection has little effect
on the innate response to incident infections (and may even
enhance it) but does impair adaptive responses that control rep-
lication of established infections. For example, in the case of TB,
a recent trial on effects of anthelminthic treatment on bovine
TB among wild buffalo in South Africa’s Kruger National Park
found that regular anthelminthic treatment had no impact on
Mycobacterium bovis infection incidence, but resulted in lower
mortality among M. bovis infected animals.83 Similarly, we found
little evidence that helminth co-infection affects susceptibility to
TB infection in humans,84 but recent results suggest that treat-
ment of helminths may abrogate regulatory T cells-mediated
suppression of Th1 cell frequency and function in helminth-TB
co-infection85 and hints at improved clinical outcome.86
Worms and allergy-related disease
Results from epidemiological studies on the relationship
between helminths and allergy have been inconsistent. As for
vaccine studies, different helminth species interact with the
host’s immune system differently, resulting in different clinical
outcomes. An earlier review and meta-analysis87 found that
hookworm had an inverse association with asthma (summary
odds ratio [OR] 0.50, 95% CI 0.28–0.90), with a ‘dose-response’
by infection intensity, A. lumbricoides showed a positive associ-
ation and T. trichiura showed no relationship. Another meta-
analysis88 showed an inverse association between helminthic
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infections and allergen skin sensitisation (summary OR 0.69,
95% CI 0.6–0.79).
Exposure to helminth infections in-utero and in early child-
hood is negatively associated with allergy risk in childhood.
Our birth cohort in Uganda showed that maternal hookworm
during pregnancy was associated with a reduced incidence of
eczema in childhood (adjusted hazard ration [aHR] 0.71, 95% CI
0.51–0.99), with a dose-response, and that early childhood
infections with T. trichiura and hookworm were associated with
a reduced incidence of childhood eczema.89 Treatment of
maternal helminths during pregnancy increased the incidence
of eczema in childhood.24,90 A study in Brazil also showed that
early childhood infections with T. trichiura and A. lumbricoides
were associated with a lower prevalence of allergen skin reactiv-
ity in later childhood.91 In Gabon, a lower prevalence of skin
reactivity to house dust mite was reported among children
infected with Schistosoma haematobium compared to those
without the infection.92 Most studies have considered helminths
as an independent variable in regression models, but there is
increasing evidence that helminths are effect-modiﬁers of the
relationship between atopy and clinical allergy. We found that
maternal hookworm during pregnancy attenuated the associ-
ation between Dermatophagoides-speciﬁc IgE and eczema in
childhood, as well as the effects of other known risk-factors for
eczema such as mother’s history of eczema and female gen-
der.89 This effect-modiﬁcation has also been reported in studies
in Ecuador.93, 94 A study conducted in Uganda found a positive
association between Dermatophagoides-speciﬁc IgE and hista-
mine release among children without hookworm but not
amongst children with hookworm.95
Despite the inconsistencies outlined, epidemiological studies
have consistently shown a lower prevalence of clinical allergy
(and sometimes atopy) in rural compared to urban areas in low
and middle income countries.96–98 This is consistent with the
observed low prevalence of asthma/allergy among children
raised on farms compared to city dwellers in high income coun-
tries.97 In the high income countries, this farm effect has been
attributed to exposure to diverse microbiome on the farm and
to the consumption of unpasteurised dairy products.98 For low
and middle income countries, the protective effect had been
attributed partly to geohelminths,93 but the possible role of the
microbiome has not yet been extensively explored. Animal stud-
ies have demonstrated interactions between helminths and
microbiota.99 Could the microbiome in rural settings explain
why, in Ugandan island communities, we found a very low
prevalence of clinical allergies, despite positive associations
between helminths and reported wheeze (and atopy)?100
Additionally, there is increasing evidence of attenuation of
the relationship between atopy and allergy among children in
rural compared to urban areas in low and middle income coun-
tries.93,101,102 This has been attributed partly to geohelminths,
but the role of other infections and microbiome deserves
investigation.
Studies on immigrants from rural to urban setting represent
natural experiments. One such study103 found that immigrants
from rural Ethiopia to Israel had a low prevalence of atopy and
allergy, and a negative association between helminth infection
and atopy on arrival, which was quickly reversed after a year of
living in Israel. This was attributed to the treatment of
helminths, a decline in helminths among the untreated, and
exposure to a novel environment.
The helminth-allergy relationship is complicated by the many
inter-related factors at play. To obtain a conclusive stand, we
need to conduct comprehensive studies that take into account
the various helminth-related variables, and the potential inter-
action and confounding with the microbiome, other infections
(such as malaria) and interaction and other environmental
exposures. This will require extensive data collection and
advanced statistical analyses. But the potential beneﬁts are
worth it, for we will be able to understand better how to har-
ness the beneﬁcial effects of worms or the rural environment
for the primary, secondary and tertiary prevention of asthma,
allergies and other chronic inﬂammatory conditions that may
be associated with a life without worms.
Worms and metabolic disease
A recent systematic review showed that individuals with a previ-
ous or current helminth infection were 50% less likely to have
metabolic dysfunction.104
In diet induced obese mice, chronic infection with
Schistosoma mansoni lowered whole body insulin resistance
and glucose intolerance and improved peripheral glucose uptake
and insulin sensitivity. Injection of schistosome antigens induced
a similar effect41 and, in a separate study, reduced atheroscler-
osis in mice.105 Mice infected with H. polygyrus had lower blood
glucose, insulin resistance, fat accumulation than uninfected
mice106 and beneﬁts were sustained even after clearance of the
helminth.107 Nippostrongylus brasiliensis infection was asso-
ciated with decreased weight gain and improved glucose meta-
bolism.108 Similarly, diet induced obese mice infected with
Litomosoides sigmodontis or exposed to its antigen had
improved glucose tolerance.109
In humans, a cross-sectional study in rural China showed
that individuals with a history of schistosomiasis infection exhib-
ited lower fasting blood glucose levels compared to controls
who had never had schistosomiasis.110 A study in India111
reported a lower prevalence of ﬁlarial infections in patients with
type 2 diabetes than in non-diabetic controls. Patients with type
2 diabetes and lymphatic ﬁlariasis had lower concentrations of
pro-inﬂammatory cytokines—IL-6 and GM-CSF—than patients
without lymphatic ﬁlariasis. Among aboriginal adults in
Australia, prior Strongyloides stercoralis infection was associated
with reduced type 2 diabetes risk.112 Infection with STH has also
been associated with decreased insulin resistance and lower
body mass index, abdominal obesity, and lipid levels.113,114
Together, these recent ﬁndings indicate that helminth infec-
tions may convey important beneﬁts for metabolic disease in
humans. If so, understanding the mechanisms with a view to
harnessing this knowledge for prevention and therapy of meta-
bolic disease is important.
Conclusions
Helminths can be damaging, especially when there are intense
infections: therefore, control is good. Some authors have also
argued that MDA is a cost-effective health investment for
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governments115 although, as we have discussed, controlled
trials to date have struggled to conﬁrm a major impact of MDA
on the subtle morbidities and mortality associated with worm
infections in observational studies. As the debate on MDA con-
tinues, we need to note that removal of helminths leaves the
immune system out of balance. We postulate that helminth
elimination will result in a broad array of additional effects, both
beneﬁcial and detrimental to human health. The consequences
may include altered responses to vaccines and to infectious dis-
eases, and increased susceptibility to inﬂammatory conditions such
as allergy-related disease and metabolic disease (Figure 2). Further
work is needed to understand helminth-human interactions and
their mechanisms, so that we can mitigate adverse consequences
in the event that helminth infections in humans are eliminated.
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Abstract
Background: Parasitic helminths are potent immunomodulators and chronic infec-
tions may protect against allergy-related disease and atopy. We conducted a
cross-sectional survey to test the hypothesis that in heavily helminth-exposed
fishing villages on Lake Victoria, Uganda, helminth infections would be inversely
associated with allergy-related conditions.
Methods: A household survey was conducted as baseline to an anthelminthic inter-
vention trial. Outcomes were reported wheeze in last year, atopy assessed both by
skin prick test (SPT) and by the measurement of allergen-specific IgE to dust mites
and cockroach in plasma. Helminth infections were ascertained by stool, urine and
haemoparasitology. Associations were examined using multivariable regression.
Results: Two thousand three hundred and sixteen individuals were surveyed.
Prevalence of reported wheeze was 2% in under-fives and 5% in participants
≥5 years; 19% had a positive SPT; median Dermatophagoides-specific IgE and
cockroach-specific IgE were 1440 and 220 ng/ml, respectively. S. mansoni,
N. americanus, S. stercoralis, T. trichiura, M. perstans and A. lumbricoides preva-
lence was estimated as 51%, 22%, 12%, 10%, 2% and 1%, respectively. S. man-
soni was positively associated with Dermatophagoides-specific IgE [adjusted
geometric mean ratio (aGMR) (95% confidence interval) 1.64 (1.23, 2.18)]; T.
trichiura with SPT [adjusted odds ratio (aOR) 2.08 (1.38, 3.15)]; M. perstans with
cockroach-specific IgE [aGMR 2.37 (1.39, 4.06)], A. lumbricoides with wheeze in
participants ≥5 years [aOR 6.36 (1.10, 36.63)] and with Dermatophagoides-specific
IgE [aGMR 2.34 (1.11, 4.95)]. No inverse associations were observed.
Conclusions: Contrary to our hypothesis, we found little evidence of an inverse
relationship between helminths and allergy-related outcomes, but strong evidence
that individuals with certain helminths were more prone to atopy in this setting.
Allergy-related diseases increased dramatically in affluent and
middle-income countries during the twentieth century (1, 2):
asthma now affects about 300 million people (3), and eczema
5–20% of children (4). Although these conditions remain rel-
atively rare in low-income countries (LICs), they appear to
be increasing (5, 6). It has been hypothesized that helminth
infections, still highly prevalent in LICs (7), may contribute
to these geographic differences. Globally, the majority of
asthma and eczema cases are associated with allergen sensiti-
zation or atopy. However, in LICs, the role of atopy in
allergy-related disease is less certain (8, 9).
Parasitic helminths evolved to coexist with their mam-
malian hosts, are often asymptomatic and cause limited mor-
tality. To this end, they have developed mechanisms for
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evading or modulating the host immune response. Evidence
from animal models, and from in vitro studies on human
samples, suggests that helminths can modulate the immune
response not only to themselves, but also to unrelated patho-
gens, antigens and allergens (10, 11). Helminths contain a
range of molecules homologous to known allergens, but
absent from mammals or markedly different from mam-
malian homologues. These induce IgE responses in mam-
malian hosts, and there is a strong evidence that this
pathway is involved in protective immunity against helminths
(12). Modulation of this atopic pathway is likely, therefore,
to be particularly important for helminth survival, while con-
comitantly protecting against allergic disease (13).
Associations between helminths and allergy-related condi-
tions have been investigated in a variety of settings [reviewed
in (14–16)]. The majority of studies investigating helminth–
atopy associations have either reported an inverse association
or no evidence of association. However, results for allergy-
related diseases such as asthma and eczema have been less
consistent, varying both within and across helminth species.
Meta-analyses have indicated that for asthma, Ascaris lumbri-
coides infection is positively associated and hookworm inver-
sely associated, with borderline evidence of a positive
association for Trichuris trichiura and no association for
Strongyloides stercoralis (15). Very few studies have investi-
gated associations with schistosomiasis, although those that
have generally report an inverse association with atopy (17–
20).
Helminths may have an important role as modifiers of
associations between markers of atopy and allergy-related
diseases. It has been reported that IgE and SPT responses to
house dust mite are positively associated in the absence of
hookworm but unrelated among hookworm-infected individ-
uals (21). Similarly, studies have found that positive associa-
tions between atopy and wheeze, and between atopy and
eczema, exist only among individuals who do not have hook-
worm and not among those infected with hookworm (22,
23). Finally, it has been reported that atopy and wheeze are
only positively associated in the absence of concurrent
Ascaris infection and not in its presence (24).
Intervention studies are an important tool for understand-
ing the relationship between helminths and allergy-related
diseases; however, findings of previous studies on the impact
of anthelminthic treatment on atopy among children are con-
flicting (25–28) and none showed effects on wheeze or
eczema, although statistical power for these outcomes was
usually limited. Variable findings for atopy may be a conse-
quence of heterogeneity between study settings in helminth
species; of note, no trial has yet investigated the effects of
treatment of schistosomiasis on asthma, eczema and atopy.
We designed a cluster-randomized trial, the Lake Victoria
Island Intervention Study on Worms and Allergy-related Dis-
eases (LaVIISWA; ISRCTN47196031), to investigate the
impact of intensive vs standard anthelminthic treatment over
a 3-year period on allergy-related diseases, in a setting with
heavy helminth burden, in particular schistosomiasis (29).
We herein report the findings of a household survey, con-
ducted as baseline, to investigate the hypothesis that helminth
infections would be inversely associated with allergy-related
conditions.
Methods
Study design and procedures
LaVIISWA is being conducted in 26 fishing villages on the
Lake Victoria islands of Koome subcounty, Mukono district,
Uganda, a remote setting accessible in 2–3 h from Entebbe by
powered canoe. Full details of the trial design are described
elsewhere (29). The baseline household survey was conducted
between October 2012 and July 2013, across all trial villages,
immediately preceding intervention roll-out. All households in
participating villages were eligible for inclusion in the survey.
Available household listings were checked and updated by the
research team, and simple random samples of 45 households
were selected from each village. In selected households, all
members were eligible for inclusion in the survey.
Questionnaires were completed regarding household fea-
tures and individual social-demographic characteristics.
Information regarding asthma, eczema and allergy symptoms
was obtained using questions from the International Study
on Allergy and Asthma in Children (ISAAC) questionnaire,
with supplementary questions from the UK diagnostic crite-
ria for atopic eczema (30, 31).
A general history and examination, including height,
weight and hepatosplenomegaly, was performed. All individ-
uals were examined for visible flexural dermatitis: for this, all
team members were trained in the standardized approach
described in (32). SPTs were performed on participants aged
≥1 year, using standard methods, with three allergens [Der-
matophagoides mix, Blomia tropicalis and German cockroach
(Blatella germanica)] and positive and negative controls
(ALK-Abello; supplied by Laboratory Specialities (Pty) Ltd.,
Randburg, South Africa). Each participant was asked for
one stool sample; mid-stream urine samples were requested
from all participants in the 15 villages surveyed from Febru-
ary 2013 onwards. Blood samples of 14 ml were obtained
from individuals ≥13 years, 10 ml from children 5–12 years
and 6 ml from children 1–4 years. Individuals were offered
HIV counselling and testing in collaboration with local
health service providers.
Ethical approval was granted by the Research and Ethics
Committee of the Uganda Virus Research Institute, the
Uganda National Council for Science and Technology, and
the London School of Hygiene and Tropical Medicine. Indi-
vidual written informed consent (for adults ≥18 years and
emancipated minors, and for children by a parent or guar-
dian) and assent (for children 8–17 years) was sought for sur-
vey participation.
Laboratory methods
Two slides from each stool sample were examined (by different
technicians) using the Kato-Katz method (33). The remaining
sample was suspended in ethanol and stored at 80°C to allow
further investigation for Necator americanus and Strongyloides
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stercoralis, and, among a subset of 200 participants, for Ancy-
lostoma duodenale, using real-time polymerase chain reaction
(RT-PCR) (34). Quality control for PCR assays was con-
ducted at St Elisabeth’s Hospital, Tilburg, NL. The Uganda
results were comparable for N. americanus and A. duodenale,
but had a lower detection rate for S. stercoralis. The presence
of circulating cathodic antigen (CCA) of S. mansoni in urine
was assessed (Rapid Medical Diagnostics, Pretoria, South
Africa). Infection intensity based on Kato-Katz results was
classified using WHO-recommended cut-offs (35). For PCR
results, there are no standard cut-offs for categorizing infec-
tion intensity; however, based on results from Verweij et al.
(34), individuals with Ct > 30 would have parasite loads diffi-
cult to detect by microscope. Mansonella perstans infection
was determined by a modified Knott’s method (36); malaria
was determined by thick blood film.
IgE specific to Dermatophagoides and cockroach allergens
was measured by ELISA (29). The lower detection limit for
our in-house ELISA was 15.6 ng/ml. We used 20-fold diluted
plasma samples in our assay; hence, the lower detection limit
in undiluted plasma was calculated as 312 ng/ml. This was
used as a cut-off to create binary variables for detectable vs
undetectable responses for each allergen.
Statistical methods
This was a cross-sectional analysis of survey data. Outcomes
were reported wheeze in the last 12 months for children
<5 years and for participants ≥5 years; visible flexural der-
matitis; atopy defined as positive SPT response to any allergen
for participants ≥1 year; atopy assessed as concentration of
asIgE and analysed both as a continuous outcome and as
detectable/nondetectable using the cut-off of 312 ng/ml. Expo-
sures for the analysis were helminth infections. The following
variables were considered as potential confounders: individual
socio-demographic characteristics (age, sex, birth order, num-
ber of siblings, area of birth, area resided in for first 5 years,
preschool attendance; occupation, maternal tribe, paternal
tribe); behavioural and clinical characteristics (hand-washing
behaviour, BCG scar, maternal or paternal allergy/asthma/
eczema, immunization history, breastfeeding, exposure to
anthelminthic treatment in utero, anthelminthic treatment in
last 12 months, artemisinin combination treatment for malaria
in last 12 months, malaria infection, HIV infection); and
household characteristics (crowding, animal ownership, asset
score, indoor cooking, toilet access, drinking water source,
washing water source, malaria control measures).
Assuming an average of 2.8 people per household, we
expected that sampling 45 households per village would yield
at least 3250 participants. For common exposures (prevalence
≥20%), assuming a design effect of 1.5 and outcome preva-
lence of 10%, the study would have over 80% power to
detect risk ratios ≥1.5.
All analyses employed the ‘svy’ survey commands in Stata
to allow for clustering of respondents within villages using lin-
earized standard errors (37) and for variable village sizes using
weights. Village-level weights were calculated based on the
numbers of included and total households in each village. For
binary outcomes, univariable and multivariable logistic regres-
sions were used to obtain crude and adjusted odds ratios (OR)
and 95% confidence intervals (CI). P-values were calculated
using Wald tests. Adjustment was made for any potential con-
founder for which there was evidence of crude association with
the outcome or which was considered to have a possible role, a
priori.
Raw asIgE responses were skewed. Therefore, we used sim-
ple and multiple linear regressions to examine the association
between helminth infections and log10 levels of asIgE, and
back transformed results to obtain geometric mean ratios
(GMRs) and 95% CIs. For all outcomes, the role of S. man-
soni infection intensity was assessed using the test for trend.
The population attributable fraction (PAF) for reported
wheeze due to atopy was estimated as p’(OR1)/OR with p’
the prevalence of a positive SPT response among individuals
with reported wheeze and OR the odds ratio for the wheeze–
SPT association. We prespecified that we would examine
whether helminth infections modified the associations between
the atopy and the wheeze outcomes, by fitting interaction
terms in multivariable logistic regression models. We also
undertook a series of additional exploratory interaction analy-
ses between helminth infections for each outcome, in an
attempt to understand the primary association findings.
Finally, as most previous studies have been performed in chil-
dren, we conducted an exploratory investigation into whether
associations between allergy-related outcomes and between
helminths and allergy-related outcomes differed by age group
(<16 vs ≥16 years).
Results
Study participant characteristics
Of 1170 households selected, 144 (median per village 5, range
0–13) were excluded, because nobody was available to take
part (n = 74), household members refused (n = 34), house-
hold was unoccupied (n = 28), household members’ main
place of residence was another selected household (n = 6),
and household members were ill (n = 2). From the remaining
1026 households, 2316 individuals were surveyed. Character-
istics of the participating individuals are shown in Table 1,
with further details described elsewhere (29).
Reported wheeze in the last 12 months was rare (Table 1)
but increased with age (Fig. 1A); 15 participants (0.7%) had
visible flexural eczema (four satisfied the UK criteria for atopic
eczema). Nineteen per cent of participants were atopic based
on SPT with cockroach the most common allergen to elicit a
response. Prevalence of positive SPT response to cockroach
peaked in school-aged children while for other allergens,
prevalence increased with age (Fig. 1A). Median (IQR) asIgE
was 1440 (170–3990) ng/ml for Dermatophagoides and 220
(70–650) ng/ml for cockroach, with 73% of participants hav-
ing detectable levels of Dermatophagoides IgE, 41% having
detectable levels of cockroach IgE and 80% having detectable
asIgE for either allergen.
The numbers and survey design-adjusted percentages of
individuals infected with each helminth are shown in Table 1.
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S. mansoni was most commonly detected, with infections
peaking in prevalence and intensity among school-aged chil-
dren (Fig. 1B), followed by N. americanus, S. stercoralis,
T. trichiura, M. perstans and A. lumbricoides (Table 1). We
did not detect any A. duodenale among the subgroup of 200
participants investigated. A third of those infected with
S. mansoni based on Kato-Katz had heavy infections. For
both T. trichiura and A. lumbricoides, all but seven infected
individuals had light infections; therefore, we were not pow-
ered to look for associations between intensities of these hel-
minths and the study outcomes. Infection intensities for
N. americanus and S. stercoralis were generally light, with
median (IQR) Ct values of 35.7 (33.0, 39.1) and 34.2 (31.9,
37.1), respectively. Based on urine CCA, 72% of 917 individu-
als tested were infected with S. mansoni (compared to 48%
classified as infected by Kato-Katz in this subgroup). Of the
421 individuals who were S. mansoni uninfected based on
Kato-Katz and for whom CCA results were available, 218
(52%) were positive on CCA and could be considered as hav-
ing ‘very light’ infections not detected with Kato-Katz analysis
of a single stool sample.
Associations between allergy-related outcomes
Key associations between allergy-related outcomes and
between helminths and allergy-related outcomes are summa-
rized in Fig. 2. Individuals with a positive SPT response to
any allergen were more likely to report wheeze [OR 2.49
(95% CI: 1.43, 4.33), P = 0.002]; the PAF for reported
wheeze associated with atopy based on SPT was 19.9%. This
association was seen consistently for both under- and over-
fives and for each of the three allergens used for SPT, and
was stronger as the number of allergens for which partici-
pants had a positive SPT increased (P-value for trend test
<0.001). Individuals with higher Dermatophagoides-specific
IgE were more likely to have a positive SPT response to Der-
matophagoides [OR for each unit increase in log Der-
matophagoides-specific IgE 1.69 (95% CI: 1.30, 2.20),
P < 0.001]; cockroach-specific IgE and cockroach-specific
SPT response were also positively associated albeit less
strongly [OR 1.19 (1.04, 1.36), P = 0.02]. Dermatophagoides-
specific IgE level and reported wheeze (all ages) were weakly
positively associated [OR 1.21 (0.96, 1.51), P = 0.10]; cock-
roach-specific IgE level and reported wheeze were inversely
associated [OR 0.77 (0.64, 0.91), P = 0.01].
Associations between helminths and allergy-related outcomes
For reported wheeze in under-fives, we were only able to
examine associations with S. mansoni and T. trichiura (as for
Table 1 Characteristics of survey participants
Characteristic n/N (%*)
Socio-demographic characteristics
Age in years, median (IQR) 24 (8, 32)
Male sex 1268/2316 (54.1)
Place of birth
Fishing village 617/2302 (26.6)
Rural village 1381/2302 (59.2)
Town or city 304/2302 (14.1)
Occupation
Child/student 737/2299 (32.8)
Housewife 125/2299 (6.0)
Fishing or lake related 836/2299 (36.6)
Shops, saloons, artisans, service
providers
125/2299 (6.0)
Bars, restaurants, food providers,
entertainment
152/2299 (5.8)
Agriculture, lumbering, charcoal 266/2299 (10.0)
Professional 15/2299 (0.9)
Unemployed 43/2299 (2.0)
Number of siblings, median (IQR) 5 (3, 8)
P. falciparum infection 139/2115 (7.3)
HIV infection (≥16 years) 244/1376 (17.5)
Any previous worm treatment
in last 12 months
949/2284 (40.6)
Helminth infections
S. mansoni (Kato-Katz) 1041/1996 (51.4)
S. mansoni (urine CCA) 661/917 (72.0)
S. mansoni intensity (Kato-Katz)
Uninfected 955/1996 (48.6)
Low 429/1996 (21.0)
Moderate 288/1996 (13.7)
Heavy 324/1996 (16.6)
N. americanus (PCR) 453/1994 (21.9)
N. americanus intensity (PCR),
Ct median (IQR)
35.7 (33.0–39.1)
S. stercoralis (PCR) 259/1994 (11.9)
S. stercoralis intensity (PCR),
Ct median (IQR)
34.2 (31.9–7.1)
T. trichiura (Kato-Katz) 230/1996 (9.8)
T. trichiura intensity (Kato-Katz)
Uninfected 1766/1996 (90.2)
Low 223/1996 (9.5)
Moderate 6/1996 (0.2)
Heavy 1/1996 (0.0004)
M. perstans 51/2099 (2.5)
A. lumbricoides (Kato-Katz) 27/1996 (1.2)
Allergy-related outcomes
Wheeze in last 12 months, <5 years 12/434 (2.1)
Wheeze in last 12 months, ≥5 years 95/1862 (5.1)
Atopy (SPT)
Any 404/1976 (19.1)
Dermatophagoides 190/1978 (9.0)
Blomia 205/1976 (9.6)
Cockroach 272.1977 (13.2)
Atopy (detectable asIgE)
Any 1685/2116 (79.7)
Dermatophagoides 1534/2115 (72.7)
Table 1 (continued)
Characteristic n/N (%*)
Cockroach 886/2117 (41.0)
Visible flexural dermatitis 15/2145 (0.7)
*Percentages adjusted for the survey design.
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all other helminths, no infected child had reported wheeze)
and found no evidence of association with either [adjusted
OR (95% CI), P: 2.12 (0.23, 19.20), 0.49 and 3.06 (0.65,
14.49), 0.15, respectively].
Table 2 summarizes associations between helminth infec-
tions and wheeze in over-fives, and atopy based on SPT.
Table 3 summarizes associations between helminths and asIgE
response [analysed as detectable vs nondetectable and as log
(asIgE)]. S. mansoni was positively associated with Der-
matophagoides-specific IgE [aOR for detectable vs nonde-
tectable 1.43 (1.19, 1.72), P < 0.001 and aGMR from
continuous analysis 1.64 (1.23, 2.18), P = 0.001, respectively].
There was a dose–response relationship, with individuals with
the heaviest infections most likely to have high IgE (test for
trend P < 0.001, Table 3). T. trichiura was positively associ-
ated with atopy based on SPT response [aOR 2.08 (1.38, 3.15),
P = 0.001 for SPT to any allergen] with the strongest associa-
tion seen for cockroach SPT. Individuals infected with S. ster-
coralis were somewhat more likely to have detectable
cockroach-specific IgE [aOR 1.31 (1.00, 1.72), P = 0.05]. Indi-
viduals with M. perstans were more likely to have detectable
cockroach-specific IgE and to have higher levels [aOR 2.48
(1.51, 4.07), P = 0.001 and aGMR 2.37 (1.39, 4.06),
P = 0.003, respectively]. Finally, A. lumbricoides was posi-
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Figure 1 (A) Prevalence of positive SPT response (any allergen,
German cockroach, Dermatophagoides mix, Blomia tropicalis) and
reported wheeze in last 12 months, by age group. (B) Prevalence
and intensity of S. mansoni infections, by age group.
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tively associated with wheeze in individuals ≥5 years [aOR
6.36 (1.10, 36.63), P = 0.04] and with Dermatophagoides-speci-
fic IgE [aOR 2.58 (1.24, 5.34), P = 0.01 and aGMR 2.34 (1.11,
4.95), P = 0.03]. No inverse associations between the hel-
minths and the allergy-related outcomes considered were seen.
Investigation of effect modification by helminths and age
group
The positive association between Dermatophagoides IgE level
and wheeze was only seen among those infected with S. man-
soni [OR = 1.75, (1.22, 2.52), P = 0.004] and not in unin-
fected individuals [OR = 1.04 (0.81, 1.33), P = 0.77;
interaction P = 0.01], Table S1. A similar pattern was seen
for the association between cockroach SPT and wheeze
[OR = 3.27 (2.08, 5.14), P < 0.001 among S. mansoni-infected
individuals, OR = 1.37 (0.52, 3.61), P = 0.51 among S. man-
soni-uninfected individuals, interaction P = 0.09, Table S1].
Conversely, there was some evidence that the positive associ-
ation between cockroach-specific IgE and SPT was sup-
pressed among those infected with hookworm [OR = 0.95
(0.72, 1.26), P = 0.72 among hookworm-infected individuals,
OR = 1.38 (1.10, 1.74), P = 0.008 among hookworm-unin-
fected individuals, interaction P = 0.11, Table S1]. No inter-
active effects of other helminths were seen. The inverse
association between cockroach IgE and reported wheeze was
only seen among adults [OR = 0.70 (0.59, 0.83), P < 0.001
among those aged ≥16 years), OR = 1.40 (0.98, 2.02),
P = 0.07 among those aged <16 years, interaction P = 0.002].
The positive associations between T. trichiura and SPT
response and between A. lumbricoides and wheeze in over-
fives were enhanced by concurrent infection with S. sterco-
ralis (interaction P = 0.004 and P < 0.001, respectively;
Table 4) and the former was also enhanced by concurrent
hookworm (interaction P = 0.05; Table 4). M. perstans infec-
tion was associated with higher levels of Dermatophagoides-
specific IgE in the absence of concurrent S. mansoni infection
(interaction P = 0.007). There was no evidence of effect mod-
ification between age group and helminths for any outcome.
Discussion
In these remote fishing communities of Lake Victoria where
helminths are highly prevalent, atopy was more common in
individuals infected with Trichuris, schistosomiasis, M. per-
stans or Ascaris, and reported wheeze in the last year was
more common among those with Ascaris infection. Our find-
ings are in contrast to the hypothesis that chronic helminth
infections protect against atopy and allergy-related diseases.
We explored various explanations for why our findings
might differ from those reported by others. Concurrent infec-
tion with other helminths or pathogens could be a factor: we
found some evidence that the association between Trichuris
infection and SPT response was enhanced by concurrent
infection with S. stercoralis or hookworm (Table 4); these
results could also be interpreted as indicating that S. sterco-
ralis and hookworm infections were inversely associated with
atopy, in the absence of Trichuris co-infection. The fact that
our survey was not restricted to children (unlike most other
studies) is unlikely to be the explanation: although we found
that the inverse association between cockroach IgE and
reported wheeze was not seen in children, there was other-
wise no evidence for effect modification by age. Our findings
were consistent for both cockroach and dust mite allergens;
Figure 2 Summary of associations between helminths and allergy-
related outcomes. Red arrows denote positive associations and
blue arrows denote inverse associations, with the thickness of the
arrow indicating the magnitude of the P-value.
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Table 2 Associations between helminth infections and (i) reported
wheeze in individuals aged over 5 years, (ii) positive skin prick test
to Dermatophagoides mix, cockroach, Blomia tropicalis, any aller-
gen. Adjusted associations with P < 0.05 are highlighted in bold
Helminth infection
status n/N (%)*
Adjusted OR
(95% CI)†,‡ P
Outcome: wheeze, over 5 years
S. mansoni§
Uninfected 39/665 (6.5) 1
Infected 49/940 (4.7) 0.81 (0.47, 1.40) 0.44
S. mansoni intensity¶
Uninfected 39/665 (6.5) 1
Light 19/361 (4.6) 0.76 (0.42, 1.38) 0.64
Moderate 11/266 (4.2) 0.73 (0.32, 1.66) (0.83)**
Heavy 19/313 (5.3) 1.00 (0.39, 2.58)
N. americanus
Uninfected 65/1196 (5.2) 1
Infected 23/408 (6.3) 1.20 (0.60, 2.41) 0.60
T. trichiura
Uninfected 78/1416 (5.4) 1
Infected 10/189 (6.3) 1.55 (0.73, 3.30) 0.24
S. stercoralis
Uninfected 74/1369 (5.5) 1
Infected 14/235 (5.5) 0.81 (0.45, 1.47) 0.47
M. perstans
Uninfected 90/1707 (5.3) 1
Infected 4/50 (7.4) 1.27 (0.30, 5.42) 0.73
A. lumbricoides
Uninfected 84/1585 (5.3) 1
Infected 4/20 (19.2) 6.36 (1.10, 36.63) 0.04
Outcome: atopy (skin prick test positive to any allergen)
S. mansoni§
Uninfected 147/805 (16.5) 1
Infected 215/965 (20.6) 1.13 (0.86, 1.47) 0.37
S. mansoni intensity¶
Uninfected 147/805 (16.5) 1
Light 96/395 (22.5) 1.26 (0.85, 1.86) 0.67
Moderate 56/271 (19.6) 1.02 (0.74, 1.41) (0.96)**
Heavy 63/299 (19.2) 1.02 (0.70, 1.50)
N. americanus
Uninfected 290/1367 (19.5) 1
Infected 71/400 (15.9) 0.72 (0.47, 1.10) 0.12
T. trichiura
Uninfected 301/1567 (17.6) 1
Infected 61/203 (29.7) 2.08 (1.38, 3.15) 0.001
S. stercoralis
Uninfected 327/1532 (19.6) 1
Infected 34/235 (12.5) 0.55 (0.29, 1.06) 0.07
M. perstans
Uninfected 392/1900 (19.4) 1
Infected 9/48 (16.0) 0.68 (0.28, 1.68) 0.39
A. lumbricoides
Uninfected 356/1744 (18.7) 1
Infected 6/26 (23.4) 1.31 (0.40, 4.26) 0.64
Outcome: atopy (skin prick test positive to Dermatophagoides)
S. mansoni§
Uninfected 68/806 (7.6) 1
Infected 104/966 (9.9) 1.13 (0.89, 1.44) 0.31
Table 2 (continued)
Helminth infection
status n/N (%)*
Adjusted OR
(95% CI)†,‡ P
S. mansoni intensity¶
Uninfected 68/806 (7.6) 1
Light 46/395 (10.0) 1.12 (0.74, 1.70) 0.74
Moderate 28/271 (10.1) 1.17 (0.76, 1.80) (0.50)**
Heavy 30/300 (9.6) 1.11 (0.74, 1.65)
N. americanus
Uninfected 139/1369 (9.3) 1
Infected 32/400 (7.3) 0.72 (0.43, 1.21) 0.20
T. trichiura
Uninfected 147/1569 (8.4) 1
Infected 25/203 (12.7) 1.73 (1.03, 2.90) 0.04
S. stercoralis
Uninfected 152/1534 (8.9) 1
Infected 19/235 (8.0) 0.84 (0.38, 1.86) 0.65
M. perstans
Uninfected 184/1902 (9.1) 1
Infected 3/48 (7.1) 0.78 (0.27, 2.26) 0.63
A. lumbricoides
Uninfected 168/1746 (8.7) 1
Infected 4/26 (17.6) 2.46 (0.73, 8.31) 0.14
Outcome: atopy (skin prick test positive to cockroach)
S. mansoni§
Uninfected 92/805 (10.5) 1
Infected 152/966 (14.8) 1.29 (0.88, 1.90) 0.18
S. mansoni intensity¶
Uninfected 92/805 (10.5) 1
Light 69/395 (17.1) 1.58 (0.96, 2.61) 0.20
Moderate 41/271 (13.8) 1.14 (0.75, 1.72) (0.95)**
Heavy 42/300 (12.8) 1.02 (0.60, 1.73)
N. americanus
Uninfected 19/1368 (13.1) 1
Infected 51/400 (11.7) 0.73 (0.40, 1.31) 0.27
T. trichiura
Uninfected 198/1568 (11.8) 1
Infected 46/203 (21.8) 1.98 (1.30, 3.01) 0.003
S. stercoralis
Uninfected 219/1533 (13.3) 1
Infected 25/235 (9.3) 0.62 (0.32, 1.18) 0.14
M. perstans
Uninfected 267/1901 (13.5) 1
Infected 5/48 (9.4) 0.58 (0.21, 1.62) 0.28
A. lumbricoides
Uninfected 240/1745 (12.8) 1
Infected 4/26 (15.0) 1.06 (0.33, 3.37) 0.92
Outcome: atopy (skin prick test positive to Blomia tropicalis)
S. mansoni§
Uninfected 81/805 (8.5) 1
Infected 98/965 (9.7) 1.02 (0.66, 1.59) 0.92
S. mansoni intensity¶
Uninfected 81/805 (8.5) 1
Light 42/395 (9.2) 0.97 (0.58, 1.63) 0.89
Moderate 23/271 (8.6) 0.95 (0.59, 1.52) (0.65)**
Heavy 33/299 (11.2) 1.18 (0.64, 2.19)
N. americanus
Uninfected 139/1367 (9.2) 1
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thus, differences between studies in allergens used is unlikely
to explain our different findings. Another possible explana-
tion that we cannot exclude is that individuals in our study
setting may have suffered more long-term and chronic infec-
tions compared to those in other studies. Finally, although
hookworm infection as detected by PCR was fairly common,
it was generally of low intensity; hence, this may have
reduced our ability to detect associations for this helminth.
We estimate that in this setting, the population fraction of
reported wheeze attributable to atopy is around 20%, lower
than reported in most high-income settings, but similar to
many other LICs (9, 38). Consistent with findings from other
developing country settings (21), hookworm infection
appeared to suppress associations between IgE and SPT for
cockroach responses; however, schistosomiasis had the oppo-
site effect, promoting associations between atopy and wheeze
for both dust mite and cockroach allergens.
Helminth infections could promote atopy either by non-
specifically driving the antigen presentation-T-cell-to-B-cell
immune response axis towards greater production of IgE, or
by inducing cross-reactive IgE. Regarding the latter, asthma
severity has been shown to be related to Ascaris IgE levels,
which correlate with mite-specific IgE (39), cross-reactivity
has been demonstrated for selected Ascaris and mite antigens
(40), and immunization of rabbits with Ascaris antigens
induces IgE which cross-reacts with house dust mite (41).
This accords with our observed association between Ascaris
and elevated dust mite-specific IgE. Likewise, molecular mod-
elling indicates that S. mansoni contains cysteine proteases
homologous to the house dust mite antigen Der p 1 (42) and
S. mansoni infection was associated with elevated house dust
mite-specific IgE in our study. Cross-reactive IgE can also
occur to molecules such as tropomyosin which are highly
conserved between invertebrates (including nematodes, schis-
tosomes, mites and cockroach) (43) and, consistent with
cross-reactivity, the prevalence of positive SPT responses to
cockroach and the heaviest S. mansoni infections both
peaked in school-aged children in our study.
Mechanisms for a positive association between helminths and
wheeze could include exacerbation of allergen-specific atopic
responses or a direct response to the allergen-like helminth pro-
teins experienced during larval migration through the lungs.
The former might explain our finding that concurrent S. man-
soni infection strengthens the association between allergen-spe-
cific IgE and wheeze. The latter may explain the association
between Ascaris and wheeze – the long-recognized L€offler’s syn-
drome (44) – although cross-reactivity between Ascaris and mite
allergens may also contribute, as discussed above.
For each of these possible mechanisms, concurrent infec-
tion with a helminth species that down-modulates allergy-
related immune responses might modify the association
between pro-allergenic helminth species and allergy-related
outcomes in the same way that hookworm has been observed
to modify the link between allergen-specific IgE and his-
tamine release (21). However, our interaction analyses
showed little evidence of such effects: the only result consis-
tent with this hypothesis was that S. mansoni infection modi-
fied the association between M. perstans and house dust
mite-specific IgE production.
Despite the positive associations observed between hel-
minths and allergy-related outcomes in this study, the overall
prevalence of wheeze, eczema and SPT positivity was low
compared with developed countries and urban settings in low
or middle-income countries (8, 45). This suggests that factors
other than current active helminth infection in these commu-
nities have important protective effects against allergy-related
outcomes. These factors could include prenatal exposure to
helminths (22, 46), exposures to a myriad of infectious, xeno-
Table 2 (continued)
Helminth infection
status n/N (%)*
Adjusted OR
(95% CI)†,‡ P
Infected 39/400 (8.8) 0.89 (0.56, 1.44) 0.63
T. trichiura
Uninfected 155/1567 (8.8) 1
Infected 24/203 (11.8) 1.45 (0.79, 2.56) 0.22
S. stercoralis
Uninfected 163/1532 (9.5) 1
Infected 15/235 (6.3) 0.59 (0.26, 1.34) 0.20
M. perstans
Uninfected 195/1900 (9.6) 1
Infected 7/48 (13.8) 1.37 (0.58, 3.26) 0.45
A. lumbricoides
Uninfected 174/1744 (9.0) 1
Infected 5/26 (21.7) 3.73 (0.91, 15.26) 0.07
*Percentages adjusted for the survey design.
†Adjusted odds ratio (OR) and 95% confidence intervals (CI)
adjusted for survey design.
‡All adjusted ORs adjusted for age, sex, occupation, number of sib-
lings. For associations with wheeze, all ORs were also adjusted for
household asset score and household crowding and helminth-speci-
fic ORs were additionally adjusted as follows: S. mansoni – malaria
infection, hand-washing behaviour, A. lumbricoides infection; hook-
worm – malaria infection, hand-washing behaviour, HIV infection,
A. lumbricoides infection; T. trichiura – hand-washing behaviour;
M. perstans – malaria infection; A. lumbricoides – maternal history
of asthma. For associations with SPT (any and allergen-specific), all
ORs were also adjusted for number of siblings, area of birth, and
helminth-specific ORs were additionally adjusted as follows:
S. mansoni – T. trichiura infection; hookworm – S. mansoni infec-
tion, S. stercoralis infection, T. trichiura infection. For associations
with Dermatophagoides SPT, helminth-specific ORs were addition-
ally adjusted as follows: S. mansoni – maternal tribe, hand-washing
behaviour; hookworm – household toilet access; T. trichiura –
maternal tribe, household toilet access; M. perstans – maternal
tribe. For associations with cockroach SPT, helminth-specific ORs
were additionally adjusted as follows: hookworm – household asset
score; T. trichiura – household toilet access; S. stercoralis – house-
hold asset score. For associations with Blomia tropicalis SPT, ORs
for S. mansoni and hookworm were additionally adjusted for hand-
washing behaviour.
§Based on Kato-Katz.
¶Light: 1–99 eggs per gram, moderate: 100–399 eggs per gram,
heavy: ≥400 eggs per gram.
**P-value for test for trend.
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Table 3 Associations between helminth infections and allergen-specific IgE. Adjusted associations with P < 0.05 are highlighted in bold
Helminth infection status n/N (%)/geometric mean* Adjusted OR/GMR (95% CI)†,‡ P
Outcome: atopy (Detectable Dermatophagoides-specific IgE)
S. mansoni§
Uninfected 588/873 (67.4) 1
Infected 771/1007 (76.8) 1.43 (1.19, 1.72) <0.001
S. mansoni intensity¶
Uninfected 588/873 (67.4) 1
Light 298/411 (71.8) 1.13 (0.89, 1.42) 0.002
Moderate 216/279 (79.3) 1.69 (1.22, 2.35) (<0.001)**
Heavy 257/317 (81.0) 1.95 (1.28, 2.95)
N. americanus
Uninfected 1029/1446 (71.4) 1
Infected 329/432 (75.9) 1.10 (0.75, 1.61) 0.60
T. trichiura
Uninfected 1188/1659 (71.9) 1
Infected 171/221 (76.7) 1.13 (0.82, 1.56) 0.44
S. stercoralis
Uninfected 1169/1630 (71.5) 1
Infected 189/248 (79.0) 1.26 (0.95, 1.67) 0.11
M. perstans
Uninfected 1483/2044 (72.7) 1
Infected 40/51 (83.8) 1.53 (0.68, 3.41) 0.29
A. lumbricoides
Uninfected 1336/1853 (72.2) 1
Infected 23/27 (88.0) 2.58 (1.24, 5.34) 0.01
Outcome: atopy (Detectable cockroach-specific IgE)
S. mansoni§
Uninfected 362/874 (41.0) 1
Infected 425/1008 (41.6) 0.88 (0.58, 1.35) 0.56
S. mansoni intensity¶
Uninfected 362/874 (41.0) 1
Light 174/411 (40.4) 0.85 (0.52, 1.39) 0.92
Moderate 112/279 (43.3) 0.94 (0.48, 1.82) (0.62)**
Heavy 139/318 (41.7) 0.89 (0.57, 1.39)
N. americanus
Uninfected 598/1447 (40.4) 1
Infected 188/433 (44.2) 1.06 (0.75, 1.49) 0.73
T. trichiura
Uninfected 690/1660 (41.1) 1
Infected 97/222 (43.1) 1.03 (0.85, 1.24) 0.76
S. stercoralis
Uninfected 667/1632 (40.4) 1
Infected 119/248 (47.3) 1.31 (1.00, 1.72) 0.05
M. perstans
Uninfected 852/2046 (40.7) 1
Infected 31/51 (61.9) 2.48 (1.51, 4.07) 0.001
A. lumbricoides
Uninfected 776/1855 (41.3) 1
Infected 11/27 (42.6) 0.96 (0.55, 1.67) 0.87
Outcome: level of Dermatophagoides-specific IgE
S. mansoni§
Uninfected 253 1
Infected 530 1.64 (1.23, 2.18) 0.001
S. mansoni intensity¶
Uninfected 253 1
Light 344 1.14 (0.77, 1.69) 0.001
Moderate 602 1.94 (1.31, 2.87) (<0.001)**
Heavy 817 2.69 (1.46, 4.95)
N. americanus
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Table 3 (continued)
Helminth infection status n/N (%)/geometric mean* Adjusted OR/GMR (95% CI)†,‡ P
Uninfected 350 1
Infected 475 1.09 (0.65, 1.83) 0.72
T. trichiura
Uninfected 361 1
Infected 523 1.24 (0.78, 1.99) 0.35
S. stercoralis
Uninfected 350 1
Infected 613 1.27 (0.92, 1.77) 0.14
M. perstans
Uninfected 378 1
Infected 997 1.69 (0.73, 3.90) 0.21
A. lumbricoides
Uninfected 370 1
Infected 970 2.34 (1.11, 4.95) 0.03
Outcome: level of cockroach-specific IgE
S. mansoni§
Uninfected 164 1
Infected 165 0.78 (0.54, 1.13) 0.18
S. mansoni intensity¶
Uninfected 164 1
Light 158 0.76 (0.51, 1.21) 0.53
Moderate 174 0.77 (0.37, 1.61) (0.26)**
Heavy 167 0.84 (0.57, 1.22)
N. americanus
Uninfected 155 1
Infected 201 1.12 (0.84, 1.48) 0.42
T. trichiura
Uninfected 162 1
Infected 194 1.17 (0.93, 1.47) 0.17
S. stercoralis
Uninfected 162 1
Infected 180 0.98 (0.62, 1.54) 0.92
M. perstans
Uninfected 162 1
Infected 428 2.37 (1.39, 4.06) 0.003
A. lumbricoides
Uninfected 164 1
Infected 242 1.57 (0.85, 2.89) 0.15
*For binary outcomes, figures shown are n/N with percentages adjusted for the survey design. For continuous outcomes, figures shown are
geometric means adjusted for the survey design.
†For binary outcomes, figures shown are adjusted odds ratios (OR) [95% confidence intervals (CI)] adjusted for survey design. For continuous
outcomes, figures shown are adjusted geometric mean ratios (GMR) (95% CI) adjusted for survey design.
‡All adjusted ORs adjusted for age, sex, occupation, area of birth. For associations with detectable Dermatophagoides IgE, ORs were addition-
ally adjusted as follows: S. mansoni – preschool attendance, A. lumbricoides infection; hookworm – S. mansoni infection, S. stercoralis infec-
tion; T. trichiura – household crowding, animal ownership, S. mansoni infection, A. lumbricoides infection; S. stercoralis – household
crowding, animal ownership; A. lumbricoides – S. mansoni infection. For associations with detectable cockroach IgE, ORs were additionally
adjusted as follows: hookworm –S. stercoralis infection; T. trichiura – animal ownership; S. stercoralis – animal ownership.
All adjusted GMRs adjusted for age, sex, occupation, area of birth. For associations with Dermatophagoides IgE, GMRs were additionally
adjusted as follows: S. mansoni – number of siblings, preschool attendance, hand-washing behaviour, A. lumbricoides infection; hookworm –
number of siblings, malaria infection, S. mansoni infection, S. stercoralis infection; T. trichiura – household crowding, hand-washing behaviour,
animal ownership, S. mansoni infection, A. lumbricoides infection; S. stercoralis – number of siblings, household crowding and animal owner-
ship; M. perstans – malaria infection; A. lumbricoides – S. mansoni infection. For associations with cockroach IgE, GMRs were additionally
adjusted as follows: S. mansoni –maternal history of asthma, hookworm infection; hookworm – anthelminthic treatment in last year; T. trichiura
– HIV infection, animal ownership, hookworm infection; S. stercoralis – HIV infection, animal ownership, anthelminthic treatment in last year.
§Based on Kato-Katz.
¶Light: 1–99 eggs per gram, moderate: 100–399 eggs per gram, heavy: ≥400 eggs per gram.
**P-value for test for trend.
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biotic or commensal organisms (47, 48), and a range of life-
style factors (49), which await further investigation in this
setting.
We found high levels of allergen-specific IgE. This could
be a consequence of immunological cross-reactivity between
helminth allergens and aeroallergens or a result of nonspecific
stimulation of IgE production resulting from intense hel-
minth exposure (as discussed above), or an artefact of our in-
house assay. Further studies to determine the characteristics
of the IgE present in this population are in progress.
Our study had some limitations. We could only evaluate
helminth infections endemic to our study setting: for example,
for hookworm, we could investigate associations between
N. americanus and allergy outcomes, but not A. duodenale, as
the latter was not found. The cross-sectional design of this sur-
vey means that, strictly speaking, we cannot tell the relative
timing of allergen sensitization and helminth exposure. How-
ever, our age-prevalence profiles show that both prenatal hel-
minth exposure and infection in infancy and early childhood
are likely in this setting so prior exposure to helminths, or con-
current exposure to helminths and allergens, is likely to have
occurred. Although the use of reported wheeze in the last
12 months has been validated as a proxy measure for asthma
in many settings (50), there is no direct translation of the word
‘wheeze’ in the local language; thus, this outcome is likely to
be subject to misclassification. Indeed, the increasing preva-
lence of reported wheeze with age that we observed could indi-
cate that the phenotype being captured was to some extent
related to chronic bronchitis rather than asthma. We investi-
gated the use of a video questionnaire for wheeze in the study
and found that agreement between the two approaches was
fairly low although participants reporting wheeze had, on
average, reduced levels of lung function parameters (29).
Although we collected data on reported allergic rhinitis (a
common disease caused by the allergens tested in our study, in
some settings) in our survey and investigated it as an explora-
tory outcome, we found it to be uncommon and there was no
evidence of association with any helminth; however, it is possi-
ble that this outcome was subject to misclassification, for simi-
lar reasons to wheeze. An additional source of
Table 4 Interactions between helminth infections in their association with allergy-related outcomes
Helminth infection status
S. stercoralis status T. trichiura status n/N (%)* Adjusted OR (95% CI)†,‡ P Interaction P-value
Outcome: SPT response for any allergen
Uninfected Uninfected 279/1364 (18.7) 1 0.004
Infected 48/168 (28.0) 1.85 (1.18, 2.88) 0.01
Infected Uninfected 21/201 (8.9) 1
Infected 13/34 (40.2) 9.88 (2.27, 43.01) 0.004
N. americanus status T. trichiura status
Uninfected Uninfected 251/1234 (18.7) 1 0.05
Infected 39/133 (28.4) 1.73 (1.10, 2.73) 0.02
Infected Uninfected 49/331 (13.0) 1
Infected 22/69 (32.6) 4.06 (2.09, 7.88) <0.001
S. stercoralis status A. lumbricoides status n/N (%)* Adjusted OR (95% CI)†,‡ P Interaction P-value
Outcome: wheeze, over 5 years
Uninfected Uninfected 73/1352 (5.5) 1 <0.001
Infected 1/16 (7.7) 1.63 (0.13, 19.80) 0.69
Infected Uninfected 11/231 (4.5) 1
Infected 3/4 (71.6) 485.9 (5.71, 41 341.5) 0.008
S. mansoni status M. perstans status Geometric mean (ng/ml)* Crude GMR (95% CI)†,‡ P Interaction P-value
Outcome: Dermatophagoides-specific IgE
Uninfected Uninfected (n = 839) 27.9 1 0.007
Infected (n = 19) 113.7 3.12 (1.67, 5.80) 0.001
Infected Uninfected (n = 979) 47.6 1
Infected (n = 25) 57.2 0.94 (0.50, 1.78) 0.85
*For binary outcomes, figures shown are n/N with percentages adjusted for the survey design. For continuous outcome, figures shown are
geometric means adjusted for the survey design.
†For binary outcomes, figures shown are adjusted odds ratios (OR) [95% confidence intervals (CI)] allowing for survey design. For continu-
ous outcome, figures shown are adjusted geometric mean ratios (GMR) (95% CI) allowing for survey design.
‡All adjusted OR/GMR adjusted for age, sex, number of siblings, occupation. Associations for SPT additionally adjusted for area of birth,
associations for wheeze additionally adjusted for household crowding and asset score, associations for IgE additionally adjusted for area of
birth, preschool attendance, malaria infection, hand-washing behaviour.
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misclassification is that we used single stool samples to assess
helminth infection status (51, 52). Indeed for the subgroup of
participants who underwent urine CCA testing, the prevalence
of S. mansoni was found to be much higher than when tested
using Kato-Katz of the single stool sample. Also, the PCR
method used had limited sensitivity for Strongyloides. This
could have led to underestimation of the size of any true asso-
ciation. The study involved a large number of statistical tests,
for which we made no formal adjustment; however, the consis-
tent patterns of positive associations are unlikely to be
explained by chance. Findings from our interaction analyses
should be treated with caution. Although not all of these anal-
yses were preplanned, we felt they were important to try to
shed light on our unexpected findings.
In conclusion, we found that certain helminth infections
were positively associated with allergy-related outcomes in
this setting, with inverse associations only being seen in sub-
group analyses. The LaVIISWA trial is currently ongoing
and the impact of intensive vs standard anthelminthic treat-
ment will be investigated in a further cross-sectional house-
hold survey in 2016. At that time, we will be able to assess
not only the direct impact of worm removal on allergy-
related outcomes, but also the effect of the trial interventions
on the associations reported herein. If there is a causal rela-
tionship underlying the observed associations, then the
allergy-related outcome prevalence might reduce with the
removal of helminth infection, rather than increasing as ini-
tially hypothesized.
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9.3.1 Supplementary Table 1. Associations between allergy outcomes stratified by S. mansoni and N. americanus status. 
S. mansoni N. americanus 
Infection 
status 
OR (95% CI) p Interaction 
p-value 
Infection 
status 
OR (95% CI) p Interaction 
p-value 
Outcomes: Dermatophagoides SPT and reported wheeze 
Uninfected 2.18 (0.64, 7.40) 0.20 0.53 Uninfected 2.59 (1.15, 5.84) 0.02 0.71 
Infected 3.32 (1.85, 5.97) <0.001  Infected 3.37 (1.23, 9.21) 0.02  
Outcomes: Dermatophagoides IgE level and Dermatophagoides SPT 
Uninfected 1.55 (1.03, 2.35) 0.04 0.37 Uninfected 1.68 (1.21, 2.34) 0.003 0.54 
Infected 1.88 (1.41, 2.51)  <0.001  Infected 1.95 (1,41, 2.69) <0.001  
Outcomes: Dermatophagoides IgE level and reported wheeze 
Uninfected 1.04 (0.81, 1.33) 0.77 0.01 Uninfected 1.32 (0.99, 1.77) 0.06 0.29 
Infected 1.75 (1.22, 2.52) 0.004  Infected 1.01 (0.64, 1.59) 0.96  
Outcomes: Cockroach SPT and reported wheeze 
Uninfected 1.37 (0.52, 3.61) 0.51 0.09 Uninfected 1.91 (1.05, 3.49) 0.04 0.19 
Infected 3.27 (2.08, 5.14) <0.001  Infected 3.59 (1.84, 7.02) 0.001  
Outcomes: Cockroach IgE level and cockroach SPT 
Uninfected 1.15 (0.86, 1.55) 0.34 0.47 Uninfected 1.38 (1.10, 1.74) 0.008 0.11 
Infected 1.35 (1.06, 1.73) 0.02  Infected 0.95 (0.72, 1.26) 0.72  
Outcomes: Cockroach IgE level and reported wheeze 
Uninfected 0.75 (0.55, 1.02) 0.06 0.96 Uninfected 0.80 (0.60, 1.07) 0.12 0.39 
Infected 0.75 (0.60, 0.95) 0.02  Infected 0.62 (0.41, 0.93) 0.02  
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The Impact of Intensive Versus Standard Anthelminthic 
Treatment on Allergy-related Outcomes, Helminth 
Infection Intensity, and Helminth-related Morbidity in 
Lake Victoria Fishing Communities, Uganda: Results From 
the LaVIISWA Cluster-randomized Trial
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Prossy Kabuubi Nakawungu,1 Emmanuel Niwagaba,1 Elson Abayo,4 Joyce Kabagenyi,1 Christopher Zziwa,1 Josephine Tumusiime,4 Esther Nakazibwe,4 
James Kaweesa,5 Fred Muwonge Kakooza,6 Mirriam Akello,1 Lawrence Lubyayi,1 Jaco Verweij,7 Stephen Nash,8 Ronald van Ree,9 Harriet Mpairwe,1 
Edridah Tukahebwa,5 Emily L. Webb,8 and Alison M. Elliott1,3; for the LaVIISWA Trial Team
1Immunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, 
and 2Department of Internal Medicine, College of Health Sciences, Makerere University, Kampala, Uganda; 3Department of Clinical Research, London School of Hygiene and Tropical Medicine, 
United Kingdom; 4Entebbe Hospital, Wakiso District Local Government, Uganda, 5Vector Control Division, Ministry of Health, Kampala, Uganda and 6Koome Health Centre III, Mukono District Local 
Government, Uganda; 7Laboratory for Medical Microbiology and Immunology, St Elisabeth Hospital, Tilburg, The Netherlands; 8Medical Research Council Tropical Epidemiology Group, Department 
of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom; and 9Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
Background. The prevalence of allergy-related diseases is increasing in low-income countries. Parasitic helminths, common 
in these settings, may be protective. We hypothesized that intensive, community-wide, anthelminthic mass drug administration 
(MDA) would increase allergy-related diseases, while reducing helminth-related morbidity.
Methods. In an open, cluster-randomized trial (ISRCTN47196031), we randomized 26 high-schistosomiasis-transmission fish-
ing villages in Lake Victoria, Uganda, in a 1:1 ratio to receive community-wide intensive (quarterly single-dose praziquantel plus 
albendazole daily for 3 days) or standard (annual praziquantel plus 6 monthly single-dose albendazole) MDA. Primary outcomes 
were recent wheezing, skin prick test positivity (SPT), and allergen-specific immunoglobulin E (asIgE) after 3 years of intervention. 
Secondary outcomes included helminths, haemoglobin, and hepatosplenomegaly.
Results. The outcome survey comprised 3350 individuals. Intensive MDA had no effect on wheezing (risk ratio [RR] 1.11, 95% 
confidence interval [CI] 0.64–1.93), SPT (RR 1.10, 95% CI 0.85–1.42), or asIgE (RR 0.96, 95% CI 0.82–1.12). Intensive MDA reduced 
Schistosoma mansoni infection intensity: the prevalence from Kato Katz examinations of single stool samples from each patient was 
23% versus 39% (RR 0.70, 95% CI 0.55–0.88), but the urine circulating cathodic antigen test remained positive in 85% participants 
in both trial arms. Hookworm prevalence was 8% versus 11% (RR 0.55, 95% CI 0.31–1.00). There were no differences in anemia or 
hepatospenomegaly between trial arms.
Conclusions. Despite reductions in S. mansoni intensity and hookworm prevalence, intensive MDA had no effect on atopy, aller-
gy-related diseases, or helminth-related pathology. This could be due to sustained low-intensity infections; thus, a causal link between 
helminths and allergy outcomes cannot be discounted. Intensive community-based MDA has a limited impact in high-schistosomi-
asis-transmission fishing communities, in the absence of other interventions.
Clinical Trials Registration. ISRCTN47196031.
Keywords. helminths; Schistosoma mansoni; mass drug administration; allergy-related disease; Africa.
The prevalence of allergy-related diseases (ARD), such as 
eczema, rhinitis, and asthma, increased rapidly in high-income 
countries in the twentieth century [1] and is now increasing in 
tropical, low-income countries (LICs) [2]. Nevertheless, popu-
lations in LICs, particularly in rural settings, remain relatively 
protected [3]. Understanding this phenomenon is crucial to 
elucidating the causes and improving prevention of ARD.
By contrast, LICs carry the largest burden of parasitic hel-
minth infections: these are associated with some severe and 
much subtle morbidity [4, 5]. Major anthelminthic mass drug 
administration (MDA) has taken place in the last decade but, 
although prevention of severe helminth-induced morbidity is 
important, wider benefits [6] and the sustainability of helminth 
control by MDA [7, 8] have been questioned.
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Certain helminth antigens are highly homologous to allergens; 
immunoglobulin (Ig)-E and the atopic pathway are presumed 
to have evolved to protect mammals against such organisms [9]. 
Parasitic helminths must modulate such responses to survive 
within mammalian hosts. Animal and human epidemiologi-
cal and in vitro studies indicate that, through bystander effects 
of such immunomodulation, chronic helminth infection pro-
tects against atopy and ARD [10]. If helminths protect against 
ARD, MDA programs may adversely affect these outcomes. 
Observational studies, many of which indicate an inverse asso-
ciation between helminths and ARD, are subject to confounding 
and reverse causation; therefore, several groups have investi-
gated the effects of anthelminthic treatment on ARD in clinical 
trials. Some studies show increased atopy after anthelminthic 
intervention, but 2 large, school-based, individually-random-
ized intervention trials focusing on soil-transmitted helminths 
(STH) reported no effect on atopy or ARD [11, 12]. A recent 
household-randomized trial of intensive albendazole for STH 
showed no effect on ARD, but upregulated pro-inflammatory 
responses and reduced immunoregulatory molecules [13].
East African fishing communities bear an intense schisto-
somiasis burden [14]. During a Schistosoma mansoni infec-
tion, adult worms reside in mesenteric blood vessels and eggs 
are excreted through intestinal mucosa, causing intestinal and 
tissue (notably liver) pathology [5]. Schistosoma infection has 
shown even stronger inverse associations with atopy than STH 
[15] and there is evidence of increased SPT reactivity with 
treatment [16], but no large-scale randomized trial on the aller-
gy-related effects of intensively treating schistosomiasis has 
been conducted.
We undertook the Lake Victoria Island Intervention 
Study on Worms and Allergy-related diseases (LaVIISWA; 
ISRCTN47196031) [17], a cluster-randomized trial of extended 
(3-year) intensive versus standard anthelminthic intervention, 
to assess the causal role of helminths in allergy-related outcomes 
and the benefits of intensive intervention for helminth-related 
morbidity in a schistosomiasis hot spot.
METHODS
Design and Setting
This was a 2-arm, open, cluster-randomized trial of intensive 
versus standard anthelminthic treatment conducted among 
fishing villages in the Koome islands, Lake Victoria, Uganda, 
between September 2012 and August 2016. The protocol has 
been published previously [17]. We randomized 26 villages 1:1 
to either intensive or standard intervention. Village-level clus-
ter-randomization aimed to minimize contamination from 
reinfection by untreated neighbours. Before the study, annual 
praziquantel treatment was offered to these communities, but 
hampered by logistics. In our baseline survey, 17% participants 
reported treatment in the prior year [17].
Interventions
Standard intervention, based on the Uganda Ministry of Health 
guidelines, was annual single dose praziquantel at 40  mg/kg 
(Cipla; CSPC OUYI Pharmaceuticals, India; AGOG Pharma, 
India) to community members ≥94 cm, as estimated by a height 
pole, plus 6 monthly single dose albendazole at 400 mg (CSPC 
OUYI Pharmaceuticals, India; AGOG Pharma, India; Medreich, 
India) to all aged ≥1 year. Intensive intervention was quarterly 
single dose praziquantel at 40 mg/kg to individuals ≥60 cm (to 
allow treatment of younger children) [18], as estimated by an 
extended height pole, plus quarterly triple dose albendazole 
(400 mg daily for 3 days) to all aged ≥1 year. Pregnant women 
were included in both arms, receiving single dose albendazole 
[19, 20].
Treatment, distributed house-to-house in collaboration with 
the Uganda Ministry of Health Vector Control Division, was 
directly observed and documented against household registers, 
with the exception of post–day 1 albendazole in the intensive arm.
Participants and Surveys
Leaders of all 27 Koome fishing villages gave written consent for 
their village’s participation. Allocated interventions were given 
to all community members (of eligible age and height) unless 
they were absent, sick, or refused.
Household-based surveys were conducted at baseline [21] 
and after 3  years of intervention. All primary and most sec-
ondary outcomes were assessed in both baseline and outcome 
surveys. Smaller surveys were conducted at years 1 and 2 to 
assess helminth trends (Supplementary Figure). Separate ran-
dom household samples were selected for each survey (overlap 
was possible). There was no individual participant follow-up. 
Surveys were conducted immediately prior to respective quar-
terly treatments.
Household registers were updated before each survey. 
Villages generally comprised an intensely-populated center 
and a scattered periphery. Peripheral households were excluded 
from surveys to avoid contamination from neighboring vil-
lages, but received allocated interventions.
Baseline survey methods (previously reported) were similar 
to the 3-year outcome survey described below [21]. For interim 
surveys, stool and blood samples were collected from commu-
nity members selected using a 2-stage method: 1 person was 
randomly selected from each of 15 randomly-selected house-
holds per village. For the 3-year survey, 70 households per vil-
lage were randomly selected using a Stata program (StataCorp, 
College Station). In the selected households, all members 
≥1 year were invited to participate. Household heads gave per-
mission for household participation and provided the demo-
graphic details (age, sex) of all household members. Written 
informed consent was obtained from all adults and emanci-
pated minors and from parents/guardians for children, with 
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additional assent from children ≥8 years. For each participant, 
a questionnaire was completed; an examination and SPT were 
performed; and blood, urine, and 1 stool sample were obtained. 
Abdominal ultrasonography was performed on children.
Outcomes
Primary outcomes were recent (last 12  months) self-reported 
wheezing, stratified by age (<5  years, ≥5  years); SPT positiv-
ity to mites (Dermatophagoides mix, Blomia tropicalis) and 
German cockroaches (Blattella germanica); and allergen-spe-
cific IgE (asIgE) to Dermatophagoides and German cockroaches 
(common allergens in Uganda [22]). Secondary outcomes were 
visible flexural dermatitis (assessed using standardized proce-
dures); helminth infections; haemoglobin; growth (height-for-
age, <20 years; weight-for-age, <11 years; and weight-for-height, 
<6 years, z-scores); and hepatosplenomegaly (by palpation). An 
additional secondary outcome, schistosomiasis-related liver 
and spleen morbidity assessed by abdominal ultrasonography 
(<18 years), was included after trial interventions commenced, 
when additional funding became available. Exploratory out-
comes were recent urticaria and rhinitis. For logistical reasons, 
we could not provide infant vaccines ourselves or obtain post-im-
munization samples at consistent timepoints, so planned vaccine 
response secondary outcomes are not reported. Details on out-
come ascertainment are provided (Supplementary Methods).
Randomization
At a public ceremony, 1 village was randomly selected for pilot-
ing while 26 were randomized 1:1, using restricted randomiza-
tion to balance village size, prior praziquantel treatment, and 
distance from the sub-county health center [17] (Supplementary 
Methods).
Statistical Methods
For the outcome survey, we planned to sample 1540 individuals 
per arm (Supplementary Methods). Data were analyzed using 
Stata v14.0. Baseline characteristics were tabulated. Characteristics 
of survey participants were compared with those of non-partici-
pants by chi-squared tests. Treatment uptake was calculated both 
by village and treatment round as the number of people receiving 
treatment divided by the total number of residents.
Trial analyses were done at the cluster level. Crude and 
adjusted analyses (adjusting for sex, age, and the correspond-
ing baseline summary measure of the outcome, where available) 
were performed. For binary outcomes, risk ratios (RRs) were 
calculated as the mean of the intensive-arm cluster proportions 
divided by the mean in the standard arm, with 95% confidence 
intervals (CI) calculated using a Taylor series approximation for 
the standard error and P values from unpaired t-tests. Where 
the distribution of cluster proportions was skewed, the log-clus-
ter proportions were compared and the results were back-trans-
formed. A 2-stage approach was used for adjusted analyses [23] 
(Supplementary Methods).
For continuous outcomes, intervention effects were quan-
tified as the differences in mean outcome between trial arms, 
with 95% CIs calculated using the t-distribution. Non–normally 
distributed continuous outcomes were log-transformed and the 
results were back-transformed to obtain geometric mean ratios. 
For ordered categorical outcomes, a proportional-odds model 
was used.
Trial analyses were conducted in 2 populations: the primary 
analysis population (intention-to-treat population) included all 
individuals. The secondary analysis population comprised all 
individuals who had lived in their village throughout (or were 
born into their village during) the intervention period (per-pro-
tocol analysis).
Using a cluster-level approach [24], we conducted post hoc 
subgroup analyses by age group (<4 years, ≥4 years) for the pri-
mary outcomes to assess whether intervention effects differed 
among those exposed to differential anthelminthic interven-
tions from birth.
Ethics Statement
Ethical approval was given by the Uganda Virus Research 
Institute (GC127), Uganda National Council for Science and 
Technology (HS 1183), and London School of Hygiene and 
Tropical Medicine (6187).
RESULTS
Participants and Intervention Uptake
Characteristics assessed in the baseline survey (October 2012–
July 2013) were balanced between trial arms, with the excep-
tion that, compared to villages in the intensive arm (intensive 
villages), villages in the standard arm (standard villages) had 
fewer public toilets but contained more households with private 
toilets [17].
Figure 1 summarizes the treatment uptake. Both the prazi-
quantel and albendazole uptake increased during the trial. The 
mean uptake per round was 63% for praziquantel and 64% 
for albendazole (intensive villages), compared to 56% and 
73% (standard villages). In standard villages, the albendazole 
uptake was lower in the treatment rounds where praziquantel 
treatment was also given. Reported receipt of ≥1 dose of prazi-
quantel in the preceding year was higher in intensive, compared 
to standard, villages (93% versus 75%, respectively). Reported 
receipt of ≥1 dose of albendazole was universally high (99% ver-
sus 98%, respectively).
Between September 2015 and August 2016, 70 households 
from each village were randomly selected for the outcome 
survey (Figure  2): 84 (5%) households refused to participate, 
17 (1%) consented but no demographic data were captured, 
and 300 (17%) had no members that could be contacted. The 
remaining 1419 participating households contained 3566 res-
idents aged ≥1 year. Overall, 3350 (94%) household members 
provided data for at least 1 primary outcome (recent wheezing 
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3323 [99%], SPT 3037 [91%], IgE 2955 [88%]), with numbers 
balanced between trial arms (Figure 2). Further details of par-
ticipant characteristics are provided (Supplementary Material).
Outcome survey participant characteristics were comparable 
between trial arms (Table 1). Only 8 villages had access to any 
non-lake water supply, with public toilets available in 11 villages 
and private toilet access limited. The participant median age was 
24  years (interquartile range 8–34) and 52% were male. Most 
participants (71%) had lived in their village throughout the trial. 
Migration between trial arms was low (1.5%). The adult human 
immunodeficiency virus prevalence was 22% and the reported 
maternal history of allergy, eczema, or asthma was 16%.
Impact of Intensive Versus Standard Anthelminthic Treatment on Primary 
Outcomes
The prevalence of reported wheezing among ≥5-year-olds was 
3%, with little difference between trial arms (Table  2). There 
were 9 individuals <5 years old who reported wheezing; no for-
mal analysis was done for this outcome. Regarding atopy, 19% 
participants had a positive SPT to ≥1 allergen. Of those tested 
using ImmunoCAP, 54% were positive (IgE  >  0.35kUa/L) 
for either cockroach or dust mite allergens. Enzyme-linked 
immunosorbent assay (ELISA) and ImmunoCAP results were 
positively correlated for both dust mites and cockroaches 
(Spearman’s correlation coefficient 0.32 and 0.29, respectively). 
There was no effect of intensive versus standard treatment on 
atopy (by SPT or IgE; Table 2). For all primary outcomes, there 
remained little evidence of a difference between trial arms in 
the per-protocol analysis (Supplementary Table  1) or among 
age groups (Supplementary Table  2), although RRs for SPT 
responses to individual allergens increased in both the per-pro-
tocol analysis and in children <4 years old.
Impact of Intensive Versus Standard Anthelminthic Treatment on 
Secondary and Exploratory Outcomes
The Schistosoma mansoni infection prevalence was lower in 
the intensive-treatment villages when assessed by stool Kato 
Figure 2. Trial flowchart. Abbreviations: ELISA, enzyme-linked immunosorbent assay; IgE, immunoglobulin E; SPT, skin prick test positivity.
Figure  1. Praziquantel and albendazole treatment coverage, by trial arm and 
treatment round.
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Table 1. Characteristics of Outcome Survey Participants
Cluster-level Characteristics
Standard Arm Intensive Arm
 (n = 13)  (n = 13)
Mean no. of households per village (range) 307 (124–882) 289 (87–544)
Mean no. of participating households (range) 55 (48–63) 54 (48–64)
Mean no. of individuals resident in participating households (range) 137 (89–161) 137  (85–177)
Mean no. of individuals included in analysis (range) 129 (84–150) 129 (79–169)
Villages with any public toilets 5 38% 6 46%
Median no. of public toilets (range) 0 (0–16) 0 (0–20)
Median no. of private toilets (range) 8 (0–59) 3  (1–29)
Water supply other than lake 3 23% 5 38%
 Piped water 2 67% 2 40%
 River or open spring 1 33% 2 40%
 Open well 0 0% 1 20%
Household-level characteristics (n = 714) (n = 705)
Median no. of household members (IQR) 2 (1–3) 2 (1–3)
Individual-level characteristics (n = 1675) (n = 1675)
Sex, male 881 53% 857 51%
Age in years, grouped
 0–4 283 17% 264 16%
 5–9 173 10% 219 13%
 10–14 66 4% 115 7%
 15–19 102 6% 79 5%
 20–24 212 13% 179 11%
 25–29 239 14% 216 13%
 30–34 198 12% 211 13%
 35–39 175 10% 140 8%
 40–44 86 5% 106 6%
 45+ 141 8% 146 9%
Place of birth (mv 9, 19)
 This fishing village 439 26% 477 29%
 Other fishing village 48 3% 20 1%
 Other rural village 1021 61% 1002 61%
 Town 127 8% 127 8%
 City 31 2% 30 2%
Has remained in village during intervention period (mv 9, 19) 1190 71% 1170 71%
Has lived in other trial arm during intervention period (mv 9, 19) 18 1% 32 2%
Maternal history of allergic diseases (mv 9, 19)
 No history 1193 72% 1204 73%
 History of asthma, eczema or allergies 258 15% 266 16%
 Don’t know 215 13% 186 11%
Paternal history of allergic diseases (mv 9, 19)
 No history 1248 75% 1244 75%
 History of asthma, eczema or allergies 145 9% 155 9%
 Don’t know 273 16% 257 16%
Occupation, grouped by type (mv 8, 19)
 Child, not at school 289 17% 275 17%
 Student 257 15% 345 21%
 Housewife 120 7% 101 6%
 Fishing or lake related 564 34% 467 28%
 Shops, saloons, artisans, service providers 118 7% 102 6%
 Bars, restaurants, food providers, entertainment 114 7% 103 6%
 Agricultural, lumbering, charcoal 157 9% 201 12%
 Professional 11 1% 19 1%
 Unemployed 37 2% 43 3%
Treated with albendazole in the last 12 months (mv 360, 253) 1291 98% 1404 99%
Treated with praziquantel in the last 12 months (mv 355, 253) 989 75% 1318 93%
Malaria treatment with coartem (mv 190, 167) 708 42% 747 45%
Malaria positivity by blood smear (Plasmodium falciparum; mv 213, 214) 50 3% 52 4%
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Katz (23% versus 39%, respectively; adjusted RR 0.70, 95% CI 
0.55–0.88; Table 3) and stool polymerase chain reactions (39% 
versus 60%, respectively; adjusted RR 0.76, 95% CI 0.65–0.88), 
but urine circulating cathodic antigen positivity remained high 
and similar across trial arms (both 85%; Table 3), indicating that 
the intensive treatment was more effective than the standard 
treatment in reducing heavy-intensity Schistosoma infections, 
particularly in younger age groups, but had little impact on 
the light-infection prevalence (Figure  3). The incidence of 
Schistosoma infections was lower in both trial arms, compared 
to baseline, with 49% and 23% pre- and post-intervention in the 
intensive arm, respectively, and 56% and 39% in the standard 
arm, respectively. Our interim survey data suggested a greater 
initial reduction in intensive villages, which then plateaued, and 
Table 2. Impact of Intensive Versus Standard Anthelminthic Treatment on Primary Outcomes
Outcome
n/N (%)/Geometric Mean Unadjusted
Adjusted for Outcome at 
Baseline by Age and Sexa
Standard Intensive
RR/GMR
(95% CI) P Value
RR/GMR
(95% CI) P Value
 Wheeze (age ≥5 years)b 44/1384 (3.2%) 43/1392 (3.1%) 1.06 (0.61–1.87) .82 1.11 (0.64–1.93) .69
 Wheeze (age <5 years) 6/284 (2.1%) 3/264 (1.1%)
Atopy (SPT)
 SPT positivity to any allergen 273/1514 (18.0%) 303/1523 (19.9%) 1.09 (0.83–1.44) .51 1.10 (0.85–1.42) .46
 SPT positivity to Dermatophagoides 162/1514 (10.7%) 164/1523 (10.8%) 0.98 (0.72–1.35) .92 1.00 (0.74–1.36) .99
 SPT positivity to Blomia tropicalis 102/1514 (6.7%) 127/1522 (8.3%) 1.26 (0.83–1.90) .26 1.27 (0.85–1.91) .22
 SPT positivity to German cockroach 156/1513 (10.3%) 194/1522 (12.8%) 1.24 (0.87–1.77) .20 1.22 (0.87–1.71) .21
Atopy (IgE detected by ImmunoCAP)
 Dermatophagoides or cockroach  
positivity (>0.35 kUa/L)
214/390 (54.9%) 210/390 (53.9%) 0.97 (0.83–1.13) .67 0.96 (0.82–1.12) .60
 Dermatophagoides positivity (asIgE > 0.35 kUa/L) 134/390 (34.4%) 130/390 (33.3%) 0.95 (0.76–1.20) .67 0.96 (0.77–1.19) .68
 German cockroach positivity (asIgE > 0.35 kUa/L) 201/390 (51.5%) 192/390 (49.2%) 0.94 (0.80–1.11) .47 0.94 (0.79–1.11) .42
 Concentration of asIgE to Dermatophagoides (kUa/L)c GM: 0.158 GM: 0.129 0.78 (0.51–1.17) .22 0.77 (0.52–1.13) .17
 Concentration of asIgE to German cockroach (kUa/L)c GM: 0.342 GM: 0.289 0.82 (0.55–1.22) .31 0.81 (0.55–1.20) .28
Atopy (IgE detected by in house ELISA)
 Concentration of asIgE to Dermatophagoidesd GM: 60.3 GM: 73.8 1.13 (0.36–3.50) .83 1.17 (0.39–3.51) .78
 Concentration of asIgE to German cockroachd GM: 72.4 GM: 161.0 1.98 (0.59–6.63) .25 1.51 (0.45–5.04) .49
Abbreviations: asIgE, allergen-specific IgE; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GM, geometric mean; GMR, geometric mean ratio; IgE, immunoglobulin 
E; RR, risk ratio; SPT, skin prick test positivity.
aAtopy outcomes assessed by IgE were adjusted for age and sex only.
bFor this outcome, a natural log transformation was applied to village-level proportions to correct skewed distributions, and the data in parentheses are the geometric means of village 
proportions. 
cLog10(+0.001) transformation at the individual level.
dLog10(+1) transformation at the individual level. 
Cluster-level Characteristics
Standard Arm Intensive Arm
 (n = 13)  (n = 13)
Individuals aged 13 years and over (n = 1176) (n = 1112)
Frequency of lake contact (mv 9, 19)
 Every day 911 78% 776 71%
 Almost every day 126 11% 147 13%
 Once a week 95 8% 124 11%
 Once a month 30 3% 35 3%
 Less than once a month 4 0% 10 1%
 Never 1 0% 1 0%
Individuals aged 18 years and over (n = 1116) (n = 1041)
HIV+ (mv 173, 176) 192 20% 198 23%
 HIV+ on ART 90 47% 103 52%
 HIV+ not on ART 93 48% 90 45%
 HIV+ not known if receiving ART 9 5% 5 3%
Numbers for mvs are in the standard and intensive arms, respectively.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; mv, missing values; no., number.
Table 1. Continued
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a gradual reduction in standard villages (Figure  3). The STH 
prevalence was relatively low. The intensive treatment reduced 
hookworm prevalence; no significant reductions were seen for 
other nematodes (among all participants; Table 3). There was 
no impact of the intensive versus standard treatment on anthro-
pometric or clinical outcomes, including hepatosplenomegaly, 
Table  3. Impact of Intensive Versus Standard Anthelminthic Treatment on Helminths, Clinical Outcomes, Hepatosplenomegaly by Palpation, and 
Anthropometry
Outcome
n/N (%)/Arithmetic Mean Unadjusted
Adjusted for Outcome at 
Baseline by Age and Sex
Standard Intensive
RR/Mean Difference 
(95% CI) P Value
RR/Mean Difference 
(95% CI) P Value
Helminth infections
 Schistosoma mansoni, stool Kato Katz 523/1355 (38.6%) 323/1396 (23.1%) 0.64 (0.43–0.94) .02 0.70 (0.55–0.88) .003
 Schistosoma mansoni, stool PCR 797/1353 (59.9%) 541/1394 (38.8%) 0.68 (0.52–0.89) .007 0.76 (0.65–0.88) .001
 Schistosoma mansoni, urine CCA 1229/1444 (85.1%) 1216/1435 (84.7%) 0.99 (0.91–1.08) .85 1.00 (0.93–1.08) .93
 Hookworm, stool PCRa 147/1353 (10.9%) 112/1394 (8.0%) 0.54 (0.28–1.02) .06 0.55 (0.31–1.00) .05
 Strongyloides stercoralis, stool PCR 112/1353 (8.3%) 78/1394 (5.6%) 0.74 (0.50–1.11) .14 0.78 (0.54–1.14) .21
 Trichuris trichiura, stool Kato Katza 137/1355 (10.1%) 108/1396 (7.7%) 0.91 (0.40–2.09) .82 0.85 (0.48–1.50) .55
 Ascaris lumbricoides, stool Kato Katz 11/1355 (0.8%) 3/1396 (0.2%)
Clinical outcomes
 Visible flexural dermatitis 1/1558 (0.1%) 4/1553 (0.3%)
 Haemoglobin 14.0 13.9 -0.06 (-0.37–0.25) .70 0.00 (-0.24–0.25) .97
Anthropometry
 Height-for-age z-score, age 1–19 years -0.48 -0.49 -0.01 (-0.20–0.19) .95 0.02 (-0.16–0.20) .83
 Weight-for-age z-score, age 1–10 years -0.06 -0.17 -0.11 (-0.31–0.09) .27 -0.05 (-0.23–0.12) .52
 Weight-for-height z-score, age 1–5 years 0.15 0.19 -0.09 (-0.43–0.26) .62 -0.06 (-0.40–0.28) .72
Hepatosplenomegaly, palpation
 Hepatomegaly, palpation 100/1546 (6.5%) 98/1546 (6.3%) 0.97 (0.71–1.32) .83 0.96 (0.70–1.32) .80
 Splenomegaly, palpation 87/1549 (5.6%) 63/1547 (4.1%) 0.73 (0.43–1.25) .20 0.70 (0.43–1.15) .13
 Hepatosplenomegaly, palpationa 22/1548 (1.4%) 14/1548 (0.9%) 0.85 (0.52–1.39) .49 0.78 (0.47–1.30) .33
Reported clinical outcomes (exploratory)
 Urticaria, last 12 months 162/1667 (9.7%) 172/1656 (10.4%) 1.06 (0.86–1.30) .59 1.06 (0.88–1.27) .51
 Rhinitis, last 12 months 78/1667 (4.7%) 74/1656 (4.5%) 1.02 (0.73–1.42) .92 1.00 (0.74–1.36) .99
Abbreviations: CCA, circulating cathodic antigen; CI, confidence interval; PCR, polymerase chain reaction; RR, risk ratio.
aFor this outcome, a natural log transformation was applied to village-level proportions to correct skewed distributions.
Figure 3. (A) Intensity of schistosomiasis infection in the outcome survey, by age group and trial arm, with prevalence assessed by KK examination of a single stool sample, 
PCR, and urine CCA. (B) Prevalence of Schistosoma mansoni infection over time (pre-intervention baseline survey, interim survey at 1 year, interim survey at 2 years, outcome 
survey at 3 years), by trial arm. Data are shown as the mean of village prevalences over time +/- 95% confidence intervals, assessed using KK analysis of a single stool sample 
(with duplicate slides) at each time point. Abbreviations: CCA, circulating cathodic antigen; KK, Kato Katz; PCR, polymerase chain reaction.
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assessed either by  palpation (Table  3) or ultrasound (among 
children; Supplementary Table  3). The per-protocol analysis 
did not yield any hitherto-unseen differences (Supplementary 
Table 4).
Serious Adverse Events
In total, 77 739 praziquantel treatments and 102 219 albenda-
zole treatments were given. There were 4 serious adverse events 
reported (2 in each trial arm), all among adults and within 
2 days of treatment: gastrointestinal symptoms leading to hos-
pitalization (1) or requiring intravenous fluids (1); abdominal 
pain and vaginal bleeding in a non-pregnant woman (1); and 
vaginal bleeding 1  day after treatment in a pregnant woman, 
followed by delivery 3  days later (probably premature) and 
subsequent neonatal death (1). Clinic records suggested that 
this last woman had concurrent malaria, but this remained 
unconfirmed.
DISCUSSION
We report the first trial to address the community-level effects 
of intensive anthelminthic MDA in a high–Schistosoma man-
soni–transmission setting. After 3  years, we found no effect 
of an intensive, compared to standard, intervention on aller-
gy-related or helminth-associated disease outcomes. Intensive, 
compared to standard, treatment with praziquantel achieved a 
substantial reduction in S. mansoni intensity, most marked after 
1 year, but infection remained almost universal. Intensive, com-
pared to standard, treatment with albendazole achieved a mod-
est reduction in hookworm prevalence, but had little impact on 
Trichuris or Strongyloides.
The prevalence of wheezing was lower than anticipated based 
on previous reports [25], limiting power for this outcome. 
However, the understanding of “wheeze” in our study commu-
nities was poor: there are no words for wheeze or asthma in 
the vernacular and asthma is rare. That said, there was no effect 
of the intensive intervention on wheezing, and no increase in 
wheezing during the intervention (5% at baseline [13], 3% after 
3  years). These results provide reassurance that anthelmin-
thic MDA is unlikely to have an immediate adverse effect on 
asthma among high-schistosomiasis-transmission communi-
ties, although no conclusions can be drawn on the impact of 
effective, universal S. mansoni removal.
SPT positivity was common. There was no increase in SPT 
positivity during the intervention (19% at baseline [13], 18% 
and 20% in the standard and intensive arms, respectively, after 
3 years). There was a suggestion, especially in the per-protocol 
analysis and in under–4 year olds, that SPT responses increased 
with intensive treatment. This could be a chance finding, since a 
substantial number of (planned) statistical tests were conducted. 
This warrants more detailed investigation, as it may presage the 
emergence of increased atopy and ARD when helminth infec-
tions are more completely cleared. The effect of treatment may 
have differed based on pre-treatment infection intensity [26]. 
We could not assess this hypothesis, because our study was not 
a cohort of individual subjects.
Despite our emphasis on schistosomiasis and on long-term, 
community-based intervention, our results accord with pre-
vious, shorter-term trials focussing on STH [10]. However, it 
seems premature to conclude that high helminth prevalence has 
no causal link with the low ARD prevalence in LICs, given the 
strong effects and demonstrated mechanisms in animal models 
and experiments using human samples in vitro [27].
The most obvious explanation for a lack of impact on 
allergy-related (or helminth-associated) diseases is a failure 
to clear helminth infections. All villages were continuously 
exposed to S. mansoni–infested lake water because of a lack 
of alternative safe water, an involvement in fishing, and 
open defecation due to a scarcity of latrines. Although sin-
gle- and first-dose treatments were directly observed, com-
pliance was imperfect; albendazole uptake in the standard 
arm was lower in the rounds where praziquantel was given, 
indicating that villagers were averse to the praziquantel side 
effects. Furthermore, we cannot rule out the possible role 
of reduced drug efficacy [28, 29]. However, as a differen-
tial effect on helminth intensity was achieved, particularly 
for schistosomiasis, our results cast doubt on the extent to 
which intensity reduction (without elimination) substan-
tially modifies the overall immunological or pathological 
effects in high-schistosomiasis-transmission settings.
Other factors contributing to the lack of impact on aller-
gy-related outcomes may include the long-term immunological 
effects of helminth exposure through a persistence of antigen or 
through epigenetic changes in immunological pathways [30]. 
Also, in tropical, low-income settings, numerous other expo-
sures—including immunomodulating infections such as malaria, 
exposure to dirt and domestic animals, or the microbiome pro-
file—may impact allergy-related outcomes, such that modifying 
helminth exposure alone may have a limited impact [31].
A recent meta-analysis examined the effects of schistosomi-
asis treatments on related morbidity [32]. The results indicated 
wide-ranging benefits, with an increased impact when egg 
reduction rates were greatest and, for anemia and chronic mor-
bidities, when treatments were repeated over periods of greater 
than 24  months. Thus, we were disappointed that, despite 
a differential reduction in schistosome intensity, we found 
no evidence that 3  years of intensive (compared to standard) 
intervention achieved improvement in any morbidity measure. 
This adds to the evidence base showing the limited effects of 
MDA on such outcomes at the community-level. We identified 
surprisingly little severe Schistosoma-related morbidity in this 
community, despite intense infections, consistent with earlier 
work from Lake Victoria communities; it is possible that inten-
sive interventions would have a greater benefit in settings (such 
as Lake Albert) where severe pathology is more common [33].
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Our experience emphasizes that MDA may struggle to 
eliminate helminths as a public health problem, especially in 
high-transmission environments. The substantial decline in 
S. mansoni infections (as measured by Kato Katz) achieved in 
year 1 led us to hope that intensive intervention could make 
an important contribution to schistosomiasis control in these 
challenging hot spots. The subsequent plateau and persistent 
infection (as measured by by circulating cathodic antigen) were 
disheartening. This phenomenon (a large drop in prevalence, 
followed by a subsequent plateau) has also been reported in 
Kenyan districts bordering Lake Victoria [34]. Besides reinfec-
tion, the possibility of selection for praziquantel-resistant or -tol-
erant strains is of concern [35]. A radically different approach is 
needed, with complementary interventions, including improved 
water supplies and sanitation, behavior changes, and vector con-
trols, as well as an effective vaccine against schistosomiasis [36].
Observational analyses addressing the effects of helminths 
remain limited by confounding by poverty and environment. 
Our strategy aimed to pinpoint helminth effects by random-
izing their treatment, but was constrained by difficulties in 
achieving removal. Trials designed so that helminths are cleared 
in settings where reinfection can be avoided, and with substan-
tial follow-up, are needed for a full understanding of the risks 
and benefits of deworming.
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9.5 Supplementary information for Research paper 7 (also available in this 
article’s online repository at https://doi.org/10.1093/cid/ciy761) 
 
9.5.1 Supplementary Methods 
9.5.1.1 Outcome assessment 
Recent wheeze was assessed by ISAAC (International Study of Asthma and Allergies in 
Childhood)1 questionnaire. Visible flexural dermatitis was assessed by using interview 
questions adopted from the UK diagnostic criteria on atopic eczema and by direct 
physical examination. Staff were trained in diagnosis of visible flexural dermatitis using 
the on-line tool by Williams.2 Pictures of lesions were taken for a second opinion. SPT 
reactivity to allergens (ALK-Abelló, supplied by Laboratory Specialities (Pty) Ltd, South 
Africa) was assessed using standard methods. SPT outcomes were examined as any 
positive response versus none and as positive versus negative for individual allergens. 
Ultrasonography was performed using a portable machine (Aloka SSD-900, 3.5 mH 
curvilinear probe, Hitachi Aloka Medical, Japan) using the Niamey protocol.3   
Total IgE and asIgE (D. pteronyssinus- and B. germanica-specific) were measured by 
ImmunoCAP® (Phadia AB, Sweden) in a random sample of 780 participants (30 per 
village; selected from those with SPT data and adequate sample volume) and all 
participants by in-house ELISA.4 ImmunoCAP outcomes were examined as any positive 
response versus none (using the standard cutoff of 0.35kUa/L), as positive versus 
negative for individual allergens, and as continuous variables. 
Intestinal helminth infection was investigated by the Kato-Katz method (two slides per 
sample, read by different technicians)5 and by stool PCR for S. mansoni, Strongyloides 
stercoralis and Necator americanus.6 Urine was assessed for circulating cathodic 
antigen (CCA, Rapid Medical Diagnostics, South Africa) of S. mansoni. S. haematobium 
is not present in the study area.7 Mansonella perstans was determined by the modified 
Knott’s method,8 malaria by thick film. Voluntary HIV counselling and testing was offered 
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to all participants. Haemoglobin was determined by HemoCue® (HemoCue AB, 
Angelholm, Sweden).  
9.5.1.2 Randomisation: further details 
A computer-based system was used to generate all possible allocations for assigning 13 
villages to each arm of the trial, satisfying restriction criteria. A list of 1000 of these 
possible allocations, selected at random from the full list, was provided for the 
randomisation ceremony.  One of these was selected by village leaders using numbered 
balls drawn from an opaque bag (ten balls, numbered 0 to 9, selected separately for 
each digit). 
9.5.1.3 Sample size justification 
For the final survey, we planned to sample 1540 individuals per arm. Based on baseline 
survey data,9 estimates for primary outcome prevalence in the standard arm were recent 
wheeze over the age of five years 5%, SPT positivity 20% and detectable asIgE 40%.  
Assuming a conservative coefficient of variation (k) of 0.3, a sample size of 1540 
individuals per arm would give over 80% power to detect (at 5% significance level) a 1.5-
fold difference for SPT positivity and detectable asIgE and a 1.8-fold difference for 
wheeze. From the baseline survey, we calculated that randomly selecting 70 households 
per village would yield the planned sample size (allowing for absenteeism). 
9.5.1.4 Approach for adjusted analysis of trial outcomes 
Adjusted analysis was done using a two-stage approach as described by Hayes and 
Moulton. For binary outcomes, in the first stage logistic regression of individual-level 
outcomes was done, including covariates to be adjusted for (but not trial arm allocation) 
and from this risk ratio-residuals (the ratio between observed and predicted prevalence 
for each cluster) were calculated. In the second stage, these risk ratio-residuals were 
used as the data points for the cluster-level analysis, using the same methods as 
described above for the unadjusted analysis. For continuous outcomes, For the two-
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stage adjusted analysis, linear regression was used in the first stage and mean 
difference-residuals were data points for the second stage. 
9.5.2 Supplementary Results 
9.5.2.1 Comparison of characteristics of survey participants and non-participants 
There were 3566 household members aged one year or above, resident in the 1419 
participating households. Of these males were less likely to participate in the 
questionnaire than females (90% versus 97%), or to give blood (80% versus 87%), stool 
(75% versus 81%), urine (79% versus 84%) samples or undergo SPT examination (82% 
versus 89%) (all p<0.001). In both arms low numbers of school-aged children were 
surveyed because of absence, on the mainland, for schooling. Of those surveyed, 
working age (15-45 years) and pre-school aged (under 5 years) members were less likely 
to provide samples or undergo SPT (p<0.001) than other age groups (working age 81%, 
74% and 82% for blood, stool and SPT, respectively; pre-school age 74%, 78% and 
87%, respectively; other age groups 89%, 86% and 92%, respectively). Younger age 
groups were under-represented in the subgroup for whom ImmunoCAP assays were 
done (162 (12%) of <20 year olds versus 618 (28%) of ≥20 year olds, p<0.001), due to 
lower amounts of available plasma. 
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Supplementary Figure. Trial treatment and survey timeline 
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Supplementary Table 1. Impact of intensive versus standard anthelminthic treatment on primary outcomes, restricting to those who 
had lived in their village throughout (or been born into their village during) the three-year intervention period (“per protocol” 
analysis) 
1For this outcome, a natural log transformation was applied to village level proportions to correct skewed distributions; 2 log10(+0.001) transformation at 
individual level; 3 log10(+1) transformation at individual level; 4log10(+1) transformation at individual level; 5Atopy outcomes assessed by IgE were adjusted 
for age and sex only; RR: risk ratio; GM: geometric mean; GMR: geometric mean ratio; CI: confidence interval  
  
n/N (%) / geometric mean  Unadjusted  Adjusted for outcome at baseline, age and sex5 
Outcome Standard Intensive 
 RR/GMR 
(95% CI) p-value 
 RR/GMR 
(95% CI) p-value 
 Wheeze (age≥5 years)1 29/956 (3.0%) 36/960 (3.8%)  1.23 (0.75, 2.02) 0.40  1.14 (0.66, 1.95) 0.63 
 Wheeze (age<5 years) 6/234 (2.6%) 3/210 (1.4%)       
Atopy (SPT)          
 SPT positivity to any allergen  194/1065 (18.2%) 220/1063 (20.7%)  1.15 (0.84, 1.57) 0.37  1.15 (0.86, 1.55) 0.33 
 SPT positivity to Dermatophagoides 114/1065 (10.7%) 126/1063 (11.9%)  1.10 (0.76, 1.59) 0.59  1.13 (0.80, 1.61) 0.47 
 SPT positivity to Blomia tropicalis 71/1065 (6.7%) 97/1062 (9.1%)  1.41 (0.88, 2.24) 0.14  1.44 (0.91, 2.26) 0.11 
 SPT positivity to German cockroach 106/1064 (10.0%) 144/1062 (13.6%)  1.41 (0.95, 2.07) 0.07  1.38 (0.94, 2.02) 0.08 
Atopy (IgE detected by ImmunoCAP)          
 Dermatophagoides or cockroach positivity (>0.35kUa/L) 157/280 (56.1%) 146/259 (56.4%)  1.00 (0.80, 1.24) 0.97  0.99 (0.79, 1.24) 0.95 
 Dermatophagoides positivity (asIgE>0.35kUa/L) 105/280 (37.5%) 94/259 (36.3%)  0.95 (0.75, 1.20) 0.64  0.95 (0.75, 1.20) 0.63 
 German cockroach positivity (asIgE>0.35kUa/L) 148/280 (52.9%) 131/259 (50.6%)  0.95 (0.74, 1.21) 0.63  0.95 (0.74, 1.21) 0.66 
 Concentration of asIgE to Dermatophagoides (kUa/L)2 GM: 0.170 GM: 0.149  0.84 (0.51, 1.37) 0.46  0.84 (0.52, 1.37) 0.47 
 Concentration of asIgE to German cockroach (kUa/L)2 GM: 0.336 GM: 0.297  0.84 (0.53, 1.34) 0.45  0.86 (0.54, 1.35) 0.49 
Atopy (IgE detected by in house ELISA)         
 Concentration of asIgE to Dermatophagoides4 GM: 59.9 GM: 74.1  1.10 (0.33, 3.67) 0.87  1.18 (0.37, 3.76) 0.77 
  Concentration of asIgE to German cockroach4 GM: 56.9 GM: 155  2.05 (0.59, 7.17) 0.25  1.63 (0.47, 5.72) 0.43 
343
	 
Supplementary Table 2. Impact of intensive versus standard anthelminthic treatment on primary outcomes, stratified by age group 
(<4 years, ≥4 years) 
 
 
  
  <4 years 
 ≥4 years   
Outcome RR/GMR (95% CI) p-value 
 RR/GMR (95% CI) p-value  Interaction p-value 
Atopy (SPT)  (n=382)   (n=2655)    
 SPT positivity to any allergen  1.63 (0.68, 3.91) 0.23  1.07 (0.81, 1.41) 0.63  0.57 
 SPT positivity to Dermatophagoides 1.49 (0.41, 5.34) 0.51  0.97 (0.71, 1.33)  0.84  0.48 
 SPT positivity to Blomia tropicalis 1.44 (0.48, 4.27) 0.50  1.26 (0.82, 1.94) 0.28  0.83 
 SPT positivity to German cockroach 2.12 (0.37, 12.32) 0.35  1.22 (0.86, 1.73) 0.24  0.79 
Atopy (IgE detected by ImmunoCAP)  (n=44)   (n=736)    
 Dermatophagoides or cockroach positivity (>0.35kUa/L) 1.38 (0.26, 7.34) 0.72  0.96 (0.84, 1.11) 0.60  0.69 
 Dermatophagoides positivity (asIgE>0.35kUa/L) 0.55 (0.05, 6.73) 0.61  0.95 (0.76, 1.19) 0.65  0.88 
 German cockroach positivity (asIgE>0.35kUa/L) 2.41 (0.37, 15.71) 0.41  0.93 (0.80, 1.10) 0.39  0.39 
 Concentration of asIgE to Dermatophagoides (kUa/L) 0.43 (0.10, 1.80) 0.24  0.77 (0.50, 1.17) 0.21  0.43 
 Concentration of asIgE to German cockroach (kUa/L) 0.95 (0.27, 3.30) 0.93  0.80 (0.55, 1.16) 0.22  0.91 
Atopy (IgE detected by in house ELISA) (n=309)   (n=2646)    
 Concentration of asIgE to Dermatophagoides 0.94 (0.18, 4.98) 0.94  1.17 (0.38, 3.58) 0.78  0.70 
  Concentration of asIgE to German cockroach 1.77 (0.36, 8.69) 0.46  2.03 (0.63, 6.53) 0.23  0.69 
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Supplementary Table 3. Impact of intensive versus standard anthelminthic treatment on schistosomiasis-related liver and spleen 
morbidity assessed by ultrasonography, in children<18 years 
 n (%)  Unadjusted  Adjusted for age and sex 
Outcome Standard (n=414) Intensive (n=488)  OR (95% CI) p-value  OR (95% CI) p-value 
Liver size left lobe1         
Normal 171 (41.3%) 212 (43.4%)       
Enlarged 212 (51.2%) 229 (46.9%)       
Much enlarged 31 (7.5%) 47 (9.6%)  0.97 (0.58, 1.61) 0.90  1.05 (0.63, 1.72) 0.86 
Spleen size1         
Normal 248 (59.9%) 302 (61.9%)       
Moderate splenomegaly 135 (32.6%) 142 (29.1%)       
Marked splenomegaly 31 (7.5%) 44 (9.0%)  0.87 (0.40, 1.89) 0.71  0.86 (0.40, 1.86) 0.69 
Portal vein score2         
Normal 319 (77.1%) 383 (78.5%)       
Dilation 94 (22.7%) 103 (21.1%)       
Marked dilation 1 (0.2%) 2 (0.4%)  0.70 (0.40, 1.24) 0.23  0.84 (0.50, 1.42) 0.51 
Degree of hepatic fibrosis3         
Normal 386 (93.7%) 445 (91.4%)       
Peri-portal fibrosis 26 (6.3%) 42 (8.6%)  1.52 (0.75, 3.07) 0.26  1.45 (0.72, 2.94) 0.31 
Measurements from ultrasonography were classified according to the Niamey protocol, taking height into account; 1For liver size left lobe and spleen size, 
ORs were calculated using a proportional odds model; 2Portal vein score was analysed as a binary variable, combining dilated and marked dilated categories; 
3Degree of hepatic fibrosis was classified as normal (Niamey protocol image pattern A) or peri-portal fibrosis (Niamey protocol image patterns B-F) and 
analysed as a binary variable, degree of hepatic fibrosis missing for 2 children in standard arm, 1 child in intensive arm 
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Supplementary Table 4. Impact of intensive versus standard anthelminthic treatment on helminths, clinical outcomes, hepatosplenomegaly 
by palpation, and anthropometry, restricting to those who had lived in their village throughout (or been born into their village during) the 
three-year intervention period (“per protocol” analysis) 
 n/N (%) / arithmetic mean 
 Unadjusted  Adjusted for baseline value, age and sex 
Outcome 
Standard Intensive  
RR/mean 
difference (95% 
CI) 
p-value  RR/mean difference (95% CI) p-value 
Helminth infections         
 Schistosoma mansoni, stool Kato Katz 373/965 (38.7%) 225/989 (22.8%) 
 0.62 (0.41, 0.94) 0.02  0.69 (0.53, 0.90) 0.005 
 Schistosoma mansoni, stool PCR 576/964 (59.8%) 367/987 (37.2%)  0.65 (0.48, 0.88) 0.006  0.73 (0.62, 0.87) 0.001 
 Schistosoma mansoni, urine CCA 872/1015 (85.9%) 838/1002 (83.6%) 
 0.98 (0.90, 1.07) 0.61  0.99 (0.92, 1.07) 0.81 
 Hookworm, stool PCR
1 84/964 (8.7%) 62/987 (6.3%)  0.56 (0.27, 1.19) 0.12  0.58 (0.29, 1.13) 0.10 
 Strongyloides stercoralis, stool PCR 84/964 (8.7%) 51/987 (5.2%) 
 0.63 (0.40, 0.99) 0.04  0.68 (0.44, 1.04) 0.07 
 Trichuris trichiura, stool Kato Katz
1 100/965 (10.4%) 79/989 (8.0%)  0.84 (0.38, 1.84) 0.64  0.77 (0.48, 1.23) 0.26 
 Ascaris lumbricoides, stool Kato Katz 8/965 (0.8%) 3/989 (0.3%) 
      
Clinical outcomes         
 Visible flexural dermatitis 1/1099 (0.1%) 1/1085 (0.1%) 
      
 Haemoglobin 14.0 13.9 
 -0.12 (-0.47, 0.22) 0.48  -0.01 (-0.25, 0.24) 0.96 
Anthropometry         
 Height-for-age z-score, age 1-19 years -0.39 -0.42 
 0.05 (-0.21, 0.30) 0.71  0.09 (-0.16, 0.34) 0.45 
 Weight-for-age z-score, age 1-10 years -0.09 -0.13 
 -0.08 (-0.31, 0.16) 0.51  -0.05 (-0.23, 0.12) 0.52 
 Weight-for-height z-score, age 1-5 years 0.12 0.16  -0.08 (-0.47, 0.30) 0.65  -0.06 (-0.44, 0.31) 0.73 
Hepatosplenomegaly, palpation         
 Hepatomegaly, palpation 84/1088 (7.7%) 78/1080 (7.2%) 
 0.93 (0.65, 1.33) 0.69  0.93 (0.64, 1.35) 0.68 
 Splenomegaly, palpation 59/1090 (5.4%) 40/1081 (3.7%) 
 0.72 (0.40, 1.31) 0.22  0.72 (0.40, 1.30) 0.22 
 Hepatosplenomegaly, palpation
1 14/1089 (1.3%) 8/1082 (0.7%)       
Reported clinical outcomes (exploratory)         
 Urticaria, last 12 months 108/1190 (9.1%) 127/1170 (10.9%) 
 1.20 (0.91, 1.58) 0.19  1.20 (0.94, 1.53) 0.13 
 Rhinitis, last 12 months 58/1190 (4.9%) 47/1170 (4.0%) 
 0.89 (0.60, 1.32) 0.56  0.87 (0.58, 1.31) 0.50 
1 For this outcome, a natural log transformation was applied to village level proportions to correct skewed distributions; RR: Risk Ratio; CI: confidence interval; 
CCA: circulating cathodic antigen; PCR: polymerase chain reaction 
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Supplementary Table 5: CONSORT 2010 checklist of information to include when 
reporting a cluster randomised trial  
Section/Topic Item 
No 
Standard Checklist 
item 
Extension for 
cluster designs 
Page 
No * 
Title and abstract   
1a Identification as a 
randomised trial in the 
title 
Identification as a cluster 
randomised trial in the title 
Page 1 
1b Structured summary of 
trial design, methods, 
results, and 
conclusions (for 
specific guidance see 
CONSORT for 
abstracts) 
See table 2 Pages 5-6 
Introduction  
Background 
and objectives 
2a Scientific background 
and explanation of 
rationale 
Rationale for using a 
cluster design 
Pages 7-8 
2b Specific objectives or 
hypotheses 
Whether objectives pertain 
to the cluster level, the 
individual participant level 
or both 
Pages 7-8 
Methods  
Trial design 3a Description of trial 
design (such as 
parallel, factorial) 
including allocation 
ratio 
Definition of cluster and 
description of how the 
design features apply to 
the clusters 
Page 8 
3b Important changes to 
methods after trial 
commencement (such 
as eligibility criteria), 
with reasons 
 
NA 
Participants 4a Eligibility criteria for 
participants 
Eligibility criteria for 
clusters  
Pages 8-9 
4b Settings and locations 
where the data were 
collected 
 
Page 8 
Interventions 5 The interventions for 
each group with 
sufficient details to 
allow replication, 
including how and 
when they were 
actually administered 
Whether interventions 
pertain to the cluster level, 
the individual participant 
level or both 
Page 8 
Outcomes 6a Completely defined 
pre-specified primary 
and secondary 
outcome measures, 
including how and 
when they were 
assessed 
Whether outcome 
measures pertain to the 
cluster level, the individual 
participant level or both 
Pages 9-10, 
Supplementary 
Methods 
6b Any changes to trial 
outcomes after the 
trial commenced, with 
reasons 
 
Page 10 
Sample size 7a How sample size was 
determined 
Method of calculation, 
number of clusters(s) (and 
whether equal or unequal 
Page 10, 
Supplementary 
Methods 
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cluster sizes are 
assumed), cluster size, a 
coefficient of intracluster 
correlation (ICC or k), and 
an indication of its 
uncertainty 
7b When applicable, 
explanation of any 
interim analyses and 
stopping guidelines 
 
N/A 
Randomisation:  
 Sequence 
generation 
8a Method used to 
generate the random 
allocation sequence 
 
Page 10, 
Supplementary 
Methods 
8b Type of 
randomisation; details 
of any restriction (such 
as blocking and block 
size) 
Details of stratification or 
matching if used 
Page 10, 
Supplementary 
Methods 
 Allocation 
concealment 
mechanism 
9 Mechanism used to 
implement the random 
allocation sequence 
(such as sequentially 
numbered containers), 
describing any steps 
taken to conceal the 
sequence until 
interventions were 
assigned 
Specification that 
allocation was based on 
clusters rather than 
individuals and whether 
allocation concealment (if 
any) was at the cluster 
level, the individual 
participant level or both 
Page 10, 
Supplementary 
Methods 
 Implementation  10 Who generated the 
random allocation 
sequence, who 
enrolled participants, 
and who assigned 
participants to 
interventions 
Replace by 10a, 10b and 
10c 
 
 
10a 
 
Who generated the 
random allocation 
sequence, who enrolled 
clusters, and who 
assigned clusters to 
interventions  
Page 10, 
Supplementary 
Methods 
 
10b 
 
Mechanism by which 
individual participants were 
included in clusters for the 
purposes of the trial (such 
as complete enumeration, 
random sampling) 
Pages 9-10 
 
10c 
 
From whom consent was 
sought (representatives of 
the cluster, or individual 
cluster members, or both), 
and whether consent was 
sought before or after 
randomisation  
Page 9 
    
 
Blinding 11a If done, who was 
blinded after 
assignment to 
interventions (for 
example, participants, 
care providers, those 
 
N/A 
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assessing outcomes) 
and how 
11b If relevant, description 
of the similarity of 
interventions 
 
N/A 
Statistical 
methods 
12a Statistical methods 
used to compare 
groups for primary and 
secondary outcomes 
How clustering was taken 
into account 
Pages 10-11, 
Supplementary 
Methods 
12b Methods for additional 
analyses, such as 
subgroup analyses 
and adjusted analyses 
 
Page 11, 
Supplementary 
Methods 
Results  
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the 
numbers of 
participants who were 
randomly assigned, 
received intended 
treatment, and were 
analysed for the 
primary outcome 
For each group, the 
numbers of clusters that 
were randomly assigned, 
received intended 
treatment, and were 
analysed for the primary 
outcome 
Pages 11-12, 
Figure 2 
13b For each group, 
losses and exclusions 
after randomisation, 
together with reasons 
For each group, losses 
and exclusions for both 
clusters and individual 
cluster members 
N/A 
Recruitment 14a Dates defining the 
periods of recruitment 
and follow-up 
 
Pages 11-12 
14b Why the trial ended or 
was stopped 
 
N/A 
Baseline data 15 A table showing 
baseline demographic 
and clinical 
characteristics for 
each group 
Baseline characteristics for 
the individual and cluster 
levels as applicable for 
each group 
Table 1 
Numbers 
analysed 
16 For each group, 
number of participants 
(denominator) 
included in each 
analysis and whether 
the analysis was by 
original assigned 
groups 
For each group, number of 
clusters included in each 
analysis 
Figure 2, 
Tables 2 and 3, 
Page 12 
Outcomes and 
estimation 
17a For each primary and 
secondary outcome, 
results for each group, 
and the estimated 
effect size and its 
precision (such as 
95% confidence 
interval) 
Results at the individual or 
cluster level as applicable 
and a coefficient of 
intracluster correlation 
(ICC or k) for each primary 
outcome 
Pages 12-13, 
Tables 2 and 3, 
Supplementary 
Table 3 
17b For binary outcomes, 
presentation of both 
absolute and relative 
effect sizes is 
recommended 
 
 
Ancillary 
analyses 
18 Results of any other 
analyses performed, 
including subgroup 
analyses and adjusted 
analyses, 
 
Pages 12-13, 
Supplementary 
Tables 1, 2 and 
4 
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distinguishing pre-
specified from 
exploratory 
Harms 19 All important harms or 
unintended effects in 
each group (for 
specific guidance see 
CONSORT for harms) 
 
Pages 13-14 
Discussion  
Limitations 20 Trial limitations, 
addressing sources of 
potential bias, 
imprecision, and, if 
relevant, multiplicity of 
analyses 
 
Pages 14-16 
Generalisability 21 Generalisability 
(external validity, 
applicability) of the 
trial findings 
Generalisability to clusters 
and/or individual 
participants (as relevant) 
Pages 15-16 
Interpretation 22 Interpretation 
consistent with results, 
balancing benefits and 
harms, and 
considering other 
relevant evidence 
 
Pages 14-16 
Other information 
 
 
Registration 23 Registration number 
and name of trial 
registry 
 
Page 5 
Protocol 24 Where the full trial 
protocol can be 
accessed, if available 
 
Page 8 
Funding 25 Sources of funding 
and other support 
(such as supply of 
drugs), role of funders 
 
Page 17 
* Note: page numbers optional depending on journal requirements 
1. Ellwood P, Asher MI, Beasley R, Clayton TO, Stewart AW. ISAAC Phase Three 
Manual. ISAAC International Data Centre, Auckland, New Zealand, 2000. 
2. Williams HC. So how do I define Atopic Eczema? A practical manual for 
researchers wishing to define atopic eczema. 
http://www.nottingham.ac.uk/dermatology/eczema/index.html (accessed 15th 
September 2010. 
3. WHO. Ultrasound in schistosomiasis: a practical guide to the standardized use 
of ultrasonography for the assessment of schistosomiasis-related morbidity2000. 
http://apps.who.int/iris/bitstream/10665/66535/1/TDR_STR_SCH_00.1.pdf (accessed 
28th May 2017). 
4. Mpairwe H, Webb EL, Muhangi L, et al. Anthelminthic treatment during 
pregnancy is associated with increased risk of infantile eczema: randomised-controlled 
trial results. Pediatr Allergy Immunol 2011; 22(3): 305-12. 
5. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear 
technique in Schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de Sao 
Paulo 1972; 14(6): 397-400. 
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6. Verweij JJ, Canales M, Polman K, et al. Molecular diagnosis of Strongyloides 
stercoralis in faecal samples using real-time PCR. Transactions of the Royal Society of 
Tropical Medicine and Hygiene 2009; 103(4): 342-6. 
7. Emmanuel IO, Ekkehard D. Epidemiology, of bilharzias (schistosomiasis) in 
Uganda from 1902 until 2005. African health sciences 2008; 8(4): 239-43. 
8. Melrose WD, Turner PF, Pisters P, Turner B. An improved Knott's concentration 
test for the detection of microfilariae. Transactions of the Royal Society of Tropical 
Medicine and Hygiene 2000; 94(2): 176. 
9. Nampijja M, Webb EL, Kaweesa J, et al. The Lake Victoria Island Intervention 
Study on Worms and Allergy-related diseases (LaVIISWA): study protocol for a 
randomised controlled trial. Trials 2015; 16: 187. 
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9.6.1 Copy of ethical approval to conduct PhD studies at LSHTM 
 
 
 
Observational	/	Interventions	Research	Ethics	Committee	
	
	
	Mr	NKURUNUNGI	GYAVIIRA	LSHTM		23	November	2016				Dear	NKURUNUNGI		
Study	Title:	Immunological	mechanisms	of	helminth-allergy	associations	in	Uganda		
LSHTM	Ethics	Ref:	11838			Thank	you	for	responding	to	the	Observational	Committee’s	request	for	further	information	on	the	above	research	and	submitting	revised	documentation.	The	further	information	has	been	considered	on	behalf	of	the	Committee	by	the	Chair.	
Confirmation	of	ethical	opinion	
	On	behalf	of	the	Committee,	I	am	pleased	to	confirm	a	favourable	ethical	opinion	for	the	above	research	on	the	basis	described	in	the	application	form,	protocol	and	supporting	documentation	as	revised,	subject	to	the	conditions	specified	below.		
Conditions	of	the	favourable	opinion	
	Approval	is	dependent	on	local	ethical	approval	having	been	received,	where	relevant.		
Approved	documents	
	The	final	list	of	documents	reviewed	and	approved	by	the	Committee	is	as	follows:		
Document 
Type 
File Name Date Version 
Advertisements 1. LaVIISWA. Information and permission, LC committees_original 08/03/2012 1 
Local Approval UVRI REC LaVIISWA Approval april 2012 02/05/2012 01 
Local Approval UNCST LaVIISWA Approvals 2012-2015 25/05/2012 01 
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Local Approval LSHTM LaVIISWA Approvals 2012-2016 28/05/2012 01 
Information Info and consent form, adults, LaVIISWA main Surveys v 3.2 05/03/2013 3.2 
Sheet    
Information Info and consent form,adults, LaVIISWA main Surveys v 3.2 Luganda 05/03/2013 3.2 
Sheet    
Information Info and consent form, parents and guardians, LaVIISWA main surveys v 3.2 05/03/2013 3.2 
Sheet    
Information Info and consent form, parents and guardians, LaVIISWA main survey v 3.2, 05/03/2013 3.2 
Sheet Luganda   
Information Info and Assent form, LaVIISWA main Survey, v 3.2 05/03/2013 3.2 
Sheet    
Information Info and Assent form, LaVIISWA main survey, v 3.2, Luganda 05/03/2013 3.2 
Sheet    
Local Approval UNCST LaVIISWA APPROVAL_Immunological mechanisms_sept 2015 25/09/2015 01 
Local Approval LAVIISWA MTA approval UNCST 15/10/2015 01 
Information 
Sheet 
LAVIISWA Inf for adult members - English 05/01/2016 5 
Information 
Sheet 
LAVIISWA Inf for adult members - Luganda 05/01/2016 5 
Information 
Sheet 
LAVIISWA Inf for children - English 05/01/2016 5 
Information 
Sheet 
LAVIISWA Inf for children - Luganda 05/01/2016 5 
Information 
Sheet 
LAVIISWA Inf for parents & guardians - English 05/01/2016 5 
Information 
Sheet 
LAVIISWA Inf for parents & guardians - Luganda 05/01/2016 5 
Information 
Sheet 
Urban Survey Information and Assent for children _Storage of Blood Samples 
English 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Assent for children _Storage of Blood Samples 
Luganda 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Assent for children English 08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Assent for children Luganda 08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for adults _Storage of Blood Samples 
English 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for adults _Storage of Blood Samples 
Luganda 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for adults English 08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for adults Luganda 08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for Parents & Guardians _Storage of Blood 
Samples English 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for Parents & Guardians _Storage of Blood 
Samples Luganda 
08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for Parents & Guardians English 08/03/2016 3 
Information 
Sheet 
Urban Survey Information and Consent for Parents & Guardians Luganda 08/03/2016 3 
Local Approval LAVIISWA UNCST Approval of transfer of samples to Cambridge University 
UK[2] 
26/04/2016 01 
Local Approval Urban survey_approvals 26/07/2016 01 
Local Approval LSHTM Letter _Urban Survey 26/07/2016 01 
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Protocol / 
Proposal 
Gyaviira Nkurunungi_protocol_2016 29/07/2016 01 
Protocol / 
Proposal 
Gyaviira Nkurunungi_data management plan 29/07/2016 1 
Investigator CV Curriculum vitae_Gyaviira Nkurunungi_08_2016 23/08/2016 01 
Covering Letter Cover letter_Gyaviira Nkurunungi_ref11838_final 08/11/2016 01 
	
After	ethical	review	
	The	Chief	Investigator	(CI)	or	delegate	is	responsible	for	informing	the	ethics	committee	of	any	subsequent	changes	to	the	application.	These	must	be	submitted	to	the	Committee	for	review	using	an	Amendment	form.	Amendments	must	not	be	initiated	before	receipt	of	written	favourable	opinion	from	the	committee.		The	CI	or	delegate	is	also	required	to	notify	the	ethics	committee	of	any	protocol	violations	and/or	Suspected	Unexpected	Serious	Adverse	Reactions	(SUSARs)	which	occur	during	the	project	by	submitting	a	Serious	Adverse	Event	form.		At	the	end	of	the	study,	the	CI	or	delegate	must	notify	the	committee	using	an	End	of	Study	form.		All	aforementioned	forms	are	available	on	the	ethics	online	applications	website	and	can	only	be	submitted	to	the	committee	via	the	website	at:	http://leo.lshtm.ac.uk	Additional	information	is	available	at:	www.lshtm.ac.uk/ethics	Yours	sincerely,	
 
Professor	John	DH	Porter	
Chair	ethics@lshtm.ac.uk	http://www.lshtm.ac.uk/ethics/		
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Your Ref: ...,.,
09th September 2014
Dr. Harriet Mpairwe,
RE: I;VRI REC review of protocol titled oostudy on asthma and parasitic infections among children in
Uganda (SONA)."
Thank you for submitting your responses to the queries addressed to you by UVRI REC.
This is to inform you that your responses dated 04ft September 2014 were reviewed and met the
requirements of the UVRI Research Ethics Committee.
UVRI REC annual approval has been given for you to conduct your research up to 09ft September 2015.
Annual progress ..port and request foi extension should be submitted to UVRI REC prior to the expiry
date, to allow timely review.
The reviewed and approved documents included;
1. Study protocol Version 1-4 Sept 2014
2. UVRI REC Application form
3. Consent forms and information sheets
4. Screening questionnaires
5. Applicants'CVs.
You can now continue with your study after
and Technology (UNCST).
Note: UVRI REC requires you to submit
registration with the Uganda National Council for Science
a copy of the UNCST approval letter for the above study
C.C The Director-UVRI
C.C Secretary, WRI REC
ttHPL:Br.l( d)f u€&t4tlA,
before commencement.
Mr. Tofi Lutalo
Study on Asthma and Parasitic Infections: copies of ethical approvals9.6.4
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9.7 APPENDIX 5: example of a Stata do file used to perform permutation testing 
 
 
**************************PERMUTATION TESTING*********************** 
 
**This is to assess differences between comparison groups, by controlling 
**for multiple testing of these correlated (non-independent) anti-glycan 
**responses. It is an alternative to other methods of accounting for multiple 
**testing that assume that variables are independent of each other, such as 
**Bonferroni corrections. 
 
** The code for analysing the data and outputting p-values to a matrix, and  
**then to a dataset, uses a Mann whitney U-test here (note that this can  
**easily be adapted to other tests, such as regression if adjusting for 
**confounders). Here we assess differences between S. mansoni infected and 
**uninfected individuals. Variable name for S. mansoni infection is ‘kasinf’. 
**The outcomes are IgE responses to the 135 glycans on the array (from G1 to 
**G136). 
 
** loop through the outcome variables from G1 to G136. When you see `x' it 
takes values from 1 to 136. 
 
foreach x of varlist G1-G136 { 
 
** conduct a Mann whitney test 
 
ranksum `x', by(kasinf) 
 
** then extract the p-value 
 
scalar p = 2 * normprob(-abs(r(z))) 
di p 
 
** add this p-value to a matrix, so have all the p-values from a single 
** analysis of all outcomes, in one place. 
  
if `x'==G1 matrix pval_vec=p 
else matrix pval_vec=(pval_vec \ p) 
} 
 
*** Look at the output 
 
matrix list pval_vec 
 
**This gives the p-values from tests of association between exposure and  
**outcome for all 135 outcomes. These are our actual results. 
** We want to do this thousands of times, but rather than using the original 
** dataset, we want to "muddle up" the exposure variable so that we destroy 
** any genuine associations between exposure and the outcome. 
** The idea is that we can then see, under the null hypothesis of no 
**association, how many times we would expect to see a result with this small  
**a p-value by chance alone. 
** For each outcome variable, we can then compare our p-value with the 
**calculated p-values from each permutation, to see where our p-value lies in 
**relation to these. 
 
** We can also look globally, i.e. from each permutation, we take the  
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**smallest p-value and we then compare our smallest p-value (from the true)  
**data with the distribution of smallest p-values from all of the  
**permutations. 
 
*** Firstly, permute the exposure values and repeat: 
** To do this, use a command called shufflevar which needs to be installed 
 
ssc install shufflevar 
 
** Look through 1000 iterations and for each iteration shuffle up the 
exposure variable (keeping other data the same). 
 
foreach num of numlist 1(1)1000 { 
gen eper`num'=kasinf 
shufflevar eper`num', dropold 
rename eper`num'_shuffled eper`num' 
} 
 
**Now that have the mixed-up exposure labels, need to loop through and apply 
the statistical tests to the permuted data. 
 
set more off 
foreach y of numlist 1(1)1000 { 
foreach x of varlist G1-G136 { 
 
** conduct statistical analysis 
 
ranksum `x', by(eper`y') 
 
** then extract the p-value 
 
scalar p = 2 * normprob(-abs(r(z))) 
di p 
 
** add this p-value to a matrix, so have all the p-values from a single 
** analysis of all outcomes, in one place.  
 
if `x'==G1 matrix pval_vec`y'=p 
else matrix pval_vec`y'=(pval_vec`y' \ p) 
} 
} 
 
*** Look at the output 
 
matrix dir 
 
**We now have a matrix (with 1 column each) of results for the permuted 
**datasets. 
** Each has 136 p-values, one corresponding to each outcome variable. 
*** Now need to combine the separate matrices so have all in one place. 
*** Easiest way to do this is to export as .csv file, then bring back into 
**Stata. 
** Output true results p-values first. 
 
matrix pval_vect=pval_vec' 
mat2txt, matrix(pval_vect) saving("permute_laviiswa_glycan_IgE.csv") replace  
 
** Then output the permutation results. 
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foreach x of numlist 1/1000 { 
matrix pval_vec`x't=pval_vec`x'' 
mat2txt, matrix(pval_vec`x't) saving("permute_laviiswa_glycan_IgE.csv") 
append  
} 
 
 
** Bring the p-values back into Stata and do some tidying up 
 
import delimited permute_laviiswa_glycan_IgE.csv, clear 
drop if v2=="r1" 
drop v1 
set more off 
foreach x of varlist v2-v136 { 
destring `x', replace 
} 
 
drop v137 
 
** In this dataset, each column represents one of the 30 outcomes. 
** The first row represents the true results (from the actual data) - p-
values. Each row after that represents the p-values from one permutation. 
 
** We can generate a new variable for the minimum p-value from each 
permutation 
 
egen minp=rowmin(v2-v136) 
 
** We now have the option of comparing our best p-value from the true 
analysis with our best p-values from all permutations, or we can compare 
results for each outcome variable to their permuted equivalents individually 
(or both). 
 
** Globally: 
 
gen global=0 if _n>=2 
replace global=1 if minp[1]>minp[_n] & _n>=2 
 
** get p-value from the proportion of permutations that have a p-value 
** smaller than the actual p-value 
 
tab global 
 
** We are looking for a small number of 1s, e.g. if there are only 3 1's out  
** of 1000 permutations, then the p-value would be 3/1000 = 0.003. If there 
were 500 1's out of 1000 permutations, then the p-value would be 0.5. 
 
** For each outcome: 
 
foreach x of numlist 2/136 { 
local y=`x'-1 
gen kasinf`y'p=0 if _n>=2 
replace kasinf`y'p=1 if v`x'[1]>v`x'[_n] & _n>=2 
} 
 
set more off 
foreach x of varlist kasinf1p-kasinf135p { 
tab `x' 
} 
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